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Foreword
Phencyclidine (PCP), or “angel dust” as it is more commonly known
to drug users, posed until recently a relatively modest problem.
While some illicit use occurred as early as the mid ‘6Os, the drug’s
initially poor street reputation seemed to make it decidedly unlikely
that it would ever become popular as a drug of choice.
More recent events have made it abundantly clear that our initial
optimism was poorly founded. A change in mode of use from oral
ingestion to smoking or snorting, which may enable the user to better
control aversive consequences of use, together with the ease with
which PCP can be synthesized, have markedly changed the phencyclidine
abuse picture.
In one year (from 1976 to 1977) the number who had used phencyclidine
as measured by NIDA’s National Drug Use Surveys nearly doubled in the
12 to 17 year age group. Among young adults between 18 and 25, the
number of PCP users increased nearly fifty percent in that same year.
Although the level of use detected was still modest, there is good
reason to believe that the standardized indicators of the extent of
PCP use and of its adverse consequences represent significant under-
estimates of the seriousness of the problem. Clinical reports have
also indicated that phencyclidine use can precipitate violent acting
out and seriously self-destructive behavior as well as psychotic
thinking and behavior.
Because of the relatively recent emergence of phencyclidine abuse as
a problem of widespread proportions, our knowledge remains fragmen-
tary. If the dimensions of the problem continue to be in doubt,
still more remains to be learned about the implications of use,
especially on a chronic basis. This volume represents an attempt to
bring together our present knowledge. It is based on a small working
conference of researchers and clinicians with extensive PCP experi-
ence which was held in late February of this year (1978). We hope
that it proves to be a useful compendium of information on the prob-
lem as well as a stimulus to further work to answer some of the
critical questions with which we are confronted. In addition,
because phencyclidine may well prove to be prototypic of a range of
easily synthesized psychoactive drugs susceptible to abuse, we hope
it will stimulate thinking about better ways both to anticipate newly
emerging drug problems and to cope with them.
The Editors
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Chapter 1
Phencyclidine: An Overview
Robert C. Petersen, Ph.D., and Richard C. Stillman, M.D.
Although phencyclidine was first abused in oral form over a decade
ago, it is only in recent years as a smoked or snorted drug that
it has become a more serious problem involving significant numbers
of users. This overview is intended to review and summarize what
is presently known about the drug with special emphasis on the con-
tributions of the authors of this volume. By providing a relatively
brief integrated view of our current knowledge we hope to convey
the limitations of that knowledge and to encourage others to en-
large our presently modest understanding of the implications of
phencyclidine abuse.
THE MATERIAL
Phencyclidine,or PCP, one of the group of arylcyclohexylamines, is
in pharmaceutically pure form a white powder which readily dissolves
in water. In “street” form PCP is often adulterated and quite often
misrepresented as a variety of other drugs. It is highly variable
in appearance, being sold in liquid, powder, and tablet form, the
latter two in many colors. As a powder or liquid, it is often placed
on parsley or on other leaf mixtures to be smoked as cigarettes
(joints). When misrepresented, PCP is most commonly sold as THC
(the principal psychoactive ingredient in marihuana, which in reality
is not available on the street). But phencyclidine has also been
sold as cannabinol (another marihuana constituent), mescaline,
psylocybin, LSD, and even as amphetamine or cocaine. Because of
the variability in street names and its frequent misrepresentation,
the casual user may be unaware of what he or she has ingested or
may be mistaken about its true identity.
Some of the street names for phencyclidine include: angel dust,
dust, crystal, cyclones, embalming fluid, elephant or horse tran-
quilizer, killer weed, superweed, mintweed, mist, monkey dust,
Peace Pill, rocket fuel, goon, surfer, KW, and scuffle. The wide
range of regional names for this illicit drug, as well as variations
in its appearance, mean that the casual user may not be aware that
he or she has used PCP or may fail to report its use in surveys because
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he or she does not know the drug by the survey designation. A fur-
ther complication in user identification of PCP is the fact that
phencyclidine is sometimes also used in combination with such other
drugs as barbiturates, heroin, cocaine, amphetamine, methaqualone,
LSD, mescaline, and procaine (cf. Lerner and Burns, this volume).
Depending on the care with which the synthesis of PCP is carried out,
the street drug may contain a variety of impurities, including potas-
sium cyanide. Although PCP is sometimes smoked after sprinkling it
on marihuana, it is apparently rarely sold in that combination. At
least one major laboratory on the West Coast which does street drug
analysis has never encountered the combination in samples submitted
to it.
In addition to phencyclidine itself, there are over thirty chemically
similar analogs, some of which are capable of producing similar psychic
effects. These also can be synthesized with varying degrees of diffi-
culty, and some have already appeared on the street. Those reportedly
abused thus far include: PCC, PCE, PHP, TCP, and the anesthetic,
ketamine . Details of their chemical formulas and structure are given
by Domino (this volume) . The addition of these compounds, and possi-
bly others in the future, makes the problem of “tracking" PCP and
related drug use more difficult.
Adding to the risk of PCP use, especially when it is taken orally,
is the wide variability in purity of the street drug. Even when it
is not misrepresented, the percentage of PCP contained in street
samples has been found to be quite variable.
When PCP is sold as a granular powder (“angel dust”), it is usually
relatively pure, consisting of perhaps 50-100 percent phencyclidine.
However, sold under a variety of other names and/or in other forms,
the purity is from 5 to 30 percent, with leafy mixtures generally
containing the smallest amounts of the drug. While in the past
street samples of phencyclidine have often been found on analysis
to contain other drugs as well, more recently such samples appear
less likely to contain other drugs in addition to PCP. It should,
of course, be noted that samples submitted by users for analysis are
not necessarily representative of street drugs overall. Users are
far more likely to have analyzed drugs about which they have some
doubt or from which they have had some unusual reaction. Nevertheless,
it does appear that the purity of PCP street samples has increased
in that it is less frequently sold mixed with other psychoactive
materials.
Phencyclidine can be easily synthesized. The “starting” chemicals
are widely available and because of their important industrial uses
do not lend themselves to more stringent controls. While some of
the mass media accounts have exaggerated the ease with which phen-
cyclidine can be made. it is not particularly difficult and can be
done by individuals with only modest technical training and without
elaborate equipment.
The precise classification of PCP is presently unsettled. PCP has
stimulant, depressant, hallucinogenic, and analgesic properties
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which are dose-dependent. One proposed classification is with
ketamine as a “dissociative anesthetic” (cf. Domino, this volume).
Phencyclidine is used legally in veterinary medicine as an animal
immobilizing agent. Although it was originally developed as an
anesthetic for use with humans, it was later abandoned for that
purpose because in some patients it produced post-operative thought
disturbances and agitation. PCP made its first illicit appearance
in 1965 on the West Coast. At that time it rapidly developed a
bad street reputation and had only limited popularity. Since then
there have been sporadic outbreaks of its use. Most recently there
is evidence from a variety of sources suggesting a marked increase
in use (cf. Extent of Phencyclidine Abuse, below).
Although originally orally ingested, PCP is now most commonly smoked
or snorted. Intravenous use is much less frequent, but has been re-
ported. By smoking, the experienced user is better able to limit
his dose (self-titrate) to a level with which he or she is comfort-
able and is probably less likely to overdose. By contrast, when the
drug is taken by mouth there is a longer period before the drug takes
effect, it continues to be absorbed after the user may have concluded
he has had enough, and the dose is frequently larger--all factors
more likely to result in adverse reactions due to an overdose.
BIOLOGICAL, NEUROCHEMICAL, AND PRECLINICAL BEHAVIORAL ASPECTS
Three of the papers in this volume focus specifically on what is
presently known about the neurobiological, neurochemical, and pre-
clinical behavioral aspects of phencyclidine. Domino (this volume)
divides and summarizes the major pharmacological properties of PCP
and related compounds as follows:
Central Nervous System Effects
a. Small doses lead to a “drunken” state with numbness of the
extremities and in some species produces excitation.
b. In moderate doses, analgesia and anesthesia are produced.
c. A psychic state somewhat resembling sensory isolation is
produced. Sensory impulses in grossly distorted form do,
however, reach the neocortex.
d. Cataleptiform motor responses occur.
e. Large doses, expecially of PCP, may produce convulsions.
f. There are marked inter-species differences in effects. Pri-
mates and especially man show predominantly depressant effects.
Autonomic and Cardiovascular System Effects
a. Sympathomimetic effects are produced including increases in
heart rate and blood pressure.
b. Catecholamines are potentiated through a cocaine-like action.
Balster and Chait (this volume) in their review of the preclinical
behavioral pharmacology of PCP emphasize several points. They too
underscore the interspecies differences in PCP effects. For example,
in rodents, unlike primates, PCP has excitatory rather than depressant
effects.
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Unlike virtually all other hallucinogens, with which PCP is sometimes
categorized, monkeys will self-administer phencyclidine. This sug-
gests that animal testing of other PCP analogs may be useful in
predicting their dependence liability in man. Experiments with PCP
to date do not, however, suggest that phencyclidine produces compar-
able physical dependence to that of the opiates or other CNS depres-
sants. Tolerance from two to four times the original amounts develops
if the drug is administered chronically to test animals. Finally,
work done thus far indicates the PCP enhances the depressant effects
of delta-9-THC (the principal psychoactive ingredient in marihuana)
and the anesthetic effects of pentobarbital. When administered with
d-amphetamine, there is preliminary evidence that PCP increases
amphetamine stereotype in rats.
Johnson, in his review of the neurochemical pharmacology of phency-
clidine (this volume), emphasizes that our knowledge in this area is
in its infancy, but that it appears unlikely that the diverse spectrum
of effects is mediated by PCP’s action on any one neurotransmitter.
He also points out that there have been virtually no studies exploring
the neurochemistry of chronic use.
EXTENT OF PHENCYCLIDINE ABUSE
Attempts at estimating the extent of PCP use are fraught with dif-
ficulty. Since the drug is often sold as any one of a variety of
other psychoactive substances, the user, especially if he or she
is inexperienced, may not realize PCP is involved. The fact that
phencyclidine is known by an unusually large number of street names
and varies widely in its physical appearance also contributes to
confusion in casual user identification. Most official reports of
drug use have in the past lumped PCP with other hallucinogens, making
trend detection from such sources difficult. Moreover, the patient
admitted for emergency treatment of PCP-induced bizarre behavior is
likely to be diagnosed as acutely schizophrenic rather than as a toxic
drug reaction. Patients admitted with injuries from automobile acci-
dents, fires and drownings in which PCP was a cause may not be so
identified. Thus a marked increase in use and in use-related drug
emergencies may not be reflected in emergency room or medical exam-
iner statistics.
Despite these limitations, there are a number of converging lines
of evidence suggesting increased use in recent months. These range
from reports of law enforcement agencies on disruption of illegal
laboratory production to self-reports by users. While available
survey data has definite limitations, they provide minimal estimates
of the level of phencyclidine use as well as some short term trend
indicators. In NIDA’s 1976 National Survey, 3 percent of youth
between 12 and 17 years of age at the time of the survey acknowledged
having used PCP at some time in their lives. Among young adults
18-25, the age category in which virtually all drug use peaks, nearly
one in ten reported having used PCP prior to the 1976 survey. By
contrast, data from the 1977 National Survey suggests that the per-
centage who had ever used in the 12-17 year-old group had nearly
doubled since the earlier survey (5.8 percent vs. 3.0 percent in 1976).
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Use by the 18-25 age group had also increased markedly, from 9.5
percent to 13.9 percent. The likelihood that these increases were
simply the result of year to year survey sampling variation is small
(less than one in a hundred).
Some indication of the extent to which a drug poses serious problems
is provided by the Government’s Drug Abuse Warning Network (DAWN).
DAWN is a national reporting system which collects reports of drug-
related deaths and drug-related emergencies involving hospital emer-
gency room treatment. For reasons that have already been outlined,
such figures are likely to be minimal estimates of the overall PCP
problem. They are, however, also useful in providing some indication
of trends. When data are examined from the 662 emergency rooms which
consistently reported to DAWN from November 1974 to October 1976,
the rate of PCP emergencies doubled during that period (there were 111
mentions in October 1976 contrasted with 54 in October 1974). Reports
of PCP-related deaths show nearly as great an increase when the period
from April 1976 to March 1977 is contrasted with that of the previous
year (30 PCP-related deaths vs. 17 the year before). Again, such
figures are likely to be minimal estimates of the actual extent of
PCP-related mortality.
A major reported cause of PCP deaths in California has been drowning.
In one series of 19 PCP deaths investigated in two California counties,
11 of the 19 were from drowning--one while in the shower. The PCP
user readily loses his orientation while swimming or immersed and
frequently drowns, sometimes in very small amounts of water. Unless
PCP in the body is specifically searched for under such circumstances,
it is very likely to be missed. Similarly, deaths resulting from
violent behavior and accidental deaths resulting from PCP intoxication
may not be reported as PCP-related. Suicide while under the influence
of the drug was the cause of death of three additional persons in the
California study. Another death was the result of threatening behav-
ior leading to the individual’s being shot (Burns and Lerner 1978).
Another source of data which provides some indication of the extent
of phencyclidine use among chronically drug-using youth is the
National Youth Polydrug Study (NYPS), in which 97 drug abuse treatment
programs specializing in treating youthful drug abusers participated.
During the period from September 1976 to March 1977 interviews were
conducted collecting detailed data on patterns of drug abuse for 2750
new clients under age 19. Within this sample nearly a third (31.8
percent) reported having ever used PCP. It was more often used than
inhalants, sedatives, cocaine and opiates (other than heroin and
methadone). Females in the sample were as likely to have used PCP
as males. Whites were far more likely to report using it than either
black or Hispanic clients (42.3 percent of whites, 8.5 percent of
blacks and 9.0 percent of Hispanics). Females in the sample were
found to have first used PCP at a slightly earlier age (14.4 years)
than males (14.7 years). American Indians began use at the earliest
age (13.9) followed by Hispanics (14.0) whites (14.6) and blacks,
(15.3). Two-thirds of those who reported ever having used PCP re-
ported continuing use at a rate of at least once a week for at least
one month. PCP users had also used twice as many other recreational
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drugs as had non-PCPusers (6.0 vs. 2.8 substances respectively).
Half the current PCP users were using PCP once a week or more
often during the three month period that was studied. While this
data source is obviously not representative of youth generally,
it does suggest that PCP use is quite common among abusers of other
drugs.
THE SUBJECTIVE EXPERIENCE -- MOTIVES FOR PHENCYCLIDINE USE
One of the more puzzling questions about PCP use is just why users
continue to use in the light of the widely noted and even user
acknowledged negative aspects of the experience. Several of the
papers in this volume provide some insight into this important
question both on the basis of user reports and on theoretical
grounds. One answer that emerges is that initial reports both
in the clinical literature and in the mass media have stressed
the negative aspects and failed to note user-perceived more
positive aspects. In a major study of some 319 adult users
ranging in age from 21 to 38, Siegel (this volume) specifically
questioned users regarding the subjective effects of the phency-
clidine experience. Interestingly enough, users in this sample
reported negative or undesired aspects on every occasion of PCP
use and positive or desired effects of use, only 60 percent of
the times used. Effects reported positively included heightened
sensitivity to outside stimuli (by 94 percent of users), stimu-
lation (92 percent), dissociation (88 percent), mood elevation
(61 percent), inebriation (55 percent), and relaxation or tran-
quilization (by 55 percent of users). Only one in twelve (8
percent) reported experiencing euphoria, however. Negative effects
reported by the majority of users included perceptual disturbances
(by 75 percent), restlessness (by 76 percent), disorientation
(63 percent), and anxiety (61 percent). Approximately a quarter
to a third of users reported such troublesome effects as paranoia
(34 percent), hyperexcitability (27 percent), irritability (22
percent), and mental confusion (22 percent). Four out of five
users had speech difficulties (dysarthria) while using the drug.
Fauman and Fauman (this volume) studied twenty-five chronic
phencyclidine users under treatment in an Illinois residential
treatment program. Their average age was nearly nineteen (18.8
years), and they had used PCP for an average of 3.6 years. Half
(12) described their initial PCP experience in such positive
terms as “fantastic,” “mind blowing,” an intense high or a happy
experience. Ten of the twenty-five found the first experience
neutral or mildly unpleasant. Only seven of the twenty-five re-
ported their typical PCP experience was positive. Eleven reported
their usual PCP experience to be unpleasant and three described
it as making them feel “rowdy” or ‘Violent.” Lerner and Burns
(this volume) in a study of 20 chronic users in the San Francisco
area, report that four out of five found their first PCP experience
“fun” “exhilarating,” and that they (the users) felt “happy” or
“euphoric.”  Marsella and Hicks (this volume) emphasize the role of
drug use among native Hawaiian youth in the Job Corps as a way of
relieving boredom and the possible importance of the drug experience
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in fostering a new sense of what is “real” in contrast to the more
usual conceptions of non-drug using groups. Given this new norma-
tive standard, continued drug use may be important in maintaining
it .
A theoretical framework for explaining the persistence of PCP-
using behavior despite its obviously negative aspects is offered
by Mello (this volume). She emphasizes the reinforcement value
of the drug experience regardless of certain aversive consequences
because of its role in changing the user’s subjective state. In
practical terms this means that a drug which has the ability to
markedly alter the individual’s subjective feelings may be rein-
forcing even though that alteration is not always marked by posi-
tive aspects in the usual sense.
Another aspect of the PCP experience that may be important in its
continued use is the very risk taking it entails. The excitement
of not knowing just how the experience will turn out and the ability
to later boast of the risks taken, may convey a certain amount
of status, especially in drug-using peer groups (perhaps in a
way analogous to the telling of “war stories” by those who have
been in the military). Related and perhaps easier to understand
are some of the other effects reported by many PCP users: feelings
of strength, power, and invulnerability.
As indicated, difficulties with speech are common. It is frequently
blocked, sparse, and purposeless. Auditory and sometimes visual
hallucinations may occur, more frequently at higher doses, and
feelings of severe anxiety, impending doom or death may appear
and disappear. Touch and pain sensations, as might be expected
since PCP was originally developed as an anesthetic, are dulled
and, as a result, even severe injuries sometimes occur with the
user unaware or only minimally aware of their occurrence. Bizarre
behavior of many types has been reported.
Users typically describe the drug as stronger than marihuana
(“superpot”), perhaps more comparable to LSD, but basically “in
a class by itself.” As with these other drugs, a few users speak
of attaining distinctly new perspectives, of a more “philosophical
outlook” and of seeing their lives freshly with a new sense of
unity. Great variability exists in the effects from one user to
the next.
MODES OF USE
The novice user is often introduced to the drug openly or covertly
by smoking it sprinkled on such leafy materials as tobacco, mari-
huana, or dried parsley in a “joint” (a hand rolled cigarette).
Occasionally a manufactured mentholated cigarette is dipped in
liquid PCP and later smoked (“superkools”). Although other routes
of ingestion are sometimes used (e.g., snorting, oral ingestion,
or more rarely, intravenous injection), the effects of the differ-
ing routes are similar, differing primarily in rapidity of onset
of effects (as previously indicated, overdoses may be more likely
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with oral doses because of the longer latency period before the
drug has an effect and the lessened ability to “self-titrate” the
dose). In typical use, the “high” from a single dose lasts from
four to six hours with an even longer “coming down” period.
Both animal data (cf. Balster and Chait, this volume) and human
reports suggest that a degree of tolerance develops, with increas-
ing doses being required at the end of a “run” to achieve the
same effects as at the beginning. PCP is a social drug in the
sense that virtually all users report taking it in groups rather
than as a solitary experience.
Chronic users are reported (Lerner and Burns, this volume) to
take the drug in “runs” that may extend over two or three days
during which they remain sleepless. Appetite is also reportedly
suppressed, resulting in weight losses of ten to thirty-five
pounds during repeated periods of chronic use. Following a “run”
users need great amounts of sleep and may awaken feeling disorien-
ted and depressed. In later stages of chronic use, outright para-
noid and violent behavior with auditory hallucinations may appear.
The possible role of PCP in precipitating long term psychosis is
at present poorly understood. It may be that persistent psychosis
occurs in individuals who are latently schizophrenic as a result
of some “triggering” function of phencyclidine. Whatever the
cause, there is some evidence that individuals who have used PCP
in the past may later develop a more persistent schizophrenia
despite some months of abstinence from the drug (cf. Luisada,
this volume).
Having used phencyclidine repeatedly without serious adverse
effects is apparently no guarantee that more serious consequences
will not occur unexpectedly on another occasion of use. At least
one group of clinical investigators (Burns and Lerner, 1978)
believes that if use is persistent, adverse consequences will
almost invariably follow.
The premorbid personalities of PCP abusers are not consistently
described in the literature. PCP users appear to have a variety
of personalities, not fitting a single pattern. Fauman and Fauman
(1977) made the point that many of those who become psychotic with
this drug appear to resemble persons who become psychotic using
LSD. However, PCP abusers include not only socially marginal
people, but also people of substantial achievement without obvious
premorbid psychopathology.
For chronic PCP users, PCP is in fact a drug of choice. Lerner
and Bums (this volume) report that chronic phencyclidine users
experienced persistent cognitive and memory problems. Speech
difficulties included stuttering, poor speech articulation, and
difficulties in expressing themselves to others, effects lasting
6 months to a year following prolonged daily PCP use. Mood dis-
orders also occurred; viz: depression, anxiety, and violent be-
havior. Purposive activity became more difficult with resultant
loss of employment or impaired school performance.
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TREATMENT OF CHRONIC PCP USER
As with other drug abuse, the motivations of the user are crucially
important in the approach to treatment. In at least one geo-
graphic area of high PCP abuse, a downturn in emergency cases,
possibly indicating less widespread general use, followed an
intensive effort by the local community mental health center to
publicize the adverse effects of the drug. Unfortunately, numerous
case accounts suggest that the user who consistently enjoys PCP
will be reluctant to give up its use, since it is relatively
cheap, easily available, and quite powerful. Although for many
it is a particularly disagreeable drug, for others it is quite
enjoyable. Whether this reflects a psychopharmacologic difference
between these groups is not known, but its genuine appeal to some
must be taken into account in any therapeutic or educational pro-
gram. Not only is the drug readily available, but so is the ex-
ample of users who experience severe depression while taking the
drug, but who continue their use of it notwithstanding.
In their discussion of long term residential treatment of adolescent
PCP abusers, DeAngelis and Goldstein (this volume) emphasize the
importance of dealing with underlying emotional conflicts in their
clients rather than focusing on their phencyclidine use itself.
Discussion of drug abuse itself, they feel, is often a way in
which the disturbed adolescent can avoid coming to grips with
his or her real problems which cause drug abuse. In their popu-
lation they have found that about half reported PCP use. They
report that many of their PCP users in treatment show “flattened
affect, depression, agitation, hostility, and belligerence.”
As a result, staff have lower initial expectations of PCP users’
participation in such activities as therapy, school or recreational
programs and are initially more tolerant of angry outbursts.
Chronic PCP users were found to stay in the program longer than
other types of drug abusers (DeAngelis and Goldstein, this volume).
PCP OVERDOSE (cf. Done, Aronow and Miceli; Aronow, Miceli
and Done; Luisada; Smith et al. - all in this volume)
Diagnosis
The victim of an overdose of PCP may exhibit many different
symptoms during the course of his intoxication, depending on the
dose, how recently it has been ingested, and frequency of prior
use. Some cardinal signs of PCP overdose are: ataxia, vertical
and horizontal nystagmus, assaultiveness or catatonic staring,
and generalized anesthesia. Severe convulsions may also occur
in extremely heavy overdoses, and PCP exhibits the lethal proper-
ties of a central nervous system depressant, with respiratory
depression, coma and death.
The dose of PCP which may result in a trip to an emergency room
is as varied as the presenting symptoms. A single cigarette may,
in the inexperienced (or deceived) user, produce overwhelming
feelings of acute anxiety requiring prompt but relatively
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brief reassurance and therapeutic support. In adults, quantities
in excess of a half a gram have been used and it is particularly
in this dose range (or higher) that life-threatening effects
are likely to be manifested along with severe behavioral distur-
bance.
The diagnosis of PCP over-dosage is frequently missed (Fauman and
Fauman 1977). Because the presenting symptoms so often closely
resemble those of an acute schizophrenic episode, this is a common
misdiagnosis. Aronow and Done provide a useful summary (Aronow
and Done 1978) of the range of physical and psychological symptoms
likely to be encountered in the emergency room situation.
At relatively low doses (on the order of 5 mg in the adult, lead-
ing to an estimated serum level of 20-30 ng/ml) they describe
the patient as likely to show some of the following symptoms:
agitation and excitemnt
gross incoordination
blank stare appearance
catatonic rigidity
catalepsy
inability to speak
horizontal or vertical nystagmus
loss of response to pinprick
flushing
diaphoresis
hyperacusis
Psychologically the patient may have the following subjective
responses: changes in body image, estrangement, disorganization
of thought, feelings of inebriation, drowsiness and apathy. The
patient may show marked negativism and hostility as well as bizarre
behavior. Later, the patient may be amnesic for the drug episode.
At moderate doses (approximately 5-10 mg., leading in the adult
to serum levels of 30-100 ng/ml) they list the following symptoms:
coma or stupor
eyes remain open
pupils in midposition and reactive
nystagmus
vomiting
hypersalivation
repetitive motor movements
myoclonus (shivering)
muscle rigidity on stimulation
flushing
diaphoresis
fever
decreased peripheral sensations (pain,
touch, and position)
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At still higher doses (over 10 mg, leading in the adult to serum
levels of 100 ng/ml and higher) the authors note the following:
prolonged coma (from 12 hours to many days)
eyes closed
variable pupil size, but reactive
hypertension
opisthotonic posturing
decerebrate positioning
repetitive motor movements
muscular rigidity
convulsions (at doses of 0.5 to 1 mg/kg)
absent peripheral sensation
decreased or absent gag and corneal reflexes
diaphoresis
hypersalivation
flushing
fever
(The doses cited are rough guidelines; other investigators suggest
that significantly higher doses of PCP are needed to produce
each of these clinical pictures.)
If the symptoms found are suggestive of recent PCP ingestion, a
urine or blood sample may reveal the presence of the drug. If
a large amount has been ingested, considerable quantities of PCP
will be present in urine for several days (or more). Attempts
should be trade to elicit a drug history from informants, although
it is quite possible that they may only know the drug under one
of its street names (cf. The Material) or may not even know that
the patient has taken phencyclidine if the drug has been misrepre-
sented. Since the drug often renders the patient amnesic for
the circumstances of taking it, he or she may not remember having
taken it or may only recall it during a later period of recovery.
A history of recent ingestion of other drugs may complicate the
diagnosis and treatment. Thus the diagnosis may sometimes be
established by history, sometimes by laboratory tests, by the
physical and psychological course of the patient or by some combi-
nation of these.
Treatment of PCP Overdose
Life-support measures
The hospital management of the PCP overdose victim is divided into
phases corresponding to the time course of action of the drug.
The initial phase requires symptomatic, often intensive medical
management. It includes the most acute physical effects of the
drug, including the possibility of respiratory depression, con-
vulsions, and coma. Treatment of this phase frequently requires
the full life-support capabilities of a good intensive care unit.
Acidification of the urine and gastric drainage (see below) will
markedly hasten the excretion of PCP. Since there is no specific
antagonist for PCP other treatments are symptomatic. PCP often
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induces hypersecretion in the pharnyx, which must be suctioned.
Respiratory depression calls for external respiratory assistance.
Hyperthermia can be treated with external cooling. Life-threaten-
ing consequences of rapid development of hypertension can be treated
with diazoxide (Hyperstat) or hydralazine hydrochloride (Apreso-
line). Convulsions can be managed with IV diazepam and constant
attention to maintenance of an unimpaired airway. However, some
feel diazepam may prolong the course of the intoxication.
Isolation
Most clinicians advocate placing the patient in an isolated envi-
ronment during this period, reducing sensory stimulation as much
as possible in order to minimize the phase of excitability,
irritability, anxiety, paranoia and violence which often follows
the obtunded or comatose phase. Needless to say, such isolation
of the patient (in quiet rooms, etc.) cannot be at the expense of
vigilant medical monitoring of the patient’s vital signs and his/
her response to emergency life-support management. Patients are
often so unmanageable that restraints are necessary, and the help
of four or five (not one) burly aides will often be needed to
prevent injury to staff or patients. If it is necessary to ad-
minister tranquilizing agents to keep the patient manageable, do
not use phenothiazines during this acute stage because of the
anti-cholinergic potentiation with PCP. Haloperidol (Haldol) has
been recommended (5 mg IM repeated hourly until the patient is
under control).
Detoxification
Recently ingested drugs should be removed by gastric lavage.
Done (1978) and Aronow and Done (1978) describe an emergency
detoxification procedure which achieves greatly enhanced urine
concentrations of PCP by lowering the urine pH to 5 or less.
They recommend administration of ammonium chloride by gastric
intubation or, in severe cases, intravenously. (Prior screening
must be done for the concomitant presence of such other drugs
as phenobarbital or salicylates, whose excretion might be adversely
affected by acidification; the presence of liver damage contra-
indicates the use of ammonium chloride.) To acidify by intubation
they use 2.75 mEq/kg ammonium chloride in 60 cc or saline solution
every 6 hours along with intravenous ascorbic acid (2 gm/500 cc
IV fluid q 6 hours) until the urine pH drops below 5. For patients
in deep coma, they advise using intravenous ammonium chloride
(2.75 mEq/kg as a 1-2 percent solution in saline) with precise
and repeated monitoring of blood pH, blood gases, BUN, blood ammonia
levels, and electrolytes. These guidelines must be adapted for
every patient individually by a medical team experienced in
electrolyte management.
The treatment of acute toxic effects usually belongs in an inten-
sive care unit, not an emergency room. Constant gastric suctioning
is essential because PCP can pool in gastric contents, and should
be continued well past the point of awakening from coma. The
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excretion of PCP is variable and prolonged. Ten days to two weeks
of further acidification using cranberry juice is indicated,
because of remaining body stores of PCP.
If medical treatment is successful, the patient’s coma will lighten,
only to be replaced, frequently, by delirium, paranoia, and violent
assaultiveness. This may occur at the same time as life-support
measures are still necessary, requiring constant attention from
the medical staff so that intubation and intravenous lines remain
open and intact. Any patient in whom coma is followed by a pro-
longed period of confusion should, as recommended by Burns and
Lerner (1978) have a psychiatric consultation prior to discharge
to evaluate residual paranoia or potentially suicidal depression.
PCP Psychosis
a. Diagnosis
Some patients experience a psychotic phase which lasts from several
days to several weeks despite abstinence from further PCP. The
psychosis may occur after single doses of PCP. Luisada (this
volume) divides these psychoses into three stages, each lasting
several days: the initial stage, characterized by violent psy-
chotic behavior; the second stage, with restless but more con-
trolled behavior and a lessening of delusional activity; and the
final stage, characterized by rapid improvement of thought dis-
orders and amelioration of paranoia.
It should be emphasized that this psychotic stage may be the first
stage at which the patient enters treatment, often through a
psychiatric hospital emergency room rather than a general medical
hospital emergency service. The PCP user may at this point be
misdiagnosed as schizophrenic, especially if a drug history is
unavailable or inaccurate. He may or may not have passed through
an earlier stage of reduced consciousness or coma in the company
of friends or by himself, but presents with a psychotic-like
picture of confusion, incoherent speech, paranoia, assaultiveness,
restlessness, autism, preoccupation, mutism, auditory halluci-
nations, and grandiosity. An erroneous diagnosis of schizophrenia
does not complicate his or her immediate treatment, which is much
the same for acute schizophrenia, but labels him with a diagnosis
which may be quite inappropriate and misleading for future medical
contacts.
b. PCP psychosis - a psychiatric emergency
Phencyclidine psychosis constitutes, in this initial phase, a
psychiatric emergency, one often misidentified (in St. Elizabeth’s
hospital in Washington, D.C., PCP psychosis actually became for
two years the leading cause of inpatient psychiatric admission,
outstripping both schizophrenia and alcoholism). The patients
are dangerous to themselves, because of depression and suicidal
impulses, and dangerous to others, because of paranoia and strong
tendencies toward violence. For patients fitting this description,
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psychiatric inpatient treatment is indicated. Voluntary hospitali-
zation is seldom acceptable to the hostile, suspicious patient.
The immediate goals of treatment for this acute PCP-induced psy-
chosis (Luisada, this volume) are:
1. prevention of injury to the patient or others
2. assurance of continuing treatment
3. reduction of stimuli
4. amelioration of psychosis
5. reduction of agitation
c. Treatment of PCP psychosis
In treating the psychosis, most clinicians prefer to use
haloperidol, 5 mg IM given hourly if needed, to avoid the
possibility of potentiation of PCP anticholinergic effects by
a phenothiazine. Chlorpromazine is also effective, but prior to
instituting any phenothiazine treatment of a psychotic patient
with a history of PCP use, it is essential to determine whether
the patient is still intoxicated with PCP. The patient should
be examined for the presence of nystagmus and ataxia, which, if
present, indicate intoxication. The pupils should also be examined
to guard against anticholinergic drug intoxication. If there is
no possibility of continuing intoxication by a cholinergic drug,
chlopromazine may be given instead, starting with 400 mg/day
orally in divided doses (after a test dose of 50 mg) and increased
as necessary by 200-600 mg/day. On the average, a daily dose of
1600 mg/day of chlorpromazine will be reached by the end of the
initial phase of treatment. The response of PCP psychosis to this
aggressive treatment is characteristically slow, distinguishing
it from paranoid schizophrenia, which usually responds much more
rapidly.
As the psychotic symptomatology abates, there are sometimes un-
predictable reexacerbations. Patients will often wish to sign
out against medical advice, with encouragement from others to do
so, only to experience unexpected suicidal or homicidal impulses
following their discharge (the patient may still not realize,
because of drug-induced amnesia, that PCP was responsible for his
hospitalization). When feasible, group and milieu psychotherapy
can help.
Outpatient follow-q treatment is aimed at keeping the patient
away from resuming drug use, a task which is not always easy des-
pite the dysphoria associated with the experience which led to
hospitalization. Luisada and Brown (1976) make the provocative
observation that “about one-fourth of the patients originally
treated for phencyclidine psychoses return about a year later
with schizophrenic ones in the absence of drug use. . . These
later episodes have lacked the characteristic violence of the
phencyclidine-induced ones, and they have been much more quickly
responsive to antipsychotic drugs.” Thus, some of the users who
became psychotic under PCP may have been “at risk” for schizophre-
nia, which later reappeared without the precipitating drug. (Some,
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in fact, may have been identifiably schizophrenic prior to using
the drug.)
Profound depression is experienced by significant numbers of users
(not just overdose cases). They must be followed carefully to
monitor their suicidal potential (Smith et al. 1978).
PHENCYCLIDINE -- THE UNANSWERED QUESTIONS
Our present knowledge of phencyclidine as an abused drug is de-
cidedly modest. Indeed, as was pointed out earlier in this account,
even the basic data pertaining to the incidence and prevalence
of its abuse are largely lacking. What information is available
represents a minimal estimate of both the extent of PCP use and
of possible adverse effects of such use. Since PCP is often
misrepresented as some other drug, inquiring about its use is
certain to represent an underestimate of such use, especially
by the less chronic user. And, as we have seen, the individual
who suffers from a schizophrenic-like reaction to the drug is
likely to be diagnosed as an acute schizophrenic reaction rather
than as a toxic drug reaction.
Our understanding of the personality characteristics of more
chronic users and the effect that phencyclidine has on their
lives is also limited. For example, there is some question whether
or not the acute schizophreniform reaction sometimes encountered
in users may not be indicative of a latent schizophrenia precipi-
tated by the drug. Similarly, we know little of the frequency and
circumstances under which PCP potentiates aggression, although
there have been many individual clinical reports of highly destruc-
tive behavior related to drug use.
Although it is believed that PCP ultimately results in “burned
out,” dulled intellectual functioning after repeated use, this
has yet to be verified objectively. Besides possible adverse
effects on intellectual functioning, phencyclidine may also dis-
rupt psycho-social functioning in ways that remain to be delineated.
Because it is widely used during adolescence, it is especially
important to assess its possible effects at this age.
A still puzzling paradox not yet fully explained is the apparent
increase in PCP use in recent years despite a continued poor
street reputation of the drug. This increased popularity may
reflect the improved ability of the user to avoid overdose when
the drug is smoked or snorted rather than taken orally, the desir-
ability of simply changing one’s state (Cf. Mello, this volume),
the marked increase in PCP availability or some combination of
these and possibly other factors as well. Despite speculation,
the motives for use of phencyclidine remain poorly understood.
Lasting biological implications of use and especially of chronic
use arc largely unknown. These include possible reproductive
effects of PCP use as well as possible alterations in neurophysio-
logical functioning that may be related to prolonged use. While
15
higher doses of this drug are unquestionably incapacitating, much
less is known about the effects of lower doses which may be more
typical of recreational use, especially when the drug is smoked.
Thus the wide range of possible dose response relationships involving
PCP needs elucidation. Carefully designed experiments which investi-
gate the relationships between dose, tissue and fluid levels,
and pharmacological and behavioral effects of PCP and its analogs
should be conducted in man where medically and ethically possible.
Since PCP is often used in association with such other drugs as
alcohol, marihuana, and the barbiturates, it is important to know
the effects of such combinations. For example, doses of alcohol
or PCP which are not seriously toxic alone may become so when both
drugs are taken concomitantly.
Similarities and differences between PCP and other abused sub-
stances can be evaluated in animals with sensitive behavioral
techniques. Behavioral and drug-specific variables which contri-
bute to the initiation and maintenance of PCP self-administration
should be studied. The effects of PCP on a wide range of behaviors
(e.g., aggression, punishment- induced conflict, cognitive function
and sensory discrimination) remain to be investigated. The long
term behavioral- toxicological consequences of phencyclidine admini-
stration should be examined in these contexts.
Unfortunately , phencyclidine has about 30 analogs -- drugs with
slightly different chemical structures which nevertheless have
similar effects. Little is known about the similarities or
possible differences in effects between these compounds and PCP.
Recent attention to the detection and quantification of phencyclidine
in biologic samples has provided valuable techniques, which are
based on standard and existing methods. These must be made
readily available for clinical and research purposes. There is
considerable need for detailed information on the metabolism,
disposition, and pharmacokinetics of phencyclicline and its analogs
in acute and chronic situations. This must in turn be matched
with carefully gathered clinical data and used to improve treat-
ment methods for overdoses.
Finally it is important that we develop effective prevention
strategies to discourage PCP use. In the past, some success has
been obtained in discouraging the use of other drugs by making
widely known their harmful effects.
would not seem to work with PCP.
Unfortunately this approach
The dangers of its use -- both
short and long term -- are apparently quite well known to its
users. We will have to understand the reasons for its use and
the most effective ways to reach and dissuade the user. These
goals become particularly important for a drug, or family of
drugs, whose street availability cannot be substantially diminished
by means presently known.
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Chapter 2
Neurobiology of Phencyclidine–An Update
Edward F. Domino, M.D.
INTRODUCTION
About 22 years aqo I was on a plane flying from San Francisco to
Detroit. On the same plane was Dr. A.C. Bratton, at that time the
Director of Pharmacological Research at Parke Davis Laboratories
in Detroit. It took about six hours to fly across the country so
we had much to talk about but especially about a fascinating com-
pound that they had just discovered (Chen et al. 1959). Dr.
Bratton said that in rodents it was amphetamine-like but it also
made them drunk and ataxic. In dogs the chemical caused yelping
and convulsions. Monkeys were beautifully "tranquilized" and in
larger doses anesthetized by this agent. The Parke-Davis research
staff was confused. They really did not know what to do with this
compound. They were wondering whether they should take it into
man or drop it. Would I be interested in taking a look at it? My
response was positive and we did take a preliminary look at the
compound. Our initial studies were in the Macaca mulatta monkey.
In this species the agent was remarkable! It caused serenity,
hence the trade names Sernyl or Sernylan. As far as I was con-
cerned, it was the best anesthetic agent I had ever seen for the
monkey. It appeared to be very safe compared to other general
anesthetics. So remarkable was this state of anesthesia that a
decision was made to file this new drug, whose code number was
CI-395 and which was subsequently called phencyclidine, with the
Food and Drug administration. Greifenstein, in Anesthesiology at
Detroit General Hospital and Wayne State University, was asked to
test it as a general anesthetic in patients. This he did (Greifen-
stein et al. 1958). He was so amazed at the remarkable anesthetic
state it induced that with Meyer in Neurology at Wayne State
University, he concluded that phencyclidine produced sensory dep-
rivation (Meyer, Greifenstein and De Vault 1959). At that time
Luby, also from Wayne State, was studying sensory deprivation as
a model of schizophrenia at the Lafayette Clinic. After he heard
about phencyclidine, he decided to compare it to actual sensory
deprivation in both normals and schizophrenic patients (Luby et
al. 1959). Luby was so impressed with the findings that he recom-
mended to Jacques Gottlieb, then Director of the Lafayette Clinic,
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that I be asked to be their pharmacological consultant, for he
knew that I had done some of the animal studies with this drug.
So began my clinical introduction to phencyclidine and a long and
fruitful association with the Lafayette Clinic.
In 1964, when we reviewed the neurobiology of phencyclidine (Domino
1964) it impressed us that the development of a new drug provides
the pharmacologist and clinician with a number of surprises. That
conclusion is even more true today. Who would, in their wildest
imagination, predict that a dissociative anesthetic, which pro-
duced a high incidence of anesthetic emergence phenanena and was
adrugwhichmimicked the primary symptoms of schizophrenia by
distorting body image, would become the number one drug of abuse
in the United States in 1978? Yet that is what the drug culture
of our country has acomplished with phencyclidine. Surely a
schizophrenomimetic drug in low dosage, and anesthetic and a con-
vulsant in large doses, would not seem to be reinforcing - yet
it apparently is to many people who now call it by many different
names, including PCP, synthetic THC, angel dust, hog, crystal,
animal tranquilizer, horse tranquilizer, peace pill, Pea Ce Pill,
crystal joint, CJ, KJ, sheet, and rocket fuel. People who abuse
phencyclidine have been called parsley monsters when the drug is
applied to parsley and smoked. Those who are "high" on phency-
clidine are said to be "crystalized." The drug is taken by in-
halation, orally, intranasally (snorted), and intravenously. Know-
ing what we now know, would any of us who were involved with the
early pharmacological birth and development of phencyclidine have
ventured further? What have we thought?
Depending on the dose and species, phencyclidine is a excitant or
a cataleptoid anesthetic. While it is an anesthetic in man, small
doses cause a rather remarkable psychotomimetic picture. Emergence
delirium is often seen. Phencyclidine and related compounds have
been called cataleptoid and or sympathomimetic anesthetics. Dur-
ing induction the patient often feels dissociated from his environ-
ment with analgesia and some amnesia.
A related congener of phencyclidine is ketamine, a valuable anes-
thetic agent used therapeutically throughout the world. Its anes-
thetic properties in humans were first described as representing
a new class of "dissociative" anesthetics because of its unique
pharmacological actions (Domino, Chodoff, and Corssen 1965; Corssen
and Domino 1966). During anesthesia, the patient may keep his
eyes open and seems "disconnected" from the environment. It seems
as if higher associational functions of the brain are markedly
depressed, a clinical impression for which there is some human
and animal physiologic data (Corssen, Miyaska, and Domino 1968;
Miyasaka and Domino 1968; Corssen, Domino, and Bree 1969; Winters
1972). During emergence from dissociative anesthesia, the patient
may go through a phase of vivid dreaming with and without psycho-
motor activity, manifested by confusion and irrational behavior.
Chemically, phencyclidine, ketamine and related compounds are
arylcyclohexylamines. While they have somewhat similar pharma-
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cological actions, they also have important differences,both
quantitatively and qualitatively. The major pharmacological
properties of these agents can be summarized as follows:
1. Central nervous systan
a. Small doses produce a "drunken" state with numbness of
the extremities; saw species are excited.
b. Moderate doses are analgesic and anesthetic.
C. The psychic state crudely resembles sensory isolation,
except that sensory impulses, if tested electrophysio-
logically, reach the neocortex but the neuronal signals
are grossly distorted.
d. Cataleptoid motor phenomena are seen.
e. barge doses may produce convulsions. This is especially
true of phencyclidine.
f. Marked species differences are present. Primates,espec-
ially man, are most susceptible to the depressant effects
which predominate.
2. Autonomic and cardiovascular system
a. Sympathomimetic.
b. Tachycardia.
C. Hypertension.
d. Potentiation of catecholmines through a cocaine-like
action.
CYCLOHEXYLAMINES ABUSED
To date, at leasts six cyclohexylamines have been either given to
or taken by humans in the context of drug abuse. Their chemical
structures are shown in figure 1.
Kalir et al. (1969) have provided us with the best structure-
activity studies of these compounds to date. Shulgin and MacLean
(1976) have described the illicit synthesis of phencyclidine and
several of its analogs as well as relative potency data of com-
pounds now available on the street.
As described above, the first arylcyclohexylamine studied in man
as a general anesthetic was phencyclidine (Greifenstein et al.
1958). It is longer acting and has stimulant and convulsant prop
erties in man. Ketamine (Ketalar, Ketaject) has more depressant
properties than phencyclidine and is shorter acting. It is used
as a nonbarbiturate anesthetic in man. When phencyclidine is
taken by humans, it produces more emergence delirium, in which
some patients show post anesthetic psychiatric complications for
as long as two weeks after a single dose. Although phencyclidine
is no longer used as a general anesthetic in man, it is still a
veryusefulanesthetic in veterinary medicine, especially for
primates (Domino, McCarthy, Deneau 1969).
Widespread use of phencyclidine as a psychedelic agent by the
drug subculture in the United States is now generally acknowledged.
The early warning drug network (DAWN) has emphasized that phen-
cyclidine has been a major drug abuse problem for same time. One
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FIGURE 1
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of the clinical problems associated with phencyclidine overdosage
is that the patients not only may be in coma but they may also
convulse and die of respiratory arrest. The prolonged emergence
delirium is observed in patients who may be psychotic for at
least several weeks or more. This may be due to metabolic or
psychiatric variables such as pre-morbid or borderline schizophrenia.
The clinical toxicology of phencyclidine is of such importance
that an entire issue of Clinical Toxicology in August of 1976
was devoted to it (Burns and Lerner, Guest Editors, 1976).
If one has a vivid imagination, there is a structural relation-
ship between phencyclidine, amphetamines and LSD-25. I have
drawn 2-methoxyamphetamine and phencyclidine to approximate the
A and C rings of LSD-25 as shown below:
2-Methoxyamphetamine Phencyclidine
NEUROCHEMISTRY
The most recent review of the neurochemical pharmacology of phen-
cyclidine is by Johnson in this monograph. Our own interests in
this area may provide an additional point of view and will be an
update of our own brief review (Domino and Luby 1973).
A. Monoamines, Especially Catecholamines and Serotonin.
Because of the structural similarities, one would expect phency-
clidine to interact with the monoamines in the body, especially
the catecholamines (CA) and 5-hydroxytryptamine (5-HT). Chen and
his associates (1959) compared the sympathomimetic effects of
phencyclidine with cocaine and desoxyephedrine. They concluded
that it had similarities to both drugs, especially cocaine.
O'Donnell and Wanstall (1968) studied the action of phencyclidine
on the perfused rabbit ear. They postulated that phencyclidine
inhibited the uptake of both norepinephrine (NE) and tyramine by
adrenergic neurons in a manner similar to that of cocaine. High
concentrations of phencyclidine (Ki = 1.5 x 10-4M), like many
other psychotropic drugs, inhibit monoamine oxidase (MAO) activity
but this does not appear to be significant in relation to its
in vivo actions (Usdin and Usdin 1961).
The effects of phencyclidine on the pressor responses to norepine-
phrine (NE), epinephrine (EPI), and serotonin (5-HT) in the pento-
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barbital-anesthetizeddog are consistent with a cocaine-like
action as illustrated in figure 2 below.
Note that 0.5 mg/kg of i.v. phencyclidine itself produces an
initial transient hypertensive response which is probably related
to peripheral CA release. Ketamine produces a similar hyperten-
sive response but apparently has less of a cocaine-like potenti-
ating action than phencyclidine.
Tonge and Leonard (1969) compared the effects of phencyclidine,
Ditran, mescaline and LSD-25 on rat brain 5-HT, 5-hydroxyindole-
acetic acid (5-HIAA), MAO and aromatic amino acid decarboxylase
activity. All four drugs in doses larger than those heeded for
behavioral effects increased brain 5-HT and decreased 5-HIAA over
a three hour period. Phencyclidine reduced 5-HT depletion after
reserpine and para-chlorophenylalanine. It had no effect on the
associated 5-HT enzymes. Tonge (1971) later pointed out that
this effect was dependent on the source of rats. Tonge and
Leonard (1970) found a small reduction in brain and plasma try-
ptophan levels after a small dose of phencyclidine. A parallel
study of these same investigators (Leonard and Tonge 1969) showed
that all four drugs decreased rat brain NE and slightly elevated
brain dopamine (DA). The fall in brain NE paralleled the time
course in the rise in 5-HT. Phencyclidine increased the degree
of depletion of NE by reserpine. All four psychototmimetic agents
increased the depletion of NE and DA by alpha-methyl-metatyrosine,
but strangely had no effect on depletion of these catecholamines
by alpha-methyl-paratyrosine. Normetanephrine brain levels were
unaffected by phencyclidine and LSD-25 or were decreased slightly
by Ditran and mescaline, indicating that the decrease in NE was
not due to enhanced release. Their assay for normetanephrine
was not very sensitive. In a subsequent study, phencyclidine was
shown to reduce normetanephrine levels in the fore- and hindbrain,
indicating decreased NE release from adrenergic neurons (Tonge
and Leonard 1972). Brain and plasma tyrosine are elevated after
a small dose of phencyclidine (Tonge and Leonard 1970). In the
mouse, Hitzemann, Loh, and Domino (1973) showed decreased 14C-NE
and 14C-DA levels after an intracerebral injection of 14C-tyrosine
after phencyclidine. An increase in 14C-3-methoxytyramine and
14C-normetanephrine was noted. In the mouse striatum phencyclidine
does not significantly change homovanillic acid levels (Sharman
1966).
Sung, Frederickson, and Holtzman (1973) have shown that 40 mg/kg
of ketamime increased the turnover of DA and decreased the turn-
over of 5-HT in rat brain four to six hours postinjection, al-
though the behavioral effects lasted only two to three hours.
The cocaine-like actions of phencyclidine have also been reported
for ketamine. Miletich et al. (1973) have shown that ketamine
prevents the neuronal reuptake of NE in rat heart.
Leonard and Tonge (1968, 1970) looked at other putative neuro-
transmitters in the rat brain following phencyclidine. They found
no changes in whole brain acetylcholine, cholinesterase and
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FIGURE 2
Effects of phencyclidine on the arterial blood pressure responses
of norepinephrine, epinephrine, serotonin in the pentobarbital
anesthetized dog.
Each agent was given us a bolus i.v. injection at 5-10 minute
intervals. Note the cocaine-like action of phencyclidine to
enhance the pressor responses of the CA in contrast to 5-HT where
the effects are more variable.
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histamine. However, a high dose of phencyclidine decreased brain
GABA They also found an increase in 5-hydroxytryptamine decar-
boxylase activity. In a preliminary study, Tonge (1973) found
that chronic phencyclidine during the pre- and post-neonatal
periods produced elevated 5-HT levels in the rat hypothalamus
and pons-medulla.
B. Acetylcholine
There have not been enough studies on the complex effects of the
arylcyclohexylamines on the cholinergic system. In vitro phency-
clidine (5 x 10-5M) inhibits primate serum cholinesterase using
benzoylcholine as substrate (Becker 1969). In humans, the usual
and fluoride variants of serum cholinesterase are inhibited by
phencyclidine whereas the dibucaine variant shows increased resis-
tance. This differential inhibition suggests that phencyclidine
is useful in estimating human genotypes for cholinesterase. Appar-
ently, phencyclidine and acetylcholine have similar charge distri-
butions in relation to muscarinic cholinergic receptors (Weinstein
et al. 1973; Paster et al. 1974; Maayani et al. 1974). This would
account for phencyclidine having an atropine-like effect. However,
phencyclidine not only inhibits serum or butyrylcholinesterase,
it also inhibits acetylcholinesterase with a larger Ki (about 80
times greater). These mixed agonist and antagonist actions of
phencyclidine tend to antagonize each other. However, the alge-
braic sum of the actions of phencyclidine on guinea pig ileum is
predominantly antagonistic (Maayani et al. 1974). Amazingly, in
mice, scopolamine has been reported to prevent tolerance develop
ment to cyclohexamine (Pinchasi, Maayani and Sokolovsky 1977).
Ketamine is also reported to inhibit both serum butyrylcholines-
terase (Schuh 1975) and brain acetylcholinesterase (Cohen et al.
1974). Although in large doses phencyclidine has been reported
to elevate slightly brain ACh (Giarman and Pepeu 1962), Leonard
and Tonge (1968, 1970) and Domino and Wilson (1972) have shown
that smaller but behaviorally effective doses do not alter total
ACh levels. Phencyclidine also increases the depletion of rat
brain ACh after hemicholinium-3, suggesting an increased utiliza-
tion of ACh in smaller doses. Like LSD-25, phencyclidine does
not significantly alter the release of ACh fran the cat cerebral
cortex in contrast to the isomers of Ditran, which increase ACh
release, and general anesthetics like pentobarbital which decrease
ACh release (Domino and Bartolini (1972). Ngai, Cheney and Finck
(1978) measured regional ACh and Ch concentrations in the brains
of rats given halothane, enflurane and ketamine as well as the
turnover rate of ACh in vivo. ACh concentrations in various
brain areas did not change during anesthesia with any of the
anesthetics studied. This is noteworthy in itself because keta-
mine in vitro is a cholinesterase inhibitor (see above). Yet
in vivo steady state levels of ACh were not elevated, as would
be expected. During anesthesia with ketamine, ACh turnover rates
were reduced in the caudate nucleus and hippocampus, but not in
the cerebral cortex, thalamus and hypothalamus. Halothane de-
creased ACh turnover in all of the brain regions while enflurane
only decreased ACh turnover in the cortex. These investigators
25
felt that the changes in ACh turnover were related to known anes-
thetic-induced electrophysiologic changes in cortical and sub-
cortical structures.
C. Energy production
Phencyclidine has still other effects on the enzymes involved
with energy production. In vitro phencyclidine (5 x 10-4M) is
an uncoupler of oxidative phosphorylation (Lees 1962, 1968). The
drug in vitro increased rat liver mitochondrial respiration in
low concentrations and depressed it in high concentrations.
ATPase activity was stimulated and the inorganic phosphate-ATP
exchange reaction inhibited. These in vitro effects of phen-
cyclidine onrespiration, ATPase activity,and the inorganic
phosphate-ATP exchange reaction were crudely similar to-those
of chlorpromazine except higher concentrations of phencyclidine
were required. Only in even greater concentrations was the drug
inhibitory.
NEUROPHYSIOLOGY
It is clear that phencyclidine produces its own unique EEG; changes
in nomal humans. Van Meter, Owens and Hinwich (1960) using rab-
bits provided evidence that phencyclidine acts on the cerebral
cortex. Our own studies (Domino 1964; Miyasaka and Domino 1968)
also implicate a thalamo-cortical action of phencyclidine and its
congener, ketamine. Adey and Dunlop (1960) have pointed out
that phencyclidine and cyclohexamine in cats suppresses or
seriously interferes with learned approach in a T-maze situation.
This was correlated with EEG; spikes and abolition of normal hippo-
campal activity. After these drugs stimulation of the thalmic
nucleus ventralis anterior failed to elicit nomal hippocamal
theta wave activity. Drug-induced changes in the reticulo-corti-
cal system were also seen, but the hippocampal changes were
especially apparent. Winters et al. (1967) compared the EEG;
effects of phencyclidine in cats with other general anesthetics.
They suggested that hallucinatory and epileptoid phenomena as
well as general anesthesia were in part a continuum with reticular,
thalamic, cortical and hippocampal alterations, depending upon
the class of drugs studied. Winters and Ferrar-Allado (1972)
showed that ketamine induced a catatonic state in cats which was
accompanied by intermittent or continuous hypersynchronous dis-
charges from the cortex, limbic structures and the medial genicu-
late nucleus. An especially provocative viewpoint was expressed
by Winters (1972) When he suggested ketamine was causing epilepsy
instead of anesthesia in man. This point of view has been criti-
cized by Corssen, Little, and Tavakoli (1974) and Domino (1974).
Nevertheless, Winters and his colleagues have documented exten-
sively the stimulant and convulsive properties of both phen-
cyclidine and ketamine, especially in animals. There is no ques-
tion that given enough of each of these substances in an appropri-
ate species, convulsions are seen. This is well documented in
human overdosage With phencyclidine in particular. The extensive
studies of Winters as well as a review of the literature on the
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neuropharmacology of anesthetics were recently summarized by him
(Winters 1976).
Phencyclidine effects on the EEG; of chronic schizophrenics, both
lobotomized and not, were studied by Itil et al. (1967). While
the two groups showed symptoms to 0.05 mg/kg of phencyclidine
given over a 5 minute period, the lobotomized patients showed
much less alteration to both clinical symptoms and the alpha
frequency decrease in the EEG. These investigators concluded
that the inability of lobotomized patients to exhibit marked
phencyclidine effectsin comparison to the nonlobotamized patients
was because thalamcortical integrative mechanisms are necessary
to produce typical phencyclidine responses. Fink (1969) reviewed
the effects of phencyclidine along with many other psychoactive
compounds on the human EEG. Stockard et al. (1975) have reported
that the unusual delta wave activity followed by low voltage fast
wave activity we have previously reported in the monkey was ob-
served in a 25 year old male patient who inhaled a rather large
amount of "angel dust." His serum phencyclidine levels were
reported as being 0.34 µg/ml. These investigators reported simi-
lar EEG; changes due to 2 to 4 mg/kg of ketamine given intra-
venously. They suggested that these EEG manifestations of
diffuse monorhythmic theta activity with superimposed periodic
events should raise the suspicion of cyclohexylamine intoxication
in comas of unknown etiology. It is not known if the other cyclo-
hexylamines besides phencyclidine and ketamine produce similar
EEG manifestations and whether these are correlated with plasma
levels.
BEHAVIORAL STUDIES
The meager animal and human behavioral studies available until
a few years ago were reviewed by us previously (Domino 1964;
Domino and Luby 1973). Since then, the behavioral pharmacology
of phencyclidine has been reviewed by Balster and Chait (1976)
and again very recently (Balster and Chait, this monograph). Es-
pecially important is the evidence that both phencyclidine (Balster
and Johanson 1973; Pickens, Thanpson and Muchow 1973) and ketamine
(Moreton et al. 1977) are self-administered by animals. In addi-
tion, drug discrimination studies indicate that phencyclidine,
cyclohexamine, and ketamine belong to a class of their own for
they do not transfer stimulus control to morphine, chloropromazine,
Ditran, 9-tetrahydrocannabinol or pentobarbital. It is especially
important to know whether in low dosage there is stimulus generali-
zation of phencyclidine to cocaine and amphetamine-like drugs and
in larger dosage to general anesthetics including nitrous oxide,
halothane and convulsants like phentylenetetrazol. Whether the
technical behavioral problems can be solved remains to be seen.
One extensive locomotor activity study using 5 mg/kg i.p. of
phencyclidine has been reported by Kanner et al. (1975). It was
previously known that phencyclidine produces increased locomotor
activity in mice which can be augmented by pretreatment with
iproniazide (Chen et al. 1959). Phencyclidine also enhances motor
27
activity in rats. Kanner et al. found that pretreatment with alpha-
methyl-paratyrosine (250 mg/kg, i.p.) decreased phencyclidine-
elicited activity by 43 percent (p < .05) in one hour. Iproniazid
(100 mg/kg, i.p.) increased phencyclidine-elicited activity by
61 percent. Pretreatment with phenoxybenzamine (10 mg/kg, i.p.)
decreased phencyclidine-elicited activity by 85 percent (p < .05)
while pretreatment with propranolol (25 mg/kg, i.p.) increased
phencyclidine-elicited activity by 56 percent (p < .05). Pimozide
(1 mg/kg, i.p.) decreased phencyclidine-elicited activity by 57
percent (p < .05) while haloperidol (0.5 mg/kg) decreased phen-
cyclidine-elicited activity by 90 percent (p < .05). Trihexy-
phenidyl (5 mg/kg, i.p.) and atropine (10 mg/kg, i.p.) signifi-
cantly increased phencyclidine-elicited activity by 93 percent
and 43 percent, respectively, while arewline (10 mg/kg, i.p.) and
physostigmine (0.4 mg/kg, i.p.) decreased phencyclidine-elicited
activity by 23 percent and 61 percent, respectively. Their data
indicate that the stimulation of locmotor activity produced by
phencyclidine can be influenced by noradrenergic, dopaminergic,
and cholinergic inputs. The major criticism of this kind of re-
search is that most agonists and antagonists are known to alter
rat locomotor activity. Hence, interpretation of such findings
is must difficult and probably not very rewarding fran a thera-
peutic point of view.
Perhaps the most important behavioral study that must be done is
to answer the question, why do animals and people take these drugs?
Why is it reinforcing to mimic the primary symptoms of schizophrenia,
to be in coma, convulse, and maybe die from overdosage? I cannot
imagine that being a "parsley monster" or being "crystalized" is
really very wonderful.
BIOTRANSF0RMATION AND PHARMACOLOGICAL ACTIVITY OF METABOLITES
The biotransformation of phencyclidine is just beginning to be
understood. Some of the proposed matabolites of phencyclidine
are shown in figure 3 below.
FIGURE 3
Some Metabolites of Phencyclidine
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Lin et al. (1975) have described some of the metabolities of phen-
cyclidine they found in urine of intoxicated human patients. Two
conjugated hydroxylated compounds were found. These were 1-(1-
phenyl-4-hydroxycyclohexyl)-piperidine (4-OH cyclo PCP) and 1-(1-
phencyl-cyclohexyl)-4-hydroxylpiperidine (4-OH pip PCP). In addi-
tion, a dihydroxylated metabolite tentatively identified as 1-(1-
phencyl-4-hydroxy-cyclohexyl)-4-hydroxy piperidine has been found
in monkey urine. Wong and Biemann (1975) have reported that 1-
phenycyclohexylamine is also a metabolite of phencyclidine in man
and mouse. The findings of Lin et al. are in partial agreement
with those of Ober et al. (1963), who reported that monkeys ex-
crete mainly the dihydroxy metabolite. In their preliminary re-
port, they stated that the dihydroxy metabolite did not have any
phencyclidine activity. Our own studies (Domino 1978) indicate
that both 4-OH cyclo PCP and 4-OH pip PCP have biologic activity
in both the rat and dog. one would expect the hydroxylated de-
rivatives of phencyclidine to be more water soluble and to pene-
trate the blood-brain barrier less. Although these compounds 
are less potent than phencyclidine, they apparently cross the
blood-brain barrier in sufficient amounts, for they have important
convulsant components. Hence they may play a role in phencyclidine
overdosage in man. Much more work is obviously needed to deter-
mine not only the detailed biotransformation of phencyclidine but
also the pharmacological properties of its metabolites.
The biotransformation of ketamine is also imcompetely understood.
The scheme proposed by Chang and Glazko (1974) is given in figure
4.
FIGURE 4
Biotransformation Pathway of Ketamine, proposed by Chang and Glazko
1974
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Our own proposed scheme is based on that of Chang and Glazko (1974)
but introduces a further order of complexity, as shown in figure
5.
FIGURE 5
One should realize how meager is our knowledge of the pharmacology
of each of these proposed metabolites. In most cases, they need
to be synthesized and studied further.
CHEMICAL ANALYSIS
Phencyclidine has been analyzed chemically from biological samples
using both qualitative and quantitative techniques. Thin layer
chromatography, gas chromatography, and gas chromatography-mass
spectrometry and radioimmunoassays have been used. Hawks and
Willette (1977) briefly reviewed these methods with the exception
of the radioimmunoassay procedure developed by Kalir et al. (1976).
The latter seems very pranising but unfortunately, has not attrac-
ted any interest in the United States to date.
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From a practical point of view, the most available quantitative
procedures in the United States at this time involve gas chroma-
tography using a flame ionization detector or combined gas chroma-
tography-mass spectrometry using either electron impact or chemical
ionization. Reynolds (1976) and Marshman, Ramsay, and Sellers
(1976) have employed gas chromatographic techniques for the
quantitative assay of phencyclidine from urine, tissues, and
plasma. Reynolds used ether extraction of the urine with OV-1
and OV-17 GLG columns at a temperature of 180°C. The tissue
and blood samples were prepared with 0.5 N HCl. Mepivicaine was
used as the internal standard. After strong alkalization, phen-
cyclidine was extracted with chloroform and assayed as above.
Marshman, Ramsay, and Sellers used a similar assay except that
ketamine was the internal standard. In addition, 3.8 percent
UCW-98 on Gas Chrom Q at a temperature of 200° C was used. Gupta
et al. (1975) used methadone as the internal standard for phen-
cyclidine in human urine using Chromasorb W coated with Apiezon
L at 200°C. Finkle's gas chromatographic method (quoted by
Hawks and Willette 1977) uses SKF 525A as the internal standard
using a 3 percent OV-1 or OV-17 with a column temperature of 130-
270°C. It should be noted that these investigators all used
column and/or injection port temperatures of 200°C or above. We
know now that phencyclidine undergoes thermal decomposition to 1-
phenylcyclohexene at temperatures above 150ºC (Lin et al. 1975;
Wong and Biemann 1975, 1976). These investigators recommend tem-
peratures below 200°C for quantitative purposes.
Obviously, the most specific assays involve the use of gas chro-
matographic-mass spectrometric methods using a stable isotope as
the internal standard (MacLeod, Green and Seet 1976; Pearce 1976;
Lin et al. 1977). We have modified the gas chromatographic-mass
spectrometric chemical ionization assay of Lin et al. (1975) for
electron impact (Wilson and Domino 1978). Phencyclidine was de-
termined by gas chromatography-mass fragmentography in six dogs
and seven monkeys. Aliquots of venous blood were taken over 4
hours in the monkey after 1.1mg/kg and over 24 hours in the dog
after 1.0 mg/kg of phencyclidine, i.v. Pentadeuterated phency-
clidine was used as the internal standard. In the electron impact
mode the most abundant fragments in the mass spectrum of phency-
clidine were m/e 91 and 200, and. 96 and 205 in the deuterated
phencyclidine spectrum. These fragments were used to quantify
the amount of phencyclidine present. In both species, a complex
exponential decline of plasma phencyclidine was found in sane
animals that fit a two or three compartment open model. In monkeys,
the mean biological half life (B phase) was 2.03 hours and in the
dog it was 2.1 hours. Compared to the monkey, the dog exhibited
considerable emergence delirium. The two species had rather dif-
ferent pharmacokinetics, which may be relevant to the observed
differences in degree of anesthesia and recovery.
After our initial analytic successes with phencyclidine, we sub-
sequently developed a highly sensitive and specific method for
quantitation of ketamine and two of its metabolites in dog, mon-
key and human plasma using gas chromatography-mass spectrometry
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operated in both electron impact and chemical ionization modes.
CL-394, the bromo analog of ketamine, was used as the internal
standard. We compared these two assays with the gas chromato-
graphic, electron capture assay of Chang and Glazko (1972). Cur
results were in complete agreement. However, when dealing with
a limited amount of sample, the mass fragmentography assay was
superior. We concluded that the use of gas chromatography, elec-
tron capture for routine plasma analyses was adequate for ketamine
and barely satisfactory for ketamine metabolite I. However, for
ketamine metabolite II mass fragmentography was essential for the
small amounts in plasma. For urine analyses, gas chromatography,
electron capture is quite satisfactory and we recommend it for
routine assays (Lau and Domino 1977).
THERAPEUTIC CONSIDERATIONS OF PHENCYCLIDINE OVERDOSE
In our earlier studies in animals (Domino 1964), it was apparent
that the behavioral effects of phencyclidine were potentiated by
chlorpranazine. Although some of the cardiovascular effects were
antagonized by chlorpromazine, others were not. Hence, chlorpro-
mazine was certainly not useful in treating phencyclidine over-
dosage in man, at least not during the state of acute intoxica-
tion. Our subsequent studies in rat and dog (Domino 1978) in-
dicated that diphenhydramine, droperidol, diazepam, tetrahydro-
aminoacridine (a cholinesterase inhibitor like physostigmine),
physostigmine and scopolamine were not very useful antagonists.
The status of naloxone as an antagonist is confusing at the moment,
for it recently has been shown to antagonize the locomotor stimu-
lant effects of both nitrous oxide and ketamine in mice (Hynes
and Berkowitz 1978) as well as to potentiate the hypersensitivity
effects of phencyclidine on electroshock in rats (Markowitz and
Komestsky 1978).
At present we have no specific antidotes to phencyclidine. Ob-
viously much more needs to be done in this area.
Our development of a quantitative gas chromatographic-mass spec-
trometric assay for both phencyclidine and ketamine led to some
very interesting clinical studies. The first relates to phen-
cyclidine. A number of years ago one of my graduate students,
Lindsay Hough, and my Research Associate, Ann Wilson, decided
to measure the pKa of phencyclidine at room temperature. It
turned out to have a pKa of about 8.5. We really need sameone to
measure again the pKa of this and related compounds. Verbal com-
munications to me of the pKa of phencyclidine have varied from
8.5 to 9.5.
As shown in figure 6 below, the degree of ionization of this com-
pound varies as a function of its pKa and pH.
Pharmacologists for years have stressed the importance of urinary
pH as a functionof the amount of an ionized drug excreted. The
ionized form of a chemical does not readily cross the kidney
tubules unless there is a specific transport system for it. Hence,
32
basic drugs are ionized in an acid medium and acidic drugs in an
alkaline medium. The urinary excretion of basic substances such
as nicotine and amphetamines is enhanced in an acid urine and
that of acidic drugs such as the barbiturates in an alkaline
medium. Although urinary acidification is not the treatment of
choice for nicotine or amphetamine poisoning, there is no doubt
that this technique is of value, especially in amphetamine over-
dosage. Hence, this technique should work for phencyclidine.
Our task was to prove it with our new phencyclidine assay. Urinary
samples fran phencyclidine overdosage cases were obtained from
both our own University Hospital in Ann Arbor and from Children's
Hospital in Detroit. An account of our experience with the first
cases from University Hospital was recently published (Domino
and Wilson 1977) and that from Children's Hospital (Done et al.
1977; Aronow and Done 1978; Aronow, Miceli, and Done 1978; Done,
Aronow, and Miceli 1978). There is no doubt that acidification
of the urine results in enhanced phencyclidine levels, as shown
in table 1 for one of our patients from the University Hospital.
FIGURE 6
Percent Ionization of Phencyclidine at Room Temperature
as a Function of pH
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TABLE 1
EFFECTS OF pH ON HOURLY URINARY EXCRETION OF PHENCYCLIDINE IN
A COMATOSE PATIENT
Urinary pH Range pH PCP Urine Volume Total PCP
µg/ml ml/hr Excretion
in µg/hr
5.0-5.9 5.3
5.8
5.6
5.7
5.3
5.4
5.5
5.7
Mean 5.5
± SE ±.1
6.0-6.9 6.4
6.4
6.5
6.0
6.5
6.0
6.0
6.0
Mean 6.2
± SE +.1
P Value <.001
7.0-7.9 7.5
7.5
7.2
7.3
7.5
7.9
7.9
7.6
Mean 7.5
± SE ±.1
P Value <.001
4.348
.558
.812
.799
.750
.767
.910
.426
1.171
±.457
300
520
280
320
350
650
450
450
415
+45
2.089 160
.863 40
.151 1200
.223 700
.167 550
.189 700
.255 450
.302 675
.503 559
±.237 ±127
NS NS
.026
.OlO
.032
.036
.078
.036
.034
.102
.044
±.011
<.03
65
60
150
930
570
330
30
670
351
±119
NS
1304.4
290.2
227.4
255.7
262.5
498.6
409.5
191.7
430.0
+129.9
334.2
34.5
181.2
156.1
91.8
132.3
114.8
203.8
156.1
± 31.6
<.06
1.7
0.6
4.8
33.5
44.5
11.9
1.0
68.3
20.8
± 8.9
<.01
Group comparison "t" test of each set of urine values to the most
acid urine (pH 5.0-5.9).
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The patient was comatose for a period of time and had a great
deal of i.v. fluids pushed in order to promote diuresis. In ad-
dition, furosemide was periodically given, which accounts for
the occasional very large urine volumes obtained for the one
hour intervals. All samples were compared to the most acid urine
with a pH 5.0 to 5.9. It is abundantly clear that under acidic
urine conditions more free phencyclidine is excreted. Inaperiod
of 65 hours this patient excreted into the urine 9.46 mg of a
total of 500 mg or 1.9 percent of the phencyclidine ingested.
This suggests that the majority of this drug may be biotransformed
rather than excreted as the free base. Obviously careful quanti-
tative studies must be done in the future.
Aronow and Done believe that urinary acidification is a most
effective therapy of phencyclidine overdosage. There are many
ways to acidify human urine including ammonium chloride, ascorbic
acid, and very dilute i.v. infusion of hydrochloric acid. What
seems crucial is that the pH be at least 3 units away from the
pKa of phencyclidine to achieve 99.9 percent ionization, which
mans a urinary pH of 5.5 or less. This may be difficult to
achieve in some patients, which is why we had to resort to i.v.
techniques to acidify rapidly. Another very important fact is
that the marked skeletal muscle movements that occur during phen-
cyclidine overdosage in man can lead to profound increases in
serum creatinine phosphokinase and myoglobin in the urine. Meltzer,
Nankin, and Raftery (1971) reported that acute schizophrenic pa-
tients showed an increase in serum creatinine phosphokinase. This
is the isoenzyme of skeletal muscle. Phencyclidine in a biphasic
dose relationship markedly enhanced serum creatinine phosphokinase
increases produced by restraint stress in rats (Meltzer 1972).
Similar elevations in serum creatinine phosphokinase have been
observed by us in documented phencyclidine poisonings that have
been accompanied by acute rhabdomyolysis (Cogen et al. 1978). We
believe the skeletal muscle injury to be the result of excessive
involuntary isometric activity rather than a direct effect of
of phencyclidine on skeletal muscle. Our reasoning is that pa-
tients who do not have excessive skeletal muscle contractions but
still have toxic levels of plasma phencyclidine have much less
elevation of their serum creatinine phosphokinase. Skeletal
muscle restraints should not be used in patients with phencyclidine
overdosage unless the patients are very severe threats to them-
selves or others. This impression is supported by the study of
Goode et al. (1977) that limb restraint markedly elevates serum
creatinine phosphokinase and related muscle enzymes in normal
volunteers. It is our crude and preliminary impression that
acidification of the urine may reduce excessive muscular tonus
in phencyclidine overdosage, but this needs to be verified ex-
permentally. What urinary acidification, which is now widely be-
ing used, does to the pharmacological actions of phencyclidine
and its metabolism is unknown.
Diazepam reduces some of the unwanted cardiovascular and emer-
gence phenomena of ketamine when given as a pretreatment (Zsigmond,
Kelsch and Kothary 1976; Kothary and Zsigmond 1976). We have some
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unpublished observations that diazepam may elevate the plasma
levels of ketanine in man. Borondy and Glazko (1977) reported
that diazepam interferes with the biotransformation of ketamine
in the rat. Our dog studies with diazepam (Domino 1978) indicate
that it reduced the convulsions but may have enhanced the central
nervous system depression. Hence, unless convulsions are uncon-
trollable, diazepam would not seem to be indicated in phencyclidine
overdosage.
Until a specific antidote for phencyclidine found, those of
us dealing with overdose cases will have to be satisfied with
symptomatic therapy and urine acidification. However,having
helped in the birth and delivery of this drug, I will not rest
until that specific antagonist is found.
36
REFERENCES
Adey, W.R., and Dunlop, C.W. The action of certain cyclohexamines
on hippocampal system during approach performance in the cat. J
Pharmacol Exp Ther, 130:418-426, 1969.
Aronow, R., and Done, A.K. Phencyclidine overdose: An emerging
concept of management. J Amer Coll Emerg Phys, 7:56-59, 1978.
Aronow, R., Miceli, J.N., and Done, A.K. Clinical observations
during phencyclidine intoxication and treament based on ion
trapping. National Institute on Drug Abuse: Research Monograph
Series, Conference on Phencyclidine, February 1978.
Balster, R.L., and Chait, L.D. The behavioral pharmacology of
phencyclidine. Clin Toxicol 9(4):513-528, 1976.
Balster, R.L., and Johanson, C.E. Phencyclidine self-administra-
tion in the rhesus monkey. Pharm Biochem Behav, 1:167-172, 1973.
Becker, C.E. Sernylan inhibition of primate serum cholinesterases.
Clin Chem, Abst. #41:780-781, 1969.
Borondy, P.E., and Glazko, A.J. Inhibition of ketamine metabol-
ism by diazepam. Fed Proc, 36:938, 1977.
Burns, R. S., and Lerner, S.E. Perspectives: acute phencyclidine
intoxication. Clin Toxicol, 9(4):477-501, 1976.
Chang, T., and Glazko, A.J. A gas chromatographic assay for
ketamine in human plasma. Anesthesiology, 36(4):401-404, 1972.
Chang, T., and Glazko, A.J. Biotransformation and disposition of
ketamine. Int Anesthes Clin, 19(2):157-177, 1974.
Chen G., Ensor, C.R., Russell, D., and Bohner, B. The pharma-
cology of 1-(1-phenylcyclohexyl) piperidine-HCl. J Pharmacol
Exp Ther, 127:241-250, 1959.
Cogen, F. C., Rigg, G., Simmons, J.L., and Domino, E.F. Phencycli-
dine-associated acute rhabdomyolysis. Ann Int Med, 88:210-212,
1978.
Cohen, M.L., Chan, S.L., Bhargava, H.N., and Trevor, A.J. Inhibi-
tion of mammalian brain acetylcholinesterase by ketamine. Biochem
Pharmcol, 23:1647-1652, 1974.
Corssen, G., and Domino, E.F. Dissociative anesthesia: Further
pharmacologic studies and first clinical experience with the
phencyclidine derivative, CI-581. Anesth Analgesia, 45:29-40,
1966.
37
Corssen, G., Danino, E.F., and Bree, R.L. Electroencephalo-
graphic effects of ketamine anesthesia in children. Anesth Anal-
gesia; Current Res, 48:141-147, 1969.
Corssen, G., Miyasaka, M. and Domino, E.F. Changing concepts in
pain control during surgery. Dissociative anesthesia with CI-581,
a progress report. Anesth Analgesia; Current Res, 47:746-749,
1968.
Corssen, G., Little, S.C., and Tavakoli, M. Ketamine and epilepsy.
Anesth Analgesia; Current Res, 53:319-335, 1974.
Corssen, G., and Domino, E.F. Discussion. Anesth Analgesia;
Current Res, 53:333-335, 1974.
Domino, E.F. Neurobiology of phencyclidine (Sernyl), a drug
with an unusual spectrum of pharmacological activity. Int Rev
Neurobiol, 6:303-347, 1964.
Domino, E.F. Discussion of ketamine and epilepsy. Anesth Anal
gesia; Current Research, 53:333-335, 1974.
Domino, E. F. Some aspects of the pharmacolgy of phencyclidine.
From: Technical Review of the Psychopharmacology of Hallucinogens
sponsored by the National Institute for Drug Abuse October 21-22,
1976, Bethesda, Md., Published 1978.
Domino E. F., and Bartolini, A. Effects of various psychotomimetic
agents on the EEG; and acetylcholine release from the cerebral cor-
tex of brainstem transected cats. Neuropharmacol 11:703-713, 1972.
Domino, E. F., Chodoff, P., and Corssen, G. Pharmacologic effects
of CI-581, a new dissociative anesthetic, in man. Clin Pharmacol
Ther, 6:279-291, 1965.
Domino, E.F., and Luby, E.D. Abnormal mental states induced by
phencyclidine as a model of schizophrenia. In Cole, J.O.,
Freedman, A.M., Friedhoff, A.J. eds., Psychopathology and Psycho-
pharmacology, Johns Hopkins University Press, 1973.
Domino, E.F., McCarthy, D.A., and Deneau, G.A. General anesthesia
in infrahuman primates. Fed Proc, 28:1500-1509, 1969.
Domino, E.F., and Wilson, A.E. Psychotropic drug influences on
brain acetylcholine utilization. Psychopharmacologia, 25:291-298,
1972.
Domino, E.F., and Wilson, A.E. Effects of urine acidification on
plasma and urine phencyclidine levels in overdosage. Clin Pharmacol
Ther, 22:421-424, 1977.
38
Done, A.K., Aronow, R., Miceli, J.N., and Lin, D.C.K. Pharmaco-
kinetic observations in the treatment of phencyclidine poisoning.
Management of the poisoned patient. Science Press, New Jersey,
1977.
Done, A.K., Aronow, R., and Miceli, J.N. Pharmacokinetics of
phencyclidine (PCP) in overdosage and its treatment. National
Institute on Drug Abuse: Research Monograph Series, Conference
on Phencyclidine, February, 1978.
Fink, M. EEG and human psychopharmcology. Ann Rev Pharmacol,
9:241-258, 1969.
Giarman, N.J., and Pepeu, G. Drug induced changes in brain acetyl-
choline. Brit J Pharmacol Chemother, 19:226-234, 1962.
Goode, D.J., Weinberg, D.H., Mazura, T.A., Curtis, G., Moretti,
R.J., and Meltzer, H.Y. Effect of limb restraints on serum crea-
tinine phosphokinase activity in normal volunteers. Biol Psychiat,
12(6):743-755, 1977.
Greifenstein, F.E., De Vault, M., Yoshitake, J., and Gajewski,
J.E. A study of a 1-arylcyclohexyl amine for anesthesia. Anesth
Analgesia, 37:283-294, 1958.
Gupta, R.C., Lu, I., Oei, G.L., and Lundberg, G.D. Analysis of
phencyclidine (PC) in illicit stress samples and urine. Clin
Toxical, 8(6):611, 1975.
Hawks, R.L., and Willette, R.E. Phencyclidine: analytical meth-
odology. Research Technology Branch, Division of Research,
National Institute on Drug Abuse, Rockville, Md., December 1977.
Hitzemann, R.J., Loh, H.H., and Domino, E.F. Effect of phency-
clidine on the accumulation of 14C-catecholamines formed from
14C-tyrosine. Arch Int Pharmacodyn, 202:252-258, 1973.
Hynes,  M.C., and Berkowitz, B.A. Nitrous oxide and ketamine pro-
duce an opiate-like locomotor response in mice. Fed Proc,
37:507, 1978.
Itil, T., Keskiner, A., Kiremitci, N., and Holden, J.M.C. Effect
of phencyclidine in chronic schizophrenics. Canad Psychiat Assoc,
12:209-212, 1967.
Kalir, A., Sadeh, S., Karoly, H., Shirin, E., Balderman, D.,
Edery, H., and Porath, G. 1-Phenylcycloalkylamine derivatives II.
J Med Chem, 12:473, 1969.
Kalir, A., Katz, E., Rauch, L., Elkavetz, R., and Torten, M.
Therorniogenology, 6(2-3):1-7, 1976.
39
Kanner, M., Meltzer, H.Y. and Davis, J.M. Pharmacologic aspects
of the  locomotor stimulation produced by phencyclidine in the rat.
Neurosci Abst, 5th Annual Meeting, 336, 1975.
Kothary, S.P., and Zsigmond, E.K. A double-blind study of the
effective anti-hallucinatory doses of diazepam prior to ketamine
anesthesia. Clin Pharmacol Ther, 21:108-109, 1976.
Lau, S.S., and Domino, E.F. Gas Chromatography-mass spectrometry
assay for ketamine and its metabolites in plasma. Biomed Mass
Spectrometry, 4:317-321, 1977.
Lees, H. The effect in vitro of 1-(1-phenylcyclohexyl) piperidine
hydrochloride (Sernyl) on oxidation by liver homogenates and mito-
chondria of rat. Biochem Pharmacol, 11:1115-1122, 1962.
Lees, H. The effects of 1-(1-phenylcyclohexyl) piperidine HCl
(phencyclidine, Sernyl) on respiratory and related reactions of
liver mitochondria in vitro. Biochem Pharmacol, 17:845-848, 1968.
Leonard, B.E., and Tonge, S.R. Some biochemical and pharmacologi-
cal properties of phencyclidine. Brit J Pharmacol Chemother,
32:415P-416P, 1968.
Leonard, B.E., and Tonge, S.R. The effects of sane hallucinogenic
drugs upon the metabolism of noradrenaline. Life Sci, 8:815-825,
1969.
Leonard, B.E., and Tonge, S.R. Some effects of an hallucinogenic
drug (phencyclidine) on neurohumoral substances. Life Sci, 9:
1141-1152, 1970.
Lin, D.C.K., Fentiman, A.F., Foltz, R.L., Fomey, R.D., and
Sunshine, I. Quantification of phencyclidine in body fluids by
gas chromatography-chemical ionization mass spectrometry and
identification of two metabolites. Biomed Mass Spectrometry, 2:
206-215, 1975.
Lin, D.C.K., Foltz, R.L., Done, A.K., Aronw, R., Arcinue, E.,
and Miceli, J.N. Mass spectrometric analysis of phencyclidine
in body fluids of intoxicated patients. In DeLeenheer, A.P., and
Roncucci,R.R.,eds. Quantitative Mass Spectrometry in Life
Sciences, Amsterdam, Elsevier, pp. 121-129, 1977
Luby, E.D., Cohen, B.D., Rosenbaum, G., Gottlieb, J.S., and
Kelley, R. Study of a new schizophrenomimetic drug-Semyl.
AMA Arch Neural Psychiat, 81:363-369, 1959.
Maayani, S., Weinstein, H., Ben-Zui, N., Cohen, S., and Sokolovsky,
M. Psychotomimetics as anticholinergic agents-I. Biochem Pharma-
col, 23:1263-1281, 1974.
40
MacLeod, W.D., Green, D.E., and Seet, E. Automated analysis of
phencyclidine in urine by probability based matching GC/MS. Clin
Toxicol, 9(4):561-572, 1976.
Markowitz, R., and Kometsky, C. Hypersensitivity to foot-shock
following administration of phencyclidine: Interaction with
naloxone. Fed Proc, 37:619, 1978.
Marshman, J.A., Ramsay, M.P., and Sellers, E.M. Quantitation of
phencyclidine in biological fluids and application to human over-
dose. Toxicol Appl Pharmacol, 35(1):129-136, 1976.
Meltzer, H.Y. Muscle toxicity produced by phencyclidine and re-
straint stress. Res Commun Chem Path Pharmacol, 3:369-383, 1972.
Meltzer, H.Y., Nankin, R., and Raftery, J. Serum creatinine phos-
phokinase activity in newly admitted psychiatric patients. II.
Arch Gen Psychiat, 24:568-572, 1971.
Meyer, J.S., Greifenstein, F., and De Vault, M. A new drug caus-
ing sensory deprivation. J Nerv Ment Dis, 129:54-61, 1959.
Miletich, D.J., Ivankovic, A.D., Albrecht, K., Zahed, B., and
Ilahi, A.A. The effect of ketamine on catecholamine metabolism
in the isolated perfused rat heart. Anesthesiology, 39:271-277,
1973.
Miyasaia, M., and Domino, E.F. Neuronal mechanisms of ketamine-
induced anesthesia. Int J Neuropharmacol, 7:557-573, 1968.
Moreton, E.J., Meisch, R.A., Stark, L., and Thompson, T. Ketamine
self-administration by the rhesus monkey. J Pharmacol Exp Ther,
203:303-309, 1977.
Ngai, S.H., Cheney, D.L., and Finck, D.A. Acetylcholine concen-
trations and turnover in rat brain structures during anesthesia
with halothane, enflurane, and ketamine. Anesthesiology, 48:
4-10, 1978.
Ober, R.E., Gwynn, G.W., Chang, T., McCarthy, D.A., and Glazko,
A.J. Metabolism of 1-(1-phenylcyclohexyl) piperidine (SernylR).
Fed Proc, 22:539, 1963.
O'Donnell, S.R., and Wanstall, J.C. Actions of phencyclidine on
the perfused rabbitear. J Pharm Pharmacol, 20:125-131, February,
1968.
Paster, Z., Maayani, S., Weinstein, H., and Sokolovsky, M. Cho-
linolytic action of phencyclidine derivatives. Eur J Pharmacol,
25:270-274, 1974.
Pearce, D.S. Detection and quantitation of phencyclidine in
blood by use of (2H5) phencyclidine and select ion monitoring
applied to non-fatal cases of phencyclidine intoxication. Clin
Chem, 22(10):1623-1626, 1976.
41
Pickens, R., Thompson, T., and Mcchow, D.C. Cannabis and phen-
cyclidine self-administration by animals. In Goldberg, L., and
Hoffmeister, F., eds. Psychic Dependence. Bayer Symposium IV,
New York: Springer-Verlag, pp. 78-86
Pinchasi., I., Maayani, S., and Sokolovsky, M. On the interactions
of drugs with the cholinergic nervous system. III Tolerance to
phencyclidine derivatives: In vivo and in vitro studies. Biochem
Pharmacol, 26:1671-169, 1977.
Reynolds, P.C. Clinical and forensic experiences with phencycli-
dine. Clin Toxicol, 9(4):547-552, 1976.
Schuh, F.T. Influence of ketamine on human plasma cholinesterase.
Brit J Anesth, 47:1315-1319, 1975.
Sharman, D.F. Changes in the metabolism of 3,4-dihydroxyphenyl-
ethylamine (dopamine) in the striatum of the mouse induced by
drugs. Brit J Pharmacol, 28:153-163, 1966.
Shulgin, A.T., and MacLean,D. Illicit synthesis of phencyclidine
(PCP) and several of its analogues. Clin Toxicol, 9(4):553-560,
1976.
Stockard, J.J., Werner, S.S., and Aalbers, J.A. Electroencephalo-
graphic findings in cyclchexylamine induced stupor and coma.
Clinical studies of acute phencyclidine intoxication and graded
intravenous ketamine infusions. Meetings of the American and
Mexican Electroence phalographic Societies, Mexico City,October,
1975.
Sung, Y.F., Fredrickson, E.L., and Holtzman, S.G. Effects of
intravenous anesthetics on brain monoamines in the rat. Anesthes-
iology, 39:478-487, 1973.
Tonge S.R. Variation of 5-hydroxytryptamine metabolism in the
rat: effects on the neurochemical response to phencyclidine. J
Pharm Pharmac, 23:71, 1971.
Tonge,S.R. Neurochemical teratology: 5-hydroxyindole concentra-
tions indiscrete areas of rat brain after the pre- and neonatal
administration of phencyclidine and imipramine. Life Sci, 12(1):
481-486, 1973.
Tonge, S.R. and Leonard, B.E. The effects of some hallucinogenic
drugs upon the metabolism of 5-hydroxytryptamine in the brain.
Life Sci, 8:805-814, 1969.
Tonge, S.R., and Leonard, B.E. The effects of some hallucinogenic
drugs on the amino precursors of brain monoamines. Life Sci,
1327-1335, 1970.
Tonge, S.R., and Leonard, B.E. Interaction of phencyclidine with
drugs affecting noradrenaline  metabolism in the rat brain. Psycho
pharmacologia, 23:86-90, 1972.
42
Tonge, S.R., and Leonard, B.E. Partial antagonism of the behav-
ioral and neurochemical effects of PCP by drugs affecting monoa-
mine metabolism. Psychopharmcologia, 24:516-520, 1972.
Usdin, E., and Usdin, V.R. Effects of psychotropic compounds on
enzyme system, II: In vito inhibition of monoamine oxidase.
Soc Exp Biol Med Proc Med, 108:461-463, 1961.
Van Meter, W.G., Owens, H.F., and Himwich, H.E. Effects on
rabbit brain of a new drug with psychotomimetic properties. J
Neuropsychiat, 1:129-134, 1960.
Weinstein H., Maayani, S., Srebrinik, S., Cohen, S., and Sokolov-
sky, M. Psychomimetic drugs as anticholinergic agents. II. Mol
Pharmacol, 9:820-830, 1973.
Wilson, A.E., and Domino, E.F. Plasma phencyclidine pharmacokin-
etics in the dog and the monkey using a gas chromatography-mass
fragmentography assay. Biomed Mass Spectrometry, In press, 1978.
Winters, W.D. Epilepsy or anesthesia with ketamine. Anesthes-
iolgy, 36:309-312, 1972.
Winters, W.D. Effects of drugs on the electrical activity of the
brain. Anesthetics. Ann Rev Pharmacol Toxicol, 16:413-426, 1976.
Winters, W.D., and Ferrar-Allado,T. The cataleptic state induced
by ketamine: A review of the neuropharmacology of anesthesia.
Neuropharmacology, 11:303-315, 1972.
Winters, W.D., Mori, K., Spooner, C.E., and Bauer, R.O. The
neurophysiolgy of anesthesia. Anesthesiology, 28:65-80, 1967.
Wong, L.K., and Biemann, K. Metabolites of phencyclidine in
humans. Biomed Mass Spectrometry, 2:204-205, 1975.
Wang, L.K., and Bieman, K. Metabolites of phencyclidine. Clin
Toxicol, 9(4):583-591, 1976.
Zsigmond, E.K., Kelsch, R.C., and Kothary, S.P. Counteraction of
circulatory effects of ketamine by pre-treatment with diazepam.
Excerpta Medica International Congress, Series No. 387, The
Sixth World Congress of Anesthesiology, April, 1976.
AUTHOR
Edward F. Domino, Department of Pharmacology, University of
Michigan, Ann Arbor, Michigan 48109, and Lafayette Clinic,
Detroit, Michigan 48207.
43
Chapter 3
Neurochemical Pharmacology of
Phencyclidine
Kenneth M. Johnson,  Ph.D.
INTRODUCTION
Phencyclidine (PCP) is an unusual CNS active drug with general anes-
thetic, psychomotor stimulant, sedative-hypnotic, hallucinatory, and
local anesthetic properties. Although PCP is often classed as an
hallucinogen, it does not produce the type of visual hallucination
associated with the use of LSD or mescaline. Instead, the hallucino-
genic activity of PCP is manifested primarily by body image and pro-
prioceptive disturbances often accompanied by thought disorders and
changes in affect. The differences between the effects of PCP and
LSD are responsible for the classification of PCP as a schizophreni-
mimetic agent.
Although PCP itself is being abused with increasing frequency, its
primary place in the illicit drug market is as an adulterant of
other drugs of abuse. In this regard it is the most often encoun-
tered drug in analyses of suspect street drug samples. Because of
its prevalence, PCP ranks very high on the list of drugs thought to
be responsible for drug overdoses. Overdoses of PCP are thought to
account for acute psychotic episodes often lasting two or more
weeks. PCP overdose often challenges the diagnostic abilities of
the clinician, who suffers from lack of a rational pharmacological
basis for treatment. Consequently, often the treatment chosen is
to leave the patient alone and let the drug effect wear off, which
can take days to weeks.
The apparent high abuse liability of PCP and its use as an adulte-
rant of other illicit drugs make it imperative that the scientific
community be aware of the effects of acute and chronic administra-
tion of PCP as well as the mechanism(s) of action underlying these
effects. Most of the known effects PCP administration are appar-
ently mediated through action the CNS. since there is an excel-
lent review of the neurobiological effects of PCP (Domino 1964),
the primary purpose of this paper is to review the results of pre-
vious studies which have measured the effects of PCP administration
on various neurochemical indices of brain function. Deficits in
either methodology or experimental design in these studies will also
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be pointed out. In addition, those areas in which there is no in-
formation currently available will be identified.
EFFECTS OF PCP ON BRAIN NEUROTRANSMITTER SYSTEMS
Many, if not all, psychoactive drugs are believed to exert their
effects by modifying the transmission of neuronal impulses from one
neuron to another. Many neuronal systems have been identified in
the CNS which probably use small chemical molecules as mediators of
neuronal impulse transmission. Alterations in the concentration,
synthesis rate, storage, release, binding, metabolism, and reuptake
Of these neurotransmitters after drug administration have been cor-
related with alterations in the functioning of various neuronal sys-
tems. Information regarding the effects of PCP on these neuro-
chemical indices of neuronal function in animals could be important
in understanding the mechanism of action of this drug, as well as
providing a rationale for treatment of the serious effects often
associated with PCP use by humans.
Effects of PCP on Brain Serotonin (5-hydroxytryptamine)
In 1969 Tonge and Leonard compared the effects of PCP, ditran, mesca-
line, and LSD. At behaviorally effective doses (10 mg/kg, i.p. for
PCP) all four hallucinogens elevated serotonin (5-HT) and depressed
5-hydroxyindoleacetic acid (5-HIAA) concentrations in the whole
brain of rats. Brain 5-HT concentrations were highest 10 min. after
PCP administration and remained elevated throughout the course of
the experiment (3 hours). grain 5-HIAA levels were significantly
lower than controls 20 and 40 minutes after PCP administration, but
were higher than controls 100 and 180 minutes following PCP. It is
possible, then that PCP caused a decrease and then a compensatory
increase in 5-HT turnover. The method used in this study for
assessing turnover prevented the assessment of this possibility. In
this study turnover was assessed by following the decline of brain
5-HT after inhibiting its synthesis with p-chlorophenylalanine (PCPA).
Control rats were injected with PCPA at time zero and sacrificied
either immediately or nine hours later. Experimental animals also
received PCP at time zero and were injected with PCP 0, 3, and 6
hours after PCPA and were sacrificed 9 hours after PCPA. The data
thus obtained were used to support the hypothesis that PCP reduced
theturnoverof 5-HT. Although this may indeed be the case, it is
difficult to conclude this fran data collected at two time points.
These investigators also observed that PCP had no effect upon two
enzymes involved in the synthesis (aromatic amino acid decarboxylase)
and metabolism(monoamine oxidase) of 5-HT. I am unaware of any
studies which have assessed either the effect of PCP on 5-HT turn-
over directly (without disturbing the steady-state) or of any which
measured the effect of PCP on the first enzyme involved in the bio-
synthesis of 5-HT, tryptophan hydroxylase. These studies clearly
need to be done in order to clarify the effects of PCP on serotoner-
gic systems.
It is now fairly well established that brain 5-HT synthesis is
dependent upon tryptophan availability since tryptophan hydroxylase
is apparently not saturated with substrate (Eccleston et al. 1965).
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In this regard, PCP has been shown to reduce the concentration of
both plasma and brain tryptophan about 20 percent (Tonge and Leonard
1970). If 5-HT. synthesis is indeed dependent on brain tryptophan,
then 5-HT levels would be decreased rather than increased as these
investigators previously indicated (Tonge and Leonard 1969). It is
possible, however, that PCP may actually increase the pool of free
tryptophan in plasma (i.e., not bound to plasma albumin) available
for transport into the brain by competing with tryptophan for
albumin binding sites, as other drugs have been shown to do (Gessa
and Tagliamonte 1974). This possibility has not been addressed.
In another study, Tonge and Leonard (1972) showed that PCP adminis-
tration to rats at a dose (10 mg/kg) comparable to that used in their
1969 study, produced the opposite effects on 5-HT and 5-HIAA, i.e.,
5-HT levels were reduced and 5-HIAA levels were elevated. To further
confuse the issue, Tonge (1971) reported that PCP produced the
opposite effect on 5-HT and 5-HIAA on populations of Wistar rats
obtained from different sources. Using the 5-HIAA/5-HT ratio as
an index of serotonergic activity, PCP decreases the turnover of
5-HT in the substrain with the higher 5-HIAA/5HT ratio while
increasing the 5-HT turnover in the strain with the lower 5-HIAA/
5-HT ratio. Because of the suggestive nature of the foregoing
studies with PCP and the proposed role of 5-HT in emotional and
psychotic behavior, it is felt that a detailed biochemical study of
the effects of PCP on serotonergic function is warranted. It should
be noted here that ketamine (a structural analog of PCP) produced
either no effect or a slight increase in rat brain 5-HT levels,
depending upon the dose administered (Sung et al. 1973). These
authors showed a significant decrease in 5-HT turnover, as deter-
mined by the method of following the rate of increase in 5-HT after
inhibition of its metabolism with pargyline.
Effects of PCP on Brain Catecholamines
Tyrosine, a precursor for both dopamine (DA) and norepinephrine (NE)
synthesis, has been proposed to exert some regulatory influence on
the synthesis of catecholamines (Wurtman et al. 1974). Tonge and
Leonard (1970) have shown that rat brain tyrosine levels were ele-
vated 30 to 40 percent after the administration of PCP. Plasma
tyrosine levels, however, were little affected.
In an experimental design which employed the conversion of 14C-tyro-
sine into 14C-catecholamine, Hitzeman et al. (1973) reported that
PCP resulted in significant decreases in the amount of 14C-DA and
14C-NE synthesized, whereas the accumulation of the O-methylated
metabolites of DA and NE (14C-3-methoxytryamine and 14C-normethan-
ephrine, respectively) appeared to be increased over control. How-
ever, when 14C-DOPA was used as the precursor, no effect of PCP was
observed. It was then concluded that PCP probably acts at the level
of tyrosine hydroxylase (the enzyme which converts tyrosine to DOPA).
Unfortunately, these authors neglected to measure the specific activ-
ity of tyrosine. dopamine and norepinephrine. In light of the
report by Tonge and Leonard that PCP elevates brain tyrosine, it is
entirely possible that these results are the artifactual consequence
of a diluted precursor specific activity, rather than an actual
decrease in synthesis. The increase in accumulation of the O-methy-
lated metabolites observed suggest that PCP either increases the
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release or decreases the reuptake of the catecholamines from the
extraneuronal space, However, it should be noted that the presumed
extreneuronal localization of catechol-O-methyltransferase is pres-
ently under dispute.
In a study similar to their study of the effects of PCP on serotonin,
Leonard and Tonge (1969) described the effects of PCP on DA and NE.
They report that 10 mg/kg PCP produced a substantial decrease in
whole brain NE concentration, no charge in normethanephrine, and a
slight increase in DA levels. Whereas previously it was demonstrated
that PCP protected against reserpine-induced serotonin depletion,
in this study PCP was found to potentiate the reserpine-induced
depletion of NE. PCP was found to have no effect on the turnover
of NE as estimated by inhibiting its synthesis with -methyl-p-
tyrosine ( -MPT) and measuring NE levels at 0 and 3 hours after  -
MPT. As was the case with the studies of the effects of PCP on
serotonin neurochemistry, the ones on catecholamine neurochemistry
suggest that a more rigorous approach would yield less ambiguous
data and allow a more meaningful interpretation of the effects of
PCP on catecholamine function.
In spite of the studies just discussed which suggest that PCP my
have little or no effect on DA or NE function, there are several
studies which suggest there may be profound effects of PCP on both
of these systems. Taube et al. (1975) reported that PCP inhibited
the uptake of 3H-NE by rat cortical slices by 50 percent at 5 x 10-6
M. Interestingly, ketamine was about 100 times less potent. This
effect of PCP on NE uptake was verified by Garvey and Heath (1976)
who used a synaptosomal preparation. These workers demonstrated
that PCP is a competitive inhibitor of both 3H-NE uptake by hypo-
thalamic synaptosomes (Ki = 4.7 x 10-7M) and of 3H-DA uptake by
striatal synaptosomes (KI = 4 x 10-7M). Very recently these obser-
vations were verified and the list of putative neurotransmitters
whose synaptosomal uptake is competitively inhibited by PCP was
extended to include serotonin (Smith et al. 1977). Ketamine has
been shown to be a much weaker competitive inhibitor of synaptosomal
uptake of 3H-NE (Smith et al. 1975).
Another interesting study which suggests the involvement of DA in
the action of PCP utilized the turning behavior of rats after uni-
lateral electrolytic lesions of the substantia nigra (Finnegan,
Kanner, and Meltzer 1976). These authors found that PCP produced a
dose-related increase (maximal at 10 mg/kg) in ipsilateral rotation.
This effect was attenuated by -MPT and haloperidol (a DA antagonist),
thereby suggesting that this action of PCP is mediated by DA. Un-
fortunately, in contrast to turning behavior after unilateral 6-
hydroxydopamine lesions, this model apparently does not distinguish
between presynaptic and postsynaptic drug actions (Costall and
Naylor 1971). A cholinergic component of this action of PCP was
also identified by the observation that the ipsilateral turning was
blocked by the cholinomimetic drug arecoline and was slightly poten-
tiated by the anticholinergic agent trihexyphenidyl. There is con-
siderable evidence that turning behavior (as well as other functions
mediated by the striatum) is regulated by a reciprocal relationship
between dopaminergic neurons and cholinergic neurons. For example,
47
both direct and indirect dopaminergic agents and anticholinergic
agents can induce ipsilateral rotation in this model. Thus PCP may
induce rotational behavior by potentiating dopaminergic transmission,
by blocking cholinergic transmission, or both.
Effects of PCP on Acetylcholine (ACh)
There has bee-n surprisingly little work done on the effects of PCP
on central cholinergic systems, despite the ample evidence obtained
in vitro that PCP both antagonizes the ACh receptor and has potent
antiacetylcholinesterase activity. One research group from Israel
has presented both theoretical and experimental evidence that PCP
and ACh have a very similar electrostatic charge distribution pattern
when they are considered in the vicinity of the muscarinic receptor
(Weinstein et al. 1973; Paster et al. 1974; Maayani et al. 1974).
PCP, however, appears to be an antagonist of ACh in the isolated
frog rectus abdominis and guinea pig ileum preparations, rather than
an agonist. This group has proposed theoretical considerations to
account for the antagonistic activity based upon the cyclohexyl
ring-induced rigidity of the molecule. Maayani et al. (1974) also
demonstrated that PCP competitively inhibits butyrylcholinesterase
(Ki = 1 x 10-6M) and acetylcholinesterase (Ki = 80 x 10-6M). The
ACh antagonist and anticholinesterase activities would, of course,
tend to offset each other. The overall activity of PCP tends to be
anticholinergic, however, as evidenced by the observation that PCP-
induced anesthesia in the guinea pig and hyperactivity in the muse
were both significantly antagonized by tacrine, a potent anticholin-
esterase (Maayani et al. 1974). Recently this group of investiga-
tors reported that scopolamine blocked the development of tolerance
in mice to the effects of cyclohexamine, a structural analog of PCP
(Pinchasi et al. 1977). In contrast, ketamine was shown to produce
a relatively weak reversible mix inhibition of acetylcholinesterase
from beef caudate (Ki = 500 x 10-6M) (Cohen et al. 1974). It is
unclear whether or not this concentration is physiologically signi-
ficant since the slight (25 percent) increase in whole brain ACh
levels observed by these authors was found to last less than ten
minutes. In a study utilizing a cholinergic antisynthesis agent
(hemicholinium-3), Domino and Wilson (1972) reported that PCP (10
mg/kg) slightly increases the turnover of ACh but is without effect
on the whole brain levels of ACh. Leonard and Tonge (1970) also
observed no effect of PCP on whole brain levels. These authors also
failed to observe any change in brain cholinesterase activity fol-
lowing the administration of PCP (10 mg/kg).
It is now evident that the synthesis of ACh is dependent upon the
high-affinity, sodium-dependent uptake of choline (Yamamura and
Snyder 1973; Haga and Noda 1973). An altered choline uptake could
conceivably play a role in the cholinergic effect of PCP. To my
knowledge no one has studied the effects of PCP on this system.
Effects of PCP on Other Biochemical Parameters
Tonge and Leonard (1970) found that PCP (10 mg/kg) resulted in no
change of whole brain levels of histamine or glutamic acid. However,
they did detect a decrease in whole brain concentration of -amino-
butyric acid (GABA) which persisted for two hours after PCP injection.
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They observed no effect on GABA after 3 mg/kg of PCP. Interestingly,
ketamine has been demonstrated to competitively inhibit glutamate
decarboxylase in vitro, but to produce no change in either brain
glutamate or GABA levels when administered in vivo (Dye and Taberner
1975).
There are several other studies documenting effects of PCP on keta-
mine on a wide variety of biochemical parameters which may be rele-
vant to this review. I will briefly describe two of them. Some
studies have previously demonstrated that subgroups of psychotic
patients of all diagnostic types exhibit increased serum levels of
type III (skeletal muscle) isoenzyme of creatinine phosphokinase
(Meltzer et al. 1971). Interestingly, phencyclidine, in a biphasic
dose-response fashion, significantly enhanced the increase in serum
creatinine phosphokinase levels produced by restraint stress (Meltzer
1972). The magnitude of this effect was rather dramatic in male
Sprague-Dawley rats, but not at all evident in guinea pigs. The sig-
nificance of these studies is uncertain, but at the very least they
emphasize that the effects of PCP varies markedly between species.
Anesthetic doses of ketamine have been demonstrated to elicit an
increase in rat plasma corticosterone levels similar to that pro-
duced by a pharmacological dose of ACTH (Fahringer et al. 1974).
This response to ketamine was blocked by hypophysectomy and adminis-
tration of dexamethasone, and partially blocked by propranolol and
haloperidol, but not by atropine or phentolamine. Aside from sup-
porting the notion that this response may be mediated by ß-adrenergic
or dopaminergic systems, it brings up the possibility that PCP may
also elicit a similar corticosterone response. In light of the
observation that tryptophan hydroxylase activity can be increased
by corticosterone treatment (Azmitia and McEwen 1969), it is possible
that some of the effects of PCP on the serotonergic system may be
mediated by this pituitary-adrenal response.
SUMMARY
In view of the diverse pharmacological spectrum of PCP, it is unlikely
that the effects of PCP are caused by an alteration in the function
of a single neurotramsmitter. Previous studies have suggested that
the central biogenic amines, 5-HT, DA and NE, as well as ACh and
GABA may be involved either directly or indirectly with the mechan-
ism(s) underlying the behavioral effects of PCP. The information
currently available on the neuropharmacological actions of PCP is
found to be deficient in many respects. In spite of the several
studies which have examined the effects of PCP on neurotransmitter
substances in the brain, relatively little is known in an unambigous
my. Most of those studies used whole brain for analysis of neuro-
transmitter concentration. Increases, decreases, or no change in
a neurotransmitter concentration for whole brain reveals little or
nothing about the functional aspects of the particular neurotrans-
mitter. Interpretation of many of these studies was made extremely
difficult by the concomitant use of relatively nonspecific drugs
such as tetrabenazine, reserpine, imipramine, etc. Many of these
studies failed to correlate their findings temporally with behavioral
activity and almost all of these studies neglected to establish a
basic dose-response relationship for the observed effect. Further-
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more, the effects of chronic administration of PCP, heretofore, have
been totally neglected in regard to neurochemical studies. In sum-
mary, these studies have only suggested that 5-HT, DA, NE, ACh, and
GABA may be involved in sane way in the mediation of the behavioral
effects produced by PCP.
As can be seen from the foregoing review of the state of knowledge
on the neurochemical pharmacology of PCP is in its infancy. It is
felt that future research in this area can provide valuable informa-
tion about the mechanism(s) of action of PCP only if each neuro-
chemical variable is examined as a function of both dose and time
and then correlated with the behavioral effects of the drug. In
addition to measuring the effects of PCP on neurotransmitter concen-
tration in discrete brain areas, future studies should not neglect
to measure the concentration of neurotransmitter precursors and
metabolites. In addition, techniques for determining the turnover
of neurotransmitter pools are available Which do not disturb the
existing steady-state of the neurotransmitter. It is felt that the
proper utilization of such techniques would result in a significant
increase in our understanding of the way this important and interes-
ting drug affects the CNS.
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Chapter  4
The Behavioral Effects of
Phencyclidine in Animals
Robert L. Balster, Ph.D., and Larry D. Chait
INTRODUCTION
Study of the behavioral pharmacology of phencyclidine (PCP) has
accelerated concurrently with the increased public health concerns
associated with its illicit use. Some important aspects of the
pharmacology of this unusual compound have been revealed by this
research, although there remain many more questions than answers.
At the conclusion of this paper we will point out some of the
future directions which behavioral research with PCP might profit-
ably take. Before doing this, we will describe the current status
of knowledge of the behavioral effects of this drug, focusing on
research which has appeared since the two previous reviews of this
area (Domino 1964; Balster and Chait 1976) and on recent research
in our laboratory. Our research has recently been most concerned
with two aspects of the behavioral effects of PCP: tolerance
development and interactions between PCP and other drugs. Before
reporting our results on these two topics, we will briefly sum-
marize some of the important results of prior behavioral work
with this drug.
SPECIES DIFFERENCES IN THE BEHAVIORAL EFFECTS OF PCP
One of the most interesting aspects of the behavioral pharmacology
of PCP is the obvious species differences in its gross behavioral
effects. These differences were noted in the early preclinical
studies of PCP by Chen and his coworkers (1959) and are con-
sistently seen in our laboratory. In rats and mice, PCP produces
behavioral effects qualitatively similar to those of psychomotor
stimulants such as the amphetamines. In rats, for example,
intraperitoneal doses above 3 mg/kg produce increased motor ac-
tivity, while doses between 5 and 10 mg/kg result in repetitive
movements, including cage circling, side to side head movements,
and repetitive sniffing not unlike the stereotyped behaviors seen
with stimulant administration in this species. These behaviors
differ from the effects of stimulants, however, in that the
animals also are markedly ataxic. A similar constellation of
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behavioral effects occurs in mice, although mice are, if anything,
more stimulated. At intraperitoneal doses above 3 mg/kg they
race around the cage, and in the range of 10 mg/kg they run off
the edge of any flat surface they are placed on. Convulsions
are not uncommon at doses above 20 mg/kg. In our experience,
there is no dose of PCP which will produce anything resembling
surgical anesthesia in the mouse.
The amphetamine-like properties of PCP in mice have also been
seen in schedule-controlled behavior. Wenger and Dews (1976)
compared the effects of PCP to the effects of d-amphetamine,
pentobarbital and ketamine using a multiple fixed interval fixed
ratio (mult. FI-FR) schedule of food reinforcement. The effects
of PCP were qualitatively more similar to those of d-amphetamine
than pentobarbital in that at some dose both PCP and d-amphetamine
increased FI response rate and decreased FR response rate. In-
terestingly, the effects of ketamine were also very similar to
PCP and d-amphetamine. A very similar effect of PCP and ketamine
on mult. FI-FR performance has also been reported in the pigeon
(Wenger 1976).
Chen et al. (1959) reported that the effects of PCP were different
in the guinea pig than in the mouse and rat. Only "calming"
effects were seen until cataleptoid or convulsant doses were
reached. We, on the other hand, have seen more typical rodent-
like effects of PCP in the guinea pig. Intraperitoneal doses
in the range of 2 to 4 mg/kg result in increased movement in the
normally sedentary guinea pig. At the higher doses repetitive
movements can be seen, and ataxia also occurs. One animal ex-
hibited obstinate progression, a continuation of walking move-
ments after reaching the cage wall. In a pilot study, PCP in-
creased motor activity of guinea pigs in a circular runway appara-
tus (Kenneth M. Johnson, personal communication) .
In rodents, PCP shares other pharmacological properties with
psychomotor stimulants. Like methamphetamine and cocaine, PCP
increases blood pressure, promotes urination, and decreases
electrically induced tonic extensor seizures (Chen, Ensor, and
Bohner 1965). In short, PCP looks a great deal like a sympatho-
mimetic which produces ataxia when studied. in rodent species.
This similarity of PCP to stimulants led us to suspect that PCP
may enhance the behavioral effects of amphetamine in rats. We
have found this to be the case (Balster and Chait 1978) and will
describe these results in more detail later in this paper.
The gross behavioral effects of PCP in subhuman primates are
substantially different from those we described for rodents. In
the rhesus monkey, for example, intramuscular doses between 0.2
and 0.4 mg/kg produce mild ataxia and a calming effect. Normally
agressive monkeys became easier to handle. Signs of repetitive
or stereotyped behaviors are not seen. At doses above 0.8 mg/kg
the animals are cataleptic. Nystagmus is frequently seen, and
occassionally marked salivation occurs. Although the monkeys are
immobile, they may show exaggerated limb and mouth movements,
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their eyes remain open and most reflexes remain intact. The
animals, however, are unresponsive to enviromental events. The
sequences of unresponsiveness, gross ataxia, motor restlessness
and nystagus is very similar to the effect of large doses in
humans.
The gross behavioral effects of PCP in squirrel monkeys are
qualitatively similar. Squirrel monkeys, however, are somewhat
more sensitive to the effects of PCP on motor coordination. For
example, an intramuscular dose of 0.2 mg/kg in the rhesus
monkey produces marginal gross behavioral effects. Slight ataxia
is seen but the animals are able to grasp objects between their
fingers and maintain normal posture with little difficulty. In
the squirrel monkey, an even lower dose (0.16 mg/kg/ intramuscu-
larly) producesmarkedincoordination, inability to grasp objects,
and inability to sit on their perch without support. In general
the effects of PCP in monkeys are quite reliable from animal to
animal. We have, however, observed one rhesus monkey who was 
quite insensitive to the effects of PCP, always requiring doses
at least three times higher than normal to produce sedation ade-
quate for handling. We are unable to explain this insensitivity,
but it suggests that there are substantial individual differences
to the effects of PCP can occur.
In spite of the differences between the effects of PCP on gross
behavior of rodents and monkeys, its effects on schedule controlled
operant behavior appear qualitatively similar. There has been
no systematic research comparing the effects of PCP on operant
behavior in various species, but some generalizations can be
made based on studies using similar schedules in different labora-
tories. The most consistent finding so far is that PCP produces
a rate dependent effect on fixed interval performance in mice,
pigeons and squirrel monkeys (Wenger and Dews 1976; Wenger 1976;
Chait and Balster 1978a). Low rates of responding during the
early portions of each interval tend to be increased by PCP,
whereas higher rates during the later portions of each interval
tend to be decreased. During the fixed interval component of
complex schedules in mice, pigeons, and squirrel monkeys, overall
response rate increases can be seen at low doses. These in-
creases are considerably more dramatic in the mouse than in the
pigeon or squirrel monkey, even though average baseline rates
in all three species were comparable (0.56 to 0.74 responses/sec.).
PCP produces only dose related decreases in fixed ratio response
rates in all three species. Although the parameters in these
experiments differed somewhat, rough estimates can be made of
relative potency of PCP for disruption of fixed ratio performance.
These are shown in table 1 along with a comparable value for the
rhesus monkey (Balster and Chait 1976).
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TABLE 1
DOSES OF PHENCYCLIDINE PRODUCING 50% DECREASES IN FIXED RATIO
RESPONDING IN VARIOUS SPECIES OF LABORATORY ANIMAIS
Species ED 50
Mouse 10.00 mg/kga
Pigeon 0.70 mg/kgb
Squirrel Monkey 0.27 mg/kgc
Rhesus Monkey 0.08 mg/kgd
a. by inspection of dose response curve in Wenger and Dews (1976)
b. by inspection of dose response curve in Wenger (1976)
c. reported in Chait and Balster (19785)
d. by inspection of dose response curve in Balster and Chait (1976)
One interesting point fran this table is the relative sensitivity
of the two species of monkey. Even though the squirrel monkey
appears slightly more sensitive to the effects of FCP on observ-
able behavior, it is about 3 times less sensitive to its dis-
ruptive effects on food-reinforced fixed ratio responding. The
significance of this is unclear but it suggests that something
different from nonspecific disruption of gross behavior is re-
sponsible for the disruption of operant behavior in one or both
of these species.
STIMULUS PROPERTIES OF PCP
The stimulus properties of PCP were discussed in our earlier re-
view (Balster and Chait 1976) and there has been very little
published on this topic since then. Two studies have demonstrated
that PCP can serve as an effective discriminative stimulus in a
variety of response choice situations (Jarbe, Johansson, and
Henriksson 1975 ; Overton 1975). One of the applications of
drug discrimination studies is that they allow drug groups to be
classified by virtue of similar discriminative effects using
stimulus generalization procedures (Barry 1974; Schuster and
Balster 1977). Drug classifications based on discriminative
stimulus properties generally follow traditional pharmacological
classifications. Stimulus generalization studies with PCP suggest
that phencyclidine and related arylcyclohexylamines belong in a
class by themselves in that they do not transfer stimulus con-
trol to morphine, chlorpromazine, ditran, 9-tetrahydrocannabinol
and pentobarbital (Jarbe, Johansson, and Henriksson 1975; Overton
1975). Ketamine appears to be qualitatively similar to PCP, and
another related compound, N-ethyl-phenylcyclohexylamine (PCE),
also transfers stimulus control from PCP. This suggests that
PCE may produce effects similar to PCP and ketamine in humans,
and we have heard reports of confiscation of street samples of
this drug. The classification of arylcyclohexylamines on the
basis of their stimulus properties may be a useful way of pro-
viding evidence of potential PCP-like abuse in human populations.
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Two papers published in 1973 reported that PCP can serve as a
reinforcing stimulus in intravenous drug self-administration
studies in rhesus monkeys (Balster et al. 1973; Pickens, Thompson,
and Muchow 1973). This is particularly interesting in view of
the fact that although most drugs of abuse will serve this func-
tion, drugs classified as hallucinogens (Deneau, Yanagita, and
Seevers 1969; Hoffmeister and Wuttke 1975) and 9-tetrahydro-
cannabinol (Harris, Waters, and McLendon 1974; Camey, Uwaydah,
and Balster 1977) generally do not. This emphasizes the unique-
ness of PCP as a "hallucinogen." Recently it has been demonstra-
ted that ketamine is also reliably self-administered by rhesus
monkeys (Moreton et al. 1977). This represents another example
of the similarity between PCP and ketamine in behavioral studies
in animals. A behavioral pharmacological basis for differences
in the abuse liability of these two compounds has yet to be
found.
PCP INTERACTIONS WITH OTHER DRUGS OF ABUSE
It is important to study the effects of PCP in combination with
other drugs of abuse, as multiple drug use is widespread. This
may be a particularly important consideration with PCP since
street samples of PCP are often mixed with other drugs. The use
of PCP concurrent with the use of nicotine, alcohol and marihuana
undoubtedly occurs frequently, the former and latter being more
common because PCP is often administered by adulteration of
smoking materials. PCP combinations with other drugs of abuse
are also likely to occur. The possibility of increased toxicity
associated with these combinations should be thoroughly investi-
gated.
There have been no behavioral studies of the interaction between
PCP and nicotine or alcohol. Such studies are clearly indicated.
Pryor et al. (1977) have completed an extensive series of experi-
ments on the interaction between PCP and 9-tetrahydrocannabinol
(THC) in rats. In general, PCP enhanced the depressant properties
of 9-THC. For example, acute doses of PCP which had little or
no effect when given alone, enhanced the effects of 9-THC (1.25
to 2.5 mg/kg intraperitoneally) on conditioned avoidance re-
sponding, photocell activity, heart rate and body temperature.
On the other hand 9-THC antagonized the motor activity increases
produced by a high dose of PCP (5.0 mg/kg).
PCP Interactions with Pentobarbital
We have completed a series of experiments on the interactions
between PCP and sodium pentobarbital (PB). We have used a PCP-PB
canbination for anesthesia with rhesus monkeys for years. The
advantage of this canbination for short surgical procedures is
that the dose of PB necessary to reach a surgical plane of
anesthesia is reduced 2 to 3 fold. As a consequence the animals
recover consciousness in substantially less time than when PB is
given alone at higher doses, reducing the risk of postsurgical
complications. This use of PCP-PB combinations obviously suggests
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that PCP enhances the depressant effects of PB; therefore we
have sought to examine this interaction in a number of species
using a variety of measures.
The results of study (Chait and Balster 1978b) of the effects of
PCP on PB lethality in mice are presented in table 2.
TABLE 2
EFFECTS OF PHENCYCLIDINE ON PENTOBARBITAL LETHALITY IN MICE
Phencyclidine Pretreatment
Dose (mg/kg i.p.)
LD50a mg/kg i.p.)
of Pentobarbital (±95% C.L.)
0 110 (±23)
80 (±16)b3
30 53 (±12)c
a. calculated by the method of Litchfield and Wilcoxon (1949)
b. significantly different from Pentobarbital + Saline (p<.05)
c. significantly different from Pentobarbital + Saline and Pento-
barbital + 3.0 mg/kg Phencyclidine (p<.05)
A dose-dependent enhancement of PB toxicity was observed. The
animals appeared to die fran respiratory depression.
We also looked at this interaction in two species of monkeys
(Chait and Balster 1978b). A rating scale was designed which
reflects degrees of CNS depression produced by pentobarbital.
Scale values were: 0- normal movement and posture, l-does not
take offered food pellet, 2- unable to climb or maintain a sit-
ting posture without support, 3- unable to sit, 4- unconscious
with corneal reflex present, 5- unconscious with no corneal re-
flex, 6- unconscious with no corneal or pain reflexes (surgical
anesthesia). In the squirrel monkey, doses of 0.16 mg/kg PCP
and 12.5 mg/kg PB were studied alone and in combination. In the
rhesus monkey, doses of 0.2 mg/kg PCP and 25 mg/kg PB were studied
alone and in combination. Injections were given simultaneously
intramuscularly. The results are summarized in figure 1.
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FIGURE 1
Phencyclidine (PCP) -- Pentobarbital (PB) interactions in rhesus
and squirrel monkeys
In the rhesus monkey it can be clearly seen that a dose of PCP
which has very little effect when given alone markedly potentiates
the anesthetic effects of PB. The dose of PB used in this study
when given alone only results in some difficulty maintaining a
sitting position without support, but combined with PCP produces
a surgical level of anesthesia of approximately one hour's dura-
tion. The results with squirrel monkeys were quite different.
Although the dose of PCP and of PB used both produced greater
effects in this species when given alone, there was no evidence
of potentiation. This is an interesting and unexpected species
difference that warrants further investigation, particularly in
light of other data we have collected in the squirrel monkey
using schedule controlled behavior in which PCP failed to enhance
the response rate decreasing effects of PB (Chait and Balster,
unpublished data).
In spite of our failure to find evidence for a PCP enhancement of
PB effects in the squirrel monkey, the data from mice and rhesus
monkeys raises the question of potential toxicity which may re-
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sult from combined use of these drugs in human populations, On
the basis of the greater phylcgenetic similarity to man of rhesus
monkeys, we would, other factors being equal, place more weight
on this result. Another question we would raise concerns the
specificity of this interaction to PB. Does PCP enhance the
depressant effects of other barbituates, nonbarbituate sedatives,
benzodiazepines, and alcohol as well? Clearly, further research
in this area is indicated.
Phencyclidine Interactions with d-Amphetamine
One benefit of studying drug interactions with PCP is that the
results may provide clues concerning the neurochemical mechanism
of action of PCP. This is the case with PCP and d-amphetamine
interactions. There is some evidence that PCP may possess
dopaminergic activity. PCP has been shown to be a potent com-
petitive inhibitor of dopamine uptake in rat striatum (Smith et
al. 1975; Garey and Heath 1976). It has also ken shown to pro-
duce ipsilateral rotation in rats with unilateral lesions in the
substantia nigra, and this effect can be reversed by pretreat-
ment with alpha-methyl-para-tyrosine, haloperidol and pimozide
(Kanner et al. 1975; Finnegan et al. 1976). Ipsilateral rotation
is generally considered to be indicative of an indirect acting
dopamine agonist and is also produced by amphetamines. Since
stereotyped behavior produced by amphetamine (and perhaps the
amphetamine psychosis as well) is generally considered to be a
dopaminergic effect, it might be postulated that PCP would en-
hance amphetamine sterotypy. We have found this to be the case
with low doses of PCP in the rat (Balster and Chait 1978).
In two separate experiments a 9 point rating scale was used to
study the effects of various doses of PCP on stereotypy produced
by d-amphetamine. PCP at 2.5 mg/kg, which had no effect when
given alone, potentiated the stereotypy produced by 1 and 3 mg/kg
d-amphetamine. Higher doses of PCP produced ataxia and stereo-
typies when given alone. These higher doses did not enhance the
effects of d-amphetamine. Although these results are preliminary,
they are consistent with the hypothesis that PCP has dopaminergic
activity and suggest that PCP may enhance the behavioral toxicity
associated with stimulant abuse. They may also serve as a start-
ing point in the investigation of commonalities among the model
psychoses elicited by amphetamines (Snyder 1972; Ellinwood and
Kilbey 1978) and PCP (Luby et al. 1959).
TOLERANCE AND DEPENDENCE WITH PCP
There is conflicting evidence on the degree of tolerance develop
ment associated with chronic PCP administration. There is some
evidence from the veterinary use of PCP that the duration of
anesthesia decreases with repeated use (Martin et al. 1972). We
have reported a preliminary study of tolerance development in
rhesus monkeys (Balster and Chait 1976). PCP was given daily,
seven days a week, over a period of four months at doses beginning
at 0.2 mg/kg/day increasing to 1 mg/kg/day. Dose effect curves
60
for PCP effects on food reinforced operant behavior were obtained
before and after this chronic regimen. In two of the three mon-
keys a greater than 4-fold shift in dose effect curve was obtained;
in the third monkey, however, there was less evidence for toler-
ance development. In addition, the duration of observable motor
disruption in these three animals after chronic PCP administration
was shorter than in untreated monkeys. These same monkeys were
observed carefully for signs of withdrawal after discontinuation
of PCP. There was no clear evidence of any withdrawal symptom-
atology.
A more systematic study of the behavioral effects of chronic
PCP administration has recently been completed in squirrel mon-
keys (Chait and Balster 1978a). In this study five squirrel
monkeys were given chronic PCP at doses beginning at 0.2 mg/kg
once a day increasing to 0.6 mg/kg four times a day (2.4 mg/kg/
day) over a period lasting from 82 to 126 days. The regimens of
PCP doses more individualized for each subject to maximize toler-
ance development. Pre- and post- chronic dose effect curves for
the effects of PCP on operant behavior revealed approximately a
two-fold tolerance development. The most dramatic indication of
tolerance was in the duration of PCP-suppressed responding follow-
ing a dose of 0.6 mg/kg given before and after chronic dosing.
At this dose operant behavior was suppressed for an average of
125 minutes before chronic PCP and only 35 minutes after chronic
PCP.
As in the study with rhesus monkeys, there was no evidence for
disruption of operant behavior after the discontinuation of PCP
administration which might indicate a withdrawal syndrome. We
had a subjective impression that four of the five subjects demon-
strated unusually high excitability and apparent fearfulness
(biting, screaming, etc. with handling) during the first or,
more commonly, the second day of the withdrawal period, although
no systematic attempt was made to quantitate these observations.
No changes in body weight or food intake occurred during with-
drawal.
On the basis of our studies of chronic PCP administration in two
species of monkeys the following conclusions can be drawn. Toler-
ance can develop to the behavioral effects of PCP: this tolerance
is most easily observed as a shortened duration of effect. Toler-
ance development appears to be in the range of 2 to 4 fold. We
have been unsuccessful in pushing the extent of tolerance further.
It is important to keep in mind that the chronic regimens we
used were designed to maximize tolerance development and would
probably represent the upper limits of human abuse pattern. Con-
sequently the degree of tolerance to be expected with less vigorous
dosage conditions remains to be seen. At this point we also do
not know the mechanism for this tolerance. Pharmacokinetic,
pharmacodynamic and behavioral factors may all play a role. Ex-
periments designed to assess the relative contribution of each
of these mechanisms are indicated.
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A second conclusion to be drawn from our research is the lack of
evidence for development of physical dependence. Clear behavioral
or autonomic signs of withdrawal comparable to those seen with
chronic administration of opioids, barbituates or alcohol have
not been observed. Sane suggestion of irritability was observed
in the squirrel monkey, however. Systematic studies of potential
physical dependence development in various species would be useful
in clearly establishing the role dependence may play in chronic
PCP abuse.
SUMMARY AND CONCLUSIONS
We have reviewed the current status of our knowledge of the be-
havioral effects of PCP in subhuman species and have pointed to
some areas where more information is most critical. The follow-
ing tentative conclusions can be drawn: (1) There are marked
species differences in the effects of PCP on grossly observable
behavior. Various species of rodents show a pattern of response
to PCP which is most similar to that of psychomotor stimulants,
suggesting that catecholaminergic effects may predominate in
these species. The effects in subhuman primates appear to be
more "depressant" and qualitatively more like effects in humans,
although differences also exist in the response of rhesus monkeys
and squirrel monkeys to this drug. In spite of species differ-
ences in gross behaviors, the effects of PCP on operant behavior
have not been shown to differ qualitatively in different species;
however, very little research has been completed that bears upon
this. (2) PCP represents a unique class of psychopharmacolcgical
agents. The discriminative stimulus properties of PCP do not
generalize to drugs fran other pharmacological classes and, un-
like other hallucinogens, PCP is self-administered by rhesus
monkeys. Studies of the discriminative and reinforcing properties
of analogues of PCP in experimental animals may be a useful way
of evaluating their dependence liability. (3) PCP has been
shown to interact with 9-THC, pentobarbital and d-amphetamine.
It enhances the depressant effects of 9-THC, the anesthetic
effects of pentobarbital and the behavioral toxicity associated
with d-amphetamine administration. (4) With frequent high dose
chronic administration 2- to 4-fold tolerance can develop to some
of the behavioral effects of PCP, particularly resulting in a
shortened duration of action. (5) Preliminary data suggest that
PCP does not produce physical dependence comparable to that of
opioids or CNS depressants.
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Chapter 5
Phencyclidine Use Among Youth: History,
Epidemiology, and Acute and Chronic
Intoxication
Steven E. Lerner, M.S., and R. Stanley Burns, M.D.
INTRODUCTION
The growing popularity of phencyclidine throughout the United
States parallels the early histories of LSD and marihuana. The
initial passage of phencyclidine through the drug subculture in
1967 resulted in "bad reviews," attributed to the relative inex-
perience of drug experimenters. However, during the past three
years its popularity has rapidly increased among the now more
experienced drug users. In addition, the extensive use of clandes-
tine drug canbinations containing phencyclidine has resulted in
part in a marked rise in acute phencyclidine intoxications.
The medical problems emerging from the illicit use of this entirely
new class of psychoactive drugs are compounded by its myriad analogs.
With the advent of the polydrug abuse phenomenon, the widespread ex-
perimental and long-term use of phencyclidine has expanded at an
alarming rate. The large quantities of phencyclidine that have been
recently confiscated by law enforcement officials in California a-
lone, commensurate with the reported Drug Abuse Warning Network
"mentions" and associated deaths, are convincing indicators of a
new major drug problem.
This paper will present an overview of the pharmacology of phency-
clidine, including its. effects on animals and humans, and the his-
tory of its illicit use which is highlighted by factors related to
phencyclidine's increasing popularity. Data from three major Fed-
eral sources are compared with the results of the authors' hospital-
based youth study. The increased problems and deaths seen in a
community where phencyclidine has been continuously available are
presented and discussed.
A profile of chronic phencyclidine use includes a description of
the patterns of use, the phencyclidine experience, tolerance, psy-
chological dependence and side effects, chronic toxicity, and lab-
oratory and neurological findings.
A review of the acute intoxicated state caused by phencyclidine
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encompasses the presentation, clinical picture and course, labora-
tory and toxicological findings, diagnosis, management and treat-
ment.
AN OVERVIEW
Phencyclidine hydrochloride (Sernyl), discovered in the mid
1950's (Domino and Luby 1972) is a white, stable solid with a melt-
ing point of 234 - 236°C (Domino 1964). It is a weak base that is
readily soluble in water (Domino 1964) and highly lipid soluble at
physiological pH (James and Schnoll 1976). Animal studies reveal
low cellular toxicity and high potency for inducing surgical anes-
thesia without respiratory or cardiovascular depression in monkeys
(Greifenstein et al. 1958).
The drug was first tested on humans in 1957 (Greifenstein et al
1958; Rodin, Luby and Meyer 1958), and when given in doses of 0.25
mg/kg intravenously produced anesthesia sufficient for minor and
major surgery (Greifenstein et al. 1958). Phencyclidine was also
used as a preanesthetic agent for postoperative analgesia, for pain
syndromes, burn dressing, as an abreactive agent, and for the
treatment of psychoneurosis. Since the drug produced postanesthetic
confusion and delerium of prolonged duration in some cases, clinical
investigations were discontinued (Domino and Luby 1972; Chen, Ensor
and Bohner 1966).
Phencyclidine hydrochloride in solution was legally manufactured by
Parke, Davis and Company for use in humans as a short-acting anal-
gesic and for general anesthesia under the trade name Sernyl (Munch
1974). In 1967 the patent was changed to permit the manufacture by
Philips Roxane of the drug in solution as an analgesic for monkeys
and other primates under the trade name Sernylan. The Comprehensive
Drug Abuse Prevention and Control Act of 1970 classified phencycli-
dine with the barbiturates and LSD in Section 202(c), Schedule
III(b) (7) as . . . "having a depressant effect on the central nervous
system" (Munch 1974).
Phencyclidine and its better known derivative ketamine belong to
the arylcycloalkylamine group (Chen and Weston 1960) and have a
similar spectrum of activity. Administered to animals in increas-
ing doses, these drugs produce excitation, ataxia, catalepsy, gen-
eral anesthesia and convulsions. The characteristic autonomic
actions of these agents, hypertension and tachycardia, appear to
be due to central sympathetic stimulation (Chen and Weston 1960).
The degree of central nervous system stimulation and depression and
the anesthetic potency vary among the species (Chen and Weston
1960; Chen et al. 1959; and Chen 1965). Based on behavioral criter-
ia, phencyclidine and ketamine act primarily as central nervous sys-
tem depressants in both humans and monkeys. Immediate excitation
does not usually occur, whereas surgical anesthesia is more readily
induced in human than in other species (Domino 1964; Chen and
Weston 1960; and Chen 1965). Ketamine is less potent, has a shorter
duration of action, and produces convulsions less frequently (Chen
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et al. 1959; Domino, Chodoff and Corssen 1956; and Corssen and
Domino 1966).
Phencyclidine is active orally as well as parenterally (IM, IV) in
humans (Domino and Luby 1972; and Domino 1964). In several studies
involving normal subjects, comparable subanesthetic doses of phen-
cyclidine of 0.1 mg/kg given intravenously over 2 - 12 minutes or
7.5 mg orally consistently produced decreased touch, pain and posi-
tion sense associated with nystagmus, ataxia and hyperreflexia
(Domino 1964; Luby et al. 1959; and Davies and Beech 1960).
Impairment or increased threshold of audiometry, perimetry, visual
acuity and taste is seen (Danino 1974). Touch sense and two-point
discrimination were found to be the earliest, most pronounced and
persistent sensory effect in one study. Changes in muscle tone
ranging from a slight increase to catatonia and rhythmic motor
behavior have been reported (Luby et al. 1959). An increase in the
diastolic blood pressure of less than 10 mm with an increase in
pulse rate of generally 20 - 30 beats per minute were also noted.
Side effects included nausea with repeated vomiting, vertigo, ptosis
and diplopia.
With intravenous administration over five minutes, effects are im-
mediate, with prominent symptoms; lasting 1 - 2 hours (Luby et al.
1959). Following oral administration, subjects have reported
changes in their physical or psychological state within 45 minutes
with maximum effects at 90 minutes (Beech, Davies and Morgenstern
1961). In a similar study of five obsessional patients,given 5
to 10 mg phencyclidine orally, the point of onset at 30 - 60 minutes
and a duration of 1 - 3 hours were reported (Davies 1961).
Given intravenously in anesthetic doses of 0.25 mg/kg (or a total
dose of 17.5 mg) over thirty-five minutes, phencyclidine increases
the minute volume, rate and depth of respirations of law order. A
mean increase in minute volume of 1140 cc was measured in seven
normal patients. Their tidal volume and respiratory rates increased
a mean of 15.3 and 2.57 cc, respectively. A consistent and signifi-
cant mean increase of 26 mm Hg in systolic and 19 mm Hg in diastolic
pressure was observed. The pulse rate change was significantly in-
creased in three subjects and decreased in three subjects (Greifen-
stein et al. 1958).
In surgical patients given 20 mg of phencyclidine intravenously
following premedication with pethidine and atropine, no response
to pain appeared after a few minutes, and most patients were com-
pletely unresponsive for periods up to ninety minutes without res-
piratory depression (Greifenstein et al. 1958). Intravenous doses
of 0.275 mg/kg to 0.44 q/kg produced anesthesia for an average of
25 minutes in 735 patients. The duration of surgical anesthesia
with 0.5 - 0.75 mg/kg of ketamine is less than 5 minutes with re-
covery in l/2 to 1 hour (Chen, Ensor and Bohner 1966).
As a local anesthetic, phencyclidine is approximately equal to
procaine. However, the analgesic activity of the arylcyclohexyl-
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amines cannot be assessed in animals by standard testing procedures.
It has been suggested that their mechanism of action may differ from
the narcotic or the analgesic and anesthetic doses are too close to
differentiate (Chen, Ensor and Bohner 1966).
In subanesthetic doses there is general impairment of sensory func-
tion with a decrease in the appreciation for touch and pain the
earliest and most pronounced effects. Subjects are awake and able
to communicate with movement preserved and impaired only by ataxia
and occasional catatonia until consciousness is lost when higher
anesthetic doses are administered. Dissociation between sensory
and motor functioning at subanesthetic doses, implying a disturbance
of sensory-motor coordination, appears to occur.
Electrophysiologically, phencyclidine and ketamine induce a contin-
uum of subcortical and cortical (EEG) changes in animals, with
catatonia or immobility, consistent with central nervous system
stimulation. In animals and epileptic human subjects with implanted
depth electrodes, limbic arid temporal electrical seizure activity
has been observed following ketamine administration. The electrical
seizure activity is not always substantiated by convulsive behavior
or reflected in the conventional surface EEG (Ferrer et al. 1973;
and Winters et al. 1972).
The arylcyclohexylmines also have anticonvulsant properties, an-
tagonizing electrically induced tonic extensor seizures in mice in
doses causing ataxia and excitation, and suppressing pentylene-
tetrazol-induced, initial clonic seizures only at doses approaching
anesthetic levels. These properties are related to effectiveness
against generalized motor seizures in humans (Chen 1973).
Electroencephalographically, phencyclidine causes diffuse theta
and delta slowing in humans. In subanesthetic to anesthetic doses
paroxysmal activity is not evident. Changes induced by intravenous
infusion ranged from slight theta slowing in one of four volunteers
at 0.03 mg/kg to marked theta activity with a dominant medium volt-
age of 4 - 5 Hz rhythm in two volunteers given 0.2 mg/kg. The on-
set of frequency changes and their restitution in the electroenceph-
alogram were either gradual and stepwise or abrupt. These effects
ranged in duration from 15 to 60 minutes depending on the dose ad-
ministered and the magnitude of the changes induced.
In six persons given intravenous infusions of phencyclidine, a
decrease in fast activity occurred after 2 - 3 mg. At approximately
7 - 10 mg, a diffuse predominant slowing in the occipital, temporal
andparietal regions was observed. In the initial clinical trials,
doses of 1.0 mg/kg intravenously produced clinically observed
seizure activity (Greifenstein et al. 1958).
In humans, phencyclidine has psychotomimetic properties. The toxic
psychosis induced by low doses is characterized more by the overt
symptoms of schizophrenia than by hallucinations. Reproducing more
of the primary symptoms than other drug models, the psychosis pro-
duced in normal volunteers is difficult to distinguish  from
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schizophrenia (Domino and Luby 1972; Collins, Gorospe and Roven-
stine 1960; and Luisada and Reddick 1975). Extreme exacerbation
of existing psychoses followed the administration of phencyclidine
to chronic schizophrenic patients (Collins, Gorospe and Rovenstine
1960; and Luisada and Reddick 1975). The drug intensified disorder
in thought processes and stimulated considerable affect. Patients
acted out sexually and became more active, assertive and hostile.
These behavioral changes continued for one month (Luby et al. 1959).
Phencyclidine produces unique and profound alterations of thought,
perception and mood  in subanesthetic doses. The mental effects in
normal volunteers include changes in body image, loss of ego bound-
ary, and depersonalization associated with feelings of estrangement,
isolation and dependency (Luby et al. 1959; and Davies and Beech
1960).
Affectively charged experiences are often evoked and some subjects
exhibit negativism and hostility or apathy (Luby et al 1959; and
Davies and Beech 1960). Thinking is slowed with disruption of
attention span, inability to sustain organized directed thought
(Davies and Beech 1960), and impairment of learning. Subjects are
distractible and perseverate. Time appreciation is disturbed, with
underestimation of time intervals. Echolalia, neologisms, and
word salad may be observed with a loss of time "boundness." Some
subjects manifest echopraxia and repetitive motor behavior (Luby
et al. 1959).
Reaction time, tapping speed, rotatory pursuit performance and
weight discrimination have been reported to be impaired (Davies
1961).
The oral "sedative" dose for humans is considered to be between 1 -
5 mg. Following oral administration of a subanesthetic dose of 7.5
mg, subjects report changes in their psychological or physical state
within 45 minutes and maximum effects at 90 minutes (Beech, Davies
and Morgenstern 1961).
Under conditions of sensory isolation or reduced visual, auditory
and tactile stimulation, less disturbances of behavior and psycho-
logical processes are evident. Subjects experienced only minimal
body image changes and felt more in control and less anxious. They
were less productive verbally and appeared quieter and calmer. They
reported experiencing "nothingness" or "emptiness." When the sen-
sory isolation was stopped, subjects were immediately aware of the
perceptual distortions and became more disturbed. Some subjects
then experienced nausea or exhibited catatonia.
Following anesthetic doses of phencyclidine, patients were amnesic
for both surgery and the recovery period.
The psychotomimetic effects of phencyclidine are most apparent fol-
lowing administration of low doses. The anesthetic properties of
the drug associated with changes in the level of consciousness pre-
dominate after high doses.
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Profouud behavioral effects are seen in several species following
phencyclidine administration (Balster and Chait 1976). In the
monkey, reinforcing properties have been demonstrated by the init-
iation and maintenance of lever-pressing for injections of phen-
cyclidine. The drug is self-administered in amounts producing a
state resembling general anesthesia (Balster and Chait 1976; and
Balster 1976). It is the only "hallucinogen" reliably self-admin-
istered by monkeys, which suggests a potential for abuse (Domino
and Luby 1972; Luby et al. 1959; and Balster and Chait 1976).
Learned behavior in animals is sensitive to impairment or disruption
by phencyclidine (Danino and Luby 1972; Rodin, Luby and Meyer 1958;
Chen, Ensor and Bohner 1966; Munch 1974; and Balster and Chait 1976).
Discrimination studies indicate that the arylcyclohexylamines pro-
duce effects in animals different from other psychoactive substances
and probably constitute a distinct class of drugs (Chen and Weston
1960; Chen et al. 1959; Domino, Chodoff and Corssen 1965; Balster
and Chait 1976; and Corssen and Domino 1966).
Repeated administration of phencyclidine to monkeys and primates
has resulted in shortened periods of effective anesthesia after
several weeks or months of use. A similar tolerance to the anes-
thetic effect of ketamine has been reported (Luisada and Reddick
1975). In monkeys receiving ketamnie 3 - 5 times per week for 6
months, the duration of anesthesia was decreased by 40 percent.
Juvenile chimps receiving 3 doses in a one-week period required 50
percent more ketamine to maintain the anesthetic effects (Luisada
and Reddick 1975). Similar observations have been made in humans
with repeated use of ketamine anesthesia in the treatment of burns
(Chen and Weston 1960).
There is some recent evidence of tolerance development to the dura-
tion and intensity of the effects of phencyclidine on operant behav-
ior in monkeys with daily administration over a 4-month period.
Studies examining physical dependence to phencyclidine associated
with the chronic intoxicated states do not appear in the literature
(Balster and Chait 1976).
In various animal species, phencyclidine has a relatively short dura-
tion of action (Domino 1964). In the monkey, for example, it is
rapidly metabolized and excreted in the urine as conjugated di- and
mono-hydroxy metabolites (Ober et al. 1963; and Glazko 1967).
After single intravenous doses, 60 percent of the radioisotope la-
bels were recovered in the urine within twelve hours, and approxi-
mately 75 percent in eight days (Ober et al. 1963). In humans, the
relative concentrations of mono-hydroxy metabolite and the parent
compound phencyclidine recovered in urine after acid hydrolysis and
assayed by gas liquid chromatography were 68 percent and 32 percent,
respectively. No di-hydroxy metabolite was evident (Ober et al.
1963). Subsequently, two mono-hydroxyl metabolites were detected in
urine from patients acutely intoxicated with phencyclidine after en-
zymatic hydrolysis (Lin et al. 1975). There is no evidence that
these two compounds possess cataleptic anesthetic activity.
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Tissue distribution studies in animals demonstrate relatively high
and persistent concentrations in adipose and brain tissue with lower
and rapidly falling blood concentrations (Lin et al. 1975; and
Corssen and Domino 1966). These results are consistent with the
drug's pKa of 8.5 and lipid partition coefficient at physiological
pH (Done et al. 1977). The half life in rat blood after IP injection
is approximately 3 l/2 hours. The drug concentration half life in
the dog followed intravenous administration is approximately one
hour (Lin et al. 1975).
No evidence of acute cellular toxicity was reported in the first
1,000 patients who received phencyclidine as an investigational
drug. However, phencyclidine with restraint stress produced in-
creased muscle enzyme (CPK, aldolase) levels and skeletal muscle
pathology in rats. One of seven human subjects had an increased
CPK level following phencyclidine administration.
In acute phencyclidine intoxication with coma, CPK levels greater
than 500 units are frequently found. In several cases where CPK
has been above 20,000 units, rhambdomyolis preceded myoglobinuria
and renal failure. Whether this represents direct muscle toxicity
or is secondary to coma and muscle compression is unknown.
Evidence of hematologic, hepatic or renal toxicity was not found by
the authors in their study of chronic use of phencyclidine for
periods greater than 6 months andupto 5 1/2 years by history.
Several female patients seen by the authors have by history used
phencyclidine regularly preceeding and during pregnancy with their
infants being in apparent good health. One infant born to mother
who used phencyclidine regularly just prior to delivery exhibited
poor feeding, a poor sucking reflex and irritability.
Phencyclidine can be detected in concentrations of 1:1000 after
extraction with an organic solvent fran an aqueous solution by a
color reaction with gold branide or potassium permanganate (Munch
1974). The drug has been identified and quantitatively determined
in extracts of body fluid (blood, urine, CSF) and. tissues by thin
layer chromatography, gas liquid chromatography with flame ioniza-
tion detection, and with gas chromatography - chemical ionization
mass spectrometry (James and Schnoll 1976; Reynolds 1976; and
McLeod, Green and Seet 1976).
The History of Illicit Phencyclidine Use
Street preparations of phencyclidine have continuously changed in
name, physical form, and content.
Phencyclidine is sold on the West Coast by such labels as Angel Dust,
Cannabinol, Crystal, PCP and THC (Lundberg, Gupta and Montgomery
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1976; Radcliff 1975; Perry 1975; Burns et al. 1975; and Burns and
Lerner 1976). In the Midwest, among its street names are DUST, TAC
and TIC (Drug Enforcement Administration 1975). On the East Coast
phencyclidine is sold as Angel Dust, Erth, Green, KW and Sheets.
Recently phencyclidine has been identified as being present in
samples sold under 46 different names (See Table 1). Many of these
street nomenclatures are regional while others arenationalin scope.
Although phencyclidine is represented under a multitude of names,
the most consistent misrepresentation is "THC" (Burns et al. 1975;
Burns and Lerner 1976a, Burns and Lerner 1976b, and Lerner and
Burns 1978).
When sold as THC in tablet or powder form the color may be beige,
brown, blue, green, orange, pink, red, strawberry, white or yellow.
Phencyclidine sold as PCP usually appears beige, gray brown, orange,
speckled pink, tan white, white gray or white yellow in color.
Physical form varies fran the frequent tablet, powder, crystalline,
and granular amorphous solid to the rare liquid.
Phencyclidine has appeared on the illicit market as a powder, a
tablet, a leaf mixture (Lundberg, Gupta and Montgomery 1976; and
Radcliff 1975), a liquid, and one gram "rock" crystals. The crys-
talline or granular form is found most frequently in capsules.
Phencyclidine on parsley, mint, oregano or other leaves is usually
found in the form of a joint. Most street preparations contain the
hydrochloride salt, although phencyclidine as the free base has been
seen (Shulgin and MacLean 1976).
Since 1975, only 25 percent of the street drug samples containing
phencyclidine have contained additional drugs, a smaller percentage
than in earlier years. In 1971 - 1974, other drugs were found in
40 - 60 percent of street samples analyzed at the Street Drug In-
formation Program at the University of Southern California of
Medicine. LSD was present in 86 percent of all combination prep-
arations, with the "caine" drugs accounting for another 4 percent.
Four percent of the samples contained two or more additional drugs.
Phencyclidine was mixed with marihuana in only two of 317 samples
(Lundberg, Gupta and Montgomery 1976). This trend has also been
reflected in other street drug analysis programs across the United
States. Recently, phencyclidine and its thienyl analog (TCP) have
been identified in over 10 percent of all samples analyzed at the
University of Southern California. Only 3 percent of the samples
containing phencyclidine were actually sold under the designation.
The crystalline or granular powder form is found most frequently as
Crystal or Angel Dust, which usually contain 50 - 100 percent phen-
cyclidine. Found under other names, the purity drops to a range
of 10 - 30 percent. Most tablets contain approximately 5 mg and
tend to range from 1- 6 mg (Lundberg, Gupta and Montgomery 1976;
Radcliff 1975; and Drug Enforcement Administration 1975). Leaf
mixtures have been found to contain between 0.24 - 7.9 percent phen-
cyclidine, averaging 1 mg phencyclidine per 150 mg leaves (Lundberg,
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TABLE 1
NAMES GIVEN FOR MATERIAL CONTAINING PCP-TCP
Name
Amphetamine
Angel Dust
Belladonna
Cocaine
Cadillac
Cannabinol
Crystal
Cyclones
Detroit Pink
DMT (N,n-dimethyltryptamine)
Dust
Elephant tranquilizer
Erth
Gocn
Green
Hashish
Hog
Horse tranquilizer
Killerweed
KJ crystal
KW
LSD (lysergic acid diethylamide)
Marihuana
MDA (3,4-methylenedlaxyamphetamine)
Mescaline
Mintweed
Mist
Monkey Dust
PeaCe Pill
PCPA (para-chlorophenylalamine)
Peaceweed
Peyote
Psilocybin
Rocket fuel
Scuffle
Sheets
Snorts
Soma
STP (3-methyl-2,6-dimethoxyamphetamine)
Superweed
Surfer
T
TAC
THC (tetrahydrocannabinol)
TIC
TT-1
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Gupta and Montganery 1976).
Phencyclidine is taken orally, by inhalation (smoking), insufflation
(snorting), and rarely by the intravenous route.
Street samples analyzed have contained phencyclidine in combination
with other drugs (barbiturates, ethyl alcohol, heroin, cocaine,
amphetamine, methaqualone, LSD, mescaline, procaine). Combination
preparations which contained phencyclidine (phencyclidine-procaine,
phencyclidine-marihuana, phencyclidine-caffeine, phencyclidine-
cocaine, phencyclidine-doxepin, phencyclidine-LSD, phencyclidine-
LSD-mescaline, phencyclidine-LSD-aspirin, phencyclidine-LSD-procaine
and some 4-5 drug combinations) have also appeared on the illicit
market. In addition the presence of PCC (1-piperidinocyclohexane-
carbonitrile) as a contaminant in some illicit phencyclidine prep-
arations has been detected (Helisten and Shulgin 1976).
The information needed for the preparation of phencyclidine was
reported over 50 years ago with descriptions of the reaction of
1-piperidinocyclohexanecarbonitrile  (PCC) with Grignard reagents
(Shulgin and MacLean 1976). The majority of the illicitly syn-
thesized phencyclidine is prepared according to the general direc-
tions of Kalir and modified in details as required by the avail-
ability of chemicals and equipment. Until recently most batch
operations were limited by the amount of piperidine to be used
(usually a maximum  of 500gms) and would produce on a 3 - 5 mole
scale (Shulgin and MacLean 1976).
Piperidine was felt to be the most guarded reagent and the easiest
to trace and for these reasons manufacturers would pay as much as
$1,000/kg for a non-traceable bottle. Now piperidine is no longer
the "limiting step" as it has become readily available, leading to
the manufacture of larger quantities of phencyclidine.
In addition, a new solvent for distillation that should prevent
fires and explosions is now available. Manufacturing is now done
in larger, better equipped laboratories that are capable of produc-
ing great quantities of phencyclidine. Illegal laboratories con-
taining as much as 25 million dollars worth of phencyclidine have
been raided. The last major seizure (in the Los Angeles area)
of an illicit laboratory in 1977 yielded 900 pounds of phencyclidine.
Recently an illegal laboratory was raided by the Drug Enforcement
Administration in the Michigan area. Officials estimated that the
$200 investment in chemicals could produce phencyclidine worth ap-
proximately $200,000 on the street.
According to the Drug Enforcement Administration, major production
centers have been discovered in Washington, D.C., Detroit, Los
Angeles and San Francisco.
Complex and formal distribution systems now exist which mirror the
heroin connection. In some areas phencyclidine has surpassed heroin
in street price. The same criminal elements that are selling
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opiates are now also selling phencyclidine. Phencyclidine sold as
THC or Angel Dust is usually worth from $25 - $200 per gram and
upwards of $1000 an ounce. Individual phencyclidine joints vary
from $1 - $20 or more.
Various patterns of phencyclidine use have emerged over the past
several years. First time users report stoking a cigarette con-
taining phencyclidine unknowingly or in an experimental fashion.
Although the occasional or recreational use pattern is seen, its
development is mediated by an initial experience of unexpected and
unpleasant effects (Burns et al. 1975; and Burns and Lerner 1978).
In areas where the drug has been continuously available, it has
gained a preferred drug status with small cluster groups of in-
dividuals who have used it on a chronic, daily basis for periods
of six months to six years (Burns et al. 1975; and Bums and Lerner
1978). Requests for the authors services through a national con-
sultation service (Lerner, Bums, Linder and Associates) reveal
chronic users in California, District of Columbia, Hawaii, Kansas,
Kentucky, Maryland, Nevada, and Washington.
In the San Francisco - Oakland area chronic users purchase phency-
clidine in gram amounts ranging from $85 - $125 per gram. Money
for the purchase of phencyclidine is generally provided by a part-
ner through dealing, hustling, or Social Security Insurance (SSI).
Wholesale dealer's costs average fran $40 - $50 per gram, $200 -
$300 per quarter ounce, and from $700 - $1,000 per ounce.
Factors Related to Increased Phencyclidine Popularity and Use
When phencyclidine made its illicit debut in 1965 it was marketed
as a mild psychedelic. Dealers described this new drug as a mild
psychedelic, "a little stronger than marihuana," and sold it in
tablet and capsule form. The effects were often unexpected. Since
the dosage could not be titrated, users often experienced an adverse
reaction. Hence, phencyclidine gained a bad reputation and subse-
quently was not seen on the streets.
By 1972, a change was observed in both themethodof use and the
attitude of users about the drug. A conversion had taken place
from using phencyclidine orally in tablet or capsules to smoking
it on leaf material. By this newly discovered method the user was
able to more effectively control the dosage, thus decreasing the
chance of overdose. Experienced users for the first time were able
to inform new users how to take it effectively and to describe what
the effects would be like. As first time users were now being
prepared for this unique experience and with better methods of con-
trolling the dosage, the popularity of phencyclidine spread rapidly.
Illicit laboratories increased in proportion to the new demand for
material.
Because of the ease of manufacturing phencyclidine in clandestine
laboratories, its availability has dramatically increased. Youth
are now using phencyclidine in social settings in a similar fashion
to marihuana. As other drugs of abuse become difficult to obtain,
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phencyclidine in many areas is continuously available. Hence,
groups of users are likely to select phencyclidine as their drug
of choice and to share it with their friends.
Due in part to the lack of full infomation about the effects and
dangers associated with phencyclidine,the drug continues to ex-
pand in popularity among youth. In general, users are still under
the misconception that phencyclidine is merely "a little stronger
than marihuana." Young users who were questioned about the dif-
ferences between LSD and phencyclidine uniformly responded that
LSD was a much more dangerous drug and that they would not use it.
Phencyclidine, however, does not have this connotation. until
this is changed, usage is likely to continue to increase.
The abuse of phencyclidine and other arylcyclohexylamines has
emerged over the past 12 years. As stated earlier, phencyclidine
was first seen illicitly in 1965, in Los Angeles (MacLean 1977).
Two Years later it appeared in San Francisco under the guise of
the "PeaCe Pill" (Bums et al. 1975). With media coverage of the
adverse effects, phencyclidine disappeared from the street scene
in the San Francisco area in 1968, at which time it surfaced on
the East Coast under the guise of "Hog." Since then it has been
seen with increasing frequency throughout the United States.
In 1969, the N-ethyl analog of phencyclidine, PCE, cyclohexamine
appeared on the streets in Los Angeles (Shulgin and MacLean 1976).
By 1972, due to the "ripple effect," phencyclidine appeared in five
states, from California to New York (see Table 2). It should be
noted that the PharmChem Research Foundation, which provided this
data, is only one of many street drug analysis programs operating
in the United States. Therefore, the epidemiology of its abuse
is riot necessarily reflected by these figures. Louisville, Kentucky,
and Eugene, Oregon presented the greatest increases in street drug
samples containing phencyclidine.
In 1974, the Thiophene analog of phencyclidine, TCP, was first
identified in Hawaii. That same year phencyclidine had spread into
another four states.
By 1975 the use of both phencyclidine and TCP had spread to 22
states. TCP was sold on the West Coast in Los Angeles, Newport
Beach, Santa Cruz and Sacramento. Outside of California, TCP was
being sold in Eugene and Coos Bay, Oregon, and Seattle and Tacoma,
Washington.
In 1976 phencyclidine appaared in another two states. The use of
TCP decreased slightly, although it remained popular in Oregon and
Washington
During the first eleven months of 1977, phencyclidine was identified
in 28 states, exceeding all prior years. For the first time samples
of phencyclidine were received from Indiana, Kansas, and Nevada.
Since these samples were in the powder form, the possibility of
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TABLE 2
DISTRIBUTION OF PCP-TCP BY STATE*
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sophisticated chronic use was evident. Although they were Pharm-
Chem's first samples from these states, it is unlikely that phen-
cyclidine had not been available previously. For example, although
PharmChem's first sample from the Kansas area was received in 1977,
the number of cases seen by the District Attorney's Office in
Plathe, Kansas, had doubled during that year.
Recently PHP 1-(1-phenylcyclohexyl)pyrrolidine was identified on
autopsy in the body of an individual who was shot and killed by
a police officer in Los Angeles - the first documented street ap-
pearance of this analog.
Demography - Epidemiology of Illicit Use
A dearth of literature exists on the nature and extent of use of
phencyclidine and its 30+ analogs. The major Federal sources for
determining changes in emerging drug trends are the Client Oriented
Data Acquisition Process (CODAP), the Drug Abuse Warning Network
(DAWN), and the National Youth Polydrug Study (NYPS).
The CODAP system provides the largest available national data
base of patients in treatment. All drug abuse treatment and re-
habilitation programs receiving Federal funds are required to
collect and report data.
Drugs of abuse are divided into 14 categories. Phencyclidine is
classified incorrectly as a hallucinogen, with LSD, mescaline,
MDA, DMT, musuhrooms, peyote, and other drugs. Since CODAP has no
flexibility in identifying and analyzing phencyclidine independently
from the other drugs, this data source is not useful for our pur-
poses.
The DAWN system has been in operation since the spring of 1973.
Hospital emergency rooms and inpatient units, crisis centers and
medical examiners (coroners) in 24 selected Standard Metropolitan
Statistical Areas (SMSA's) are contracted to report incidents of
adverse drug reactions to the DAWN central office. In each report,
the victim's age, sex, race, employment and treatment status are
noted, as well as the drug used, the route of administration, the
source of the drug, and the form in which it was acquired.
DAWN data, however, includes only those phencyclidine users who
hadadversereactions that required agency intervention. There
is no record of the user who ingests phencyclidine without an ad-
verse reactionor who handled such a reaction without agency in-
tervention.
Also, the DAWN data are collected only in the major SMSA's. As an
example, in California, DAWN data are collected only for the Los
Angeles, San Francisco - Oakland and San Diego areas. Data are not
available fran 51 of California's 58 counties. Even within these
reporting counties the DAWN reporting system- emergency rooms,
inpatient units and crisis centers - is not complete. That is,
within these communities many phencyclidine-related problems are
79
treated that are never reported to DAWN.
Those phencyclidine cases which are reported frequently lack com-
plete information. The victims are often not in sufficiently
stable condition to respond properly to questions and are not
commonly reinterviewed upon recovery.
Fran September 1972 through March 1973, phencyclidine was ranked
as the twenty-third most abused drug in the DAWN system. During
the period fran April 1973 through March 1974, it rose to the
twenty-first position. By the following year, April 1974 through
April 1975, phenyclidine use had increased to the fifth position.
For the reporting period from May 1975 through April 1976, phen-
cyclidine continued to rank overall as the sixteenth most fre-
quently abused drug. For the youth population between 12 and 18
years of age, however, it was in tenth place.
For this youth population between February and May 1976, there
were 294 patients treated in emergency rooms, 330 patients seen
in crisis centers, and 2 patients seem by coroners. During the
same period phencyclidine ranked as the eleventh most frequently
abused drug in Philadelphia and Washington, D.C.; seventh in
Chicago and Cleveland; fifth in Minneapolis and Los Angeles; fourth
in Detroit; and first in the San Francisco - Oakland area.
White males (61 percent) are twice as likely as white females
(32 percent) to report to DAWN emergency room. For crisis centers,
however, white males and females are reported at approximately the
same rate, 42 percent. The use of phencyclidine by minorities ac-
counts for only 6 percent of the mentions from crisis centers and
7 percent from emergency rooms.
Ninety-one percent of phencyclidine users seen in crisis centers
reported their source as a "street buy," whereas with emergency
rooms only 49 percent reported "street buys" as their source.
The prime motivation for phencyclidine use among patients seen in
both crisis centers and emergency rooms is for the "psychic ef-
fects," which account for 73 percent of the mentions. Phencyclidine
users from the crisis centers are much more prone (28 percent) to
report dependence as their motivation than are the users from
emergency rooms (2 percent).
Crisis centers data indicate that the age group of 12 to 13 years
for white females seems to be at particularly high risk. Further-
more, 42 percent of the phencyclidine mentions in this age group
reported dependence as their prim motivation for use.
Fran September 1976 to March 1977, youth from 12 to 18 years of age
were interviewed on admission for drug treatment as part of the
NYPS. In all, 2750 patients from 97 treatment program in 39 States
participated in this study.
These patients represented a national sample of youth in treatment
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from all regions, and from the major treatment modalities. They
were sampled selectively for sex, race, and ethnic grouping by
geographic region. Information contained in this new data base is
the most comprehensive data available on youthful abusers.
There is a high degree of similarity between the NYPS sample and
the CODAP youth subsample. Hence, information obtained from the
NYPS on drugs of abuse such as phencyclidine that are not reported
separately in CODAP may now best estimated using this new data source.
PCP Use Within the NYPS Sample
Of the 2750 clients under 19 years of age in the NYPS sample, 857
(31.8 percent) reported having ever used PCP, with 561 reporting
the use of PCP during the three months prior to admission. The
prevalence of PCP in this sample is the highest reported in any
national sample for adults or for youth. PCP ranked seventh in
prevalence among the fourteen types of drugs in the sample, and
it was abused more frequently than many other well known substances
such as inhalants (abused by 28.9 percent of the sample), other
sedatives (abused by 28.8 percent), or cocaine (abused by 25.8
percent). A comparison of PCP users with clients who never used
PCP (see Table 3) indicates that similar proportions of both males
and females use PCP (32 percent); that proportionately more whites
use it than other racial groups (42 percent of whites compared to
8 percent of blacks, 13 percent of American Indians, and 9 percent
of Hispanics); that PCP use is more frequent in the suburbs (44.1
percent of all suburban clients compared with about 30 percent
from urban and rural settings); that PCP users are slightly older
at admission, with somewhat more years of education and have a
higher Socio-Econcmic Status than users of other drugs.1
Frequency of Use of PCP. Among the 561 current users of PCP (see
Table 4) approximately 50 percent were found to be using it at an
average frequency of at least once per week during the three months
prior to admission.
The Onset of PCP use. The man age of first PCP use was 14.6 years
of age and the mean age of first continuous use was 14.8 years.
Females reported the earlier mean age of first use for PCP: 14.4
years compared to 14.7 years for males. This finding is consistent
with most other drug types in this study (except alcohol, marihuana,
and inhalants).
In the comparison of age of first use of PCP across ethnic groups,
American Indians were noted to have the earliest mean age of first
use (13.89) closely followed by Hispanics (14.00). (The number of
PCP users in these two groups, however,was too small to draw any
inferences.) Whites reported the third earliest age of PCP use
with a man of 14.58, and blacks were the oldest (15.25).
Regional Distribution of PCP Use. The National Youth Polydrug Study
divided the United States into seven sampling regions. It should
be stated that the sample was not stratified by region, which mans
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TABLE 3
COMPARISON OF SUBJECTS WHO “EVER USED” WITH THOSE WHO “NEVER USED”
PCP, ON DEMOGRAPHIC AND BACKGROUND CHARACTERISTICS
used PCP Did not use PCP Total
sex
Males 534 (31.9%) 1138 (68.1%) 1672 (100%)
Females 336 (31.6%) 725 (68.4%) 1061 (100%)
= .02(N.S.)
dfs = 1
Race
White 784 (42) 1068 (58) 1852 (100%)
Black 33 (8) 354 (92) 387 (100%)
American Indian 18 (13) 116 (87) 134 (100%)
Hispanic 27 (9) 274 (91) 301 (100%)
= 282.3
dfs = 3
p<.0001
Residence
Urban 544 (29.9) 1274 (70.1) 1818 (100%)
Suburban 194 (44.1) 246 (55.9) 440 (100%)
Rural and
Small Town 131 (29.6) 312 (70.4) 643 (100%)
= 34.2
dfs = 5
p<.001
Age
Education
Socioeconomic
status
S.D. N x S.D. N t p<
16.2 1.4 875 15.8 1.3 1874 7.1 .001
9.4 2.6 873 9.0 2.5 1853 3.7 .001
45.4 13.8 875 41.0 15.1 1874 7.6 .001
82
TABLE 4
CURRENT FREQUENCY* OF PCP USE BY SUBJECTS
CURRENTLY USING PCP
Less than once a month
Once a month
Two to three times a month
Once a week
Two to three times a week
Four to six times a week
Daily
Twice a day
Three or more times a day
N
97
69
112
83
99
28
41
12
20
561
%
17.3
12.3
20.0
14.8
17.6
5.0
7.3
2.1
3.6
100.TOTAL
* "Current" frequency is defined as the average frequency of use
during three-month period before admission
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the proportion of the youth population in treatment in each region
was not a criterion for inclusion in the sample. It may be that
certain states are overrepresented in proportion to their popula-
tion, e.g., the relatively large number of cases in the sample
from Illinois and Florida. Conversely, we know from the DAWN
system that the San Francisco Bay area is one of the centers of
PCP use, and is underrepresented in this sample.
The regional prevalence of PCP in the NYPS sample indicates that
the Great Lakes and the Midwest regions show the highest rate of
PCP use with 46.6 percent (N = 270) and 46.4 percent (N = ll6) of
each region's clients ever using PCP. Since the number of clients
from these regions is fairly large and these clients were adimitted
to 29 different treatment programs these data seem to be a valid
representation of PCP use in these regions. They exceed the rates
reported in DAWN and probably reflect the increased trend of PCP
use among youth during the past two years. Other regions show PCP
to be used by 31.5 percent of the clients from the Southeast
(N = 153); by 27.2 percent of the clients from the West Coast; by
24.2 percent of clients from the Northeast; and by 23.8 percent of
clients from the Southwest.
The PCP User vs. the Nonuser. Perhaps one of the most notable
differences those who ever used PCP and those who did not
is the greater involvement of the PCP users in polydrug abuse: PCP
users reported using twice as many substances as the nonuser of PCP,
with PCP users reporting a mean of 6.0 substances ever used (S.D. =
2.6), while nonusers of PCP reported a mean of 2.8 substances ever
used (S.D. = 1.8), (t = 33.4, p < .0001). PCP users also reported
a higher mean number of drugs used during the three months prior
to admission to treatment: 5.8 substances (S.D. = 2.6) compared to
a man of 2.6 substances (S.D. = 1.8) by nonusers of PCP (t = 28.1,
p < .0001). Thus, for this youth population seeking treatment for
drug abuse, PCP use is an integral part of a larger polydrug abuse
problem that is more serious and complex than for the nonuser of
PCP.
It is of particular interest that not a single subject who used PCP
in this study used only this substance. All PCP users used other
substances either at other times or concurrently with PCP. Almost
all of them users used marihuana: 99.5 percent. other drugs
reported used by PCP users were: alcohol (by 97.7 percent of PCP
users); hashish (by 77.8 percent of PCP users): amphetamine (75.8
percent); hallucinogens (72.2 percent). Aside from alcohol and
marihuana, which are almost universally used in this sample, and
aside from hashish, PCP is next most often used by users of ampheta-
mines and hallucinogens.
When looking at the use of multiple drugs from the other direction,
we find that the users of other sedatives (61.7 percent), over-the-
counter drugs (61.6 percent) and other opiates (61.1 percent) were
most likely also to have ever used PCP.
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A Profile of the PCP User
A correlational profile of the PCP user was developed from analysis
in which PCP use was correlated with each of 33 demographic, social
history, and background variables. A three points scale measure was
utilized for PCP use, as follows: a score of 1 was assigned for no
PCP use, a score of 2 for irregular PCP use, and a score of 3 for
regular PCP use. Table 5 presents the list of the 18 variables
(from among the 33) which had a bi-variate correlational value of
+ .10 or greater with PCP use. The profileof the PCP users (com-
pared to the nonusers), which was derived from this analysis, is
as follows, (listing the descriptors in rank order of magnitude of
the correlation): (1) used regularly a greater number of different
drugs; (2) white; (3) more often took more than one drug at a time
(in combination) "to boost, balance or counteract the effects" of
one drug; (4) became drunk from drinking alcohol more often; (5)
had more arrests for substance related offenses; (6) were picked up
more times by the police; (7) had more overdose episodes (OD's);
(8) reported more obstacles to school attendance; (9) had more
arrests for violent and weapons offenses; (10) listed more types
of problems as reasons for contacting a treatment program; (11)
more arrests for property offenses; (12) higher socio-economic
status; (13) older; (14) adjudicated delinquent; (15) tended to
reside in suburbia; (16) more often was admitted to treatment in
hospitals and residential settings than to outpatient settings:
(17) more often made suicidal attempts; and (18) less often were
referred to treatment by peers.
Predicting "Regular" use of PCP. The variables employed in con-
structing the profile of the PCP users were also used to "predict"
regular use of PCP. Clients were divided into two groups, regular
PCP users (those using PCP at least once a week for a period of
at least one month) and those who did not use PCP at all. Clients
who had used PCP minimally, but never at a frequency of at least
once per week for a period of one month, were excluded from this
analysis. The analysis was composed of two steps: first, a bi-
variate correlation of all the variables includied in the analysis;
second, a step-wise multiple regression in which the dependent
variable is the regular use of PCP and the independent variables
are a subset of the variables appearing in the correlation.
The bivariate correlation of the variables employed to predict
regular PCP use showed that the strongest association of regular
use of PCP is the number of substances regularly used ("Regsum"):
r = .63. Since it seems reasonable to consider the relationship
of demographic and other variables to PCP use separately from the
question of how many other drugs the subject has used, we did not
include this variable, "Regsum," in the equation of the step-wise
multiple regression. The other background variables accounted for
16.8 percent of the variance in the differentiation of the regular
PCP users from the nonusers (see Table 6). It might, thus, be said
that it provides only one-sixth of the information that would be
needed to "predict" accurately regular PCP use. The rank order of
these variables, according to their relative abilities to "predict"
to regular PCP use is as follows: (1) Race, (being white), ac-
counts for 9.1 percent of the variance; (2) "the number of times
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TABLE 5
CORRELATIONS OF CLIENT DESCRIPTORS WITH REGULAR USE OF PCP
Correlation With
Regular PCP Use
Number of drugs regularly used .63
Race (white) .31
Used more than one drug at a time .31
Number of times became drunk .22
Number of arrests for drug offenses .19
Number of O.D.'s .18
Number of times "picked up" by the poice .18
Number of obstacles to school attendance .17
Listed more types of problems as reasons
for entering treatment
Number of arrests for violent and
weapons offenses
Socioeconomic status
Number of arrests for property offenses
Age of admission
Adjudicated delinquent
Treatment program located in the suburbs
Admitted to outpatient drug
treatment program
Referred to treatment by peers
Number of suicide attempts
.16
.16
.14
.14
.12
.12
.11
-.11
-.10
.10
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TABLE 6
THE REGRESSION OF DEMOGRAPHIC AND OTHER HISTORY VARIABLES
ON REGULAR USE OF PCP
(STEP-WISE MULTIPLE REGRESSION PROGRAM)
(DEPENDENT CRITERION VARIABLE: REGULAR USE  OF PCP)
Variable Beta Significance Variance(R2) Simple
Race (1 = white; 0 = other) .22 p = .0001 .091 .30
Frequency of Getting Drunk .12 p = .0001 .025 .22
# of O.D.'s .11 p = .0001 .02 .18
# of Obstacles to School
Attendance .12 p = .0001 .012 .17
Age .08 p = .0001 .004 .12
Suburban (1 = from the suburbs
0 = other) .06 p = .001 .004 .11
Referred by Peer -.06 p = .002 .002 -.10
Socio Economic Status .03 p= .20 .001 .13
Months Employed Last Two Years .02 p = .21 .001 .11
Death of a Parental Figure -.03 p = .13 .001 -.03
Intact Family Structure
(0 = Intact; 1 = broken) -.02 p = .20 .001 -.02
Sex .02 p=.37 .00
# of Suicide Attempts .01 p= .68 .09
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the client got drunk" was the next variable in the equation, and
added 2.5 percent to the explained variance, after controlling for
race; (3) the number of OD's added 2.0 percent to the explained
variance, after controlling for the two previously indicated vari-
ables; (4) "the number of obstacles to school attendance" added
1.2 percent to the explained variance, after controlling for the
above-listed variables: (5) age added 1 percent; (6) suburban resi-
dence (versus living in an urban or rural location) added .4 per-
cent.
The variables that did not enter into the equation to a statistic-
ally significant degree in explaining or predicting regular PCP
use were sex, socioeconomic status, education, the number of months
employed in the last two years, intactness of the family, and the
number of suicide attempts. Some of these variables did not enter
into the equation since they are significantly correlated with
variables that had already been entered into the regression equa-
tion. For example, SES and employment are related to being white
(race) and living in the suburbs (residence). Suicide attempts
may have been excluded from the equation since they are correlated
with OD's (r = .15). Education, which is highly related to age,
was not included in the regression for the same reason. However,
the sex variable was excluded from the regression equation because
it was not associated with regular use of PCP; there is no differ-
ence between the sexes in their predisposition to be regular users
OF PCP.
The PCP User in the NYPS-A Summary. The above review of PCP use
in the NYPS indicates that the spread of this substance into the
youth population occurs primarily among the white suburban popula-
tion and that PCP has not as yet reached the same level of use
within the inner city or among the underprivileged minorities. PCP
is being added to an already existing pattern of multiple substance
use and is not used by youth who do not use other drugs.
Two thirds of those young clients in the NYPS sample who ever tried
PCP used it at least weekly. PCP is likely to be used by clients
who have a previous history of treatment either for substance use
or emotional problems. Self-destructive behavior is also much more
prevalent among the PCP users as compared with nonusers of PCP.
The PCP users were also found to have a more extensive involvement
in the criminal justice system and more dysfunction in the education
system. Lastly, the PCP users were found to be characterized by
their low level of heroin use. Whether the dependence of adults on
heroin is also associated with a lower prevalence of PCP, as found
among youth, is yet to be determined.
Hospital-Based Youth Study
The authors conducted a study of 179 youthful (age 12 - 18 years)
phencyclidine users seen at one county hospital in the San Francisco
Oakland area between 1968 and 1976.
During the eight year period the majority of these patients (76.3
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percent) were males, with a mean age of 16.8 years. The races
represented were 96.1 percent Caucasian, 2.8 percent black and
.6 percent Asian.
A large proportion of these patients were transported to the hos-
pital by public transportation. The majority were brought to the
emergency room by police vehicle (43.0 percent) or ambulance (31.8
percent). In most cases these patients were accompanied by police
(39.1 percent), emergency service attendants (32.4 percent), per-
ents (11.7 percent), friends (5.0 percent) and rarely by drug
treament staff (2.8 percent).
Reasons for hospital contact were primarily treatment (75.4 per-
cent), a medical check for juvenile hall (12.3 percent), public
service evaluation (4.5 percent), or a medical check for police
(3.9 percent). In most cases these phencyclidine users were re-
tained for observation (43.6 percent), admitted to the emergency
room (35.2 percent), or admitted to a service (2.2 percent). Only
16.8 pat-cent of these patients were immediately checked and re-
leased.
At the time of hospital contact, about half (49.2 percent) of the
patients were disoriented, a third (31.8 percent) were uncoopera-
tive, and a quarter (26.8 percent) were either awake with decreased
consciousness or were stuporous or comatose.
The majority of these patients (80.4 percent) had taken only phen-
cyclidine prior to hospital presentation. The most popular sub-
stance taken in combination with phencyclidine was alcohol (15.1
percent), followed by barbiturates (1.1 percent).
Among this youthful population, a quarter (24.0 percent) were
chronic users of phencyclidine. These patients qualified as chronic
users by having taken phencyclidine on a regular basis for greater
than a six month period with multiple hospital admissions for phen-
cyclidine-related problems. The youngest chronic user was a 15-
year-old female.
Similarities in Drug Study Findings
A number of consistent patterns appear from an analysis of the
data from the DAWN, NYPS, and the authors studies' on phencyclidine.
There is an overrepresentation of Caucasians among phencyclidine
users, accounting for more than 90 percent of all identified pa-
tients. This trend is observed in all of the major data sources.
However, it should be noted that in certain geographic areas
phencyclidine use appears to be limited to other specific groups,
such as blacks (Washington, D.C., Watts) and Mexican Americans
(San Jose).
The majority of the individuals report the "psychic effects" as
their primary reason for continued use of phencyclidine. Among
all individuals exposed to this drug, approximately 23 percent
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become chronic users. Males represent the highest number of chronic
users as well as hospital emergency room contacts for problems re-
lated to phencyclidine.
Phencyclidine users utilize and apparently need more medical treat-
mentservices than other drug users.
Problems Seen Where Phencyclidine is Continuously Available
As the availability of phencyclidine increases in a commnity, there
is a direct relationship with the number of emergency room contacts
and community problems such as driving under the influence and vio-
lent and bizarre behavior - behavioral toxicity.
In San Jose, California, the police department has gathered data on
seizures of phencyclidine for the past three years. During the
first quarter of 1975 (January - March), 69.7 grams of phencyclidine
were confiscated. The following year during the same period, 125.1
grams of illegal material were collected. For the first quarter
of 1977, 3,951 grams of phencyclidine have been recovered.
In 1976 for the first quarter there were 69 patients treated for
phencyclidine-related problems; in 1977, 100 patients were seen
during this same period.
New problems have surfaced in communities (Alameda, Santa Clara,
and Los Angeles) in direct proportion to the frequency and regular-
ity of phencyclidine abuse. Violent and bizarre behavior is seen
in the home, in public places, and in schools, often disrupting
education. Young people exhibit unexplained speech problems, men-
ory loss, thinking disorders, personality changes, anxiety, severe
depression, and suicidal and homicidal tendencies.
An increasing number of young people appearing violent, bizarre,
unresponsive, extremely confused, or acutely psychotic are being
seen in local emergency rooms. With increased use of phencyclidine,
an upsurge in violent crimes that culminate in homicide is observed.
Police report erratic driving and inappropriate behavior following
automobile accidents in individuals who have no apparent evidence
of alcohol or sedative hypnotic ingestion. On toxicological exam-
ination only the isolated presence of phencyclidine is often dis-
covered.
Young people who are observed to be highly intoxicated in public
are often arrested for sale, possession, and being under the in-
fluence of phencyclidine. In addition, an increasing number of re-
ferrals by family, friends, and the criminal justice system are made
to community drug abuse programs in an effort to deal with this new
drug problem.
The following are typical cases that illustrate the problems seen
in youth on phencyclidine.
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CASE 1
A 15-year-old Caucasian male with no clothes on was found by police
in a field, hanging on to a barbed wire fence. He was disoriented
and incoherent upon questioning. A physical examination revealed
a confused, disoriented youth with inflamed eyes, bloody mouth with
an upper incisor missing, multiple scratches of the trunk, and
scratches and lacerations of extremities. Fluctuations in orienta-
tion were observed over the next seven hours ranging from coopera-
tive and alert to unrousable. Prior to being discharged the patient
stated that he had "smoked some phencyclidine and got awfully
stoned."
CASE 2
A 17-year old Caucasian male arrested by police had allegedly in-
gested several phencyclidine joints, and over a 1 hour 45 minute
period became progressively uncommunicative and withdrawn. The
youth was transported from jail to a local emergency room. On ad-
mission he was observed lying quietly, eyes wide open, with a broad
smile on his face. Although responsive to commands, he was only
able to mouth words rather than speak. When given ipecac, he
vomited green parsley flakes. Over the next six hours he alternated
between quietly staring at the ceiling and being abusive, agitated,
combative, and fighting restraints. Upon regaining normal orien-
tation, he was observed for two additional hours and released.
CASE 3
An 18-year old Caucasian male ingested tablets and capsules in his
possession prior to a police traffic stop. Immediately after the
officers departed he was driven to an apartment where the other
occupants of the automobile induced vomiting of what they believed
was all of the ingested material. Later he began screaming and
having convulsions. He was driven to a local hospital where he
was pronounced dead on arrival. The coroner ruled that death was
caused by aspiration of gastric contents due to phencyclidine in-
gestion. Phencyclidine (urine level of 0.5 mg/ml) was the only
drug found on toxicological examination.
CASE 4
A 15-year old Caucasian male reported to be "out of hand" was seen
at a local medical center for bizarre behavior. He had been in-
volved with drugs and talked about "getting it all over." Later
that month, he was found hanging by an electrical cord from a
beam in his garage. Toxicological examination revealed a phen-
cyclidine blood level of 0.10 mg/ml. No other drugs were detected.
CASE 5
During the summer a youth gave a pool party while his parents were
away on vacation. A 17-year old Caucasian female guest was dis-
coveredatthe bottom of the swimming pool. Post mortem examination
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revealed no head or neck trauma and the isolated presence of phen-
cyclidine in the urine (0.5 mg/ml).
CASE 6
Distressed over a college setback, a 17-year old Caucasian male
snorted phencyclidine for the first time, with friends. He lost
consciousness, becoming apneic and cyanotic. On admission to the
emergency room this semiconscious patient was agitated, had writh-
ing movements of all extremities, vomited, and had copious nasal
and oral secretions. Within three hours he appeared alert; three
hours later he was cooperative and completely oriented.
CASE 7
A 16-year old Caucasian female smoked "a crystal joint" while at
school and began acting bizarre. School authorities notified her
mother who brought her to a local hospital. On admission she was
dazed and unable to recall who gave her the drug or how much she
had taken. The patient was oriented to person and place. A blood
sample taken on admission was negative for sedative hypnotics.
Urine obtained at the same time for toxicology was positive only
for phencyclidine, with a value of 0.5 mg/ml. The patient became
fully oriented 2 1/2 hours later and was discharged.
Case 8
A 16-year old male, acting belligerent and combative, was brought
to the hospital from a party where he had smoked "crystal" and
drunk beer. On admission he was drowsy but responsive to verbal
stimuli. There were abrasions on his right arm and face. Over
the next three hours he became verbally abusive, belligerent, and
uncooperative and was transferred to the county hospital. Initially
violent, he alternated between periods of sleep and moaning. Toxi-
cology screen obtained at this time revealed a phencyclidine urine
value of 1.1 mg/ml. Over the next 15 1/2 hours the patient became
alert and oriented and was subsequently discharged.
Homicides
In addition to hospital presentations for complications related to
phencyclidine intoxication, recently there have been several homi-
cides committed by youth in which phencyclidine was implicated
(San Jose and Los Angeles, California; Las Vegas, Nevada; Kansas
City, Kansas). The defense attorneys in the majority of cases
claim that their clients were not guilty either by reason of dim-
inished capacity or of insanity (drug-induced psychosis). With
defendants showing bizarre and violent behavior and sometimes de-
fendants claiming amnesia to the event, (given the unique proper-
ties of phencyclidine) and the circumstances of many of these
homicides, it appears that the legal issues raised will require
much further debate and study.
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Deaths
A large number of deaths have occurred in association with phen-
cyclidine intoxication. In the majority of cases the immediate
cause of death was asphyxia by drowning, or trauma, circumstantial
evidence suggesting that death was secondary to the "behavioral
toxicity" of phencyclidine. The user could not indicate where his
limbs were in relation to three dimensional space or could not re-
spond appropriately to imminent danger.
Other individuals have been found dead without apparent cause, the
presence of phencyclidine in high concentrations constituting the
only positive finding. The most probable cause of death in high
dose phencyclidine intoxication is primary respiratory depression.
Phencyclidine users report going swimming while intoxicated because
they experience an unusual but pleasant sensation from the water.
Sensory disturbances, incoordination, and muscle rigidity resulting
from "street" doses of phencyclidine may seriously interfere with
the user's ability to swim, drive, climb at heights, flee from a
fire, or sense imminent danger.
Suicide by self-inflicted trauma or a massive oral overdose of
phencyclidine has occurred in the chronic user who became moody or
severely depressed. It is the chronic user who is in possession of
large amounts of phencyclidine. Threatening behavior or violence
has resulted in provoked homicide.
Blood levels of phencyclidine as low as 100 mg/ml may be associated
with behavioral effects leading to death by injury or trauma.
Levels greater than 1.0 mg/ml are associated in most individuals
with coma and may result in death secondary to medical complications
or respiratory depression and seizures. Doses of 2.0 to 2.5 mg/ml
and greater are probably uniformly fatal, producing primary respir-
atory depression and seizures.
Phencyclidine deaths nationally appear to be on the increase. In
 Los Angeles alone the Coroner's Office reported 26 phencyclidine-
related deaths during 1977.
CHRONIC PHENCYCLIDINE USE
Phencyclidine became available on the illicit market in 1965 and
initially was taken orally in the form of tablets and capsules.
Around 1972, it became available primarily in the form of a leaf
mixture in California, with crystalline phencyclidine sprinkled on
parsley, mint, or marihuana and sold as "joints."
After experimenting with phencyclidine, increasing numbers of young
people began using it on a regular basis. This trend peaked around
1972 and subsequently declined until 1974 when the incidence of
phencyclidine abuse again rose. Where phencyclidine became contin-
uously available, it gained a preferred drug status with several
"cluster" groups who smoked it on a regular daily basis in Northern
and Southern California. Chronic use of phencyclidine was first
reported in 1972.
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Chronic User Study
A study designed to describe chronic phencyclidine use patterns
and determine evidence of chronic toxicity was carried out by the
authors in the San Francisco Bay Area in February 1975. Individuals
who had been treated for phencyclidine "overdose" at various music
concerts were invited to participate. They in turn brought other
known phencyclidine users into the study and in particular friends
who had used large amounts over the longest period of time.
The final study group of twenty had used phencyclidine regularly
(3 or more days per week) over a period greater than six months
without concurrent, heavy use of other drugs. Phencyclidine was
present in the urine samples obtained on both the initial and
followup visits.
The 15 male and 5 female chronic users ranged in age from 20 - 43
years old with a mean age of 25. All were Caucasian. Eighteen
(90 percent) were single and 19 (95 percent) had a heterosexual
preference.
Patterns of Use
The mean age at first use was 19.2 years, with half the group
(10) individuals 18 years old or younger. The majority (80 per-
cent) had first used phencyclidine between 1967 and 1970 at 15 to
21 years of age, with a second group (20 percent) starting in 1972
and 1973.
Most users were introduced to phencyclidine by friends (85 percent)
in a social setting, and took the drug out of curiosity (55 per-
cent) or to get "high" (45 percent). Within one year, half were
using phencyclidine regularly 3 or more times per week; by three
years, 75 percent used phencyclidine regularly.
The cumulative period of regular use from first exposure to the
time of the study ranged from 6 months to 5 1/2 years, with a mean
of 27 1/2 months. The longest period of daily or almost daily (5
or more days per week) use averaged 10.3 months and the maximum
period of abstinence averaged 5.9 months. The period of recent un-
interrupted use of phencyclidine prior to the study averaged 9.9
months. Two to four times per month, users would go on 2 - 3 day
"runs," taking phencyclidine repeatedly without sleeping. Seventy
percent continued to use marihuana and 50 percent used alcohol on
a regular basis during their use of phencyclidine.
By 1972 the availability on the illicit market of nearly pure phen-
cyclidine in amounts of 1 gram or more allowed the individual to
prepare joints for smoking of chosen strength, guarantee a long term
or continual supply for the user. With possession of large amounts
of phencyclidine, users started taking the drug on a regular basis.
The razor shavings from the "rock" crystal or the powder is sprin-
kled on parsley and smoked in the form of a joint. The amount of
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street-purchased material used in the preparation of one joint
varies from 50 mg for a "street" joint to about 100 mg for a
"regular" or "good" joint. Up to 1/4 gram was used in a "killer-
diller," "heavy" or "party joint," which is often shared by many
people.
The primary mode of taking phencyclidine was by smoking (90 percent)
or snorting (10 percent) the drug. All the chronic users had taken
phencyclidine at least once by smoking. The majority had also
snorted phencyclidine (75 percent) and taken it by mouth (60 per-
cent). Only 6 (30 percent) individuals had used phencyclidine
intravenously. Five out of the 6 used. it intravenously not more
than five times.
Smokers reported using the equivalent of 1 to 2 street joints or
about 80 mg of street-purchased material 2 to 3 times per day. The
average daily intake was about 216 mg by smoking. The reported
maximum amounts used in a 24 hour period ranged from 1/4 to 1 gram
and averaged 500 mg . The two individuals who regularly snorted
phencyclidine estimated the 2 "lines" dose to be about 5 mg of
street-purchased material. They would snort the drug 4 to 6 times
per day. Toward the end of a prolonged period of daily use of
phencyclidine, these 2 individuals would place amounts of up to
1/4 of a gram of powder (layered with parsley or as a crystal) in
a pipe, and smoke it in one sitting.
Phencyclidine users reported that the subjective effects "come on"
within 1 to 5 minutes of smoking a typical "street" joint and reach
a "peak or a plateau" over a 5 to 30 minute period. They report
staying "loaded" or "high" for 4 to 6 hours, followed by the "come
down" which lasts 6 to 24 hours after taking the drug. Following a
2 - 3 day "run," the time before the user felt normal again was ap-
proximately 48 hours to one week. A more rapid onset of 30 seconds
to 1 minute followed insufflation of a street dose in powdered form.
The time course of the subjective effects otherwise did not appear
to differ.
The Phencyclidine Experience and Why It Is Repeated
Eighty percent of the chronic users considered their first phen-
cyclidine experience to be pleasantandwanted to take the drug
again. They found it "fun," "exhilarating," and felt "happy" or
"euphoric." It seemed to be a "perfect escape" or "a dream world."
Fifteen percent disliked their first experience feeling "scared" or
finding it "terrible," while one individual (5 percent) character-
ized the experience as "strange," "weird, but interesting."
In 95 percent of the cases, first use occurred in a social setting,
with 70 percent smoking and sharing a joint at a party or with a
small group of friends (mean of 5) at someone's house. Four users
(20 percent) related minor injuries, repeated vomiting, or arrests
by the police as problems occurring with the first use. Three of
these individuals had either snorted phencyclidine or taken it by
mouth.
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The phencyclidine "high" was reported to be very intense, several
times stronger than marihuana, comparable to LSD, although shorter
in duration. Most individuals compared it with LSD, but insisted
that it was different, "in a class by itself."
The drug had a pronounced effect on the subjects' thinking, time
perception, sense of reality, and mood. Thinking was described as
"speeded" or "wired," the mind going faster while time was slowed
down, with "no more reality." Everything was reported as being
different, in another dimension, and seen from a new point of view.
Life was dramatized, a fantasy world where "you don't have to dream,
your wishes are fulfilled" and "what you want to happen comes true."
Everything was felt to be complete and make more sense. The mind
could focus on one object and see beauty in the smallest thing. A
sense of commnunity, oneness with others and with animals was report-
ed. Religious thoughts and the experience of death were frequently
mentioned. Mood states were also intensified, with users in most
cases feeling happy or euphoric, although everyone had also experi-
enced severe depression and had recognized the drug's potential
for bringing one to either "the heights or the depths of being."
Music was "absorbed"  light was "felt," and space and depth were
"distorted," "seen in 2D." Frequently users reported feeling like
they were "floating." Rarely did they relate visual hallucinations.
Users also experienced a feeling of strength and endurance. They
described feeling "powerful," "superior," "arrogant," with "bursts
of energy," "like God was with you, and you could move mountains."
There was also a loss of inhibitions. It was felt to be difficult
to do things; one had "to think about moving or talking." In ad-
dition, they described feeling restless and nervous.
Chronic use of phencyclidine also took place in a social setting
with the sharing of joints. Individuals would join in with 2 to 5
others at a friend's house or at home. The membership of a group
who shared in the use of phencyclidine remained quite stable over
long periods of regular use. They would listen to music, talk,
dame, and enjoy sex together while "high." Less often they would
go to a rock concert or go out in public. They took phencyclidine
as frequently during the daytime as in the evening.
The majority (60 percent) continued to use phencyclidine because
they enjoyed or liked the "high." Frequently all their friends
used phencyclidine and "it had become a life style." At times the
availability of phencyclidine or making money from phencyclidine
sales played a role. For 80 percent of the users, phencyclidine
was their drug of choice. Three individuals preferred heroin and
one preferred seconal. Nonavailability, incarceration, or hospital-
ization were the major factors interrupting the regular use of phen-
cyclidine. Participation in a drug treatment program or moving out
of the area also interrupted the pattern of phencyclidine use.
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Tolerance, Psychological Dependence, and Side Effects
Tolerance to the psychic effects of phencyclidine was reported by
chronic users. Initially they would get "high" after 2 or 3 puffs
on a phenyclidine joint; following a one week period of daily use
they required 1/2 to 1 joint. After smoking for a period of 2 to
6 weeks, most individuals used 1 or 2 joints at a time. Some users
reported being able to smoke up to 1/4 gram of street-purchased
material at one sitting, following several months of regular, daily
use. Psychological dependence, described as craving, was noted by
chronic users, but no withdral symptoms were reported.
Phencyclidine taken in typical "street" doses was reported to pre-
vent sleep for 8 to 12 hours, decrease appetite, and to cause con-
stipation and urinary hesitancy. Chronic users averaged one meal
or less per day and lost 10 to 35 pounds during periods of regular
use.
Chronic Toxicity
Chronic phencyclidine users reported persistent problems with mem-
ory and speech, and difficulty with thinking following long periods
of regular use of the drug. Recent memory capability appears to be
primarily affected. Users complain of stuttering, inability to
speak or blocking, and difficulty with articulation. Speech and
memory difficulties lasted as long as 6 months to 1 year following
prolonged daily use of large doses of phencyclidine.
Several chronic users complained of anxiety or nervousness during
and following periods of regular phencyclidine use and sought
psychiatric care. Some individuals became severely depressed, and
attempted suicide on repeated occasions after chronic exposure to
phencyclidine.
Chronic users reported personality change, social withdrawal, social
isolation, and divorce resulting from their use of phencyclidine.
In some cases, violent behavior was one of the effects.
Employment has been lost and education disrupted as a result of the
effects of phencyclidine with chronic patterns of use. Frequent
arrests for being under the influence of phencyclidine or for pos-
session result in a criminal status.
Chronic phencyclidine use has culminated in a picture of violent
and aggressive behavior, paranoia, delusional thinking, and auditory
hallucinations. In most cases no known behavioral disturbance or
psychiatric problems preceded the use of phencyclidine. Typically,
the individual had used phencyclidine over several months or a few
years with the same group of friends. Form apparent reason a
sudden development of paranoia and auditory hallucinations was ac-
companied by violent, unpredictable behavior. Friends and family
often became fearful and brought the user to medical attention.
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Laboratory and Neurological Findings
Fourteen (70 percent) individuals reported using phencyclidine with-
in 24 hours of the clinical examination and 85 percent within 48
hours (see Table 7). All mine samples obtained just prior to the
physical examination were found to contain detectable levels of un-
changed phencyclidine by gas chromatography-mass spectrometry and
the majority of serum samples (85 percent) obtained were also posi-
tive for phencyclidine. Phencyclidine levels were higher in cases
where the last use of phencyclidine by history was within a 48 hour
period (see Table 8).
Eight (40 percent) individuals reported using phencyclidine within
6 hours of the examination and had a "blank stare" appearance and
slurred speech. Ptosis, conjunctival infection, and vertical and
horizontal nystagmus were present. They had an ataxic gait and
were unable to tandem walk. One third appeared lethargic and were
disoriented for time and place.
Individuals reporting no phencyclidine use for 24 to 48 hours prior
to the examination had unsustained vertical and horizontal nystagmus
and difficulty with tandem gait (see Chart A).
On electroencephalographic study, one chronic user showed bursts of
spike and slow wave activity associated with observed myoclonic
twitching in response to photo-stimulation (see Photograph A).
Three chronic users selected for electroocculographic study showed
jerk nystagmus, saccadic pursuit, and hypometric slowed saccades
(see Photographs B,C,D). Urine samples concurrent with test pro-
cedures were positive for phencyclidine.
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TABLE 7
HISTORY OF PCP USE PRIOR TO PHYSICAL EXAMINATION
LAST USE NO. CASES CUMULATIVE PERCENTAGE
<6 hours 7 35.0
7 - 24 hours 7 70.0
25 - 48 hours 3 85.0
49 - 72 hours 1 90.0
97 -120 hours 2 100.0
TABLE 8
CHRONIC USERS' URINES COLLECTED PRIOR TO P.E.
LAST USE NO. CASES URINE LEVEL
1 - 12 hours 8 1.73 ug/ml
13 - 24 hours 4 0.85 ug/ml
25 - 48 hours 4 1.24 ug/ml
> 48 hours 4 0.13 ug/ml
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Chart A
Physical Examination Findings
Vital Signs <6 hours 7 - 24 hours 25 -48 hours >48 hours
B.P. - SYST. 132 132 115 109
- DIAST. 79 71 65 65
PULSE 88 79 78 72
RESPIR. RATE 15 17 14 16
ALTERED STATE OF
CONSCIOUSNESS
(Lethargic, somnolent,
'high'_
Disorientation
(time, place)
SPECH (slow, slurred,)
repetitive, inter-
mittently unable)
E.O.M.M.
'Stare' appearance
Disconjugate gaze
Nystagmus
H
V
Sustained
PUPILS
Size
Light Reaction
(Sluggish, decreased
amplitude)
Corneal reflex
(Decreased or absent)
MOTOR SYSTEM
Movements:
Repetitive
Restlessness
Catalepsy
Rigidity
Hyperreflexia (L/e)
Gait (Ataxic, broad
based)
COORDINATION
Tandem standing
(Difficulty or unable)
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Photograph A
Chronic Phencyclidine User Electroencephalogram
This abnormal electroencephalogram shows a positive photoconvulsive response. Intermittent pkotic
stimulation at botk Slow and fast flash frequencies induces bursts of spike and slow wave activity.
With sustained 20 cycles per second stimulation, involuntary myoclonic twitching is noticed on the
left face, arm and leg. This recurs with repeat pkotic stimulation, and is again clinically focal-
ized to the Zeft side, although electroencephalographically bilateral spike and slow wave discharges occur.
Photograph B
PCP-Induced Oculomotor Disorders
These records were obtained from photoelectric cells placed about
each eye in the horizontal plane and then from EOG electrodes
placed about each eye in the vertical plane.
FIXATION: Jerk nystagmus at the gaze limit of the photocell
technique, 15°.
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Photograph C
SMOOTH PURSUIT: Ramp pursuit grossly saccadic (staircase) in horizontal and
vertical planes.
Photograph D
SACCADES: Grossly abnormal horizontal and vertical hypometric Slowed saccades.
THE ACUTE STATES OF PHENCYCLIDINE INTOXICATION
History and Presentation
The spectrum of signs and symptoms and the pattern of recovery in
acute intoxication with phencyclidine vary with the dose and route
of administration
Individuals are most frequently brought to a hospital emergency room
when found unresponsive or when exhibiting bizarre or violent be-
havior (see Table 9). Others are brought in after having been
cbserved to be grossly incoordinated, driving erratically, or act-
ing inappropriately after an automobile accident. Some individuals
present with minor or major trauma.
Clinical Picture and Course
A confusional state delirium lasting less than 8 hours appears to 
follow a typical street dose after smoking one "joint." Individ-
uals who either smoke greater amounts or take a higher dose orally
or by "snorting" may present in stupor or coma. This initial state
lasts less thanthreehours in most cases and a confusional dose-
related state follows for 24 to 72 hours. Massive oral "overdose"
involving up to one gram of street-purchased material has resulted
in periods of stupor or coma of several hours to two weeks in dura-
tion. This initial stage is followed by a prolonged recovery with
a confusional state persisting up to two weeks (see Table 10).
The confusional state delirium induced by phencyclidine is charac-
terized by immobility and a "blank stare" appearance in a-patient
who is noncommunicative. The patient is disoriented and apprehen-
sive, becoming easily agitated or excited. These patients are
grossly ataxic and exhibit horizontal and vertical nystagmus and
catalepsy on testing. Muscle rigidity may be present. Most pa-
tients are communicative within 1 - 2 hours, and appear alert, or-
iented, and exhibit normal behavior within 5 hours of admission
to the emergency room.
In phencyclidine stupor or coma, the eyes may remain open although
the patient is responsive only to deep pain. Hypertension and
tachycardia are present, and in all but the more massive oral
"overdoses" respiration is normal. The pupils are initially miotic
but reactive to light. Spontaneous nystagmus, 'purposeless" move-
ments, facial grimacing, and muscle rigidity on stimulation are
characteristic findings. Repeated episodes of vomiting, increased
bronchial and oral secretions, and profuse diaphoresis are frequently
observed. An initial stage of stupor or coma lasting less than four
hours my be followed by a period of confusion or delirium lasting
up to 2 1/2 days (refer to Table 11).
105
TABLE 9
PRESENTING PICTURE AMONG 18 CASES
OF ACUTE PHENCYCLIDINE INTOXICATION
PRESENTING PICTURE CASES PERCENT
Unresponsive 11 61.0
Bizzaare behavior 4 22.0
Automobile accident 2 11.0
Violent behavior 1 6.0
TABLE  10
COURSE OF RECOVERY OF 16 INDIVIDUALS
BY STATE OF CONSCIOUSNESS ON ADMISSION
PRESENTATION CASES  DURATION OF PERIOD OF DELIRIUM TIME REQUIRED
INITIAL STATE OR CONFUSION UNTIL "NORMAL"
Group I:
Confusional
state and
history of
smoking 1
street joint 4 5 hours ------ 5 hours
(3-8 hours) (3-8 hours)
Group II:
Initial
state of
stupor or
coma 6 3 hours 34 hours 37 hours
(1-4 hours) (5-62 hours) (14-66 hours)
GROUP III:
Initial
state of
stupor or
coma (>
6 hours 4 50 hours 163 hours 212 hours
(6-103 hours) (75-288 hours) (114-360 hours)
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TABLE 11
SUMMARY OF CLINICAL HISTORIES OF 18 CASES OF ACUTE PHENCYCLIDINE INTOXICATION
ACUTE CONFUSIONAL STATE
OR DELIRIUM (N=7) STUPOR OR COMA (N=11)
PART I: VITAL SIGNS
A. Respiratory rate (normal or)
slightly increased 24 mean 21 mean
B. Blood pressure (increased) 18-32 mean 16-25 mean
Systolic 142 mean 155 mean
116-160 range 100-180 range
Diastolic 85 mean 94 mean
76-100 range 60-110 range
C. Pulse (increased) 105 mean 88 mean
88-140 range 60-112 range
D. Temperature (normal or 100.1°F 99.3°F
slightly increased) 98.8°-101.4°F range 97.0°-100.8°F range
PART II: CLINICAL FEATURES
A. Responsiveness Appears awake; initially uncommunicative, Unresponsive to verbal
may respond to commands or respond to stimuli, responds with
simple questions with nodding or eye movement to deep pain
movement later incomplete verbal responses
and then becomes communicative/talkative
TABLE 11 (Continued)
ACUTE CONFUSIONAL STATE
OR DELIRIUM (N=7) STUPOR OR COMA (N=11)
B. Orientation
C. Behavior
D. Speech
EYE SIGNS
A. Eye lids
B. Eye position & movements
C. Nystagmus
Disoriented for time and place; appears
confused and fearful; amnesia for epi-
sode
Agitated, excited, combative; regressive;
self-destructive or "bizarre" behavior;
insomnia, anorexia, incontinence; followed
by depression, irritability and emotional
lability
Dysarthria (slurred), perseveration; may
be intermittently anarthric
Eyes open ("stare" appearance) with
ptosis
Paucity of spontaneous eye movements
appearance, may be fixation instability
dysconjugate gaze or hypometric saccadest
Bilateral horizontal jerk nystagmus;
may be vertical nystagmus (upward-downward)
Vocalizations; "moaning,"
"groaning," "grunting;"
followed by anarthria and
dysfluency, initially with
automatic speech
Eyes open ("awake" appear-
ance) or eyes closed
May be roving eye movements;
dysconjugate gaze; doll's
eye movements present
Interittent horizontal and
vertical nystagmus at rest
TABLE 11 (continued)
ACUTE CONFUSIONAL STATE
OR DELIRIUM (N=7) STUPOR OR COMA (N=11)
D. Corneal reflex
MOTOR SYSTEM
A. Gait
B. Muscle tone
C. Movements
D. DTR's
E. Seizure activity
OTHER
A. Vomiting (central)
Decreased or absent
Grossly ataxic (sensory), unable to
tandem stand/walk; may be component
of muscle rigidity
Rigidity (catatonia), catalepsy
(waxy rigidity)
Motor restlessness, repetitive move-
ments, facial grimacing
Increased
Repeated episodes over 1/2 to 3 hours
period
Decreased or absent
Muscle rigidity, on stimu-
lation, opisthotonic pos-
turing, decerebrate rigidity
Spontaneous "purposeless
movement;" muscle tremor,
muscle twitching, fasicula-
tions
Increased
Generalized motor seizures
may be early or delayed in
appearance and repetitive
Repeated episodes
TABLE 11 (continued)
ACUTE CONFUSIONAL STATE
OR DELIRIUM (N=7) STUPOR OR COMA (N=11)
B. Increased secretions
(lacrimation, salivation,
diaphoresis, bronchorrhea)
C. Evidence of minor trauma
"Drooling," diaphoretic
Abrasions, lacerations, ecchymoses
Secretions in posterior
pharnys at nares and mouth;
tearing, diaphoresis
Abrasions, lacerations,
ecchymoses
Urine phencyclidine levels of 26.2 - 151.9 mg/ml were found in
samples collected within 12 hours of admission in four patients
who remained in coma for greater than 6 hours and required between
7- 15 days for recovery to normal (see Table 12).
Status epilepticus followed by cardiopulmonary arrest without re-
covery has been reported with a blood phencyclidine level of 7.0
mg/ml.
Diagnosis
Drug use is frequently considered to be the etiology of symptoms
when a young person presents acutely confused or delirious with no
focal neurological findings. But encephalitis, head injury, post-
ictal state, and metabolic causes must be ruled out.
The "blank-stare" appearance and catatonia-catalepsy appear to be
unique to phencyclidine as effects of commonly abused drugs. The
absence of mydriases, and the presence of ataxia and nystagmus rule
out the central nervous system stimulants and LSD when considering
the acutely excited and confused patient.
In coma with or without respiratory depression, hypertension and
hyperreflexia differentiate phencyclidine intoxication from a
sedative hypnotic "overdose." If, in addition, decerebrate pos-
turing or repetitive generalized seizure activity is observed
phencyclidine intoxication should be suspected, although other
serious causes producing a similar clinical picture must be ruled
out.
Cases involving the ingestion of large doses of phencyclidine pres-
ent with coma which may last several hours or days. The prolonged
recovery with a confusional state lasting up to two weeks is char-
acteristic of phencyclidine intoxication. If persistent paranoid
or depressive psychosis follows recovery, phencyclidine intoxication
should be suspects.
In combined intoxications involving phencyclidine and barbiturates,
normal or low blood pressure, hyperreflexia and respiratory depres-
sion may be observed.
Management
The acutely confused patient is best managed by sensory isolation
with observation at a distance. Minimizing verbal and tactile
stimulation does not preclude the monitoring of vital signs. Im-
portant functions to monitor are respiration, blood pressure,
muscle tone and activity, renal function, and temperature. Ideally,
the patient would be placed on a cushioned floor in a "quiet room"
with a monitor present. In most settings, protection of the pa-
tient and staff necessitates the use of restraints.
The early management of the stuporous or comatose patient involves
gastric aspiration-lavage and nasopharyngeal suctioning. In view
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TABLE 12
CLINICAL HISTORIES OF TWO CASES OF ACUTE PHENCYCLIDINE INTOXICATION
Age
Sex
Estimated dose
Route
Coma
Confusion delirium
and somnolence
Depression, irritability
and emotional lability
alert and oriented
Cardiovascular system
blood pressure (mean)
pulse (mean)
Repiratory status
Seizure and motor
activity
Toxicology
Day 1
2
3
4
5
6
CASE 1
22
Male
One gram "street" material
by mouth
25 hours
71 hours
84+ hours
Transferred to psychiatric
unit
147/92 (84 hours)
94
Excessive mucous/secretions
on admission; hypoventilation
x15 ours, Tidal; volume
tions with 5 sec. periods of
100 cc's; irregular respira-
apnea x15 ours; required
ventilatory assistance x27
hours; complications; right
upper lobe pneumonitis
Decerabrate rigidity;
opisthotonic posturing;
muscle tremors, twitching;
generalized motor seizures
at 66 and 78 hours;
treatment: Valium and
Dilantin
On admission: 26.2 µg/ml
PCP (urine)
26.2 µg/ml
18.2 µg/ml
15.9 µg/ml; 18.0 µg/ml
18.5 µg/ml; 20.0 µg/ml
4.7 µg/ml;
0.5 µg/ml;
1.3 µg/ml
1.2 µg/ml;
0.4 µg/ml;
0.1 µg/ml
0.3 µg/ml
CASE 2
22
Male
One gram+ "street" material
By mouth
103 hours
77 hours
32 hours
178 hours
151/98 (108 hours)
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Excessive Mucous/secretions,
hypoventilation on admission;
hypoventilation x60 hours,
Tidal; Volume 50 cc's; apnea
x4 hours; required ventilatory
assistance x107 hours; compli-
cations: bilateral basilar
pneumonitis
Decerbrate rigidity;
opisthotonic posturing;
muscle tremors; twitching;
focal motor seizures at 3 and
21 hours; generalized motor
seizures at 3-1/2 & 89 hours;
treatment: Dilantin
On admission: 151.9 µg/ml
PCP (urine)
151.9 µg/ml
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of the recovery of large amounts of phencyclidine from the stomach
contents in fatal "overdoses," gastric lavage is indicated in oral
ingestions.
Intubation is often difficult because of increased muscle tone.
Laryngeal reflexes are maintained and active and attempted endo-
tracheal intubation may precipitate laryngospasm. More responsive
patients fight intubation by biting the tube off or spitting it out.
However, respiratory depression may be delayed in appearance and
necessitate a prolonged period of ventilatory assistance. Position-
ing and intermittent suctioning will preclude respiratory distress
secondary to secretions in the posterior pharnyx.
Urine and blood samples should be collected at the time of admission
and screened for phencyclidine, sedative hypnotics, ethyl alcohol,
opiates and amphetamines. Urine samples should be capped to pre-
vent loss of phencyclidine, which is volatile.
The Recovery Phase
Most acutely confused patients are communicative within 1-2 hours
and alert and oriented within 6 to 8 hours of admission after in-
gesting the usual street dose. After they are alert and oriented,
patients should be monitored for a minimum of two hours. Patients
who remain oriented and alert and exhibit normal behavior can then
be discharged.
If a patient remains stuporous or comatose, responding only to deep
pain for greater than two hours, a minimal observation period of 24
hours is indicated. The recovery phase may vary from several hours
to days depending on the route and the dose ingested.
Suicide has been reported during the "come down" period, 6 to 24
hours after taking phencyclidine. Patients should be informed about
depression, irritability, feelings of isolation and nervousness that
often accompany this period, and may last up to 48 hours.
All patients in whom coma is followed by a prolonged period of con-
fusion should have a psychiatric evaluation prior to discharge.
Persistent paranoia or depression may require transfer to a psych-
iatric unit.
Treatment
No agent is known to be specific for antagonizing the toxic effects
of phencyclidine. However, some experience has been gained in the
symptomatic treatment of seizures, hypertensive crisis, and aggres-
sive and violent behavior.
Intravenous diazepam (Valium) in doses of 10 - 15 mg followed by
intravenous diphenylhydantoin (Dilantin) has been effective in the
control of seizures. In some cases it has been necessary to give
an acutely confused patient 10 - 20 mg. of Valium orally to pre-
vent injury to both the patient and staff. During the confusional
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phase of the prolonged recovery period, some patients have received
repeated doses of 10- 15 mg of Valium to control motor restless-
ness and agitation. These therapeutic doses of sedative hypnotic
agents do not appear to produce significant respiratory depression
in phencyclidine intoxication.
Diazoxide (Hyperstat) has been used to reduce blood pressure during
a hypertensive crisis associated with acute phencyclidine intoxica-
tion. Hydralazine hydrohloride (Apresoline) has also been sug-
gested as a possible substitute agent.
Phenothiazines are contraindicated in acute phencyclidine intoxica-
tion where a confusional state is associated with hypertension,
tachycardia ataxia and nystagmus. It has not been demonstrated
that phenothiazines shorten the recovery phase or antagonize the
behavioral effects of phencyclidine. In some cases they have pro-
duced prolonged, severe hypotension.
SUMMARY
Phencyclidine use appears to be in a growth phase nationally. Fac-
tors contributing to the increasing popularity include the user's
ability to control the dosage, an understanding of the immediate
effects, and its availability. Those most at risk appear to be
young Caucasian males.
Phencyclidine-related problems are often like tips of icebergs, the
underlying causes of which are hidden from public view. The prob-
lens often surface in the form of speech difficulties, memory loss,
thinking disorders, personality changes, paranoia, severe depression,
violence, accidents, suicides and homicides. Of particular concern
to law enforcement personnel is the upsurge in phencyclidine-related
violent crimes and carrying of weapons by users to protect themselves
from their imagined persecutors.
The evidence currently available supports the assumption that if
there is a solution to the problem of phencyclidine abuse, that
solution is prevention. Therefore, medical personnel and others
within the helping professions must be alerted to the fact that
phencyclidine is not just another drug problem. The findings from
users we have already studied strongly suggest that phenyclidine
is not an "upper" or a downer,"I but perhaps an "insideouter," with
long term implications.
FOOTNOTE
1The SES measure employed in this analysis was based on a formula
which was especially developed for this analysis, and which was
found to be more discriminating than the Hollingshead-Redlich form-
ula. It included educational level of both parents, rather than
only that of the head of the household, and also included codnsidera-
tion of the subject's income, and whether or not the family was on
welfare, in addition to the occupational level of the head of house-
hold.
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Chapter 6
Phencyclidine and Ketamine Intoxication:
A Study of Four Populations of
Recreational Users
Ronald K. Siegel, Ph.D.
The time is 1926. In his laboratories at the University of Chicago
psychologist Heinrich Kluver is just beginning the first experi-
mental studies of the hallucinogen mesacaline. Derived from the
peyote cactus which had been used by indigenous Indians throughout
the New World for thousands of years, mescaline had only recently
been isolated and synthesized, and was rapidly capturing the at-
tention of researchers in Germany. But before this "classic"
hallucinogen was fully investigated, other newer ones were being
developed. Elsewhere in Germany, Kotz and Merkel (1926) had just
reported the chemical groundwork for the preparation of a new
compound, phencyclidine.
The time is 1959. Chen and his colleagues at the Research Labora-
tories of Parke, Davis and Company in Detroit have just "discovered"
phencyclidine and observed its anesthetic effectiveness in animals.
That announcement added one more drug to the rapidly growing list
of psychoactive compounds, both natural and synthetic, which affect
behavior. Yet science was just beginning to dwelop techniques
for studying the effects of drugs on behavior. That year witnessed
the publication of a new journal, Psychopharmacologia, officially
announcing the pursuit.
It is now 1978. With such an evolutionary, albeit natural, lag
between the emergence of a new drug and its scientific investiga-
tion, it is not surprising that today, a generation after phen-
cyclidine's discovery, those people born when the drug was first
developed are using and exploring its psychoactive properties
while scientific investigations still lag behind. Nonetheless,
reports fromuserswho first experiment with and experience the
drug effects (the street drug users) provide a rational basis
for the questions which researchers must ultimately attempt to
ask and answer. Kluver's original studies of mescaline were based
upon and guided by reports from people using the drug at that time.
Similarly, present day studies of phencyclidine and its derivatives
may be helped by examination of the patterns of use and intoxica-
tionin contemporary nonmedical users. It is in this spirit that
the following studies with phencyclidine and its derivative
ketamine were conducted.
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Phencyclidine and ketamine are chemical compounds known as aryl-
cyclohexylamines. While many psychoactive drugs can be easily
classified as either stimulants, depressants, or hallucinogens,
the arylcyclohexylamines defy convenient classifications as they
appear to have mixed excitatory, sedative, cataleptoid-anesthetic,
and hallucinatory properties. The major questions concerning the
use of these compounds by man are: (1) Why do humans initiate
use of arylcyclohexylamines? (2) Why is such use maintained?
and (3) What are the consequences of such continued use? These
questions are addressed in this chapter. It will be presently
seen that the psychological intoxication resulting from aryl-
cyclohexylamines is a primary reason for their continued use.
The nature and extent of thisintoxicationin several groups
of contemporary users Will also be explored. Furthermore, it
will be shown that the phenomenology of intoxication with these
compounds warrants their classification as true hallucinogens.
I. PHENCYCLIDINE
STREET DISCOVERY AND INITIAL USE
Phencyclidine (PCP) or 1-(1-phenylcyclohexyl) piperidine hydro-
chloride was first reported in the context of nonmedical street
use in the Haight-Ashbury district of San Francisco in 1967. At
that time the drug was marketed as the PeaCe Pill or PCP (an
abbreviation of the complete chemical name). While the Haight-
Ashbury Free Medical Clinic reported that "use of the drug....
virtually ceased" by early 1968, it has remained consistently
available under a wide variety of names. Such names include
Hog, Angel Dust, Dust, Crystal, Crystal Joints, CJ, KJ, Peace,
Peace Weed, Supergrass, Superweed, Rocket Fuel, Elephant Tran-
quilizer, Horse Tranks, Sheets, Seams, Surfer, Snorts, Scuffle,
Cadillac, Cyclones, Sana, Mist, and Goon (cf. Perry 1975). Other
more recent common names include Amoeba, Angel Hair, DOA (dead on
arrival), Killer Weed, and Synthetic Marihuana (Young et al. 1977).
This author has also doctumented the terms Lovely, Lovely High,
and Super Kools. PCP is also the most prevalent drug in misrepre-
sented street drugs (Perry 1977) and has recently appeared under
the names THC, psilocybin, mescaline, and other hallucinogens
Which are rarely available in pure form on the illicit market.
Cases of adverse reactions, unpleasant subjective experiences,
poisoning, and prolonged psychoses are well known (e.g., Liden,
Lovejoy, and Costello 1975; Rainey and Crowder 1975) and have
probably attenuated some street use since 1971. However, the
low costof PCP and its ease of production have contributed to
its reappearance on the street (Burns and Lerner 1976). Indeed,
one gram of PCP can make more than 24 "street joints" and doses
as low as 3 mg are behaviorally effective. PCP's subjective
effects include distortions in body image, hallucinations and
dissociation. There can also be a preoccupation with death
or death-related thoughts (meditatio mortis) and this has been
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the basis for numerous criminal defenses of diminished capacity
(see "Phencyclidine, Criminal Behavior, and the Defense of Dimin-
ished Capacity," this volume). The prolonged and fluctuating
effects are believed to be due to PCP's affinity for adipose
tissue, its slow release from such tissue, and its subsequent
selective uptake by brain tissue (Bums and Lerner 1976). Some
adverse reactions are believed to be caused by related compounds
TCP (1-(1-2-thienylcyclohexyl) piperidine) , and PCC (1-piper-
idinocyclohexanecarbonitrile), often produced in illicit syntheses.
Related compounds such as PHP, which is 1-(1-phenylcyclohexyl)
pyrrolidine, may also contribute to adverse reactions.
Nonetheless, users initially experiment with the drug primarily
out of a curiosity about it and a desire to experience the antici-
pated drug effects of tranquilization, dissociation, and hallucina-
tions. More often than not, initial use of PCP comes about as a
result of users self-administering what they believe to be THC,
psilocybin, or some other alleged drug. In these latter instances,
PCP is often combined with LSD.
MAINTENANCE OF USE
The street users' initial encounters with PCP would have brought
them into contact with both the unpleasant and pleasant effects of
the drug. Independent of adverse reactions and even "schizo-
phrenomimetic" or "psychotomimetic" effects, many users found the
drug to have highly reinforcing properties. Indeed, the preclinical
animal literature is rich with examples of PCP's powerfully
psychoactive and reinforcing effects (Balster and Chait 1976),
and PCP represents one of the only hallucinogens that monkeys will
reliably self-administer. While it is difficult to determine the
unique properties that reward such animal behavior, the euphoria,
inebriation, and hallucinatory effects are undoubtedly responsible
for maintaining PCP use in man. The effects can be interpreted as
a state of intoxication with high reinforcement potential. While
many nonpharmacological factors (e.g., easy and inexpensive
illicit synthesis) may affect man's use of a drug such as PCP,
psychological intoxication appears to be the primary reinforcing
effect.
These PCP intoxications can vary greatly among users. Pollard,
Uhr, and Stern (1965) examined the effects of 10 mg (p.o.) in
a modified sensory deprivation situation. One of their college
student subjects described a typical experience marked by a pre-
occupation with abnormal bodily sensations, lack of visual imagery,
and marked feelings of depersonalization:
I feel like I can't think anything even. And I can't
express myself even if I can think because it's hard
for me to talk. My lips are numb. It's so uncomfor-
table. My perception is very bad. Nothing is clear
. . . . My mind is just a complete blank....I have such
a strange feeling. I can't explain it. Like I'm still
asleep, yet I'm not asleep. I'm awake (pp. 89-90).
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Other subjects in this study described these sensations as "I
feel dissociated with the world" (p. 131) and "I feel dead"
(p. 134). Luby and co-workers (1959) administered 1 mg/kg, i.v.,
to normal subjects who reported body image changes, estrangement,
disorganization of thought, negativism and hostility, drowsiness
and apathy, hypnagogic states, feelings of inebriation, and re-
petitive motor behavior.
These authors described the hypnagogic states as resembling
pseudohallucinations wherein subjects "reported feeling as
though they were in some specific setting and were able to
describe it in detail. While the reports typically had reference
to past events, they were expressed as though the experiences
were taking place at the moment. The lack of time-boundedness
was reminiscent of dreaming. As in dreams, multiple shifts
occurred in the settings experienced by the subjects, sometimes
in rapid succession" (p. 366). Sometimes the subjects reported
euphoria and feelings of inebriation: "When it occurred, the
subjects would often smile vacuously and compare their feelings
to those resulting from several Martinis" (p. 366).
Most users have difficulty in describing this intoxication and
simply report a state of oblivion and fantasy. Perry (1975)
summarizes some of the psychological effects of this state:
The high continues for 4-6 hours, during which time
the user often becomes very talkative, having sincere
and sympathetic conversations, usually with others
similarly intoxicated. This gradually develops into
a state of mild depression as the high wears off; the
person is irritable, feels isolated and sometimes
paranoid. These users generally require 24-48 hours
to completely return to what they consider normal
(p.2).
Many users find the experience a positive one and emphasize the
rewarding aspects of the same  symptoms that other users cite as
negative. Consider the following account provided by one of
the author's respondents:
Immediately after smoking the Dust (PCP) I started
experiencing the effects. All my troubles seemed to
go away. I felt a little drunk and had some trouble
walking around the apartment. Objects appeared either
very far away or very close and I couldn't really
judge distance at all. This reminded me a lot of
Acid (LSD). I closed my eyes for a while but didn't
see much more than a few colored geometric patterns.
Not nearly as trippy as other psychedelics, but it
was clearly a psychedelic. I liked being apart from
things, and felt outside my body for most of the
trip. That was fun. Before I smoked I had been
troubled about some exams coming up and felt I wasn't
really prepared. All that anxiety vanished with the
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Dust. I even looked at my books and work but
couldn't get excited about it. I felt at peace. It
was a good feeling. When I started coming down, I
felt sad that I was leaving such a lovely place. I
think I even cried. I hadn't done that in years.
But most of all, I remember the peace and tranquility.
Everything was good. I want to be there always.
That's why I like to call Dust PPP - Perpetual Peace-
ful Place.
Recent studies of phencyclidine users are beginning to uncover
an increased occurrence of these pleasurable and positive effects
among those who continually self-administer the drug. For ex-
ample, Walters (1978) has studied a group of multiple drug users
in Philadelphia, primarily intranasal PCP users, and found that
PCP use is rarely involved with PCP-related emergencies or
clinical crises:
Our respondent population is small, somewhat transient
and currently just under 50 youths ranging in age from
14 to 24 years, divided about evenly between males and
females. Of these, 34 have some history of PCP use,
with 15 of them using it between five and 10 times per
week. Finally their histories of PCP use range from
between one and seven years, with three years' use
being average. Yet by far, most of the drug-using
youths with whom we have had contact are not dulled,
depressive, anomic bundles of pathology described in
the literature and the media. Rather, they are bright,
level-headed and stable and eager and willing to
experience life, including drugs that are a part of
that life (p. 9).
Stickgold (1977) has recently commented on the emergence of PCP
as a drug of choice among may users. He describes this population
of users:
Those who are today using PCP, tend to come from a
different place, both socio-economically and in their
drug-taking behavior. Rather than the middle class
seekers of the new sensate worlds to explore, PCP is,
today, becoming the drug of choice of the lower class
oppressed minority group member seeking an escape from
persecution. In the past s/he has found this escape
in other depressant drugs such as heroin and barbitu-
rates. Today PCP not only provides that escape, but
also produces a degree of increased awareness that is
different enough to be interesting, and mild enough
not to be too frightening (p. 2).
CONSEQUENCES OF CONTINUED USE
Despite the obvious negative effects, and the apparent attractive-
ness of the positive effects, the consequences of continued
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phencyclidine use are still largely unknown. The rather prolonged
recovery time from acute intoxication, sometimes lasting as long
as 15 days (Burns and Lerner 1976), confuses the issue of long-
term effects. In addition, the persistent psychoses seen in a
very small number of cases (Burns and Lerner 1976; Fauman et al.
1976) may represent either a psychopharmacological effect from
the drug or an individual sensitivity to it. Nonetheless, most
investigators agree that these psychiatric sequelae of continued
phencyclidine use can be serious and represent classic schizo-
phrenic symptoms. With still other chronic users, there is both
preclinical (e.g., Balster and Chait 1976) and clinical (e.g.,
Burns and Lerner 1976) evidence to suggest tolerance to the
psychological effects of phencyclidine requiring use of increasing
doses. Psychological dependence, albeit not physical addiction,
appears prominent among long-term users.
Recently, Ashley (1978) has commented on the consequences of
continued use among PCP users or "peepheads":
Chronics users clearly enjoy PCP and experience it in
a positive way . . ..Most say it takes a few days to re-
turn to normal, but many of them don't bother to and
use the drug every day.... (they) almost always complain
of being spaced and worry about turning into 'vege-
tables'. They are noticeably depressed when not high,
so much so that some have committed suicide at this
point. Serious accidents are commonplace among users.
Almost all report having been in an automobile accident
or knowing someone who was, while on PCP. Falls are
common, even off cliffs or out of boats and windows.
Impairment of motor and sensory functions makes many
normal physical activities dangerous (p. 64).
VARIABLES AFFECTING USE AND INTOXICATION
The precise description of the state of phencyclidine intoxica-
tion requires information about concomitant variations between
the characteristics of the behavior and the drug (cf. Siegel
1977a). Information about the behaviors should be specific
with-respect to individual variability, type of behavior and
behavioral history. Information about the drug should be
specific with respect to dose, adulterants, routes of administra-
tion, dose-response and time-response relationships, among
others. Such variables can be further modified by environmental
variables such as set and setting. While a full understanding
of these interactions is presently restricted by limited know-
ledge concerning arylcyclohexylamines, the presence of such a
myriad of interacting variables should temper a desire to simplify
use and intoxication with succinct labels such as "lovely high,"
"perpetual peaceful place," "psychotic," or "schizophrenomimetic."
The studies described below were undertaken in an attempt to
elucidate some of these variables in relation to the psychological
intoxication.
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THE SAMPLE
A large population of recreational drug users, recruited through
advertisements in several Los Angeles area newspapers, was initially
screened. by a telephone interview and a subsequent drug history
questionnaire. A total of 319 phencyclidine users (referred to
as Adult Group) were eventually selected for study. All subjects
in the sample met the initial requirement of having used PCP
more than once in the last year. All subjects were male, 21-38
years old, and were examined and tested in the Neuropsychiatric
Institute at UCLA. Examination procedures included a personal
history questionnaire, drug history questionnaire, mental status
examination, Minnesota Multiphasic Personality Inventory (MMPI),
Experiential World Inventory (El-Meligi and Osmond 1970), in-
depth interview, physical examination (for most subjects) and
visual imagery and perception tests.
One additional group of chronic PCP subjects was also recruited
for study. This latter group (referred to as Juvenile Group)
consisted of 20 juvenile males, 14-17 years of age, who were
initially referred to the author for evaluation by the courts
or law enforcement officials. All subjects in this sample met the
initial requirement of having used PCP at least once per week for
the previous 6 months.
MULTIPLE DRUG USE
All subjects in the Adult Group had past or present histories of
multiple drug use. Concomitant with their use of PCP, 86 percent
were using caffeine preparations; 81 percent were using alcohol;
81 percent were using cannabis preparations: 62 percent were using
hallucinogens other than cannabis; 58 percent were using tobacco
products; and 20 percent were using cocaine, amphetamine and other
stimulants. Prior to their PCP use, subjects reported experiences
with barbiturates (11 percent), tranquilizers (10 percent), and
opiates (2 percent).
All subjects in the Juvenile Group had past or present histories
of multiple drug use. Concomitant with their use of PCP, 100
percent were using caffeine preparations (mostly cola beverages
and chocolate); 40 percent were using alcohol: 40 percent were
using cannabis preparations: and 15 percent were using barbitu-
rates. Prior to their PCP use, some subjects (20 percent) reported
experiences with stimulants while one (5 percent) used heroin
intranasally. Interestingly, none of the Juveniles had tried
hallucinogens other than cannabis, while 16 (80 percent) had
used volatile solvents in the past.
PREPARATIONS AND PURITY
All subjects used PCP in the form of either tablets, capsules,
powders, botanical mixtures, or liquids. It should be noted that
Helisten (1977) has reported that 88 percent of street THC samples
contain either PCP, PCP and PCC, or PCP and other drugs. Almost
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5 percent of street THC samples are combinations of TCP and PCC.
Since these are all arylcyclohexylamines, whenever subjects in
these studies reported use of street THC, it was recorded as PCP
use. Lundberg, Gupta, and Montgomery (1976) have identified the
quantitative and qualitative aspects of street PCP in the Los
Angeles area. They report that tablets contained 1.O-6.4 mg
each (mean of 5.3 mg); powder averaged 88-100 percent PCP; botanical
leaves (usually mint or parsley leaves) varied from 0.2-7.9 per-
cent; and prerolled cigarettes ranged from 1.0-3.0 mg total for
each cigarette. Another street drug assay laboratory in Cali-
fornia (PharmChem, Palo Alto) has found some parsley "joints"
of PCP containing from 3.2-28.3 mg of PCP (Perry 1975). The
most common adulterants for samples received by these laboratories
are LSD and TCP. Recently, NIDA (DuPont 1977) has noted that
street preparations of PCP may be combined with other psychoactive
drugs including heroin, cocaine, methaqualone, methylenediox-
amphetamine (MDA), aspirin, and caffeine. Liquid forms of PCP
are usually diverted licit vials of Sernylan (formerly called
Sernyl, phencyclidine hydrochloride, from Bio-Ceutics Laboratories
in Missouri). These vials are usually 10 ml each with each ml
containing either 20 or 100 mg. Illicit PCP in liquid form is
often seen in small "cokevials" or similar glass bottles.
The most common street preparation is in the form of botanical
mixtures sometimes referred to as leaf mixtures. These consist
of PCP mixed with mint leaves, oregano, or parsley. Rarely  catnip
is used and, because of the hallucinogenic nepetalactone oils
present in this material, the resultant mixture may be more
hallucinogenic than PCP alone. Lundberg, Gupta, and Montgomery
(1976) also report that marihuana or other cannabis products are
sometimes present in street PCP material.
The Juvenile Group often employed a special preparation called
"Super Cools." This consisted of a mentholated tobacco cigarette
that had been dipped in liquid PCP and dried. The additive effects
of nicotine and PCP in such preparations often resulted in states
of extreme intoxication.
ROUTES OF ADMINISTRATION
In the Adult Group, 280 subjects (88 percent) had experience with
smoking PCP preparations, 38 subjects (12 percent) had orally
ingested tablets or capsules, 15 subjects (5 percent) had used
PCP intranasally via snuffing or snorting, and three subjects
(0.9 percent) had injected PCP intramuscularly.
All 20 Juvenile subjects (100 percent) used PCP exclusively via
the smoking route.
DOSAGES
A number of researchers have attempted to calculate dosages em-
ployed in recreational use of PCP. Burns and Lerner (1976) have
estimated that the average amount smoked "per episode" is 35-75 mg,
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usually delivered in one or two cigarettes or "joints." When
PCP was used intranasally, subjects usually self-administered one
"cokespoonful" per nostril or one "line" per nostril. The amount
of pure PCP in commercially available "cokespoons" has been deter-
mined (by this author) to range from 3.5-7.1 mg for a level coke-
spoon. Assuming an average street purity of 95 percent (cf. Burns
and Lerner 1976), this amounts to an average intranasal dose of
approximately 10 mg (total for both nostrils) per administration.
The average line of PCP is about 0.5 x .15 inches and amounts to
approximately 5 mg of PCP if pure or 4.75 mg if street PCP is
used. Since two lines are used per administration, this amounts
to approximately 9.5 mg, considerably more than previously esti-
mated (cf. Burns and Lerner 1976). when PCP is taken by mouth,
the average dosage is estimated to be 5 mg.
DOSE REGIMES
Subjects in both the Adult and Juvenile Groups fell into several
patterns of PCP use (discussed below). In general, when smoking
the drug, Adult subjects tended to "titrate" or adjust their
dose intake to what was perceived to be an optimal level of in-
toxication. Most subjects (Adults) used approximately one cigarette
per week in this manner (range = 0.3-4.0). This amount was
generally consumed in one episode per week. When Adults used PCP
intranasally or orally, a single administration would occur ap-
proximately once every 8 weeks. In the Juvenile Group, 10 sub-
jects (50 percent) reported that they always attempted to titrate
their use but these users consumed approximately 28 grams of leaf
mixture per month each. However, doses were not evenly distributed
across time. Generally, Juveniles consumed their supply within
a few days, but such use was marked by much sharing and selling
among peers. The remaining 10 Juvenile subjects reported that
they always attempted to stay chronically intoxicated and used
approximately 5 cigarettes per day (range = 2-20).
These doses and dose regimes have created what researchers have
generally agreed are three distinct levels of intoxication: low
(5-10 mg), moderate (10-20 mg), and high (100 + mg). (See Burns,
Lerner, and Corrado 1975 for discussion of dose-effect relation-
ships).
PATTERNS OF USE
The dose regimes together with the set and setting define the
pattern of drug use. Five patterns of drug use have been designated
by The National Commission on Marihuana and Drug Abuse (1973)
and will be used for discussion here.
Experimental Use
Of the 319 Adult subjects, 267 (84 percent) were classified as
experimental users engaged in short term, nonpatterned trials
of PCP with varying intensity and a maximum frequency of 10 times
in their entire drug history. These users were primarily motivated
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by curiousity about PCP and a desire to experience the anticipated
drug effects of tranquilization, euphoria, inebriation, dissocia-
tion, and hallucinations. Their use was generally social and
among close friends. Most did not enjoy the experience and did
not express a desire to repeat the drug use. Interestingly, most
of the Adult users endorsed the street myth that PCP is a "bad"
drug that inevitably produces adverse reactions. Only those ex-
perimental users who expressed a belief that their PCP was really
THC or some other drug also expressed a desire to continue using
it beyond the experimental stage. These latter users typically
claimed that PCP was simply "strong marihuana and something you
could probably learn to handle." This latter finding suggests
the importance of psychological set and setting in determining
drug reactions.
None of the Juveniles were classified as expertimental users.
Social-Recreational Use
The remaining subjects in the Adult Group (52, or 16 percent) were
classified as social-recreational users who engaged in more regular
use than experimenters. Use generally occurred in social settings
among friends or acquaintances who wished to share an experience
perceived by them as acceptable and pleasurable. These users
were primarily motivated by social factors and their use was
always voluntary. It did not tend to escalate to more individually
oriented patterns of uncontrollable use. Many of these Adult
subjects started as expermental users but only 12 of them (23
percent) engaged in episodes of more frequent use (see below),
although their primary pattern was the social-recreational one.
In the Juvenile Group, 10 subjects (50 percent) were classified
as social-recreational users. Unlike their Adult counterparts,
these Juveniles all tended to engage in more frequent patterns
of use.
When asked to rank all drugs in terms of recreational drugs of
choice, the Adult social-recreational users ranked cocaine first,
cannabis second, and, surprisingly, PCP third. This may be re-
lated to the findings that both PCP and cocaine share similar
sympathomimetic effects (Chen, Ensor, and Bohner 1965). When
asked to rank all drugs in terms of potency in producing intoxi-
cation, 93 percent ranked PCP first. Other drugs ranked above
PCP in this category included LSD and Ketamine (discussed in the
second part of this chapter). Juveniles ranked marihuana first
as a recreational drug of choice and PCP second. All Juveniles
also ranked PCP first in potency.
PCP retained popularity as a recreational drug among may Adults
and Juveniles for several reasons:
1) PCP was viewed by Adult users as a misunderstood drug
which opened new altered states of consciousness for ex-
ploration. These states were considered to be unobtainable
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or less easily reached via conventional hallucinogens.
2) PCP was viewed by Juvenile users as economical and readily
available.
3) PCP was viewed by both Adults and Juveniles as an extremely
effective and different hallucinogen that could induce intoxi-
cation quickly and with such rapid onset of action allow
one to titrate dose. It was considered by these users to
be a "social hallucinogen" which, because of the paucity of
visual effects, allowed the user to be more social than with
the more "visual" psychedelic hallucinogens like LSD.
most social-recreational users felt that the possibility of un-
pleasant and adverse reactions was a rate-limiting determinant
of PCP use. Consequently, they engaged in stable, low frequency
patterns of use which did not escalate to individually oriented
patterns of uncontrollable use. They also felt that PCP was not
physiologically harmful but rather "expanded consciousness" in
long-lasting ways. Indeed, many of the Adults felt that the drug
took the user "to places that LSD only suggested were there" and
"with PCP the afterglow stays with you for a long time."
Circumstantial-Situational Use
Only three Adult users and four Juveniles engaged periodically in
circumstantial-situational use, defined as a task-specific, self-
limited use which was variably patterned, differing in frequency,
intensity, and duration. This use was motivated by a perceived
need or desire to cope with a specific condition or situation.
The motivations cited by users, in order of decreasing frequency,
were: to alleviate the dysphoria associated with situation de-
pression (81 percent); to enhance appreciation of social situations
or musical events (73 percent); and as general entertainment when
other recreations were unavailable (56 percent).
Intensified Drug Use
Nine Adult users (3 percent) and 10 Juvenile users (50 percent)
engaged in episodes of intensified use characterized by long term
patterned use of at least once a day. Such use was motivated
chiefly by a perceived need to achieve relief from a persistent
problem or stressful situation, or a desire to maintain a certain
self-prescribed level of intoxication. Nonetheless, users here
referred to their intensified use as "too much," "loaded most of
the time," "really Dusted," or "bombed." or "toasted" and were
aware of negative effects including unpleasant feelings. For most
intensified users this subsequently curtailed such patterns of
intensified use for varying periods of time.
Compulsive Drug Use
None of the subjects studied engaged in compulsive use, which is
characterized by high frequency and high intensity levels of
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relatively long duration, producing some degree of psychological
dependence. Two Adult users did appear to become compulsive users,
but they dropped out of the study before adequate assessments of
their behavior could be made.
PHENOMENOLOGY AND INCIDENCE OF INTOXICATION EFFECTS
The acute physiological and psychological effects reported by
users did not differ substantially from these described in the
literature (e.g., Burns and Lerner 1976) or elsewhere in this vol-
ume. Briefly, subjects (Adults and Juveniles are combined here)
repeatedly sought and experienced heightened sensitivity to
stimuli (94 percent), stimulation (92 percent), dissociation (88
percent), mood elevation (61 percent), inebriation (55 percent),
relaxation or tranquilization (53 percent), hallucinations (30
percent), increased sociability (14 percent), increased cognitive
activity (11 percent), and euphoria (8 percent). A number of
untoward effects were also reported by the users: perceptual
disturbances (78 percent), restlessness (76 percent), disorienta-
tion (63 percent), anxiety (61 percent), paranoia (34 percent),
hyperexcitability (27 percent), irritability (22 percent), mental
confusion (22 percent), and partial amnesia (18 percent). Dys-
arthria was not assessed in the questionnaire but roughly 80
percent of the respondents in the interviews admitted having
experienced this effect as well.
Taken together, individuals reported experiencing negative or
untoward effects in all intoxications and positive or desired
effects in only 60 percent of the intoxications.
The chronic effects reported by the Intensified Drug Users were
also similar to those reported elsewhere in the literature. In
addition to acute intoxication phenomena, users experienced both
desired and undesired effects. The desired effects included:
a generalized feeling of well-being and detachment from worldly
tensions and anxieties (65 percent), heightened perceptual sensi-
tivity in some modalities (43 percent), and psychedelic or trans-
cendental reactions (8 percent). The undesired effects included:
disturbances in time perception (38 percent), nervousness and
irritability (38 percent), perceptual disturbances (31 percent),
fatigue or lassitude (27 percent), and memory disturbances (25
percent).
Overall, chronic negative effects experienced in all intoxi-
cations, while positive effects were experienced inapproximately
74 percent of the intoxications.
HALLUCINATIONS AND PSYCHOSES
Of the phenomena reported above, the changes in perception,mood,
and thinking are perhaps the least understood but also among the
most important in determining the precise nature and form of PCP
intoxication. Indeed, Domino and Luby (1972) have suggested that
these abnormal states induced by PCP strongly resemble schizo-
130
phrenia, especially in creating profound perceptual and cognitive
disorganization and occasionally catatonic immobility. Furthermore,
the presence of perceptual changes such as hallucinations is a
key diagnostic criterion in the determination of the psychotic
phase. Therefore, these perceptual changes were the subject of
concentrated examination and testing in the study.
The definition of the word hallucination (which comes from the
Latin Hallucinari, meaning to prate, to dream, or to wander in
mind) is far from precise. However, a widely accepted definition
in psychiatry is: "A false sensory perception in the absence of
an actual external stimulus. May be induced by emotional and
other factors such as drugs, alcohol and stress. May occur in
any of the senses." By this definition, it is not surprising
that most PCP users have experienced hallucinations. For most
such subjects (94 percent) these consist of a wandering in mind
or attention which is manifested as lapses in attention, mental
confusion, clouding, and related phenomena. Such experiences
include difficulty in maintaining attention during complicated
tasks: difficulty in maintaining thoughts during conversation;
and general preoccupation with subjective sensations. These
effects are similar to those Domino and Ludy (1972) have described
as "attention disorder," "withdrawal," and "clouding delirium."
The most common perceptual disturbance was a change in body image.
Luby and co-workers (1959) have described this state as "accompanied
by loss of 'ego boundaries', impaired ability to distinguish self
and nonself stimuli, feeling of depersonalization, and a sense
of unreality" (p. 364). Generally, subjects reported that their
bodies felt strange and distorted and these feelings were usually
coupled with changes in tactile sensations. Visual changes in-
cluded macropsia and micropsia, while tactile changes included
numbness and paresthesias.
The most common mood disturbance was a blanding of affect, although
many users tended to admit that this made them somewhat euphoric
in light of pre-existing dysphoria. Previous researchers have
described this as "ambivalence" and "affect disorder." Undoubtedly,
these changes in mood contributed to the feelings of dissociation
or estrangement from self and body which were commonly reported.
The most common thinking disturbances have been described in
the literature as "loosening of association," "overinclusive
thoughts,"   "concreteness," "delusional thinking," and general
"disorganization" Associated with these phenomena are "negativism"
and "hostility." In order to assess these states, the MMPI and
the Experiential World Inventory (EMI) were administered. Only
the intensified Adult and Juvenile users manifested abnormal
profiles on these tests. The most consistent high point on the
EMI was the ideation scale, which strongly suggests thought
disorder including unbridled fantasy activity, inability to connect
experiences purposefully, flights of ideas, and serious loss in
the capacity to select and resist thoughts and to produce and
connect new thoughts. Other consistently high scores were seen
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on both sensory perception, time perception, and body perception
scales. Surprisingly, the impulse regulation scale, an indicator
of hostility and violence, was usually the lowest point on the
profile. The MMPI profile for these intensified users indicated
a large number of experiences and symptoms which are character-
istic of psychotic thinking, including hallucinations, delusions,
paranoia, feelings of unreality, and a general sense that things
are wrong. The MMPI content scales also indicated a large number
of symptoms of the type sometimes associated with organic in-
volvement of the central nervous system. Complaints here included
skin sensations, nausea, dizziness, and difficulty with speech,
memory, concentration, ability, coordination and motor control.
Unlike the EWI results, the MMPI profile indicated that most of
these users were distractable and when faced with frustration
might become irritable, aggressive, or impulsive, often out of
proportion to the reality of the situation. Taken together, these
findings indicate that PCP produces many of the symptoms character-
istic of schizophrenia, although it most be emphasized that the
correlation of symptoms does not imply a direct causal relation-
ship.
II. KETAMINE
In the 1959 horror film, The Tingler, actor Vincent Price injected
himself with the little-known drug LSD in order to produce a
state of fear and panic. That single cultural incident heralded
a much wider phenomenon of LSD use during the psychedelic revolu-
tion of the Sixties. In the 1976 film, Family Plot, Alfred
Hitchcock depicted a kidnap victim sedated with a little-known
drug called ketamine. Once again the cultural productions of
man acted as a barometer of the social times, as the Seventies
are witnessing a growing problem of ketamine abuse.
DISCOVERY AND INITIAL USE
Dissatisfied with the clinical experience of PCP as a surgical
anesthetic druq (the duration of action and emergence excitement
were too great to recommend use of the drug), Parke Davis and
Company developed a congener of PCP for anesthesia in man. The
drug was called ketamine hydrochloride or 2-orthochlorophenyl,
2-menthylamino cyclohexanone hydrochloride (original code name
CI-581). Marketed under the names Ketalar (Parke Davis and
Company), Ketaject (Bristol Laboratories and Ketavet (for
veterinary purposes), ketamine is rapidly emerging recrea-
tional street drug.
Ketamine was enthusiastically described as a nonbarbiturate anes-
thetic that is a "rapid-acting general anesthetic producing an
anesthetic state characterized by profound analgesia, normal
pharyngeal-laryngeal reflexes, normal or slightly enhanced
skeletal muscle tone, cardiovascular and respiratory stimulation,
and occasionally a transient and minimal respiratory depression"
(Bristol official package circular for Ketaject). Anesthesiolo-
gists endorsed its use initially because surgical patients remained
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physiologically very strong and required little support of vital
processes. Surgeons were also impressed with the rapid action
but somewhat disturbed when patients appeared responsive to stimuli
in the operating room. Gradually the clinical experience demon-
strated that ketamine produced a number of complications from
which it was originally claimed to be free. The complications
included: "severe laryngospasm and respiratory arrest in neonates,
cardiac arrest secondary to respiratory depression in an adult,
severe airway obstruction with vaniting and aspiration in children,
and hysterical postanesthetic reaction" (Clin-Alert 1971). Indeed,
these latter emergence reactions have been variously described as
"confusional states," "vivid dreaming," "hallucinations," and
"preseizure and seizure activity."
Nonetheless, the drug produced extremely effective analgesia
which was still judged useful in certain situations such as for
burn dressings and radiotherapy, in emergency field work, and in
war conditions. Indeed, the drug enjoyed popularity among surgeons
as the most widely used battlefield anesthetic in Vietnam. The
analgesia is probably achieved through the drug's dissociative
action in that it appears to selectively interrupt association
pathways of the brain before producing somesthetic sensory block-
ade (Sparks et al. 1973; Weingarten 1972; Winters 1975). Some
observers (e.g., Young et al. 1977) attribute the present popular-
ityof the drug to experiences gained among patients in Vietnam
and elsewhere during the late 1960's.
Street use of ketamine hydrochloride solutions was first noted in
1971 in San Francisco and Los Angeles (Siegel, personal observa-
tion), while other forms of ketamine (e.g., powders, tablets,
etc.) were first noticed on the street in 1974 (Ashley 1978).
Solutions go under a variety of street names including: Ketalar,
Ketaject, Ketavet, K, Kay, Jet, Super Acid, 1980 Acid. Powder
forms of ketamine on the street as: Green, Purple, Mauve,
Special LA Coke, Super C, and K. For both medical and nonmedical
users, the emergence reaction characterized as adissociative
hallucinatory period is probably the most dramatic aspect of the
ketamine experiencee.
MAINTENANCE OF USE
The ketamine dissociative reactions, while producing analgesia,
also produce classic hallucinogenic reactions which undoubtedly
motivate recreational users. These reactions were originally
described in the anesthesiology literature (e.g., Kreuscher 1969)
as emergence reactions that could be quickly "managed" or sup-
pressed via treatment with a variety of agents such as diazepam,
droperidol, fentanyl, pentobarbital, or meperidine (e.g., Wantz
1977). Doenicke and co-workers (1969) reported on the phenomenology
of this reaction when it was not suppressed by other medications.
Both their patients and experimental subjects experienced analgesia
concomitant with depersonalization, derealization, changes in
body imagery, nausea, dizziness, dreams, and hallucinations.
Most of their subjects stated that the dream period and hallucina-
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tory phase was "pleasant" and a typical description of the intoxi-
cation follows:
During the first subjective experience, I imagined
myself in a complicated system of pipes which reminded
me of an oil refinery. A driving force shot me
through the colorful, occasionally angled, pips. I
was wondering about the provenance of these strange
circumstances and believed I had been hexed by rela-
tives . Now this seemed to be my eternal fate, which
made me very sad. Some time later, I was first able
to perceive acoustic impressions from my surroundings,
which previously had been missing. The voices of the
people present in the room sounded distant, but yet
loud and resounding. I could hear the sounds, but I
could not understand them. I thought that they were
voices of relatives who had hexed me. Later I was
able to perceive visual impressions. The room ap-
peared dusky-foggy to me. In the distant opening of
a pipe appeared the head of a colleague. Now I under-
stood a few words and began to answer. My speech
sounded babbling and booming to me. Intermittently
the hallucination of being hexed returned. Later I
was told that I had uttered strange sounds. My
tongue seemed to me to be extremely big, but very
light. In my extremeties, too, I felt a striking
lightness. Shortly before awakening, I was again able
to understand what was said around me and I saw my sur-
roundings again, though greatly blurred and constantly
revolving around me (pp. 149-150, translated from the
German by R.K. Siegel).
Rumpf and colleagues (1969) found their subjects described keta-
mine hallucinations as "utopic," "phantastic," "unreal," or
"mysterious." Only one out of their 18 subjects considered the
dream experiences normal and ordinary. The experience was termed
pleasant by 6 subjects, unpleasant by 8, and neutral by 4. Ex-
periences reported by these test subjects included dreams of
recent memories, feelings of floating in space or falling or riding
in various vehicles, vividly colored (primarily red) geometric
patterns and designs, and were in general similar to the phenomen-
ology of other drug-induced hallucinations (see Siegel 1977b).
Unexpectedly, Rumpf and colleagues reported that fully one third
of the experimental group (6 subjects) had true hallucinations
with the concomitant delusions that their dreams were not dreams,
but, in point of fact, real events! Such intense hallucinations
are rare in drug-induced experiences (Siegel and Jarvik 1975).
In a well controlled study, Collier (1972) demonstrated that most
ketamine dreams or hallucinations were judged by subjects as pleas-
ant and of unusual intensity. One dream sequence was markedly
transcendental as "the patient ascended to Heaven, saw God and was
re-incarnated in Italy. Luminosity, green colour, tranquility and
marked euphoria predominated. This these continued for over 2 hours
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into the awake phase during which he thought that he was speaking
Italian. A central object blindness occurred. Six months later
he had not experienced any similar dreaming or spontaneous phenom-
ena but still remembered the episode vividly" (p. 125).
Current recreational users of ketamine appear to be motivated to
achieve these dissociative hallucinatory states. Young et al.
(1977) likens this state to an LSD trip, only the ketamine tripper
"feels as if he is floating in a dreamlike state while experiencing
vivid visual images" (p. 107). Stafford (1977) has recently cited
a report from a current recreational ketamine user which illus-
trates the romantic appeal of the state similar to the "perpetual
peaceful place" described by PCP users:
And when I closed my eyes a lot of information started
to happen. Colors, patterns, cross-connections in
sensory perception. Like sound and inner visions sort
of got confused. I got deeper and deeper into this
state of realization, until at one point the world
disappeared. I was no longer in my body. I didn't
have a body. And I reached a point at which I knew I
was going to die.... .And what incredible feelings that
evoked! . . . . . .I just yielded. And then I entered a space
in which . . .there aren't any words.....I mean, at-one-
with-the-universe, recognizing-your-godhead.....The
feeling was: I was home. That's really the feeling of
it. And I didn't want to go anywhere, and I didn't
need to go anywhere. It was a bliss state. Of a kind
I had never experienced before. I hung out there awhile,
and then I came back. I didn't want to come back. I
guess in the deep state it was no longer than half an
hour (pp. 348-349).
CONSEQUENCES OF CONTINUED USE
During the acute intoxication with ketamine, there is significant
impairment in attention, learning, and memory functions (Harris et
al. 1975). In particular, subjects have impairment in organizing
and understanding the enviroment during emergence reactions. But
few, if any researchers have documented the long term consequences
of continued use of this drug. In preclinical animal studies,
chronic ketamine administration results in abnormal brain wave
activity, and withdrawal is marked by progressive increases in
epileptiform activity without gross behavioral manifestations
(Manchar, Maxwell and Winters 1972). Since such abnormal electrical
activity in the brain is not correlated with observable changes in
behavior, it is not surprising that clinical studies have failed to
detect any long term impairment of behavior or personality function-
ing. Nonetheless, "bad trips" are frequent can result in
paranoia and fear of subsequent similar intoxications (see Johnstone
1973).
A number of studies have documented recurrent hallucinations follow-
ing ketamine anesthesia as well as flashbacks (Fine and Finestone
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1973; Perel and Davidson 1976), and some have even suggested, albeit
weakly, resulting psychoses (Johnson 1971). While the incidence of
ketamine flashbacks far exceeds that for other hallucinogens
(Siegel and. Jarvik 1975), the presence of flashbacks and allied
perceptions does not normally present psychological problems; for
the patients or users. Indeed, a number of psychiatric investiga-
tors have utilized continued treatment with ketamine to create
abreactive effects in psychotherapy and research settings (e.g.,
Khorramzadeh and Lofty 1973; Lilly et al. unpublished).
VARIABLES AFFCTING USE AND INTOXICATION
The variables affecting intoxication with ketamine are similar to
those discussed above with reference to phencyclidine. In addition,
because of the more profound hallucinatory quality of the ketamine
experience, intoxication is greatly influenced by set and setting.
Because ketamine induces an extreme sensitivity to environmental
stimuli, the physical surroundings are particularly important.
Indeed, recovery personnel in hospital operating rooms have long
since learned the importance of isolating the ketamine patient
from intense light, noise, and other stimulation. The intrusion
of even the most innocent stimuli such as monitoring the patient's
vital signs can trigger hyperexcitability, psychomotor activity,
and even seizures. Accordingly, recovery from ketamine anesthesia
is usually handled with minimal verbal and tactile stimulation in
medical settings, but rarely is this precaution observed in non-
medical situations. Furthermore, since ketamine is often injected
either intramuscularly or intravenously, such factors as sterile
procedures and instruments, purity of the solution, and site of
injection are especially important determinants of the intoxication.
Respiratory depression may occur from overdosage and the presence
of sedative drugs (barbiturates, opiate narcotics, etc.) in the
body may also influence the intoxication and risk of overdosage.
THE SAMPLE
Two separate populations were sampled for studies of recreational
ketamine use. One population (referred to as the Intranasal Group)
consisted of recreational users recruited from a previous study
of cocaine use (Siegel 1977a). Another population (referred to as
the Injection Group) consisted of recreational hallucinogen users
recruited from a previous study (Siegel and Jarvik 1975). A total
of 10 Intranasal users and 13 Injection users were eventually
selected for study. All subjects in the sample met the initial
requirement for having used ketamine more than once in the last
year. Subjects were approximately equally divided between men and
women, 21-45 years of age, and were examined and tested in the
manner described in the phencyclidine section of this chapter.
MULTIPLE DRUG USE
All subjects in the Intranasal Group had past or present histories
of multiple drug use. Concomitant with their use of ketamine, 100
percent were classified as social-recreational users of cocaine
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(see Siegel 1977a). All subjects in the Injection Group also had
past or present histories of multiple drug use. Their use of
ketamine ran parallel to their use of other hallucinogens and
fully 77 percent were currently using LSD. Interestingly, none
of the Intranasal or Injection users were using phencyclidine, al-
though two subjects from each group had experimented with it in
the past.
PREPARATIONS AND PURITY
All subjects used ketamine hydrochloride in the form of capsules,
powder, crystals, tablets, or solutions. Solutions are usually
diverted legal vials of ketamine available in concentrations of
10 or 50 mg/ml (Ketaject) or 10, 50 or 100 mg/ml (Ketalar). An
occasional street adulterant of these solutions is vitamin B12
due to a  common street myth (partially true) that this attenuates
adverse reactions. Capsules (usually clear, red, or black/yellow),
powders (green, mauve, or white), crystals (white), or tablets
(usually white) are usually mixtures of ketamine hydrochloride
and various nonpsychoactive compounds such as lactose, flour, talc,
and vitamins. The most common psychoactive adulterant found in
powders or crystals is cocaine hydrochloride, although others in-
cluding amphetamines and caffeine are also found. At the present
time no quantitative information is available on these preparations.
ROUTES OF ADMINISTRATION
By definition, all subjects in the Intranasal Group employed the
intranasal route of self-administration, and none of these users
had ever experimented with other routes of ketamine administration.
Similarly, all subjects in the Injection Group employed the intra-
muscular (i.m.) route of self-administration. However, of the 13
subjects here, four subjects experimented with intravenous (i.v.)
injection and one subject had experimented with smoking ketamine.
DOSAGES
Little reliable information on recreational intranasal dosages of
ketamine is available. Young and colleagues (1977) estimate that
"the normal abuser's dose is 50 mg" (p. 107). However, judging
from the reactions and intoxications reported by users (see below)
it is estimated that intranasal doses range from 60-100 mg. For
Injection users, the surgical anesthetic dosages range from 6.5 to
13.0 mg/kg (i.m.) and 1.0 to 4.5 mg/kg (i.v.). Recreational
Injection users employ dosages of approximately 1.0 to 2.0 mg/kg
(approximately 0.5 to 1.0 mg/lb.) for both intramuscular and
intravenous administration.
DOSE REGIMES
Subjects in both the Intranasal and Injection Groups fell into
several patterns of ketamine use (discussed below). In general,
when using the drug intranasally, subjects tended to administer
the drug only once in any given episode and to repeat episodes
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of administration less than once per month. Injection users also
tended to administer the drug cnly once per episode. However,
repeated injections were usually self-administered once per hour
until a desired level or period of intoxication was achieved.
PATTERNS OF USE
The five patterns of use previously designated by The National
Commission on Marihuana and Drug Abuse (1973) will be used for
discussion here.
Experimental Use
Six subjects (60 percent) of the Intranasal Group and one (8 per-
cent) of the Injection subjects were classified as experimental
users and engaged in short term, nonpatterned trials of ketamine
with varying intensity and a maximum frequency of 10 times or less
in their entire drug history. These users were motivated by cur-
iosity about ketamine (or its advertisement as a different type of
drug such as "Green" or "K") and a desire to experience the antici-
pated effects of euphoria and hallucinations. Their use was gen-
erally social and among close friends or intimate others. Most
subjects enjoyed the experience but did not express a desire to
continue regular use because of the street myth that "something
that strong must have some harmful effects on the brain." Other
subjects desired to repeat the self-administration but found cost
to be prohibitive (the drug is in short supply).
Social-Recreational Use
In the Intranasal Group, four subjects (40 percent) were classi-
fied as social-recreational users. Ten subjects (77 percent)
in the Injection Group were also classified in this way, but three
of these subjects (23 percent) engaged in episodes of more frequent
use (see below). In general, social-recreational use occurred more
regularly than experimental use and was primarily motivated by in-
dividuals seeking to share with others an experience they judged to
be pleasant and fun. Such users describe their ketamine use as
"absolutely safe" and "better than LSD." The set and setting for
recreational use parallels that observed with other more conven-
tional hallucinogens. The Intranasal users tended to employ low
dosages (probably less than 50 mg) and found the experience to be
similar to cocaine but more "trippy." This comparison to cocaine
is probably related to ketamine's cocaine-like effects on vascular
adrenergic neurons (Nedergaard 1973). The use of the term
"trippy" refers to ketamine's hallucinatory and dissociative
effects.
Injection users tended to employ sufficient dosages to produce the
"psychedelic" effects. When asked to rank all recreational drugs
in terms of potency, all social-recreational ketamine users ranked
ketamine as the most potent hallucingen and 71 percent rated it
as the hallucinogen of choice. The remaining subjects were equally
divided between LSD and psilocybin mushrooms as their hallucinogen
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of choice. When asked to rank all drugs in terms of general rec-
reational preference, Intranasal Users ranked cocaine first, while
Injection Users ranked LSD first. Ketamine was consistently des-
cribed in several ways which contributed to the maintenance of
social-recreational patterns of use:
1) Ketamine was perceived by users to be a safe, non-
toxic, potent hallucinogen with a short duration of
action and few adverse reactions or bad trips.
2) Ketamine was perceived by most users as the only
hallucinogen that did not produce anxiety or fear
reactions.
3) Ketamine was considered to have unique euphoric-
hallucinogenic properties that enabled a user to ex-
perience, with varying dosages, effects similar to
either cocaine, amyl nitrite, phencyclidine, or LSD.
4) Ketamine was considered to be a glamorous avant-
garde drug and had associations with cotemporary
folk heroes of high status (see Duncan 1976).
Circumstantial-Situational Use
Only two subjects in the Injection Group (15 percent) engaged
periodically in circumstantial-situational use, defined as a
task-specific, self-limited use which was variably patterned, dif-
fering in frequency, intensity and duration. This use was moti-
vated by a desire to explore new states of consciousness and work
through personal problems. Such use is similar to that of keta-
mine in experimental psychotherapy situations (Khorramzadeh and
Lofty 1973).
Intensified Drug Use
Only two subjects in the Injection Group (15 percent) engaged in
intensified use characterized by long term patterned use of at
least once per week for several months. Such use was motivated
chiefly by a perceived need to achieve relief from a persistent
problem or stressful situation or a desire to maintain a certain
self-prescribed level of intoxication. Nonetheless, users here
still referred to their use as "experimental" in the sense that
they were exploring new altered states.
Compulsive Drug Use
Only one subject (8 percent) in the Injection Group characterized
herself as a compulsive ketamine user with high frequency and high
intensity levels of relatively long duration. This user admitted
to both psychological and physical addiction to the drug, although
this latter claim could not be substantiated. Indeed, she was able
to "withdraw" repeatedly from the ketamine use which continued
intermittently for several years.
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PHENOMENOLOGY AND INCIDENCE OF INTOXICATION EFFECTS
The acute physiological and psychological effects reported by
ketamine users did not differ substantially between the Intranasal
and Injection Groups. Therefore, the users are combined (total N
= 23) in discussion here. In general, most users recognized that
they were using a hallucinogen, and considered the hallucinogenic
and psychotomimetic properties to be positive effects. This atti-
tude (set) contrasts sharply with most phencyclidine users who
only recognized that they were using an intoxicant similar to
marihuana, which is commonly not considered a hallucinogen in
street usage.
Ketamine users repeatedly sought and experienced a number of posi-
tive effects, including: floating sensations and dissociation
(87 percent), stimulation (83 percent), hallucinations (78 percent),
increased cognitive or mental associations (74 percent), euphoria
(26 percent), and transcendental or religious experiences (17
percent). Despite the widespread beliefs among users about the
lack of adverse reactions, a number of untoward effects were also
reported: ataxia (100 percent), slurring of speech (70 percent),
dizziness (61 percent), mental confusion (35 percent), hyperexcit-
ability (26 percent), unpleasant imagery (26 percent), blurring of
vision (17 percent), negative hallucinations, or the inability to
see things that were really there (17percent), decreased socia-
bility (17 percent), anxiety (13 percent), nausea (13 percent),
insomia (13 percent), and decreased sexual motivation (9 percent).
Interestingly, one subject also experienced several episodes of
psychomotor seizures as a result of acute intoxication.
Taken together,ketamine users experienced more negative effects
than positive effects as a result of acute intoxication. Nonethe-
less, they continued to rate the overall experience as positive
and rewarding.
The long term effects resulting from ketamine use are similar to
those reported for many other hallucinogenslike LSD. Typically,
the ketamine users claimed a chronic elevation of mood (43 percent),
deeper insights into self and others (35 percent), and positive
changes in attitudes personality (17 percent). The undesired
long term effects included: flashbacks (57 percent), attentional
dysfunction (22 percent), and decreased sociability (9 percent).
Overall, long-term effects appeared equally divided between positive
and negative experiences.
HALLUCINATIONS
Of the phenomena reported above, the hallucinations appeared to be
conspicuous as both positive effects resulting from acute intoxica-
tion and as important determinants of positive/negative long term
effects. Therefore, the ketamine hallucinations among these non-
medical users were the object of concentrated examination and study.
In general, the nature of ketamine hallucinations in recreational
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users was similar to that reported in both surgical and experimental
subjects (e.g., Collier 1972; Siegel and Jarvik 1975). One subject
from the Injection Group described her prototypical hallucinations
in a session that she tape-recorded for the author:
I see Mexico City when I close my eyes. Crazy. I've
never been there before. Now it's just black. It
reminds me of a cave. I see people moving about in
some sort of kaleidoscope pattern. I don't know where
I am. (Laughter) The crowd of people are all having
a good tine and they're laughing. My sister has got
her Sunday blue dress on, although she's always
dressed in black. I don't recognize anyone except her
and her husband. Now they're gone. They disappeared.
Now I just see commercials from TV and lots of geometric
patterns. There's someone's stereo hanging on the wall.
(Laughter) I feel a little childish. Happy. Very
happy. (Laughter) Now I see kitty cats. Striped ones
like out of a child's coloring book.
Another Injection subject described a similar experience, also
tape-recorded for the author:
I see flowers. All colors, blue and green and purple,
yellow. And now a weird looking nightclub. Now stars.
Everything happening very fast.....vegetables, pictures,
a house, a pinwheel, there's a man sitting on a chair.
It's just like a movie or a dream. There's an igloo
and a tepee. And some more flowers. (Laughter) Now
I feel like I'm in church. Really, it's really a
church. My tongue hurts. And in the church is a tiny
dot in the middle and some black space and then from
the middle comes a white light. Surrounded by flowers
like lilacs, rippling like in the wind. And pink
flowers and white picket fence. Now I see Jesus. And
I see a man and a woman kissing. NoW I see white
flowers and just green leaves. And there is an old man
on the other side and he is waving his hand and he's
gotasuitonandahat. That must be God. Now I see
a little girl. (Laughter) That's me. She's laughing.
This is all very clear. I can even see their features
and everything.
Even Intranasal users experience similar, albeit weaker, hallu-
cinations as exemplified by one subject's report:
The first thing that happens when I snort Green (keta-
mine) is that I start to get speedy like with coke
(cocaine). I feel a rush of good feelings, almost
euphoric. Then things get a little blurry. I feel
like I'm floating and sometimes dizzy. But I usually
lie down and float along with the trip. When I close
my eyes I see the "retinal circus" that Tim Leary des-
cribed with kid (LSD)--lights, colors, patterns, even
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cartoons and memory pictures. If it's dark in the
room and I open my eyes I can sometimes project things
onto the wall or ceiling. But most of the time I just
lie there thinking great thoughts and solving lots of
problems. It's a lot like nitrous oxide only it's a
more intense body trip as well. When you snort it you
come down very quickly.
As suggested above, experienced users of ketamine can learn to
utilize the state of intoxication for personal growth and explora-
tion. This use is similar to that underlying long term recrea-
tional use of other hallucinogens, and Lilly et al. (unpublished
manuscript) describe the unique aspects of ketamine in this regard.
In our group we symbolize this by saying that this
chemical induces a state in which you live in a well
of neutral reinforcement. Typical tasks are simpli-
fied and made more efficient, condensed, abstracted,
and the nonsense removed from the computations in-
volved in carrying them out. Mental processes in a
similar way sharpen out. It looks as if the contrast
enhancement of such as edges, colors, thoughts, ideas
and so forth is forthcoming. Colors seem brighter
and yet more meaningful. Objects contain their own
meanings. People are read very readily and with
great ease and evaluated in their current state anrd
dealt with in the most efficient and energetic man-
ner possible. After some weeks of training to get
through the initial phases of the emergence symptoms
so-called, these states occur. The subject learns to
centrally control, integrate and use the neutral energy
afforded by the ketamine and becomes that which he po-
tentially could become otherwise without the chemical
at his best performance (p.4).
III. OVERVIEW
The nonmedical use of phencyclidine (PCP) and ketamine has been
examined in four populations of recreational users. The first
population sample consisted of 319 Adult users of PCP while the
second population sample consisted of 20 Juvenile users of PCP.
Both groups used PCP primarily by smoking in social-recreational
patterns and settings. However, Juveniles tended to be more
intensified users than Adults, many of whom were only experiment-
ing with the drug. PCP was viewed as a potent hallucinogen by
users, who tended to titrate dosages in order to achieve desired
levels of stimulation, dissociation, and inebriation. Such posi-
tive effects were achieved in approximately 60 percent of the
intoxications. Despite the fact that negative effects such as
perceptual disturbances, dysarthria, and hyperexcitability were
common in nearly all intoxications, a substantial number of in-
dividuals maintained continued use of and preference for the drug.
These patterns of use are probably related to the dissociation and
estrangement from self and others induced by PCP, as well as the
drug's euphoro-hallucinogenic properties.
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!The third population sample consisted of 10 Intranasal ketamine
users while the fourth population sample consisted of 13 Injection
users of ketamine. Use of ketamine was primarily experimental or
social in nature and the drug was viewed by users to be a safe,
potent hallucinogen with a short duration of action and few if any
adverse effects. Ketamine users tended to titrate their use in
order to achieve desired effects of dissociation, stimulation,
hallucinations, and transcerdental experiences. Despite the users'
beliefs that the drug was totally safe, negative effects were re-
ported; these included ataxia, dizziness, mental confusion, and
hyperxcitability.
Long term intensified use of PCP tended to be associated with
abnormal personality profiles indicating the drug's psychotomimetic
actions. Long term use of ketamine was marked by a high incidence
of flashbacks as well as attentional dysfunction. Nonetheless,
recreational users of both drugs tended to experience generalized
feelings of well-being, heightened perceptual sensitivity, and
positive and rewarding experiences which reinforced and maintained
drug use. Some tendency toward transient psychosis was noted in
the PCP groups, while the ketamine users manifested some decreased
sociability with no concomitant personality changes as measured by
standard psychometric tests. An important caveat is that these
effects are neither uniformly negative nor uniformly predictable.
The number of variables affecting their production is presently
unknown.
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Chapter 7
Epidemiology of Multiple Drug Use
with Special Reference to Phencyclidine
J. Fred E. Shick, M.D.
Recently we have witnessed growing concern about the illicit use
of phencyclidine (PCP) among this nation's youth. Epidemiological
data has been difficult to assemble quickly, since most surveys
either have included PCP within the category of hallucinogens"
or have anitted questions about it altogether (Johnston 1973;
Abelson and Fishburne 1976; O'Donnell et al. 1976). The primary
source of descriptive data, useful in estimating the range of
usage patterns and adverse reactions, has been studies of youth
in crisis from PCP use -- usually samples from hospital settings
and drug abuse programs (Burns et al. 1975; Burns and Lerner 1976;
Fauman et al. 1976; Fauman et al. 1975; Linden et al. 1975; Tong
et al. 1975).
The focus of my research has been to develop a fieldwork method-
ology to locate and gain access to heavy, multiple drug-using
youth at their congregation sites. These youth -- generally the
underemployed and undereducated 16 to 26 year old age group --
are at risk for a variety of adverse outcomes, including progres-
sion to intensified drug use, experimentation with intravenous
administration, as well as acute and chronic adverse drug reactions
My research has borrowed concepts and methods from participant
observation fieldwork methodologies (Becker 1970; Habenstein 1970;
Weppner 1977) and the work of Hughes and coworkers with heroin
addict communities in Chicago (Hughes 1977; Hughes and Crawford
1972; Hughes et al. 1971; Hughes and Jaffe 1971; Hughes, Senay,
and Parker 1972).
Our previous studies (Shick, Dorus, and Hughes 1978; Shick and
Wiebel 1978) utilized fieldwork techniques to identify sites pop-
ularly known as "hangouts" where youthful multiple drug users
congregated to buy, sell and use drugs. We also used these tech-
niques to study intensively the social organization and activities
of groups of youth at certain sites. Particularly remarkable
were the relative geographic stability of these locations during
the warmer months, the regularity with which particular groups
frequented a given site, the preponderance of males, and the rec-
reational and social quality of the groups' activities, including
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drug use. These studies suggested that youthful drug user hangouts
may be conceptualized as "neighborhood" or "regional." Neighbor-
hood hangouts were frequented by smaller numbers of visitor who
lived in the immediate neighborhood, attended the same high school,
knew one anothers' brothers and sisters,and were from similar
ethnic and socioeconomic backgrounds. Drugs available at these
sites appeared to be limited in both quantity and variety by the
small number of dealers a who generally residents of the neigh-
borhood. By contrast, regional sites were characterized by large
number of visitors who came from an extremely wide area and were
not organized into cohesive friendship groups on consisting of long-
term neighborhood friendships established during grade school and
high school. Regional sites appeared to attract the heaviest drug
users and dealers, and a wide range of drug types were regularly
available. Regional sites were well known to most visitors to the
neighborhood locations but were avoided by them and visited only
occasionally when drugs were available at their usual neighbor-
hood hangouts. Observation and informal interviews suggested that
violence among individuals and groups was more common at regional
sites, particularly those of wide social and economic diversity,
and areas frequented by delinquent gangs.
This work demonstrated that fieldworkers who themselves had been
multiple drug users and who were residents of and regular visitors
to the area under investigation were able to locate and character-
ize drug user congregation sites and could be trained to gain ac-
cess to users to perform epidemiologic field research activities.
We were fortunate in these studies to have the foresight to in-
clude in our fieldinterviewsa separate category of questions
about drugs generally analyzed to contain phencyclidine (PCP).
In this paper we report the epidemiological drug use data collected
from regular visitors to two regional congregation sites in the
Chicago area: (1) the largest congregation and drug distribution
site in the south Chicago suburbs, active during warm weather, and
(2) the largest urban congregation and drug distribution on the
near month side of Chicago, which was active throughout the year.
METHODS
The field team for each site consisted of two fieldworkers who were
regular members of the drug-using community being stuied and who
themselves occasionally used illicit drugs. They were trained in
fieldwork and interview techniques andregularly supervised by the
research sociologist and the author. A more detailed discussion
of the recruitment procedures, selection criteria, and training
for fieldworkers is presented in a forthcoming report.
We began by asking the fieldworkers for each location,who were
familiar with the area, to identify all known hangouts for multiple
drug users. Fieldworkers then made several visits to each site on
different days at different hours, and in fieldnotes they estimated
the number of visitors present, their age range, and other demo-
graphic characteristics, the drugs available, and whether visible
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dealing or use occurred. They discussed the local drug scene with
individuals they met at these sites and asked about additional dtug
user hangouts, which then were visited. The research sociologist
and the author verified the fieldworkers' observations by personal
visits and informal interviews on a regular basis.
From this data, early in the Summer of 1975, we identified for
intensive study, the largest and most popular congregation sites
in each area. Informal interviews with regular visitors to these
and other locations confirmed fieldworkers' reports that these sites
were the primary hangouts for the heaviest multiple drug users and
dealers from surrounding areas.
At the suburban forest preserve (Site one) during July through
November, 1975, fieldworkers administered structured field inter-
views detailing demographic characteristics, drug-using habits,
and service needs to 71 subjects who were selected by word–of-
mouth chains of referral from approximately 100 regular visitors
to this site. The interviews were conducted at the site in an
area away from the greatest activity or in the fieldworker's car.
At the urban congregation site (Site two) we rented a field office
in the area, and there fieldworkers administered the same inter-
views to 236 subjects similarly selected from approximately 300
regular visitors, between July 1975 and December 1976. Each
subject was paid $5 for his participation in the interview.
To minimize the effect of seasonal variation in drug availability,
popularity, and visitor attendance, in this paper we compare epi-
demiological drug use data from Site one with that from 118 of the
236 subjects selected from site two who were interviewed during
the same period -- July through November 1975.
RESULTS
Intensive Study Sites
The south Chicago suburbs include approximately 40 incorporated
cities and towns ranging in population from 1,500 to 60,000 in
the highly industrialized 180 square mile area. Most of the house-
holds consist of white, blue collar, working class families, less
than 1 percent are nonwhite, and less than 10 percent are defined
as white collar. The site of intensive study was a forest preserve
visited in the late afternoon and evening hours during good weather
by 100 to 300 youth, who arrived in cars from an extremely wide geo-
graphic area. Drug dealing and use was open and uninhibited,and
regular police patrolling seemed to have little effect (Shick and
Wiebel 1978). The drugs available at this site varied with the
attendance; on slow days only marihuana was available, but on
busy days a wide variety of drugs, including occasionally heroin,
was sold.
The near north side of Chicago is a heavily populated area sur-
rounded by affluent whites along Lake Michigan and Latino and
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TABLE  1
DEMOGRAPHIC CHARACTERISTICS OF THE
STUDY SAMPLES COMPARED
Age Forest Preserve Sample Urban Sample
(Years) (N=71) (N=118)
Males Females Total Males Females Total
< 18 17%(9) 72%(13) 31%(22) 26%(26) 16%(3) 25%(29)
18-20 34%(18) 17%(3) 30%(21) 42%(42) 53%(10) 44%(52)
> 20 49%(26) 11%(2) 39%(28) 31%(31) 32%(6) 31%(37)
Total 75%(53) 25%(19) 100%(71) 84%(99) 16%(19) 100%(118)
Mean Age
Modal Age
Median Age
Ethnicity
19.9 years 20.9 years
17 years 18 years
19.2 years 18.9 years
White 98% (70) 82% (97)
Black 2% (1) 8% (9)
Latin (0) 8% (9)
other (0) 2% (3)
Religious Training
Catholic
Protestant
Jewish
other
None
52% (37) 50% (59)
28% (20) 25% (29)
1% (1) 7% (9)
12% (8) 12% (14)
7% (5) 6% (7)
Marital Status
Single 86% (61) 89% (105)
Married or
Common-law
Partner 13% (9) 1% (1)
Separated 1% (1) 1% (1)
Divorced (0) 9% (0)
Children 11% (8) 18% (21)
Education
currently
Attnd'g
School 34% (24) 14% (17)
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TABLE 1 (cont'd.)
DEMOGRAPHIC CHARACTERISTICS OF THE
STUDY SAMPLES COMPARED
Age
(years)
Forest Preserve Sample
(N=71)
Urban Sample
(N=l18)
Last year of
School Completed
8th Grade
or less
9th
10th
llth
12th
Some College
Grad'd College
High school
Equivalency
Exam
Currently
Employed
1% (1) 15% (18)
10% (7) 19% (22)
23% (16) 19% (22)
34% (24) 16% (19)
20% (14) 20% (23)
13% (9) 10% (12)
(0) 1% (2)
3% (2) 8% (9)
25% (18) 27% (23)
Area Grew up
(to age 13)
Chicago
Chicago Suburban Area
Other Part of Illinois
Out of state
No Answer
Employment Status of Family's Major Provider
Higher Exec.,
Professional 2% (1)
Lesser
Managerial 34% (22)
Adm'n., Small
B'sns.Owner 9% (6)
Clerical
Technical 34% (22)
Skilled Manual 8% (5)
Semi-Skilled
Man'l. 13% (8)
Unskilled (0)
Public Assistance,
(0)
57% (67)
7% (8)
5% (6)
30% (35)
1% (2)
5% (6)
9% (10)
11% (13)
14% (17)
19% (22)
16% (19)
12% (14)
Orphan 14% (17)
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and lower class whites to the northwest.It is also a popular
shopping and nightlife district among young singles. The several
drug user hangouts here were within walking distance from One
another and attracted drug users from a wide area. These hangouts
were an integral part of an urban neigborhood and were active
throughout the winter months, in contrast to the isolated sites
such as parks, beaches, or forest preserves, which were active
only during warmer weather. Furthermore, the urban site attracted
diverse types of multiple drug users various ethnic and socio-
economic backgrounds and numerous adolescent runaways.Our sample
included regular intravenous users of amphetamine and heroin who
frequented the pool hall, intravenous experimenters using various
drugs, and a large number of daily or weekend users of pharmaceuti-
cals, psychedelics, PCP, alcohol, and marihuana who "hung out"
regularly at the restaurants. Subjects' occupation ranged from
legal employment to careers of crime: illegal activities included
drug dealing, male and female prostitution, pimping, shoplifting,
burglary, and con games. The full range of drugs was regularly
available from many sources including many of the youth themelves,
several large quantity dealers who lived in the nearby hotels,and
about five pathological prescribers.
Table one displays the demographic characteristics of the two
samples. Both samples included substantially more males than
females, which accurately reflected the composition of the regular
visitors, verified by fieldwork. In contrast to the suburban
forest preserve sample, there were more nonwhite subjects and a
greater number of older subjects among the urban sample.
Subjects from the suburban forest preserve sample had grown up
near the area where they presently lived. By contrast, only 64
percent of the urban sample subjects had grown up in Chicago or
its suburbs, and 30 percent had grown up outside the state of
Illinois (5 percent had grown up in Illinois outside the Chicago
metropolitan area). A greater proportion of urban samples subjects
had dropped out of school (many during grade school or early high
school), had left home at an early age, and were no longer living
with parents (78 percent). Two-thirds of the suburban sample and
86 percent of the urban sample were no longer attending school,
and threer-quarters of both samples were unemployed.
Epidemiologic Data
In contrast to the epidemiologic assessment of heroin addiction
(Hughes 1977; DuPont and Greene 1973; Greene et al. 1974) the study
of trends and patterns of drug use among multiple drug users is
complicated by the wide variety of drug types used, the various
definitions of "multiple drug use" (Elinson and Nurco 1975; Single,
Kandel, and Faust 1974), and the questionable purity of many of
these drugs (Cheek, Newell, and Jaffe 1970; Kealy and Webber 1975).
The drug use reported by subjects reflects the alleged content and
must be interpreted in the light of the prevalence of misrepresen-
tation and the considerable variability in potency of some drug
types.
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In our analysis, the drug category representing phencyclidine
(PCP) is labeled "dust." Fieldworkers were trained to question
users in detail about substances which might have contained PCP.
Preliminary fieldwork and results from the Chicago Drug Analysis
Network indicated that in Chicago during 1975-1976 the prepera-
tions most likely to contain a substantial amount of phencyclidine
were marketed under the street names "PCP, dust, angel dust, TIC,
TAC, and THC." Thus, these street names were incorporated into the
structured field interview to obtain the subject's self-report of
PCP use.
Results published by PharmChem laboratories during the period of
our study were consistent with the results from  the Chicago Drug
Analysis Network (Helisten 1977; Perry 1977; Rainey and Crowder
1974; Kealy and Webber 1975). (Four percent of subjects from Site
one and 11 percent from Site two reported having utilized the
services of a drug analysis service.) Practically 90 percent of
the drugs marketed as PCP, dust, angel dust,THC,TIC, and TAC
contained phencyclidine, and drugs sold as amphetamines, cocaine,
or psychedelics had a much higher misrepresentation rate. The
amount of PCP in samples varied from less than 5 percent to almost
100 percent. Generally less than 10 percent of the drugs sold
under these street names were analyzed to contain no identifiable
drug. Other drugs occasionally found in admixture included small
quantities of cocaine, and psychedelics such as LSD or MDA.
Although reports from the West Coast (Burns and Lerner 1976)
suggest a recent increase in smoking materials represented as mari-
huana but adulterated with PCP, fieldwork data indicated that in
Chicago during thetimeperiod studied, very seldom did this type
of use occur -- PCP was rarely marketed surreptitiously. Although
some users thought they were getting cannabinol when buying "THC,"
the majority of subjects, most of whom were experienced and "street
wise" users, knew of -- and sought -- the "animal tranquilizer"
contained in these substances.
Incidence (First Use)
Incidence data, the number of "new cases" in a particular year,
were derived from questions about season and year of first use, and
results from each sample were remarkably similar. At each site
first experimentation with every drug type (except heroin and
cocaine; see below) was declining due to the artifact of "satura-
tion." Incidence is a one-time occurrence, and by 1975, from 70
to 90 percent of subjects in both samples had tried every type of
drug surveyed except codeine, cocaine, heroin, methadone and
solvents, seriously depleting the pool of those still eligible for
"first use" (Hughes, Schaps, and Sanders 1973).
Data from both sites indicated that among every age group (<18
years; 18-20 years; > 20 years) peak incidence of PCP use occurred
more recently than any other drug type.
At Site one, peak incidence for sedative-hypnotics (1971-1972) and
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dust (1973-1974) was separated by two years. Among younger sub-
jects, peak incidence of psychedelic use occurred two years before
peak incidence of dust; among older subjects, peak psychedelic
incidence occurred four years before peak incidence of dust.
At Site two, among subjects less than 18 years old, incidence for
dust peaked in 1972 and again in 1975. This bimodal curve may be
an artifact or may represent local variations in popularity, avail-
ability, or sample selection factors (Richman and Abbey 1977). If
this bimodal incidence is considered artifactual and the curve is
interpolated, peak incidence of PCP use among younger subjects ap-
pears to have occurred very recently, 1974-1975, approximately one
year following the peak incidence of sedative-hypnotic use, and two
years following the peak incidence of psychedelic experimentation.
Among the 18 to 20 year olds at Site two, peak incidence of PCP
use occurred between 1973 and 1974, again approximately one to two
years following the peak incidence of sedative-hypnotic use, and
one to two years following peak incidence of psychedelic experimen-
tation. Among subjects over 20 years old at site two, peak inci-
dence of dust use occurred about 1972; peak incidence of sedative-
hypnotic, amphetamine, and psychedelic use occurred between l967-
1969.
Among subjects less than 18 years old at both sites, heroin and
cocaine use displayed a recent rising incidence during 1972-1974.
Among the urban sample (Site two) a similar rising heroin incidence
was observed among the 18-20 year olds; among subjects older than
20 years at this site, heroin incidence peaked between 1970-1972.
Whether the mean, modal, or median age that subjects had first tried
each drug type was inspected, results from each site suggested that
the drugs subsumed under the category of "dust" were first tried
relatively late in the sequence of use. Generally subjects had
tried alcohol, marihuana, (solvents, glue, and codeine in a minor-
ity), sedative-hypnotics, amphetamines, and psychedelics prior to
their first trial of dust. Trial of opiates, when it occurred,
appeared to follow trial of dust. Among older subjects (Site two)
the age at which they first tried dust was most closely associated
with, and generally followed, their first trials of sedative-
hypnotics and amphetamines. The younger users' first trials of
dust were more closely associated with subjects' first trials of
psychedelics and amphetamines which followed their first trials of
sedative-hypnotics.
Results suggested that younger users who regularly frequent region-
al drug user hangouts such as these may be more likely than older
users to try a variety of drugs shortly after their initial trials
of marihuana. Data from both sites suggested that in contrast to
subjects 18 years or older, whose first use of each drug was more
widely spaced in time, most of the younger subjects had tried sev-
eral different drug types within a brief period of six to 18 months.
This tendency of younger users to try "any drug available" was also
characteristic of the subjects we studied (Shick, Dorus, and Hughes
1978) on the far north side of Chicago (frequenting a much smaller,
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neighborhood site) and is consistent with our impressions from work
in adolescent drug treatment programs. Whether adolescent experi-
mentation with a variety of substances within a brief span of time
reflects a different attitude about drug use among younger adoles-
cents and is predictive of eventual heavy use deserves further
study.
Prevalence, Remission, and Frequency of Use
In Hughes and Crawford's work (1972) in heroin-copping areas, heroin
prevalence data was relatively easily collected by ex-addict field-
workers. Weekly logs of the number of addicts visiting a copping
area reflected prevalence of active addiction because most addicts
must make daily visits in order to obtain drug supplies and to
avoid the distress of withdrawal symptoms. At youthful multiple
drug user sites prevalence of drug use must be determined by self-
report, since the majority of users are not physically dependent.
There is a recreational quality to drug use at these sites, and a
visitor's mere presence does not indicate what drug(s) s/he may
be using.
Computer analysis determined the prevalence, remission and fre-
quency of use of each drug type for each of the two samples from
self-reports of frequency of use during the 12 months prior to
interview.
Figure one compares the prevalence and remission rates for the
two samples. Prevalence of drug use was defined as the percentage
of subjects who had used a particular drug type at least once dur-
ing the prior 12 months. Remission was defined as the percentage
of subjects who had tried a given drug type but had not used the
drug during the 12 months prior to interview. The percentage of
subjects reporting ever having used each drug type is the sum of
the prevalence percentage plus the remission percentage (see figure
one) .
Marihuana and alcohol displayed the greatest prevalence of use and
least remission among both samples. In rank order, sedative-
hypnotics, amphetamines dust, and psychedelics registered the
next greatest prevalence rates at both sites: prevalence rates for
these drugs were consistently greater among subjects from the sub-
urban forest preserve than among subjects at the urban site. At
both sites the magnitude of the remission rates for these drugs was
the reverse order of their prevalence: psychedelics, dust, ampheta-
mines, and sedative-hypnotics, in that order. The prevalence of
cocaine use was approximately the same for subjects from both
sites, but the remission rate for cocaine was slightly greater at
the suburban forest preserve than at the urban site. The same was
true for heroin. The slightly lower remission rates for heroin
and cocaine among the urban sample may reflect the greater number
of heroin addicts in the urban sample, and possibly their concom-
itant use of cocaine. Solvents and glue had greater remission
rates than any other drug type among both samples; however, the
prevalence of solvent use was much greater at the suburban forest
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FIGURE 1
PREVALENCE AND REMISSION RATES OF TWO SAMPLES
COMPARED: F = 71 REGULAR VISITORS TO A CHICAGO
SUBURBAN FOREST PRESERVE DRUG USER SITE, SUMMER
1975; U= 118 REGULAR VISITORS TO A CHICAGO URBAN DRUG
USER SITE, SUMMER 1975.
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FIGURE 2
FREOUENCY OF DRUG USE DURING THE 12 MONTHS
PRIOR TO STUDY OF TWO SAMPLES COMPARED: F = 71
REGULAR VISITORS TO A CHICAGO SURBURBAN FOREST
PRESERVE DRUG USER SITE, SUMMER 1975; U = 118 REGULAR
VISITORS TO A CHICAGO URBAN DRUG USER SITE, SUMMER
1975
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preserve than at the urban site. The high remission rates reported
for psychedelics may reflect users' unpleasant experiences with
these drugs, indicated by the large number of adverse reactions
reported for psychedelics. In fact, remission rates for psyche-
delics, dust, amphetamines, and sedative-hypnotics approximate the
rank order of the number of adverse reactions reported for them.
Figure two compares the frequency of use of each drug type for the
two samples. Frequency data was obtained by asking each subject
to estimate the number of times during the past 12 months s/he
had used a particular type of drug and whether her/his use occurred
on a periodic basis, for example, daily, or on weekends. Because
these subjects reported high rates of use, the following frequency
intervals were calculated: use of the drug once a month or less;
more than once a month to once a week; more than once a week to
three times a week; four times a week to almost daily use;and
daily use.
Although prevalence of marihuana and alcohol use was approximately
the same for the two samples, a greater number of subjects reported
daily use of these two drugs among the suburban forest preserve
sample. Although the prevalence rates for sedative-hypnotics,
amphetamines, dust, and psychedelics were lower among subjects in
the urban sample, there were more daily users of amphetamines (ten
subjects), sedative-hypnotics (five subjects), dust (three sub-
jects), and psychedelics (one subject) among the urban sample.
Although approximately the same percentage of subjects at both
sites had used dust and psychedelics more than once a month,
there was a greater number of heavier users among the urban sample
than among subjects at the suburban forest preserve. Frequency of
heroin, amphetamine, and cocaine use was greater among the urban
sample, reflecting the greater number of near-daily intravenous
users among these subjects (see table two).
There are numerous definitions of multiple drug use (Elinson and
Nurco 1975). We used a method modified from that described by
Hughes, Schaps, and Sanders (1973) to assess the number of drug
types (excluding alcohol and marihuana)used by each subject at
least once during the 12 months prior to interview. The results
are displayed in table three. Sixty-six percent of the subjects
from Site one and 44 percent from Site two had used between four
and six different types of drugs. There was a tendency for the
15 to 17 year olds among the forest preserve sample to have used
a wider variety of drugs than older subjects; among the urban
sample, this tendency was displayed among the 18-20 year olds. We
compared the variety of drugs used by both samples with a sample
of 216 heroin addicts entering treatment (Senay and Shick 1976)
and a 1970 sample of 13,412 Chicago suburban high school students
(Hughes, Schaps, and Sanders 1973). Results indicated that both
field samples of youthful multiple drug users had used a much
wider variety of drugs with greater frequency than did heroin
addicts entering treatment or the high school students.
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TABLE 2
MEAN FREQUENCY OF DRUG USE DURING THE PAST TWELVE
MONTHS AMONG ACTIVE USERS OF TWO SAMPLES COMPARED
Mean Frequency of Use During the Past 12 Months*
Drug
Type Al. Mh. Sol. Cd. S-H Am. Co. Dust Pd. H. O.O. Mth.
F
U
231.5 264.3 26.7 3.7 60.7 37.5 5.1 22.2 16.1 28.9 10.3 96.0
148.6 206.3 22.0 8.6 57.7 102.1 17.3 48.1 36.5 133.5 42.6 59.9
F = Forest Preserve Sample (N=71)
U = Urban Sample (N=118)
Key to Abbreviations 
Al.=Alcohol;Mh.=Marihuana; Sol.=Solvents; Cd.=Codeine; S-H=
Sedative-Hypnotics; Am.=Amphetamines; Co.=Cocaine; Dust=Phencycli-
dine; Pd.=Psychedelics; H.=Heroin; O.O.=Other Opiates; Mth.=
Methadone.
* Includes only "active users," that is, subjects who used at
least one drug one time during the 12 months prior to interview.
Frequency is expressed as the mean number of days used per year
over the past 12 month interval.
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TABLE 3
VARIETY OF DRUG USE* OF TWO SAMPLES COMPARED
Suburban
Forest Preserve
Variety of Use Category Sample Urban Sample
N = 71 N = 118
% N % N
Nonuser 0 ( 0) 0 ( 0)
Alcohol only 0 ( 0) 1 ( 1)
Marihuana and/or Alochol 1 ( 1) 6 ( 7)
One of 6 ( 4) 13 (15)
Two of 11 ( 8) 15 (17)
solvents
Three of Sedative-Hypnotics 8 ( 6) 11 (13)
amphetamines
Four of Dust 20 (14) 17 (20)
Phychedelics
Five of Cocaine 23 (16) 18 (21)
Codeine
Six of Heroin 23 (16) 9 (11)
Methadone
Seven of Other Opiates 4 ( 3) 5 ( 6)
Eight of 4 ( 3) 3 ( 3)
None of 0 ( 0) 2 ( 2)
* Adapted with modification from a method devised by Hughes, Schaps,
and Sanders (1973). Subjects included have used a drugtype at
least once during the 12 months prior to interview.
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Intravenous Drug Use
Intravenous experimentation is of particular concern since it ap-
pears to signify a "quantum jump" in drug using habits and atti-
tudes, often heralds a change in friendship group, increases the
primary drug reinforcement effects (the "rush"), places users at
risk for adverse medical consequences such as serum hepatitis, and
is a precursor to heroin (or intravenous amphetamine) addiction.
Furthermore, as deAlarcon (1971) discussed, the injecting ritual
itself is communicable."
At Site one, 40 (56 percent) of the 71 subjects, including six of
the 22 subjects 15 to 17 years old, had experimented at least once
with the intravenous route of administration. The diversity of
drugs injected was the same for every age group. In rank order,
the drugs most frequently injected were opiates (generally heroin),
amphetamines, dust, cocaine, psychedelics, and sedative-hypnotics.
Intravenous experimentation was morecommon among males (66 per-
cent) than among females (22 percent); intravenous  amphetamine
and cocaine use was more common among subjects 18 years or older
than younger subjects.
The urban sample (Site two) included a larger nunber of daily in-
travenous users of heroin and amphetamines. Sixty-nine (58 per-
cent) of the 118 subjects (including eight of the 29 subjects less
than 18 years old) had experimented at least once with intravenous
injection. In contrast to the suburban forest preserve sample,
intravenous drug use was more common among the females (84 percent)
than among males (54 percent). In rank order, the drugs most fre-
quently injected (of those who had ever tried the drug itself)
were heroin (81 percent), other opiates (29 percent), amphetamines
(52 percent), cocaine (27 percent), sedative-hypnotics (25 percent),
"dust" (23 percent), and psychedelics (18 percent). The relatively
greater percentage of subjects at Site two who had tried cocaine
and sedative-hypnotics intravenously than at Site one my reflect
the slightly older age of the sample, the association of intravenous
cocaine and heroin use among heroin addicts, or the use of intra-
venous sedative-hypnotics to substitute for heroin when unavailable
or to "come down" from amphetamine intoxication among habitual
users.
Adverse Reactions
Table four displays the total number of adverse reactions reported
by subjects from each site. There were a greater number of adverse
reactions reported at the suburban forest preserve than at the
urban site, but this was a function of the larger number reportedly
due to alcohol at site one.
Table five displays the adverse reactions reported by subjects from
Site one. Fifty-six percent of the 127 adverse reactions reported
were of a physiological nature, generally nausea, headaches, and
vomiting, and 41 percent of these were reportedly due to alcohol.
"Bad trips," predominantly acute anxiety reactions or unpleasant
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TABLE 4
NUMBER OF SELF-REPORTED ADVERSE REACTIONS
OF TWO SAMPLES COMPARED
Including Alcohol
Number of
Adverse Forest Preserve Urban
Reactions Sample Sample
Subjects Subjects
% N % N
None 10%(7) 34%(40)
one 31%(22) 35%(42)
Two 34%(24) 24%(28)
3 or more 25%(18) 7%(8)
Total 100%(71) 100%(118)
Excluding Alcohol
Forest Preserve Urban
Sample Sample
Subjects Subjects
% N % N
20%(14) 35%(42)
39%(28) 35%(41)
28%(20) 24%(28)
13%(9) 6%(7)
100%(71) 100%(118)
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TABLE 5
DRUGS SELF-REPORTED TO HAVE PRODUCED ADVERSE REACTIONS,
SUBURBAN FOREST PRESERVE SAMPLE
(N=71)
Nature of
Adverse Reaction Drugs Said to Have Caused Adverse Reaction
AlC. Pd. Dust H. Am. S-H Cd. Mh. Solv. Comb. TOTAL
Physio-
logical
"Bad
trip"
Over-
dose
With-
drawal
other
Total
Number
% of
29 9  8 7  5 4 3 2
0 25 2 1 5 1 0 1
0 1 2 4  2 2 1 0
0 0  0 1 0 0 0 0
0 0 1 4 1 0 0 0
29 35 13 13 13 11 4 3
23% 28% 10% 10% 10% 9% 3% 2%Total
Key to Abbreviations:
2
1
0
0
0
3
2%
Alc.=Alcohol; Pd.=Psychedelics; Dust=Phencyclidine; H.=Heroin;
2 71 56%
1 37 29%
0 12 9%
0 1 1%
0 6 5%
3 127
2% 100%
Am.=Amphetamines; S-H=Sedative-Hypnotics; Cd.=Codaine; Mh.=
Marihuana; Solv.=Solvents; Comb.=Combinations.
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experiences of hallucinations, accounted for an additional 29
percent of the adverse reactions, and 68 percent of these were due
to psychedelics such as LSD and MDA. Dust accounted for ten per-
cent of the 127 adverse reactions; eight were physiological, two
were "bad trips," and two were reported as "overdoses," a term
which included from overdoses requiring emergency room treatment
and less severe episodes of passing out.
Table six displays the total number of adverse reactions reported
by subjects at Site two. Although the prevalence and frequency of
alcohol use were similar at the two sites, alcohol accouuted for a
considerably smaller percentage of adverse reactions at the urban
site (four percent) compared to the suburban forest preserve (23
percent) . Psychedelics accounted for the greatest number of adverse
reactions (31 percent), predominantly "bad trips." Amphetamines,
sedative-hypnotics, and heroin were said to be responsible for a
slightly greater percentage of the adverse reactions at Site two
than Site one; the percentage of reactions due to dust was the same
in both samples (ten percent at Site one and 12 percent at Site
two). Dust was not mentioned in reactions said to be due to a com-
bination of drugs. At both sites a greater number of “bad trips"
was reported for psychedelics than for dust; but compared to
psychedelics dust was said to be responsible for a greater per-
centage of adverse physiological reactions and those labeled by
subjects as an "overdose."
Treatment of adverse reactions reported at Site two, displayed in
table seven, was practically identical to the data from Site one.
At Site two, 31 percent of the adverse reactions were treated by
friends, 32 percent were treated at hospitals, 23 percent received
no treatment, eight percent were treated by the subject himself,
four percent were treated by parents, and two percent at drug rescue
Services.
If we compare the type of drugs accounting for the adverse reaction
and the nature of treatment reported at site two (see table seven),
of all the drugs, psychedelics and dust had the greatest number of
adverse reactions treated by friends (46 percent each). Twenty-
three percent of the adverse reactions reported for dust, but nine
percent of the adverse reactions reported for psychedelics, were
treated in a hospital setting.
The data suggest that most reactions from dust and psychedelics are
treated by friends, receive no treatment, or are managed by the
individual himself. Hospitals appear to get subjects suffering from
sedative-hypnotic and heroin overdoses, and overdoses and physio-
logical reactions due to amphetamine abuse, more frequently than
reactions said to be produced by other drugs, including dust.
Twenty percent of subjects at Site one and 34 percent at Site two
had been treated at a hospital for a drug-related problem. The
rank order of types of problems was the same among both samples:
overdose, problems related to "heavy usage," adverse drug reactions,
hepatitis, "to dry out," vehicle accidents due to drug intoxication.
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TABLE 6
DRUGS SELF-REPORTED TO HAVE PRODUCED ADVERSE REACTIONS,
URBAN SAMPLE
(N=118)
Nature of
Adverse Reaction Drugs Said to Have Caused Adverse Reaction
Physio-
logical
"Bad
trip"
over-
dose
With-
drawal
Other
Total
Number
% of
Total
Alc.
3
0
1
0
0
4
4%
Pd. Dust H. Am. S-H Cd. Mh. Solv. Comb. TOTAL
7 3 8 12 3 2 1 2
27 6 0 3 0 0 2 0
0  4  7 1 5 0 0
0  0 1 0 1 0 0 0
1 0 0 0 0  0 0 0
1 42 38%
2 40 37%
5 23 21%
0 2 2%
1 2 2%
35 13 16 16 9 2 3 2 9 109
31% 12% 15% 15% 8% 2% 3% 2% 8% 100%
Key to Abbreviations:
Alc.=Alcohol; Pd.=Psychedelics; Dust=Phencyclidine; H.=Heroin;
Am.=Amphetamines; S-H=Sedative-Hypnotics; Cd.=Codeine; Mh.=
Marihuana; Solv.=Solvents; Comb.=Combinations.
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TABLE 7
SELF-REPORTED TREATMENT FOR ADVERSE REACTIONS, URBAN SAMPLE
Drug Reported
Producing
Adverse Reaction
None Friends
% N % N
Alc. (0) 75(3)
Mh. 33(1) (0)
S-H 22(2) 11(1)
Am. 31(5) 19(3)
Dust 23(3) 46(6)
Pd. 26(9) 46(16)
H. 13(2) 19(3)
Oth. 23(3) 15(2)
Total 23(25) 31(34)
Key to Abbreviations:
(N=118)
Reported Treatment
Hospital
% N
25 (1)
33 (1)
67 (6)
31 (5)
23 (3)
9 (3)
63 (10)
46 (6)
32 (35)
Self
% N
(0)
33(1)
(0)
13(2)
(0)
11(4)
6(1)
8(1)
8(9)
Parents
% N
(0)
(0)
(0)
(0)
8 (1)
6 (2)
(0)
8 (1)
4 (4)
Drug
Prog.
% N
(0)
(0)
(0)
6(1)
(0)
3(1)
(0)
(0)
2(2)
Total
% N
4 (4)
3 (3)
8 (9)
15 (16)
12 (13)
32 (35)
15 (16)
12 (13)
(109)
Alc.=Alcohol; Mh.=Marihuana; S-H=Sedative-Hypnotics; Am.=
Amphetamine; Dust=Phencyclidine; Pd.=Psychedlics; H.=Heroin;
oth.=other drugs: Drug combinations and codeine, cocaine and
glue.
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Seven percent of Site one subjects and 23 percent of those at
Site two had been hospitalized for psychiatric problems at least
once. Approximately one-quarter of subjects at both sites con-
sidered themselves to have a "drug problem," but only ten percent
wanted help with that problem. Approximately 20 percent of both
samples had previously had some contact with a drug abuse treatment
agency.
DISCUSSION
This study suggests that by utilizing a field team research model,
public health agencies and drug treatment facilities could ef-
ficiently perform case finding and identify popular congregation
areas for epidemiologic and ethnographic studies of drug use and
as target areas for intervention. Incidence trends at these sites
suggest that field intervention activity should be directed primar-
ily toward reducing prevalence and frequency of use, case identifi-
cation and early intervention with younger users prior to experi-
menting with intravenous use and opiates, and should place less
emphasis on prevention approaches to reduce incidence of new cases
experimenting with pharmaceuticals and psychedelic drugs (Hughes,
Schaps, and Sanders 1973; Shick and Freedman 1975).
Regional congregation sites, such as we have described, attract
a large population of heavy, multiple drug users, many of whom
would not be included in studies conducted in schools, drug abuse
treatment centers or industry. The large number of subjects
neither employed nor attending school, the large number of grade
school and high school droputs, and the numerous adolescent runa-
ways identified suggest that field studies at such sites can con-
tribute an added dimension to the study of multiple drug use.
Furthermore, only about one-half of subjects out of school and un-
employed could be identified through studies in hospital emergency
rooms, psychiatric hospitals, and drug abuse treatment programs.
Studies in the correctional system miss a large proportion of
these youth. Although approximately 70 percent of both samples
had been arrested at least once, approximately half of those ar-
rested had been convicted.
The concentration of heavy drug users at such congregation sites
suggests research investigating sequences of use (Kandel and Faust
1975; Gould et al. 1977) and precursors (Halikas and Rimmer 1974;
Lettieri 1976) predictive of subjects at risk for adverse reactions
or progression to dangerous patterns of multiple drug use, for ex-
ample, intravenous experimentation. Perhaps regular attendance
by adolescents at such sites itself may reflect high risk for ad-
verse drug outcomes and other deviant behavior. The school and
employment histories of subjects are in marked contrast to those of
regular visitors to neighborhood locations previously studied
(Shick, Dorus, and Hughes 1978) and suggest interaction between
education and employment difficulties, drug using behavior, and
alienation from mainstream youth more typical of other areas. The
adverse outcomes implicit in all of this suqqest field studies to
investigate causes, correlates, and consequences of social
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involvement in such settings.
Particular attention needs to be directed toward the composition
and characteristics of groups, their requirements for membership,
codes of loyalty and secrecy, status hierarchy, and territorial
hangouts. The activities, preferences, common understandings,
norms, and values need to be studied to increase our understanding
of their relationship to drug use. Studies of how these youth
chose to be certain types of teenagers, the labels they apply,
and the behavior expectations of each role -- the deviations and
the responses -- are part of our ongoing research. We need to
know how newcomers learn about such areas, and how they are social-
ized into the group. The range, patterns, and characteristics of
lifestyles in the community should be examined, and analysis should
include examination of the appeals of illegal sources of support
(or "hustles"), the socialization processes into such careers, and
the relationship between these hustles and drug use. Studies
should explore the popular folklore regarding specific drugs,
methods of administration and the effects on patterns of use. They
should describe how drug use is related to prestige -- or the loss
of it -- and how drug use reflects the values and expectations of
various groups, roles, and lifestyles.
These youth spend much of their time and activities with friends
and acquaintances. Studies which concentrate only on drug use
highlight drug centered activities to the exclusion of other be-
havior, often equally important in reinforcing or discouraging
certain facets of drug use. Comprehensive field studies should
place drug use in its broader social context by examining the
patterns of collective activities (what they do together) and how
much of their activities center around obtaining drugs and "getting
high." For example, what sorts of activities first require getting
high with drugs; when intoxicated, which activities are compatible
and which are avoided? How do individuals and groups arrive at the
decision to get high or to avoid taking drugs, and how is drug use
related to risk-taking, recreation, and the sear& for novelty or
constancy (Shick and Freedman 1975)?
Regular visitors to these sites were frequent users of a wide
variety of drugs, often intravenously, but considering their fre-
quent use, adverse reactions tended to be minimal. In fact, most
adverse reactions were managed by the youth themselves and did not
involve hospital contact, suggesting that studies of the extent and
range of adverse reactions conducted at hospital treatment settings
or identified through DAWN data may be biased toward the most severe
reactions, include youth who are loners or least involved with drug
using peer groups, or who are relative novices to the drug using
scene.
Research into consequences and outcomes attempts to define a char-
acteristic reaction, to understand a user's adaptation, and to
assess the cost to the individual and society, as well as to delin-
eate any neurochemical or tissue basis for a reaction, and/or opera-
tive personal, social or historical factors. Only rarely does
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research investigate such difficulties within the community, where
a (so far) unknown number of users experience adverse consequences,
yet define their difficulties in terms obviating -- in their minds
anyway -- medical intervention: they remain contained, tolerated,
or sheltered by their subculture.
These preliminary results suggest field studies investigating the
specifics of what youth term "adverse reactions." For example, how
do they define a "bad trip" or "overdose?" What do they mean when
they say thats someone on the street has a "drug problem?" Do they
apply the same or different criteria to themselves? Since so many
adverse reactions are managed without treatment, by the individual
himself or by his friends, what are the specifics of that manage-
ment? How, in fact, do youth come to be treated at hospital emer-
gency rooms; what are the selection factors? What drug problems
are the "ticket of admission" for psychiatric hospitalization?
How does a peer group decide that a reaction needs medical manage-
ment?
The prevalence of intravenous experimentation among all age groups
in these samples suggests a relative lack of social norms dis-
couraging intravenous use and that patterns of chronic intravenous
use my begin through acquaintances formed at such regional sites.
How does the spread of intravenous experimentation occur? Do older,
more experienced users initiate younger novices, or do friendship
groups of novices obtain drugs and injection equipment from older
users and try it for the first time among themselves? From a prac-
tical standpoint, it would seem that if a novice was determined to
experiment with intravenous drug use, the presence of more ex-
perienced user might decrease the chance of an adverse reaction.
S/he could impart the rituals and safety precautions born of ex-
perience without the novice's having to learn through trial and
error. On the other hand, the older user might more quickly teach
the novice to define the effects s/he experiences as pleasureful
and reinforce further trials and, perhaps, habitual use (Becker
1967). If initial experimentation occurs among same-age friendship
groups, how would peer pressure reinforce or discourage future
trials? What portion of the friendship group would engage in future
trials? The substance of the social norms about drug use and other
behavior, the criteria drug using youth use to designate individuals
with "drug problems," and the hierarchy of social roles in such
settings are questions to be explored in future research.
We recognize the tentative nature of our findings. Our studies have
focused on two regional (urban and suburban) congregation sites in
Chicago. The similarities and differences between geographical
and social organization of drug using groups and the patterns of
drug availability and use in other communities with different ethnic
and socioeconomic makeups should be investigated. Future compara-
tive studies will define what segment of the total adolescent drug
using population we have observed -- whether only the heaviest users
hang out at such locations or whether infrequent users and nonusers
have similiar congregation sites. At these areas we were able to
obtain interview data on a sample only of the regular visitors.
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Thus our findings do not necessarily reflect characteristics of
other groups less frequently present.
The alleged epidemic of phencyclidine use is as yet poorly de-
fined. Epidemics of drug interest and panic have occurred be-
fore, and societies have sought to regulate attitudes on the con-
sumption of new or familiar substances; for example, the gin epi-
demic of 18th century Britain, the opium problem in the United
States in the 1920's, the heroin epidemic among Chicago Negro
youths and the Japanese epidemic of amphetamine use following
World War II, and, of course, the "pot and acid" epidemic among
white, middle class youths in the late 1960's (Shick and Freedman
1975; Shick, Smith, and Meyers 1970; Musto 1973).
We most not forget the potential influence of drug education pro-
gram, of premature publication of research results, and naive,
sensational reporting in the media. The public may have become
supersaturated with the notion of drug abuse, and further input
may serve only to reinforce interest in a deviant activity that,
in reality, only small numbers engage in with seriously incapaci-
tating outcomes. The treatment response must be directed toward
those few, but what sort of treatment is effective remains a re-
search issue. The prevention response has been hurriedly imple-
mented without planning to research the needs of the receiver or
the effectiveness of the output (Shick and Freedman 1971). The
question of how and who should intervene needs careful planning
and study and has numerous ethical, social, and legal implications.
Presently, phencyclidine is classified as Schedule III under the
Controlled Substances Act of 1970. Interviews with fieldworkers
and subjects suggest that in chicago rescheduling certain pharma-
ceutically manufactured substances, for example, Tiunal, Seconal,
and Quaaludes, into Schedule II increased their cost, and initially
at least, decreased their illicit availability. In Illinois, all
Schedule II drugs require a triplicate prescription, and this may
have been equally important in reducing supply (from pharmacies and
pathological prescribers), a conclusion supported by field obser-
vations and informal interviews with users in the California area,
where, for example, Quaaludes, which do not require triplicate
prescriptions, appear to be more available (although similar in
cost) than in Chicago.
Such rescheduling (into Schedule I or II) in the case of phencycli-
dine, which is supplied predominantly from illicit manufacture,
will reduce supply less, if at all, my increase cost which is al-
ready substantial, and will have little effect on remission. It
my encourage substitution reactions of potentially more dangerous
drugs such as heroin.
Institution of tighter controls by National and State drug enforce-
ment authorities, aimed at decreasing availability of drugs, iron-
ically may have reinforced the establishment of an efficient illicit
distribution system for nonopiate drugs (as well as increased their
cost) and may have caused same users to substitute drugs, some of
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which, for example PCP, potentially may be more harmful. deAlaroon
(1971) describes similar substitution reactions: the 19th century
"ether epidemic" in Central Europe following the restriction of
alcohol, the appearance of illegal "Chinese heroin" and the wide-
spread intravenous barbiturate abuse in Britain after reducing the
legal prescribing of heroin was reduced in 1969. His study of
the effects in Britain of withdrawing injectable methedrine from
the retail pharmacies reported that although the use of that drug
declined, users transferred their preference to other drugs,and
after two years one-third were still injecting (de Alaroon 1972).
Lately, in the Chicago area, nonbarbiturate sedative-hypnotics
which do not require triplicate prescriptions have become in-
creasingly available as alternatives to barbiturates and metha-
quaalone. Amphetamine availability also dwindled subsequent to
rescheduling, but large volumes of "uppers" resembling pharma
ceuticals, but containing ephedrine and caffeine, and Schedule III
and Schedule IV CNS stimulants replaced them.
Our research suggests that the nonopiate distribution system is
more stable than previously envisioned and occurs in public places
during warm weather, the residences of friends and dealers during
the winter months, and at certain urban sites active throuhout
the year (Shick and Wiebel 1978). In contrast to heroin addicts,
visitors' regularity of attendance at these sites has little to do
with physical dependence and seems to be determined more by the
fact that adolescents hang out with drug using peers for recrea-
tional purposes. The demand (and supply) for drugs, which can be
estimated from data on preference, prevalence, remission, and
frequency of use,and their cost,appears to be great. Although
the cost of these drugs is lower than for heroin, adolescents are
not sufficiently wealthy to put-chase large quantities and may visit
distribution sites more frequently than previously supposed.
Whether this is due to problems of availability and cost or whether,
as we suspect, it has more to do with the lifestyle and the in-
fluence of peer groups who supply drugs and initiate and reinforce
certain types of drug use and their accompanying attitudes, are
intriguing questions for field research studies.
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Chapter 8
Patterns of Phencyclidine Use
David B. Graeven. Ph.D.
INTRODUCTION
In recent years the use of phencyclidine (PCP) has been increas-
ing. This increase has been accompanied by an evolution in con-
ceptions about the motivation, patterns, and effects of phen-
cyclidine use. These changing conceptions of PCP use have not
necessarily reflected actual changes in use of the drug. In some
cases they reflect the acquisition of new knowledge about the way
the drug has in fact been used for a considerable period of time.
This paper briefly examines some of the beliefs about PCP use and
presents the results of an exploratory study of PCP users.
CHANGING CONCEPTIONS OF PHENYCLIDINE USE
When PCP use began to increase one of the first beliefs was that
a person would not knowingly use the drug. Early sources of drug
information (STASH, 1975) stated that PCP was not a drug of choice
among young people. This information was found in drug information
publications as late as 1976.
One probable reason for the hesitation to acknowledge PCP as a
drug of choice was the drug's bad street reputation. This bad
reputation was based on reports from San Francisco in the late
1960's on the negative effects of the drug. Another reason for
the reluctance to acknowledge PCP as a drug of choice was the
fact that many samples sent in for analysis to drug laboratories
as THC or mescaline turned out to be PCP. The fact that PCP was
often misrepresented as some other drug led many to believe that
PCP was primarily sold that way. However, local reports from
various areas indicated that PCP was a drug of choice for many
young people during the early 1970's (Graeven 1977).
Once it was realized that there were PCP users who were aware of
what they were taking, the next issue was whether or not phen-
cyclidine use would spread. It was generally believed that PCP
was a California drug and that it might be a fad limited to cer-
tain areas of that state. During the period from 1972 to 1976
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PCP use had in fact spread to various parts of the country.
Reasons for the spread of PCP were that some users seemed to like
the effects, the drug was easy to make, and the dosage could be
regulated. Especially important for the spread of PCP was the
change in mode of administration from pill to smoking (Graeven
1977). It appeared that in order for PCP to diffuse and increase
in popularity as a drug of choice, less risky modes of administra-
tion such as smoking or snorting had to replace its use in pill
form.
Recent survey data reported by the National Institute on Drug
Abuse shows that PCP use has increased around the country (U.S.
Journal of Drug and Alcohol Dependence, 1978). There now seems
to be some agreement on the fact that many young people use PCP,
and for some proportion of the users it is their drug of choice.
Currently the predaninant conception about PCP use, as presented
in the mass media, is that PCP is an extremely dangerous drug.
With the advent of PCP as a media event there seems a remarkable
similarity to the drug information presented in the 1960's. At
that time, there was a good deal of negative publicity, horror
stories about users were published, and most often systematic
research to support the statements being made was lacking.
The picture of phencyclidine use as a primarily negative experi-
ence is due in part to the fact that the spectrum of use has not
been adequately examined. Most research reports have been based
on people having problems with PCP. Early research on most street
drugs, which is often based on persons found in treatment programs,
is likely to overstate the frequency of negative effects as a
result of using a drug, as well as overstating the importance of
a lack of personal adjustment as a factor leading to its use
(Graeven and Graeven, 1977). To present a valid picture of PCP
use it is important that research look at the broad range of users.
METHOD
To examine the spectrum of PCP use an exploratory study was con-
ducted. The goals of the study were to examine patterns of use,
what people had heard about PCP, likes and dislikes about the
drug and its perceived effects. A short questionnaire was admin-
istered to a group of 89 persons who had used PCP. Snowball
sampling techniques were used, moving from known PCP users to
their friends and acquaintances who had also used.
The majority of the sample was black (78 percent), with nine per-
cent Mexican-American and twelve percent white. The majority
came from the city of Oakland, California (68 percent), the
remainder from Hayward and Fresno. Seventy-four percent of the
sample was male and twenty-six percent was female. The median
age was 20 with a range from 15 to 33.
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USE PATTERNS
Results on total amount of PCP use shown in table 1 indicate that
the largest group of users were those who used only once or twice
(29 percent). At the other extreme, nine percent of the users
had used more than one hundred times. Regarding frequency of
use, almost half of the respondents seldom used PCP, with nine
percent using it several times a day.
TABLE 1
PATTERNS OF PHENCYCLIDINE USE
(N=89)
Total Number of Times Used %
1 or 2 29
3 to 8 21
9 to 30 28
31 to 100 13
100 or more 9
Frequency of Use
Several times a day 9
3 to 5 times a week 14
l to 2 times a week 14
Couple times a month 15
Seldan 48
Quantity used
A few hits 36
½ joint 16
1 joint 26
2 joints 7
3 or more joints 15
All subjects reported that their most common mode of administration
was smoking PCP joints. Diverse patterns were found for the amount
usually used. As shown in Table 1, the modal amount used was a
few hits from a joint. These data on use patterns indicate that
for this population of users there was a large group of persons
who seldom used the drug,but for the remaining persom there was
a diversity in the total number of times used, frequency of use
and quantity of PCP ordinarily used.
Analysis of the patterns of use by age showed that the age group
19 to 21 had the highest use. Twenty-six percent of those in the
19 to 21 year old groupused five times or more week, com-
pared to eight percent in the 18 and under group and nine percent
in the 22 to 30-year-old group. Comparing males and females,
males were somewhat more likely than females to have high use.
Twenty-three percent of the males used 31 times or more as com-
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pared to nine percent of the females.
DRUG OF CHOICE
Subjects were asked to choose which drug they preferred: alcohol,
marihuana or phencyclidine. Eight percent preferred PCP, seventy-
seven percent preferred marihuana, and fourteen percent preferred
alcohol, Of those who used PCP frequently (3 or more times a
week), a third preferred it. Marihuana was preferred by 43 per-
cent of the high PCP users, and the remaining 24 percent of the
high PCP users preferred alcohol. None of the subjects with lower
use patterns preferred PCP.
HEARD ABOUT PCP
Respondents were asked an open ended question on what they had
heard about PCP. Fifty-three percent had heard that people liked
PCP; one third had heard that PCP was physically bad for a person.
The main negative physical effect mentioned was that PCP could
kill brain cells. The third most frequent response was that
most people couldn't handle PCP (14 percent). Inability to handle
the effects of PCP was indicated by responses such as "people
would act crazy" or "people get into trouble on PCP."
Comparing patterns of use by what people had heard about PCP showed
that the more frequently PCP was used the more likely the respondent
reported that s/he had heard that people liked the drug. Forty
percent of the people who seldom used PCP had heard that people
liked it, as compared to 54 percent of those who used it a couple
of times a month and 75 percent of those used one or more
times a week.
LIKE MOST ABOUT PCP
In response to an open ended question on what was liked most about
PCP, the majority of the respondents (58 percent) said the high
they get when they use it. Twenty-nine percent said there was
nothing they liked about the drug, and twelve percent liked the
way they acted when they were on PCP. Comparing use patterns by
what they liked about the drug,the group with the lowest use
pattern,as would be expected, was most likely to mention that
there was nothing they liked about the drug.
DISLIKE MOST ABOUT PCP
In response to an open ended question on what they disliked about
the drug, nearly two-thirds (63 percent) of the respondents men-
tioned the lack of control of themselves when they weres on PCP,
e.g., "I can't control my body," or, "I can't control my thoughts."
About one-third (37 percent) stated that there was nothing they
disliked about the drug.
Those persons who used PCP most often were least likely to men-
tion lack of control as a problem and most likely to say there
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was nothing they disliked about the drug. Thirty-six percent of
those who used PCP three or more times a week mentioned lack of
control as what they disliked about the drug as compared to 73
percent of those who used the drug two or less times a week.
PERCEIVED EFFECTS OF PCP
Questions were also asked regarding whether subjects never, al-
ways, or sometimes had each of four experiences when they used
PCP: felt good, forgot their worries, liked to party, and had
mood changes. Field work suggested that PCP users varied in that
some persons liked to move around and dance  while on a PCP (party),
while others didn't. The responses to these questions are shown
below in table 2. For each of the four experiences there was no
overwhelming agrees-tent on any one of the response categories.
Modal responses showed, however, that respondents were not likely
to forget worries or feel good about themselves while using PCP,
and were somewhat likely to party and have mood changes when
using.
TABLE 2
PERCEIVED EFFECTS OF PCP
(N=89)
Behavior % Never % Sometimes % Always
Forget worries 48 33 19
Feel good about self 38 37 25
Like to party 35 42 23
Mood changes 23 38 39
There was no relationship between patterns of PCP use and mood
changes, forgetting worries; and feeling good about oneself.
For 'partying," there was a slight relationship with the amount
of drug used. Thirty-six percent of those who used PCP three
times a week or more always partied on PCP as compared to 17
percent of those who used two or fewer times a week.
LACK OF CONTROL AND PERCEIVED EFFECTS
Comparing the perceptions of those who mentioned lack of control
as one of the adverse effects of PCP with the group that said they
had no problems with the drug revealed some interesting results.
While there were no differences between groups on forgetting
worries or mood changes, there were marked differences for "feel-
ing good" and "partying." For those who disliked the lack of
control, only three percent always felt good when using PCP as
compared to forty-six percent of those who did not mention lack
of control. For partying, eight percent of the lack of control
group always partied when using PCP, as compared to forty-one
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percent of those in the other group.
The difference found in the perceived effects of PCP for those
who did and did not dislike the lack of control, poins to an
interesting dimension of an individual's reaction to PCP use.
reaction to loss of control and whether or not a person experi-
ences the loss of control seems to have consequences for how a
person behaves under the influence of PCP.
SUMMARY
Use of phencyclidine is a diverse phenomenon with wide variations
in both the amount taken and the frequency of use.There is a
large group of persons who have tried PCP once or twice and dis-
continued using. One of the key distinctions pointed out by this
exploratory study relates to the feelings of control persons have
over the effects of the drug.The PCP user who is not bothered
by the lack of control is more likely to feel good and party with
others when using and is more likely to have high use patterns.
Feelings of control over the effects of PCP indicate an important
individual difference in understanding reactions to PCP use and
further research should systematically examine this phenomenon.
There has been a discrepancy between our conceptions of PCP use
and the actual patterns of use found in the United States. It
appears that at this time most persons in the drug abuse field
are willing to accept the fact that PCP is a drug of choice among
young people and that some as yet unspecified proportion of users
is able  to use PCP and avoid major problems. While there remains
much speculation about the motivation for use and the effects of
such use,it would appear that we are ready to engage in research
which systematically looks at the spectrum of users.
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Chapter  9
The Psychiatric Aspects of
Chronic Phencyclidine Use:
A Study of Chronic PCP Users
Michael A. Fauman, M.D., Ph.D., and Beverly J. Fauman, M.D.
INTRODUCTION
Phencyclidine (PCP) first appeared on the “streets” as an abused
drug in 1967, two years after human clinical investigations of its
potent analgesic and anesthetic effects were discontinued because
of its severe behavioral side effects (Reed and Kane 1972). Since
that time illicit synthesis and abuse of PCP have increased under
the guise of various street names, such as TIC, TAC, THC, angel
dust, dust, dummy dust, rocket fuel, hog, sheets? crystal and
crystal joints (Fauman et al. 1976). Investigation of PCP’s
psychotomimetic effects were conducted in the early 1960’s,
coincident with early clinical trials of the drug (Davies and
Beech 1960; Bakker and Amini 1961: Luby et al. 1962). In the
early 1970’s the first reports of adverse medical and behavioral
side effects, including severe longterm psychotic episodes from
street PCP began to appear (Reed and Kane 1972; Stein 1973; Rainey
and Crowder 1974; Burns et al. 1975; Eastman and Cohen 1975; Fauman
et al. 1975; Luisada and Reddick 1975; Tong et al. 1975; Liden,
Lovejoy, and Costello 1975). Since that time abuse of PCP has
increased and has spread to all parts of the country. Several
recent papers have alerted physicians to the varied medical and
psychiatric presentations of PCP ingestion at low doses and in
cases of overdose (Fauman et al. 1976; Luisada and Brown 1976;
Bolter et al. 1976; Burns and Lerner 1976; Cohen 1977; Dupont 1977;
Aronow and Done 1978). Quantification of amounts of ingested
phencyclidine is often difficult because many street preparations
are mixtures of phencyclidine and other drugs, patients may come
to medical attention at varying times after using the drug, and
many medical centers do not have the necessary laboratory facilities
to test for phencyclidine (Lundberg, Gupta, and Montgomery 1976;
Aronow and Done 1978).
Recent concern has also been directed to the effects of chronic
abuse of phencyclidine (Burns and Lerner 1978). The presence of
chronic abuse implies that the phencyclidine experience is not
always as dangerous or undesirable as recent medical reports
have suggested. This paper reports the results of a pilot
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psychiatric study of a sample of chronic phencyclidine abusers
whose length of use of this drug ranged from ten months to nine
years. Specifically, we have attempted to investigate the manner
of phencyclidine use, its psychological and interpersonal effects,
bad reactions from phencyclidine, and the sequelae of its abuse.
We have also tried to determine why its use is so widespread despite
its potentially dangerous side effects, the attitudes of users
toward PCP, and its effects on their lives. Finally, we hope to
point out the direction of further studies in this area, related
to the psychiatric and neuropsychological effects of chronic
phencyclidine abuse.
A STUDY OF CHRONIC PHENCYCLIDINE (PCP) USERS
Phencyclidine Study Population
Crossroads is a residential therapeutic community for the treat-
ment of polydrug abusers between thirteen and twenty two years of
age.1 It is operated by the Illinois Dangerous Drugs Rehabilitation
Systems (IDDRS), a private not for profit corporation. The resi-
dential program maintains a census of 35-40 clients. The census
at the time of the study was 8 women and 28 men. Thirty two of
the 36 clients had used phencyclidine in the past and 29 clients
(81.1 percent) had used phencyclidine for 10 months or longer
(average 3.6 years ± 1.8 years). Twenty five clients who were
chronic phencyclidine users consented to be interviewed.
Phencyclidine Study Questionnaire
The study questionnaire consisted of 73 questions about the user’s
family, schooling, psychiatric history, knowledge about phencycli-
dine, and use of phencyclidine. The study was explained to the
client and s/he was told that participation was totally voluntary.
Confidentiality was maintained by recording only the first name
and last initial on the first page of the eleven page questionnaire.
The pages were then nunber coded and separated for analysis. The
questions were administered to the phencyclidine user in a
45 minute interview with one of the senior authors.
PCP Users: Demographic Data, Personal and Family History
Tables 1 and 2 present demographic data and some personal and
family historical data for the 25 users in the study. The five
women reported considerably less average weekly spending money
than the men. Three of the five reported that their boyfriends
supplied them with phencyclidine so they did not need to buy the
drug. A substantial number of parents of PCP users were also
reported to use some form of drugs regularly. Seven PCP users
had fathers who were alcoholic and two of these seven also had
alcoholic mothers. Alcohol was the cause of death of one of these
mothers. Three other mothers and two other fathers routinely used
depressants, mainly diazepam. Two other mothers and one other
father routinely used pain medication. Two PCP users reported
that their mothers had been hospitalized for psychiatric problems
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TABLE 1
PCP USERS: DEMOGRAPHIC DATA
REACE WEEKLY
SEX WHITE BLACK AGE YRS OF SCHOOL # OF SIBS SPENDING MONEY
MALE
FEMALE
AVERAGE
*Standard Deviation
TABLE 2
PCP USERS: DEMOGRAPHIC, PERSONAL AND FAMILY HISTORY
HISTORICAL INFORMATION
Parents separated or divorced
Mother used drugs*
Father used drugs*
User was only child
User was eldest child
Previous family psychiatric
problems
Previous user psychiatric
problems
Previous user suicide
attempt
Previous user OD from
any drug
Users who report that drugs
interfered with school
% OF USERS WHO REPORT
MALE     FEMALE AVERAGE
25 20 24
30 40 32
40 60 44
5 20 8
40 40 40
30 80 40
40 40 40
20 40 24
35 40 36
60 60 60
Sample size: 20 Male, 5 Female
* Drugs include: Downers, Marihuana, Alcohol, Heroin, Pain
Medications
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and one reported that a sister had been hospitalized for drug
problems. The remaining family psychiatric problems included
alcoholism, hyperactive siblings, marital problems and nonspecific
psychiatric problems. Ten phencyclidine users reported previous
psychiatric problems, often related to drug abuse. Nine users
reported drug overdoses and four reported more than one overdose.
Most users who attempted suicide did so by taking drug overdoses.
Others were quick to point out that their overdoses were not
conscious suicide attempts, but were instead accidents.
Many phencyclidine users reported that drugs interfered with their
schoolwork. Some were too “high” or “spacey” to be able to get up
in time for school or concentrate on their schoolwork. For others,
drug use, family and other interpersonal problems together led
them to leave school and often, their homes.
PCP Users: Drugs Used and Favorite Drugs
Table 3 presents the drugs used and favorite drugs of participants
in the study. Phencyclidine was reported as the favorite drug
for 56 percent of the users, because of its availability, low cost,
but mostly because of the effects they obtained from it. Eighty
eight percent (22) of the phencyclidine users had used LSD and
84 percent (21) had used it heavily, more than 24 times. All
88 percent reported that the experience obtained from LSD was
different from phencyclidine. Most felt that LSD has more of a
hallucinogenic effect, with colors and images, while phencyclidine
produced more of a "body high” with sensory distortions, but not
vivid visual hallucinations.
PCP Users’ Beliefs About the Dangers of PCP
Ninety six percent (24) of users had heard that phencyclidine is
a dangerous drug, and 88 percent (22) believed that it was
dangerous at the time of the study. Fifty two percent (13)
had heard this from friends, 32 percent (8) from drug counselors,
16 percent (4) from family, 24 percent (6) from reading, and
12 percent (3) decided phencyclidine was dangerous from personal
experience. Clients reported they had heard that phencyclidine
contained impurities, caused coma and death, killed "brain cells,”
makes you “rowdy” and “stupid,” causes brain damage and psychosis,
“burns you out,” causes cancer and liver damage, and can cause
convulsions. Many, if not most, of the phencyclidine users we
spoke with had heard and believed that phencyclidine was dangerous
before they entered the treatment program, but this apparently
did not stop them from using it for as long as nine years. Some
users reported that they could not stop using phencyclidine. One
20 year old user, who was asked to leave the program after six
weeks because of his behavior, immediately used phencyclidine
intravenously the day he left, even though he believed it was
dangerous. He was later readmitted to the program.
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TABLE 3
PCP USERS: DRUGS USED AND FAVORITE DRUG(S)
DRUG USED % WHO USED DRUG
Uppers
(Stimulants)
Downers
(Depressants)
Marihuana
Alcohol
Glue
Cocaine
Phencyclidine
LSD, Mescaline
Heroin
Other Opiate
72
% WHO REPORTED DRUG AS*
THEIR FAVORITE DRUG
4
92 20
52 0
36 0
12 0
80 12
100 56
88 16
40 4
20 0
Sample size: 20 Male, 5 Female
*4 Male users reported 2 favorite drugs and 1 Male
user reported no favorite drug
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Availability and Use of PCP
All of the users questioned stated that phencyclidine was easy
to obtain. Many laughed at the question and described going
into the parks or along the shores of Lake Michigan, and hearing
young dealers advertising their wares by yelling “Get your angel
dust, acid and coke here.” Another user described how student
dealers regularly used specific stalls in the school bathrooms to
sell phencyclidine and other drugs. Still others described
comparison shopping for phencyclidine on the street corner, asking
three dealers to show how much phencyclidine they would sell for
ten dollars. Most users agreed that the availability of phency-
clidine was independent of the time of year.
Phencyclidine was purchased in “dime” amounts or grams. A “dime”
cost ten dollars and contained an unspecified amount of drug,
usually arrived at by bargaining between user and dealer. A gram
of phencyclidine sold for approximately sixty dollars and contained
between 15 and 22 “dimes.” Users also referred to two, three, and
five cents worth of phencyclidine, meaning subdivisions of a “dime”
into amounts of PCP worth two, three, and five dollars.
Sixty eight percent (17) were introduced to phencyclidine by
friends and 16 percent (4) were started by dealers. Users reported
first hearing about phencyclidine at an average age of 13.4 (±1.6)
years and first using PCP at an average age of 14.2 (±1.5).
Fifty six percent (14) indicated that they used phencyclidine
continuously from the time they started until entering the treat-
ment program. Others stopped when they moved out of the country,
could no longer afford PCP, were going with women who asked them
to stop, entered drug treatment programs, or became concerned
about the side effects. Sixty percent (15) of users felt that
phencyclidine was more special than other drugs, either because
of its availability and low price, or because of the effects it
produced. Finally, users estimated that 97 percent of their
friends used drugs, and 75 percent used phencyclidine.
Table 4 shows the frequency of phencyclidine use among the study
population. The first three columns in figure 4 report the user’s
estimate of the period of his/her heaviest use, including the
number of times per day, number of days per week PCP was used, and
the number of months this heavy use continued. The last column
reports the average total number of years of PCP use. The months
of heaviest use vary the most, with a range of 0.5 to 60 months
for men, and 2 to 12 months for women. Similar high estimates
of the frequency and duration of PCP use were obtained independent
of the senior authors by one of the staff nurses.
It is possible that the reporting of these high levels of PCP use,
as well as the frequent reporting of PCP as the drug of choice, was
influenced by the fact that our subjects knew we were interested
in PCP use. We asked about the use of one other drug, LSD, in
some detail. As mentioned earlier, 21 users reported they had
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TABLE 4
PCP USERS: PERIOD OF HEAVIEST PCP USE AND TOTAL YEARS OF PCP USE
PERIOD OF
HEAVIEST USE OF PCP
DURATION IN TOTAL YEARS
TIMES/DAY DAYS/WEEK MONTHS OF PCP USE
MALE
n=19
FEMALE
n=5
AVERAGE
n=24
* Standard Deviation
¶ Range of Values
used LSD heavily. For the nine who gave more specific data about
their use of LSD, the average frequency was 3.2 (±2.8) times per
week, for an average of 18.6 (±16.0) months. The fact that they
reported a high incidence of LSD use suggests a different bias,
namely that our study sample probably consisted of heavy users
of multiple drugs.
PCP Users: Knowledge of Bad Reactions to PCP in Others
Eighty eight percent (22) of PCP users in the study reported
incidents of friends having bad reactions to phencyclidine.
One incident involved a friend who fell into the water and had to
be rescued because he couldn’t move or swim after taking phency-
clidine. Two others reported incidents of friends becoming belli-
gerent and starting fights, and four users reported bad reactions
in which friends could not move, or lost control of the car they
were driving, and hit other cars. Some became concerned that they
were going to die, while others feared that they would never
“come down.” Fifteen users had heard of or knew at least one
person who had a prolonged bad reaction to PCP, with some requiring
medical attention. Six of these were not specific about the
length or severity. Five reported the reaction lasting 3 to 5
days, two reported bad reactions lasting two weeks, and two
persisted for two months or more. Some prolonged "bad trips”
included psychotic delusion, severe paranoia and attempts at
self-mutilation.
The Phencyclidine Experience
The descriptions phencyclidine users gave of their first experience
using PCP varied considerably. One woman and 11 men described
the experience in very positive terms: fantastic, “mind blowing,"
an intense high, or a happy experience. Four women and six men
found the experience neutral or mildly unpleasant. One of these
reported he had taken an overdose on “five cents worth” of PCP
and became numb. A second fell into the water, thought he would
drown, and barely pulled himself out of the water before he
became unconscious for three hours. The third reported that he
started with a “dime” of PCP and then added more, until he
became stuporous for five days, periodically awakening with
hallucinations. A number of users described the experience as
one of feeling “light," as if they were walking on air or on
clouds. Others described feeling numb, pleasantly dissociated
from their bodies, unable to move, calm or “mellowed out,” as
if they had taken a tranquilizer, or feeling stimulated and
excited. A few had a feeling that everything was in slow motion.
One male user described feeling rowdy.
The usual phencyclidine experience varied considerably from user
to user, and was also distinctly different from the first
experience. None of the women and seven of the men reported
the usual PCP experience as being positive. They described
feeling high, calm, "mellow," or euphoric. Three women and eight
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men found the experience to be unpleasant. They described
feeling numb, unable to understand people, paranoid, scared,
exhausted, moody, unable to move, and generally isolated from
the environment. Three men described feeling “rowdy” or violent.
The usual PCP experience was generally described as more dysphoric
than the first experience. Some users began to feel increasingly
moody or chronically numb and slowed. The same feelings which
were described positively for the first experience began to be
described in a negative sense as use continued.
Phencyclidine users were asked how their friends described the
user’s behavior when s/he was taking PCP. The female users were
described as “cool,” fairly normal, calm, or “spacey.” Eight
of the males were described as becoming irritable, rowdy, or
starting fights while taking phencyclidine. One reported that
he threw a 55 gallon aquarium off a stand and burned a car while
under the influence of PCP. Two others were described as acting
erratic, from being calm to attacking others for no reason.
Phencyclidine users were also asked to describe the behavior of
their friends when they used PCP. Friends were most commonly
described as acting “goofy" or like robots, not knowing what
they were doing or saying, bumping into objects, acting stupid,
and talking slowly with slurred speech. Nine users described
friends as acting rowdy, irritable, or picking fights on phency-
clidine.
Fifty two percent (13) of users described their feeling immediately
before using PCP as scared, insecure, depressed, lonely, bored,
“uptight,” or misunderstood. Others described a need to be high
or the feeling of needing to “get away from things.” Forty four
percent (11) described feeling excited, eager, or “anticipating”
using PCP. After using PCP, some felt sad that they were right
back to the same problems they started with, while others felt
that they now had no worries. Many felt tired or worn out, and
some felt regret that they had used PCP again.
Table 5 shows information on the manner of use and experience of
phencyclidine. The predominant mode of use is “snorting,” inhaling
phencyclidine in powder form. Next most common is intravenous
injection of PCP, although only one user employed intravenous
injection as the sole method of use. Three subjects only snorted
PCP; the remaining users employed combinations of modes. Only
one reported usually taking PCP when alone. Others usually
took PCP with at least one additional person present.
Seventy six percent (19) of users reported having “bad trips” on
phencyclidine. The most commonly described severe symptoms
included numbness and loss of motor control, or paralysis,
confusion, sensory distortions and loss of consciousness. A few
reported cramps, nausea and emesis. Two users had auditory
hallucinations. two became violent, and two others became very
paranoid during the experience. Others described loss of
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TABLE 5
PCP USERS: THE PCP EXPERIENCE
% OF USERS WHO REPORT
Method of PCP Use
Intravenous
Smoked
Snorted
Eaten
96
How Used
Alone
Another Person
Group
80
One Bad Trip
Continued to Use
PCP After Bad Trip
More than One
Bad Trip
Memory Loss During
PCP Use
Paranoia During
PCP Use
Need or Crave PCP
Physical Withdrawal
Difficulty with
Directions on PCP
Flashbacks
MALE FEMALE AVERAGE
50 80
50 60
95 100
45 60
56
52
48
50
65
70
75
40
60
80
48
68
68
76
70 80 72
55 48
90 92
60
75
25
20
100
40
40
0
0
0
56
68
20
50
35
40
28
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judgement and memory which sometimes involved them in accidents.
One reported trying to cross a busy street, looking one way
and then the other for cars, but immediately forgetting what he
had seen when he turned his head. He finally decided to step
into the street and ran into a car. Only three users reported
being taken to a hospital during a "bad trip.” Two of these were
discharged within a day, and the third remained on a psychiatric
ward for two weeks. In the entire group of phencyclidine users,
this was the only report of a personal experience of a prolonged
psychotic reaction, including auditory and visual hallucinations
and violent behavior. Most users who had bad trips experienced
them alone, or waited them out with friends, rather than seek
medical attention. One woman reported that she would “check
my body out part by part” when she was experiencing the numbness
and paralysis of a bad trip. Generally, the experiences that
phencyclidine users reported for “bad trips” were similar to
some of the dysphoric sensations described during their usual
PCP experience, with the difference that the ‘bad trip” sensations
were far more intense and upsetting to them.
Despite the fact that 76 percent (19) of PCP users had one “bad
trip” and 48 percent (12) had more than one, 72 percent (19)
continued to use the drug. Six users reported that they needed
phencyclidine or liked it enough to continue. Five rationalized
the bad trip as being caused by circumstances, impure drug, too
much drug, or else felt that they had not had a bad enough “bad
trip” to deter them. Others reported that they used phencyclidine
again because it was freely available when no other drug could be
obtained.
Sixty eight percent (17) of PCP users stated that they felt a
need or craving for phencyclidine. Only 20 percent (5) reported
physical symptoms of withdrawal, describing these as nervousness,
upset stomach, “the shakes,” and “cold sweats.” One user stated
that PCP satisfied his craving for heroin. Another described
how his need for PCP caused him to carry some with him wherever
he went.
Many users reported a gradual change in their mood while using
PCP. Thirty two percent (8) indicated that their mood had
become more angry, irritable, or violent during the time they
were using phencyclidine regularly. Others reported becoming
more antisocial, depressed, lonely, or isolated from people.
Sixteen percent (4) felt that using phencyclidine had produced
positive changes in their personalities. They described feeling
more comfortable, socially easy going, hard working, and more
“masculine.” The majority of users felt that they had become more
selfish. Many reported losing their friends because of the changes
in their personalities.
We assessed cognitive functioning only superficially, by asking
users whether they had problems with memory, finding directions,
or making change (figure 5). Ninety two percent (23) indicated
substantial memory loss during the period of time they took PCP.
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Thirty six percent (9) felt that their memory had improved
within two to three weeks after stopping phencyclidine, in the
treatment program. Forty percent (10) indicated difficulty
figuring out directions while on PCP. One user reported getting
lost three blocks from his home.
“Flashbacks” are usually described as the reappearance of a drug
effect when the drug has not recently been used. Twenty eight
percent (7) of PCP users experienced one or more flashbacks.
Sixteen percent (4) of these occurred when the individual smoked
marihuana after the PCP “high” had worn off. Finally, most users
reported the development of tolerance to PCP, requiring higher
doses to achieve a high. They usually started with two or three
“cents” worth of PCP, which made them quite high. Eventually, most
subjects were using one to two “dimes” at a time, and often up to
a gram of PCP in a day.
DISCUSSION
Chronic Phencyclidinc Abuse
Recent observations have indicated that the use of phencyclidine,
and more specifically, its role as drug of choice, has increased
markedly in the last year or two (DuPont 1977; Taylor 1978). Our
study corroborates these observations, finding an extremely high
prevalence of PCP use and choice of PCP as the preferred drug for
a sample of chronic polydrug users. Considering the frequency and
combined length of PCP use (a total of 105 years) in the study
sample, most users titrated or adjusted their consumption well
enough to prevent more than rare "bad trips.” Furthermore, since
our study indicates that relatively few “bad trips” are brought to
medical attention, estimates of PCP use based on hospital statistics
may be very low.
The initial and early experience with phencyclidine is usually
reported as a pleasurable or carefree “high” or numbness. The
experience is novel, short lived, and appears to provide an escape
from anxieties, depression, or external pressure. These early
experiences are almost always with low doses of the drug: two,
three, or five “cents.” Gradually, users become tolerant to the
effects of low doses of PCP, take larger amounts more frequently,
and begin to relate increasingly dysphoric experiences
on phencyclidine. The initial enjoyable sense of being “high,”
numb, isolated, and unable to move becomes more intense and some-
times distinctly unpleasant. Although some users continue to enjoy
their experiences with phencyclidine, for the most part the
comments become more critical of the drug. It was initially
difficult for us to understand why many of those we interviewed
continued to use PCP despite these unpleasant experiences. We now
believe that many users felt trapped by the drug. They remembered
their initial good experiences, and probably still had some
enjoyable “highs” during their period of chronic use. In addition,
the drug began to assume magical properties for some users, who
reported that they carried PCP with them almost like an amulet.
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Others couldn’t explain why they continued, except to say that
they needed to use it, or that it was cheap and available.
Nevertheless, it would be a mistake to claim that availability
was the major reason for the popularity of PCP. We feel that its
popularity is a combination of the effects it produces and its
availability, with the former perhaps the more significant.
Three types of adverse phencyclidine reactions were reported as
"bad trips.” Episodes of cramps, nausea, and emesis after taking
PCP may be due to impurities in the drug caused by incomplete
synthesis (Reed and Kane 1972). Prolonged psychotic reactions of
more than two weeks duration appear rare, and will be discussed
in more detail below. The majority of reported “bad trips,”
consisting of severe numbness, isolation, paralysis, confusion,
transient psychotic behavior, hallucinations, stupor or coma,
appear to be extreme examples of the dysphoric sensations
described for the usual PCP experience. We feel that these “bad
trips” are probably due to the periodic use of very high amounts
of phencyclidine, especially in individuals who are already using
large amounts. This would suggest a continuity between early
pleasurable “highs” with low doses of PCP, and later dysphoric
feelings with larger doses. In essence, phencyclidine produces
an organic brain disorder (Fauman and Fauman 1977; Fauman 1977).
In low doses, the organic brain disorder is mild and often
pleasurable. As users become tolerant to phencyclidine and use
larger doses, they may develop a chronic organic brain disorder
(Cohen 1977). Reports of chronic memory loss support this
conclusion. Periodic additional excessive amounts of phencyclidine
may produce toxic psychotic episodes or intense isolation and loss
of body control which is very frightening to users and often
stimulates fantasies of dying or remaining permanently dysphoric.
Such "bad trips” end as the phencyclidine is metabolized and
excreted. It is also possible that the interpersonal and
social circumstances contribute to the chemical effect of a large
dose of the drug to produce the "bad trip.”
This study also suggests that there may be significant personality
changes associated with chronic phencyclidine use. Many chronic
users reported the same increase in irritability, violence and
rowdiness that has been described for the phencyclidine-induced
psychosis (Luisada and Reddick 1975). Increased irritability
and belligerence is a common finding in patients with chronic
organic brain disorders (Fauman and Fauman 1977). Our study also
suggests that many phencyclidine users have difficulty tolerating
anxiety and depression or common stresses of daily life. They
use phencyclidine as a means of escaping from these feelings,
only to have them return after the “high” passes.
The Prolonged Phencyclidine Psychosis
Before we undertook this study, it was our impression that phency-
clidine regularly caused prolonged psychotic reactions (Fauman et
al. 1975). These reactions typically are present as bizarre behavior,
with confusion and agitation: the patient may be mute and staring,
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and unresponsive to painful stimuli. There is usually a history
of a sleep disturbance if the patient presents some time after
the drug exposure, and evidence of cerebellar dysfunction,
including nystagmus, ataxia, and dysarthria, if the exposure
has been fairly recent. In some cases, the patient is also
violent or aggressive, particularly when s/he feels threatened.
In nearly all subjects there is a striking degree of fearfulness.
The patient may be diagnosed as schizophrenic if the history of
drug use has not been obtained. These symptoms persist for
several days to two weeks before beginning to remit, and may take
an additional four weeks to clear.
As an increasing number and range of reactions came to our
attention from our emergency department and in consultation
with other hospitals, most of which did not fit our description
of the psychosis we had seen initially, it began to appear that
the reactions were dose dependent. Eventually, as we learned
of the widespread availability and popularity of this drug,
we speculated that only a small number of people using the
drug were susceptible to the prolonged psychosis (Faunan et al.
1976). In our review of prolonged psychoses related to other
drugs, it appeared that this was also true for the severe
psychiatric morbidity that occurred rarely with cannabis, LSD,
and amphetamines. Most authors suggested that there was an
idiosyncratic propensity in those people who developed psychoses.
This corresponds with the data from early work with phencyclidine.
Normal volunteers experienced a brief psychotic reaction that
was dose related (Davies and Beech 1960; Bakker and Amini 1961),
but schizophrenics had prolonged exacerbations of illness
(Luby et al. 1962). Recent reports also support this, as Luisada
noted that one quarter of his series were readmitted with
recurrent psychotic illness, with no additional exposure to
phencyclidine, after an initial PCP-induced psychosis (Luisada
and Reddick 1975). He felt that these patients represented
a part of a continuum between normals and schizophrenics.
It is clear from our study that for some, phencyclidine use is not
merely recreational, weekend, or experimental, but has become a
regular and prolonged habit. With an accumulated total of 105
years of use in our study sample of 25 users, the appearance of
only one prolonged psychosis similar to those described by
Luisada and our previous observations suggests that PCP cannot
be the sole cause of the prolonged psychosis. It appears that
the prolonged phencyclidine psychosis may be the most dramatic
effect of the drug and the one most likely to come to medical
attention. Nonetheless, it is rare, and not the most devastating
effect of this drug.
The Direction of Future Investigation and Treatment
It should be realized that there are two distinct aspects of
phencyclidine abuse. The first is the special problem of the drug
phencyclidine, its use, and its dangerous sequelae. Equally
important is the type of personality problem which leads
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individuals to use drugs like phencyclidine. It is important
not to overlook the latter problem, because it is this one which
will remain long after phencyclidine has disappeared. Phency-
clidine is popular because of the effect it produces as well as
its availability and low cost. Nevertheless, there are now,
and will be in the future, other drugs which have similar effects
and may well become as much of a problem as phencyclidine is at
present.
We feel that there are three major areas for future work related
to polydrug abuse, and specifically, phencyclidine abuse. First,
the behavioral and neuropsychiatric effects of chronic phency-
clidine abuse must be studied and methods of treatment devised.
This expressly includes an assessment of the potential acute
and chronic organic brain disorder caused by phencyclidine. In
addition, the serious effects of phencyclidine should continue
to be publicized. Second, there should be more investigation
and attempts at treatment of  the underlying personality problem
that leads to abuse of drugs like phencyclidine. Finally, there
should be an active monitoring of the polydrug abuse population
for early detection of new drugs with a potential for abuse.
Hospital emergency departments should be alerted to these drugs,
and methods of treatment for the side effects and over-dosage
developed and quickly disseminated to treatment centers.
FOOTNOTE
1. This study was conducted in December 1977 - January 1978, at
the Crossroads Youth Program, 7400 West 183rd Street, Tinley
Park, Illinois 60477.
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Chapter 10
Phenomenological Aspects of Phencyclidine
Abuse Among Ethnic Groups in Hawaii
Anthony J. Marsella, Ph.D., and Russell D. Hicks, M.D.
INTRODUCTION
The fact that phencyclidine, a drug originally developed in the
early 1950's by Parke, Davis and Company for use as a nonnarcotic
intravenous anesthetic agent , could emerge as a popular recrea-
tional and quasi-therapeutic drug among our nation's youth, raises
a number of interesting questions about the nature of the phenom-
enological experience associated with phencyclidine use. The
purpose of the present paper is to examine some of these questions
through a review of our clinical experiences with phencyclidine
users and to offer some speculations about the possible reasons
why young people begin and continue to use phencyclidine.
The Hawaii Job Corps
This discussion of phencyclidine is based on our experiences as
Director of Mental Health Services and Director of Medical Ser-
vices for the Hawaii Job Corps, a Federally-funded residential
program to provide educational and vocational training for high
school dropouts between the ages of 16 and 21. It also provides
medical, psychological, and recreational services. The program
generally requires from 18 to 24 months to canplete. The Hawaii
Job corps in Honolulu has about 220 enrollees (55 females, 165
males) who reside in four dormitories. Because of disciplinary
and personal adjustment problems, the turnover is high. Neverthe-
less, the program completion rate runs around 40 percent.
The enrollees consist mainly of youth of mixed Hawaiian racial
ancestry ("locals") who cone from the rural areas of Oahu. The
second largest ethnocultural group represented consists of Micro
nesian youth. They are followed in number by Guamanians, Samoans,
Caucasians (mainly armed service dependents), Filipinos, and a
few Korean and Vietnamese immigrants. All of the enrollees are
from the lower sociceconomic class strata and many have personal
histories of delinquency and school maladjustment. Divorce, child
abuse, and parental rejection are present in many life histories.
Polydrug abuse and alcohol abuse occur in 80-90 percent of the
enrollees.
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Phencyclidine
Phencyclidine is a white crystalline solid. On the streets,
phencyclidine is called PCP, THC, or "Angel Dust." Burns
and Lerner (1976) provide an excellent overview of phencycli-
dine's pharmacological properties and clinical implications.
They note that it acts on the nervous system by either
stimulation or depression and that this variability in action
makes it difficult to classify.
Phencyclidine can be swallowed (generally in tablet form),
snorted (insufflated), or smoked (inhaled). Among the young
people we worked with, snorting and smoking are the preferred
routes of administration. When the drug is smoked, the
user spreads the phencyclidine over marihuana, parsley,
mint, or tea. This is called a "crystal joint." The time
course and active effects of phencyclidine vary as a function
of the concentration and the route of administration. The
users we have spoken with stated that the "hit" time ranges
from five to twenty minutes. Snorting results in a faster
action, and, in the opinion of some individuals, it produces
more side effects than smoking.
Phencyclidine is purchased by the "line." A "line" is about
3/4 of an inch long and 1/8 of an inch wide. This amount
sells for around $10 to $15 in Honolulu and is enough for
five users or "hits." The concentration of the phencyclidine
is determined by the number of visible crystals present among
the filler. The users indicated that phencyclidine is only
available from dealers periodically, but when available it
is very popular.
Who Uses Phencyclidine?
Because our experience with phencyclidine users is limited to
Job Corps enrollees, we clearly have no information regarding the
community distribution of phencyclidine use in Hawaii. However,
based on the comments of the Job Corps users, we are inclined to
conclude that the highest frequency of use is among preteen and
teen Hawaiian youth ("locals"). Everyone we spoke with indicated
that Micronesians and Guamanians prefer "hard liquor" and "grass"
rather than "T." They indicated that there is some use of "T"
among Samoans and Filipinos but that the highest use was clearly
among the "locals." Indeed, they noted that "T" was growing in
popularity among "local" kids and that they could not think of
any "local" friends who had not tried it. Although the Caucasian
youths use it, "T" does not seem to have much popularity among
them.
The high frequency of phencyclidine use among "locals" as opposed
to other groups raises some important questions about the reason
for this state of affairs. Our speculation is that among "locals"
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the use of all drugs is much higher and more flagrant. Thus, a
new drug like phencyclidine simply fits in with an already exist-
ing culture of users, and other ethno-cultural groups are often
excluded from these "local" drug-using groups. Indeed, some of
the other ethno-cultural groups look on the "locals" as being
crazy when it comes to taking drugs; the other groups describe
themselves as liking to drink a lot of booze and smoking a lot
of grass, but they do not see this as being really harmful, even
though they often consume entire bottles of liquor among a few
users.
In addition, it is our observation that the "locals" seen to have
the greatest ethno-cultural identity problems. The other groups
still use their native languages and follow many of their tradi-
tional customs. This is not true of the "locals"  who are English
speaking and who are often unsure of their allegiance to Hawaiian
culture, although they describe themselves as Hawaiian. Their
identity is much too superficial to provide a perceptual frame-
work for mediating life problems. The "local" youth are clearly the
most alienated and lacking in a sense of purpose and direction when
compared to other youth in the Job Corps.
Lastly, anger levels are extremely high among "locals" because of
their discontent with their social position. Unlike the Micrones-
ians, Guamanians, and Samoans, the anger among the "locals" is
long term. "The Hawaiian people are getting shafted in their own
land" is a widely shared belief which seems to be constantly re-
inforced by family and media. Further, ability of the "locals"
to articulate their problems and to attribute them to their status
as Hawaiians provides a strong self-reinforcement of their anger.
The possible role of anger in phencyclidine abuse will be further
discussed in the next section of this paper.
WHY IS PHENCYCLIDINE ABUSED?
It is tempting to say that any drug with consciousness-altering
properties is likely to be abused by today's youth if it is avail-
able. However, this type of thinking is much too general to
account accurately for the preferences and patterns of drug abuse
which have developed. It may indeed be the case that each drug
has a unique pattern of situational and personality factors which
both encourage and maintain its abuse profile. In discussing the
reasons for phencyclidine abuse, we will comment on three topics:
(1) Situational, (2) Experiential, and (3) Psychosocial.
Situational Factors in Phencyclidine Abuse
Everyone with whom we have spoken told of being "turned on" to
phencyclidine by close friends who simply said, "Try it...it will
make you feel good!" Quite obviously, the social pressure to go
along with this soft sell amidst a group of friends is quite high.
To refuse is tantamount to saying you don't trust your friends or
that you are afraid. Both of these are higher risks than the
dangers associated with a new drug. Among young people with frag-
ile or vulnerable self concepts, the pressure for acceptance
simply outweighs the pressures of rational judgment regarding the
harmful sequelae. The group dynamics are critical in getting
started and in maintaining drug abuse with a substance like phen-
cyclidine.
Phencyclidine use is not limited to a particular environment. It
is used indoors with mellow music and candlelight, and in noisy
settings with rock music and flashing lights. It is also used
outdoors at parks and beaches. Indeed, several people discussed
going swinming while on "T" and almost drowning. However, every-
one indicated that the mood  of the user is important in determin-
ing the reaction to the drug. You can get "spacey" or "mellow"
or you can just get "stoned." But, quite interestingly, everyone
said they always used "T" in a group rather than alone. This may
not be unusual, as many drugs are taken in group settings, but
it does deserve further study.
Experiential Aspects of Phencyclidine Abuse
A young "local" female with years of polydrug experience de-
scribed phencyclidine as "the — [worst] snortin' drug you
can ever take!" Yet, when asked if she would take it
again she replied, "Sure...why not?" We have been continually
impressed with the almost total disregard for any of the medical
or legal consequences of drug abuse among many of the "Local"
youth in Hawaii. They simply say, "Man, who cares!" or just
smile and shrug their shoulders and say, Wan, ain't no big
thing!" Booze, grass, and "T" are mixed readily. We never heard
anyone, however, speak of mixing acid (LSD) or speed and "T". It
is also interesting that the users seem to categorize "T" as a
hard drug: many said it gives a "rough trip."
Efforts to understand the actual phenomenological experience as-
sociated with phencyclidine have always proved frustrating be-
Cause the users tend to describe the experience in short phrases
like 'Wowie!,"  "Cloud nine!," "Far out!," or "Zap!" These phrases
are often accompanied by a throwing back of the head, a rolling of
the mouth in an almost reflexive manner.
Several individuals told us to "try it" to really understand what
it does because "you can't put it in words." "Being stoned is
something else!" We have speculated about whether the actual
subjectivity and privacy of the experience might in itself be re-
warding. "You can't put it in words!" Here is something which
is truly yours, something which is unique and not subject to loss
through intellectual understanding. In a world of intruding in-
fluence, here is something that belongs to you. A few males and
females likened the "T" experience to that of "surfing all day"
when because of the repetitive excesses of sensory stimulation
and deprivation you come to lose your sense of self and become a
part of something more - the endless rhythm of waves.
On the other hand, if you take too much "T" you are really in for
it. It is much more than just "flipping out." One male described
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his experience under a high dose as being similar to "electric
man." His entire body was numb and paralyzed and he tingled all
over. He recalled praying to God and saying "Please don't let me
die." Yet in spite of the experience he took "T" again. It was
his fault, not the drug's. Another male said he felt like a
"zombie"; but he also used it again.
When used in smaller doses or concentrations, the youth described
the sensation of their body becoming "very light" or "floating,"
almost as if they were "walking on air." This is the pleasurable
sensation that they like and seek. One individual suggested it
was very similar to inhaling "laughing gas" in the dentist's
office. Another individual indicated that it made him see things.
He noted that on one occasion he thought he was body surfing and
extended himself on the rug as if he were riding the waves. Yet
another person said he liked seeing the "dragons" and "creatures"
when he was on "T."
Apparently, the "T" experience is also a function of how often you
take the drug. A male "local" who was experiencing visions and
was becoming quite afraid reported "talking with angels" and "see-
dead relatives." He also stated that he believed that he was
really "someone special" with unique "powers." At first, he denied
taking any drugs stronger than grass, and so we were inclined to
suspect that an incipient psychotic process was operating. How-
ever, when he was asked if he had been taking "Angel Dust," he
said that he was using it in "joints." He was asked to stop this
immediately and to refrain from using it any more. He agreed to
stop, and within. two weeks the hallucinations had disappeared
and he was no longer afraid.
Although some of the young people we have worked with have beams
belligerent and antagonistic under phencyclidine, we know of one
case where violence occurred. This case was reported by a user
and involved a young "local" female who had been using "THC" for
"breakfast, lunch, and dinner" over a period of a week. The girl
dug out the cheeks of her little infant's face and then told her
mother, "Look what the devil did to my baby." A number of users
have talked of "T" users becoming "religious" after a while. HoW-
ever, they were unable to explain why this happens. They simplY
said if you use "T" for a while you become a "Jesus freak" and
"get turned on to religion."
Most of the people we have spoken with stated that they preferred
to take "T" in quiet places where they could just "space out."
One individual said, "No feel like walkin', no like talkin', just
sit back and look." When talking does occur under phencyclidine,
it was described as being slow and drawn out. On higher "hits"
they reported having difficulty walking. One person reported
falling down and described it as a "slow motion" experience in
which each movement took a very long time.
None of the people with whan we have worked could be considered a
phencyclidine "freak," that is a person who chooses only phencycli-
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dine when given a choice. Indeed, everyone agreed that they had
never encountered a "T freak" as they had encountered "acid heads"
or "speed freaks." People appear to use "T" when it is available.
It is just one of many drugs that can be used if you want to
"trip." Several people, however, said that "T" is better than
"booze" or "downers" if you want to trip out because it is faster
and stronger. They stated, "When you wanna git away, "T" is
good"; they noted that it "takes your mind off things and lets you
relax." In those circumstances, "T" is the preferred choice; they
start with grass and then snort a "hit" of "T."
In addition to the medical risks of a high dose, "T" users must
also cope with the side effects which accompany its use, even if
the dose is mall. Some people described the effects as being
similar to a hangover. They feel "wobbly" and "queasy" and have
headaches around the front of the head. Vomiting and dizziness
are also quite common. They all agreed that they were very tired
and wanted to sleep. One person said he felt "wasted" and "run
down." But, these are not very different from side effects as-
sociated with drinking too much, so they are considered worth the
risk.
Psychosocial Aspects of Phencyclidine Abuse
The medical aspects of phencyclidine intoxication will not be dis-
cussed here, since these have been very well presented in a number
of papers by Burns and Lerner (1976), Burns et al. (1975), Eastman
and Cohen (1975) and Linden, Lovejoy, arid Costello (1973). How
ever, there are several psychosocial aspects of phencyclidine
abuse which deserve comment. These include the role of chronic
feelings of anger and desperation, the role of agitated boredom,
and the results of conditioning deviant epistemic orientations.
1. Chronic Anger and Desperation
Over the years, we have increasingly wondered about the effects
of the chronically high levels of anger and desperation found
among many of the Hawaiian youth with whom we have worked. We are
reminded of the effects which "low status" and "enduring frustra-
tion" have had on black Americans, the so-called "black rage." The
"local." people appear to be relatively helpless in altering their
own lives in the face of the continued onslaught of Western tech-
nology and values presently occurring in Hawaii. Their way of
life is demeaned. In the search for an escape from their feelings
of desperation, they see themselves as having few alternatives.
Freud, in his book Civilization and Its Discontents, wrote:
Life as we find it is too hard for us; it entails too
much pain, too many disappointments, impossible tasks.
We cannot do without palliative remedies....There are
perhaps three of these mans: powerful diversions of
interest...substitute gratifications...and intoxicating
substances.
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In the absence of diversions of interest and substitute gratifica-
tions, intoxicating substances have emerged as the most available
and effective mans for handling the annipresent tensions of anger
and desperation. Both of these require expression, release, or
catharsis. Assault and other forms of violence have already re-
sulted in high rates of delinquency and crime among the "locals,"
and excessive drinking is also a major problem. To both of these
inadequate ways of coping must now be added the drug phencyclidine.
Here is an easy and quick way to relax, to remove the omnipresent
burdens of anger and desperation. Relief is just a snort away!
It's a magical release from life's pressures even though it only
lasts a short while. These points lead us to the role of boredom.
2. Chronic Boredom
In a society which requires ever increasing levels of competence
and specialization to achieve recognition, success, and financial
reward, more and more individuals are finding that there is little
they can do. Many young people are simply retreating and with-
drawing from societal demands rather than facing the challenge
of coping with life through the active pursuit of a skill or edu-
cation. Indeed, it is quite obvious that our society simply asks
youth to wait their turn to make any meaningful input. Youth are
not given a chance to be adults. They must wait and learn. But,
when the learning experience offered by our schools is sometimes
so vacuous, there is only boredom.
Boredom is a problem which more and more young people are experi-
encing, and it is also one which is readily dissipated by a "hit
of T." There is little opportunity for our youth to feel important
and meaningful, and this problem is compounded for "local" youth
because of theirlowstatus and imprboble chances for altering
their poverty. Boredom, like any other aversive affective state,
requires relief: and in the absence of alternatives, "T" serves
the purpose quite well.
Yet, we are coming more and more to wonder whether the quick escape
promised by "T" is not exacting its toll. Here, we would speculate
that the deadening of experience or the alteration of conciousness
somehow produces a subsequent need for arousal. It is tempting to
believe that the nervous system requires periods of arousal and
periods of rest. An extended period of one leads to a need for
its opposite. Thus, we would speculate that, with continued
phencyclidine use, a cycle may be developed of increased agitation
and arousal when the drug is not in use. This could be experienced
as an undifferentiated emotional state of boredom. And so the
cycle of "stimulus reduction" and "stimulus seeking" continues.
Every "hit" of phencyclidine my require a subsequent period of
arousal or of undifferentiated alertness.
In the absence of a meaningful pursuit of some knowledge or skill,
agitated boredom emerges. If an incident should occur which might
be interpreted as hostile, the agitation simply comes to be inter-
preted as anger, and an acting out occurs even if it is unwarranted.
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This cycle has yet another aspect which may ultimately prove to
be more dangerous. This latter aspect involves the conditioning
of deviant epistemic orientations.
3. The Conditioning of Deviant Epistemic Orientations
There are some individuals who argue that the judicious use of
drugs should not cause alarm (e.g., Szasz 1972; Reinert 1974).
They claim that ethically we may not have a right to deprive
people of pleasure-giving drugs. Reinert (1974) stated:
What is our right to take away pleasure-giving drugs
from a person who through early deprivation, or cur-
rent poverty, or lack of training, or lack of innate
capacity has little capability for pleasure in aesthe-
tics, intellectural pursuits, or social intercourse?...
Are we morally justified in depriving an individual
whose life is without purpose, hope, and direction--
cramped, lonely, and bitter--of the chief pleasure of
which he is capable? (Reinert 1974, p. 56).
In the case of phencyclidine use among "local" youth in Hawaii,
Reinert's comments raise some interesting questions, especially
within the context of the social deprivation to which they are
ordinarily exposed. Yet, there is a risk which Reinert is ignor-
ing, and this is the conditioning of deviant epistemic orienta-
tions which may ultimately make it impossible for an individual
ever to accomodate his life and thoughts to societal expectations
and demands.
In a previous paper (Marsella and Price-Williams, 1974), it was
argued that the continued use of consciousness-altering drugs
posed an ignored danger: the conditioning of deviant epistemic
orientations. An epistemic orientation involves certain con-
ceptions of time, space, and cause-effect relationships. Through
the course of normal everyday life within a particular cultural
context, an epistemic orientation is created which is functionally
related to other cultural forms and practices. For example, in
our own society we have a shared notion of time, space, and cause-
effect that n-takes it possible for us to function "normally."
The nervous system codes time, space, and cause-effect experiences
regardless of the consciousness level at which they are experi-
enced. This means that even on a drug which alters consciousness,
the nervous system is still coding these epistemic dimensions:
The experiences of the "trip" are no less real to the
nervous system than those of everyday "normal" life.
The "trip" experiences are assimilated, coded, and
organized into existing cognitive and neurological
structures. Thus, over long periods....of use, the
person develops a new and conflicting epistemic organi-
zation that extends beyond the actual drug states....
(Marsella and Price-Williams 1974, p. 71).
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In brief, with continued use of phencyclidine, the users may soon
find himself/herself experiencing reality according to levels of
consciousness which are in conflict with normative standards.
His/her sense of time, space, and cause-effect become deviant.
New standards of "normality" emerge which are not shared, thus
fostering deviancy and furthering the rejection cycle.
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Chapter  11
The Pharmacokinetics of Phencyclidine in
Overdosage and Its Treatment
Alan K. Done, M.D., Regine Aronow, M.D., and Joseph N. Miceli, Ph.D.
The unusually prolonged and vacillating clinical course of PCP
intoxication has been documented amply in other parts of this
publication and in citations included elsewhere (Done et al. 1977;
Aronow and Done 1978). Except for the demonstration of persistence
of urinary PCP excretion for at least several days in some cases
(refs. cited in Done et al. 1977) there had been no explanation
for that finding or the clinical course, and certainly no defini-
tion of the pharmacokinetic characteristics of PCP in overdosage,
until our recent studies (Done et al. 1977). This report sup-
plements the earlier preliminary observations with extensive
additional observations which are soon to be published incon-
siderably more detail.
SUBJECTS AND METHODS
Data presented here were obtained from seven patients whom we
treated for PCP overdosage; further clinical information about
them is presented by Aronow elsewhere in this publication. All
patients took unknown quantities of "street" PCP in various form,
and its identity and purity were established on the material it-
self and/or the gastric contents by gas chromatography/mass spec-
trometry as described elsewhere (Done et al. 1977). The procedures
for obtaining the blood, urine and gasttic fluid specimens were
also described previously. The present protocols varied somewhat
from the earlier ones and from patient to patient, particularly
in terms of the duration of urine or gastric fluid collections,
depending the aim of the particular study; however,continuous
urine and gastric contents ware collected quantitatively; and
blood specimens, insofar as possible, were obtained midway in
these collection periods. An exception is patient 1, who did not
have gastric suction because he presented before our studies had
indicated the importance of this procedure.
After our initial observations indicated the important influence
of urine pH on PCP excretion, some patients were given acidifying
agents in a manner described by Dr. Aronow (Aronow and Done 1978)
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and in some individuals furosemide diuresis was instituted,usually
at time of peak acidification of the urine. All pH measurements
on urine and gastric fluid were made immediately using a pH meter
(Beckman model 3550), and in arterial blood with a conventional
clinical blood gas electrometer.
Specimens were frozen until analyzed for PCP concentrations by
Dr. Denis Lin of Battelle Columbus Laboratories using his gas
chromatographic/chemical ionization mass spectrometric method
(Lin et al. 1975). Measurements were confined to the free,un-
changed compound.
RESULTS
Figure 1 shows (on the left) the time course of serum PCP con-
centrations and its relationship to PCP levels in urine and
gastric (G.I.) fluid. It can be seen that the gastric fluid [PCP]
FIGURE 1
[PCP] in serum, urine and gastric drainage
(left) and cumulative urinary and gastric secretions
of PCP (right) in a representative patient. In the
left half of the figure note that a log scale was used,
and urine and gastric (G.I.) concentrations were 10x
higher than shown (Done et al. 1977).
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is very much higher than that in serum, and that the two curves
are strikingly parallel and have similar half life (T½) values.
The T½ varies considerably from patient to patient and, as will
be noted below, is strongly dependent upon whether or not there
is interruption of the gastroenteric recirculation of PCP; con-
sequently, half life figures will be reserved until discussion
of this phenomenon. As will be discussed in considerable detail
later, the urine PCP concentration was strikingly dependent upon
the urine pH and so bore a variable relationship to the serum
level; however it also can be considerably in excess of the con-
centration in serum. That is to say that PCP is highly concen-
trated in an acid medium, which can cause it to achieve a tremen-
dous gradient with plasma. The cumulative excretion data (the
right half of the figure) indicate that in some individuals the
elimination by way of gastric suction can, for a time at least,
substantially exceed that achievable through urinary excretion,
though this is highly variable from one patient to another.
That the pH effect on PCP concentration gradients is reflected in
in a similar effect on clearance is indicated by table 1. The
clearance figures are not identical with those presented by Dr.
TABLE 1
EFFECTS OF pH ON (PCP) PLASMA GRADIENI
AND PCP CLEARANCE, Mean ± SEM(n)
pH:
(PCP)/(PCP)p
Gastric Urine
<2.5 >2.5 <5 5-6.5 >6.5
42±4.5 20±3.8 97±17.4 36±5.0 7±2.4
(42) (20) (19) (60) (32)
Clearance
ml/min)
53±11.2 21±5.0 86±15.0 44±6.6 10±2.4
(44) (15) (19) (59) (31)
Aronow because the data presented here include only those individu-
als who had exactly simultaneous collections of blood and the
other fluids under study; some of the clearance values presented
by her utilized interpolated serum level estimates when the curves
were sufficiently smooth that there was no sacrifice of accuracy.
Here it was desirable to compare simultaneous effects on the
gradient with serum concentration and the clearance. An interest-
ing phenomenon with regard to gastric secretion of PCP is that
pH influence appears to be somewhat less striking than it is with
urine on the basis of extrapolation of the urine pH data. There
is ample precedent for such an observation provided by Brodie and
Hogben (1957), who found that most of the basic drugs studied
were incapable of being concentrated in the acid medium of the
stomach beyond maximum of about 40 times that in serum(about
the gradient that we see here), a phenomenon that in the dog was
found to be attributable to limitations on circulation of the drug
to the gastric mucosa. In other words, the nonionized fraction
of the drug was cleared with a single passage of blood through
the stomach's circulation and so the gradient of clearance was
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limited by the bleed supply.
The present and our earlier observations (Done et al. 1977; Lin
et al. 1977) suggest that the effect of pH cm PCP distribution
is a truly tremendous me, probably due to an effect on ioniza-
tion of this weak base thought to have pKa, of about 8.5. The
remainder of this discussion will be devoted principally to
further exploration of this conceptandits possible therapeutic
implications.
The relationship of pH to urinary excretion of PCP is variable
from one patient to another and possibly influenced by a number
of factors, butatleastin some the evidence supports a pure
ionization effect (Done et al. 1977). To the extent that we
are dealing with an ionization effect and ion trapping in more
acid, media one would expect pH influences on more than just the
products of excretion. Further,such effects should be inter-
related and produce a somewhat predictable net result which might
have important clinical implications. While limited access to
the various other tissues, fluids, and compartments in the human
is an obvious obstacle to full explorations along these lines,
considerable can at least be surmised about some of the redis-
tribution consequences. Table 2 shows some representative data
obtained from a patient at two points in time
TABLE 2
pH EFFECTS CN PCP DISTRIBUTION *
pH (PC) ,ng/ml pH
Serum 7.4 66 50 7.2
CSF 140 8
Urine 7.5 43 3997 5.0
Stomach 1.4 1395 1287 2.2
*patient 5, ammonium chloride
acidification
when spinal taps were performed because the clinical picture could
not exclude other intracranial pathology. One would expect acidi-
fication of plasma to result in considerable outflow of PCP from
the central nervous system, comparative trapping in the plasma,
and, to the extent that the urine becomes acidified in the process,
also a striking increase in excretion. Such can be seen here
where a drop of serum pH from 7.4 to 7.2, caused by ammonium
chloride administration, resulted in a decline in the cerebro-
spinal fluid PCP concentration from more than twice to less than
1/6 that in serum. During this time the serum level declined
only slightly, considerably less than would have been expected
from the tenfold increase in urine PCP concentration (and clear-
ance),possibly because of shifts of nonionized drug to plasma
from less acidic compartments (such as the central nervous
system). In any event, these figures indicate the ability to
achieve desired shifts in PCP distribution and enhancement of
excretion through pH manipulations. Incidentally, these shifts
even within the body are associated with striking and immediate
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improvement in the CNS effects. Also, if you remember that the
markedly enhanced urinary elimination of PCP can be accompanied
also by elimination of that amount in the stomach through the
simple expedient of gastric suctioning, it can readily be seen
that the net result is expected to include the substantial short-
ening and improvement of the overall course that we and others
have noted. Further,as is discussed by Aronow, induced diuresis
superimposed upon urine acidification substantially augments still
further the urinary excretion of PCP.
From the gastrointestinal standpoint, with the involvement of pH
in determining ionization of a weak base such as this, and its ion
trapping in the stomach, the expectation must be that there is
substantial gastroenteric recirculation of the drug. After it
leaves the acid of the stomach it would be expected to become
relatively less ionized in the more alkaline intestine and there
fore to be reabsorbed, and this would be fully expected to play
a role in determining the course, particularly the duration, of
PCP intoxication. When the time course of serum PCP is followed
it is found that discontinuance of previously constant gastric
suctioning is associated frequently with an immediate rise in
serum [PCP], its strikingsubseqent fluctuation, and a substan-
tial slowing in the rate of disappearance from the circulation.
Table 3 compares serum [PCP] data obtained during and after dis-
continuance of constant gastric suctioning: the change of serum
concentration immediately
TABLE  3
before and after discontinuance of gastric suction is shown as a
daily rate or ke on the left; the "post absorptive" serum concen-
tration half life measurements -- i.e., after serum concentrations,
either initially or upon discontinuance of gastric suctioning,
have begun to fall -- are shown on the right. Half life values
followed by a + are minimal ones because striking rises in serum
concentration (common after discontinuance of gastric suction)
were not included in the detemination; had they been, the ap-
parent effect of gastrcenteric recirculation of PCP on serum
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half life of the drug would have been even greater than shown.
It can be seen that in all patients the elimination rate immedi-
ately after cessation of gastric suctioning, compared with the
one immediately before,was slower or was apparently overridden
by increased absorption from the gastrointestinal tract so that
the level actually climbed.
In all but one case where the comparison could be made, the serum
concentrationhalf life of PCP was considerably longer without
gastric suctioning than with it. On the average, there was more
than a doubling, even if we ignore the striking rises that often
occurred long after discontinuance of suctioning. It should be
noted that the serum concentration T½ in untreated patients must
be assumed to be longer even than those shown here on the right
(table 3) not only for the reasons mentioned, but also because
all patients except 1 and 2 in this series were subjected to
therapeutic urine acidification. The natural serum concentration
T½ would appear to be over 3 days at the concentrations encountered
here.
DISCUSSION
The finding of an appreciable gastroenteric recirculation of PCP
helps to explain the prolonged course of intoxication from this
drug. This and the strikingeffects of pH on distribution in
various compartments, may well explain the notable vacillations
in the clinical course mentioned previously. These observations
also suggest a course of therapy that has been applied with the
dramatic success described by Aronow in this publication, and
in earlier reports by this group (Done et al. 1977; Aronow and
Done 1978).
The urinary excretion of trapped PCP is so striking that, as is
discussed by Aronow, the efficiency of peritoneal dialysis with
or without added albumin is dwarfed by the results that can be
obtained with highly acidified urines. Whether extracorporeal
hemodialysis would be more efficient and whether it could be
augmented by any safe and reasonable manipulations of the acidity
of the dialysis fluid remains to determined; this could be a very
important consideration in patients with renal insufficiency. We
have had no personal experience as yet with this particular problem,
but this possibility certainly deserves exploring and in the mean-
tine the role of peritoneal dialysis and certainly that of gastric
suctioning would take on added potential importance in patients
having poor kidney function.
The gastric trapping of PCP has important forensic implications.
The drug is often smoked and occasionally is injected, but it
would be expected to appear in the stomach in large quantities
regardless of the routeofadministrationand such a finding
should not be interpreted as evidence of oral ingestion.
We are not aware of other basic weak electrolytes whose distri-
butions are so profoundly affected by pH manipulations. However,
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few bases (as contrasted with acids) have been so evaluated.
Hence, it is quite possible that ion trapping is mode of therapy
for poisoning with such compounds that has received inadquate
attention and deserves further exploration (Done 1976). We cur-
rently are actively exploring this possibility while also exploring
additional parameters of PCP pharmacokinetics that may provide
a basis for still more improvement in treatment.
The analytical method used in this study measures only unchanged
PCP, so the results are informative only with regard to the
parent drug. However, the hydroxylated derivatives known to be
pruduced by humans have not been demonstrated in the blood, ap-
parently because they are converted to the glucuronides and ex-
creted as rapidly as they are formed. All of the urinary meta-
bolites are present as the glucuronides, and there is extensive
excretion of the free, unchanged drug. Thus, studies of the
partent compound alone probably suffice to define the toxicologi-
cally important kinetic parameters; however, studies of the
metabolites as well are required before this concept can be accept-
ed without reservations. Such studies are currently underway in
this laboratory.
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Chapter 12
Clinical Observations During Phencyclidine
Intoxication and Treatment Based on
Ion-Trapping
Regine Aronow, M.D., Joseph N. Miceli, Ph.D., and Alan K. Done, M.D.
Since technology to detect phencyclidine (PCP) in body fluids became
available to us, fifty cases of PCP overdose have been treated at the
Children’s Hospital of Michigan. The patients ranged in age from
nine months to almost twenty years. Preliminary observations in over-
dosed adolescent boys of the pharmacokinetics of the drug (Done et al.
1977) have led us to successfully treat a number of severely over-
dosed patients utilizing ion trapping by continuous gastric suctioning
and acidification of urine and/or blood with ammonium chloride (Aronow
and Done 1978). Although many of the children under eight years of
age presented after rapid onset of coma, only three seemed of suffi-
cient severity to require urine acidification in addition to contin-
uous gastric suctioning and supportive care. We have, however, no
quantitative data on young children. This report offers additional
data on seven patients above the age of thirteen years who are being
studied in detail and who are also discussed in Dr. Done’s paper in
this volume.
BACKGROUND
In the early 1970’s a number of small children with symptoms now
recognized as associated with phencyclidine overdose were seen at
the Children’s Hospital of Michigan, supposedly having ingested street
drugs, variously representedas THC, mescaline or LSD. Paper chrom-
atography spot tests done elsewhere failed to reveal the presence of
narcotics, sedatives or tranquilizers commonly used in our area.
Beginning in December 1972, arrangements were made with a private
research laboratory to screen blood and urine samples on selected
patients for mescaline, LSD and PCP, the latter having been brought
to our attention by the Drug Enforcement Agency. By mid 1974 an
emergency service utilizing a GC-MS system became available (Horowitz
et al. 1976) and urine, gastric and blood samples have since been
submitted there for initial screening. Retrospectively, we learned
that although this system would identify large amounts of PCP, the
injection temperature used could destroy small amounts of PCP
(personal communication, Dr. Lin, 1978). Thus we may have missed
some cases.
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All cases of PCP overdose referred to in this paper gave positive
evidence of PCP in body fluids by one of the methods mentioned above.
EPIDEMIOLOGY
Our experience with children younger than eight years of age (figure
1) shows an age distribution not unlike that of accidental poisoning
in general (National Clearinghouse Bulletin 1977), an indication of
the fact that the drug was commonly in their environments and subject
to being ingested by the children. Social service investigations
revealed someone may have purposefully administered the drug to two
of the children. All the cases had child abuse/neglect filed.
FIGURE 1
There were no cases recognized in the eight to thirteen year age
range.
Total patient data reveal an equal distribution between males, females,
blacks and Caucasians in the under eight years of age group, but a
disproportionate number of Caucasian males in the 13 to 20 year old
group (tables 1, 2).
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TABLE 1
Patient Experience: Dec. 1972 - Feb. 1978
AGE (yrs.) SEX RACE
M - F B  - C
<8 20 18 18 20
13-20 10 2 1 11
TABLE 2
Patient Experience: Dec. 1972 - Feb. 1978
AGE (yrs.) SEX by RACE
BF BM CF CM
<8 8 10  10 10
13-20 0 1 2 9
In the early calendar years included, there was a fifty percent
greater incidence of black children identified with PCP overdose than
of Caucasian children. This has reversed in the last year to sixty-
six percent Caucasians (table 3).
TABLE 3
Patient experience (AGE vs RACE)
CALENDAR AGE
YEARS ( y r s . ) No. BLACK CAUCASIAN
1972(1 mo.)
1973 <8 10 8 2
1974
13-20 2 0 2
1975 <8 12 5 7
13-20 2 0 2
1976 <8 5 2 3
13-20 3 0 3
1977
1978 <8 11 3 8
(1 mo.)
13-20 5 1 4
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Only rarely are adult PCP overdose cases seen at Detroit General
Hospital, the major inner city emergency service, which gives credence
to the race distribution. Most of the older Caucasian patients seen
at our hospital have come from communities other than Detroit.
SUBJECTS AND METHODS
The clinical courses of eight patients are given in summary form
in table 4. Patients 1, 2 and 3 were described previously with their
pharmacokinetic data (Done et al. 1977). The varying symptomatology
associated with PCP overdose has been described by many authors and
is tabulated and referenced in our previous publication (Aronow and
Done 1978).
Patient 4 was treated at another hospital with a representative of
our group in attendance from six hours to 36 hours after admission.
Quantitation of phencyclidine in his blood was done at a different
laboratory (Domino and Wilson 1977) than his gastric secretion and
urine. These were analyzed along with all specimens from the other
patients, as previously described (Done et al. 1977).
Patient 8 presented in an acute psychotic state after taking re-
peated doses of PCP over a Period of one to two weeks. Only limited
specimens were obtained and the patient’s clinical course was actually
biphasic. He showed dramatic improvement after twelve hours of ion-
trapping, with his personality becoming intact. All therapy was dis-
continued, only to have his psychosis resurface in 4 hours. Therapy
was again instituted, resulting in fluctuating improvement until 53
hours into therapy, when he regained normalcy. Modified therapy was
continued until discharge five days later. On the third day post
discharge the patient became agitated and paranoid, so he was rehos-
pitalized and transferred to a psychiatric service. Unfortunately
no studies were done on his second admission.
Methods of collecting specimens and their treatment are described in
Dr. Done’s paper in this volume.
The lowest serum PCP levels collected within 2-3 hours of consistent
improvement of the patients’ sensorium are given in table 5. Although
the levels were taken at very diverse times in relation to estimated
time of PCP ingestion, there is a rather striking similarity in the
levels. It is not surprising that patient 5, with the longest period
of coma, had a lower serum level. This will be discussed in detail later.
TREATMENT
Principles for treatment of PCP overdose at varying levels have
recently been described (Aronow and Done 1978). In addition, careful
examination for coexisting injuries should be made, as these patients
are at high risk.
Patient 1 came to us late in his course and was given protective and
supportive care until obvious symptomatology disappeared. Patient 2
was in consistent coma with repeated convulsions and severe laryngo-
spasm requiring tracheal intubation for five days. He was maintained
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TABLE 4
PHENCYCLIDINE OVERDOSE
Patient Data
TABLE 4 (continued)
TABLE  5
PHENCYCLIDINE OVERDOSE
Lowest Serum Levels (ng/ml)
Related to State of Sensorium
Transferred
CHM Approx.
Time After Ingestion Coma Semicomotose
2.5 days
7 hours
? ?
125 95
Patient
1
2
3
4
5
6
7
8
24 hours 125 95
? (Another Hosp.) 114 68
9 days 71 63
31 hours 130 109
23 hours 132 61
Chronic Use
Disoriented
<42
25
25
?
23
24
22.4
<1.83– –
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on gastric drainage, initially to reduce aspiration hazard, and then
on a theoretical basis in hope of removing PCP if the tube advanced
to the duodenum. No consideration of the possibility of ion-trapping
in an acid medium was given at that time. Faced with the severity of
the patient’s symptoms, and a dearth of pharmacokinetic data on PCP,
peritoneal dialysis was undertaken in a heroic effort over 72 hours,
without obvious clinical improvement. Slowly, by the fourth day, coma
became semicoma, which changed to disorientation on the seventh day,
lasting for another week. The patient fully recovered.
Analysis of the data obtained from this patient’s blood and urine
samples revealed that PCP clearance seemed to be pH dependent (Done
et al. 1977; Lin et al. 1977).
Patients 3, 4, 5, 6 and 7 all presented with coma of varying durations.
The approach to their therapy was based on ion-trapping with varia-
tions in the dosage and route of ammonium chloride used. To attempt
to bring the urine pH to 5 or lower, the dose of ammonium chloride
delivered down the gastric tube was 75 to 125 mg/kg (Edelmann et al.
1967; Chan et al. 1974) every six hours. This was diluted in 2 ounces
of saline. If the patient vomited or had evidence of marked gastric
irritation, the dose was sometimes delivered in two small increments
one half hour apart. The gastric tube was then clamped for one to
two hours before continuous drainage was reestablished. Most
patients’ urines converted to a pH of 5 or lower after the second dose.
Concurrently, ascorbic acid, varying in dose from 500 mg to 2 gms,
was added to the intravenous fluids every six hours.
Particular attention must be paid to maintaining good urine flow
(2 mg/kg/hr) by adequate intravenous fluids and electrolytes,
especially potassium.
Once urine pH was at 5 or lower, furosemide (1/2 to 1 mg/kg) was ad-
ministered. Often this was followed by a marked improvement in the
patients’ sensorium and symptoms. Repeat use of the diuretic was
dependent on the patient’s fluid balance as evidenced by the central
venous pressure, and could probably be repeated more often than was
done in these patients.
Patients 5 and 6 received ammonium chloride intravenously at a dosage
of 2.75 mg/kg as a 1 percent or 2 percent concentration in saline
(derived from Quadrate, a 21.4 percent solution of ammonium chloride)
purposefully to lower blood pH so as to create a gradient with spinal
fluid and hopefully clear the central nervous system and spinal fluid
of PCP more rapidly. Blood pH fell in patient 5 before urine pH
reached five, and the level of PCP in this patient’s spinal fluid
markedly decreased with concurrent clinical improvement.
Duration of gastric drainage was arbitrarily set at three to four
days but in some patients was discontinued earlier because of nasal
irritation and bleeding (patient 6), anxiety about gastric erosion
from the ammonium chloride solution, and patient discomfort as clear-
ing of the sensorium occurred.
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In patient 7 betazole hydrochloride (Histalog) was used once to
increase gastric secretions. There was no adverse effect reflected in
blood pressure; however, there was no dramatic change in sensoriun
following three hours of marked increase in volune and decrease in
pH of gastric secretions.
Once the patients’ sensorium had cleared and the nasogastric tube had
been removed, ascorbic acid, two to eight grams in divided doses, was
given daily as well as several glasses of cranberry juice (excreted
as hippuric acid in the urine), to maintain an acid urine for at
least another week.
DISCUSSION
Ion-trapping to enhance PCP excretion has been employed successfully
in acute PCP overdosed patients, as evidenced by a lack of
convulsions or hypertensive episodes once treatment is underway,
relief of muscle hypertonicity, and steady improvement in sensoriun
until out of coma (even after 9 days of coma). With careful atten-
tion to good supportive care, there have been no complications of
therapy.
Cumulative data on these patients clearly show the influence of pH
on clearance of PCP (table 6). Although peritoneal dialysis can clear
some of the drug, it is the least efficient unless 5 percent albumin
is used. With only two samples on which to make a judgment, we would
reserve this treatment possibility for the patient with renal insuf-
ficiency.
Gastric suctioning may appear to be somewhat lower in efficiency
than it is, due to several factors. Patient 5 generally had lower
gastric clearance than other patients with her clinical severity,
perhaps because of the long time she was in coma before ion-trapping
was instituted, allowing for distribution of PCP into other body com-
partments. Also, from the pharmacokinetic data shown by Dr. Done
elsewhere in this volume, it is evident that even clamping the gas-
tric tube following ammnonium chloride instillation adversely affects
the serum PCP level. We have also found that the pH of the ammonium
chloride solution used is in the range of 4.5 and raises the gastric
pH temporarily.
Histalog more than doubled the PCP clearance in the gastric secretion
but requires further evaluation before being used routinely as a
possible adjunctive approach, It may be especially helpful for pa-
tients with renal insufficiency. The observation that several of the
young children who presented in coma regained consciousness immedi-
ately following gastric lavage is further evidence of the importance
of the pool of PCP that may be in the gastric compartment.
Clearly the most dramatic increase in clearance occurs as urine pH
dips to 5 or lower and furosemide is given. This probably accounts
for the marked improvement that often occurs in the patients immed-
iately following diuresis under these conditions.
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TABLE 6
PCP CLEARANCE (ml/min)
(cumulative data on 7 patients)
Mean SEM
Urine, pH> 6.5
pH 5 - 6.5
+ furosemide
pH < 5
+ furosemide
Peritoneal dialysis
with 5% albumin
Gastric suction
after Histalog
7.0 ± 0.70
57.4 ± 6.57
(205.3) 
134.5 ±25.55
(299.3) 
2.4 ± 0.39
(4.1, 
4.5)
44.8 ± 8.40
(95.7) 
No. of Samples
34
128
3
44
7
11
2
61
3
278
Whether it is better to give furosemide when the urine pH is 5.5 or
to wait to get it down below 5 is not quite clear. Perhaps utiliza-
tion of another diuretic agent would be more efficacious. These are
some of the refinements in the therapeutic approach that we have
under study.
There are other methods to acidify urine, but we have preferred to
use ammonium chloride. It is contraindicated, however, in anyone
with liver disease. Three of the children under eight years of age
have received one or two doses, as a gastric bolus, with successful
acidification of urine to pH 5 or lower. Although we did not find
evidence of hyperosmolarity in the patients given ammonium chloride
intravenously, this treatment must be used cautiously in small children
as they are exceedingly sensitive to hyperosmolar states.
Although all but one of the patients were considered acute overdoses,
there was reason to believe at least three were regular members of
the drug culture. No doubt chronic use of PCP can result in storage
of the drug in various compartments in the body and influence the
course of an acute overdose. This may account for certain variations
in data seen among patients. The cursory application of our
emerging concept of treatment (Aronow and Done 1978) to one patient
with a history of chronic use resulted in at least an initial improve-
ment. This has led us to undertake further studies of such cases.
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Chapter 13
The Diagnosis and Treatment of the
PCP Abuse Syndrome
David E. Smith, M.D., Donald R. Wesson, M.D., Millicent E. Buxton,
Richard Seymour, M.A., and Honey M. Kramer
INTRODUCTION
Our first exposure to PCP occurred during the summer of 1967 in
the Haight-Ashbury District of San Francisco in which the drug
was first introduced as the "PeaCe Pill" during a rock concert.
We saw that day between twenty-five and thirty acute PCP toxic re-
actions. In some respects, these reactions were like the bad LSD
trips we were used to treating, but in other respects quite dif-
ferent, with greater physical toxicity and paranoid thinking. We
had samples of the "PeaCe Pill" analyzed through a local Bay Area
toxicology laboratory and found that the psychoactive drug was PCP.
The "PeaCe Pill" was not well received by the majority of individ-
uals in Haight-Ashbury at that time, although PCP became the
drug of choice for a small number of users who continued to use
it on a chronic basis. For them most part, PCP was a drug of de-
ception, usually marketed as "THC" or as one of the psychedelics
which were more in demand. Within the past five years, however,
PCP has become increasingly visible as a primary drug of abuse
under a variety of street names, including "hog," "krystal," and
"angel's dust." The drug is illicitly manufactured and taken in
a variety of ways: orally, intranasally, and by intramuscular or
intravenous injection. This paper provides the clinician who
treats PCP problem with a conceptual framework for the diagnosis
and treatment of the PCP abuse syndrome. Certainly not everybody
who uses PCP develops toxic consequences, but we have seen a
variety of short term and long term adverse reactions and have
found that many clinicians have difficulty in both the diagnosis
and treatment of PCP-induced problems. (Our work is based primar-
ily on the following clinical experience: 1) the Haight-Ashbury
Free Medical Clinic Drug Detoxification and Aftercare Program;
2) our Emergency Medical Service at rock concerts; 3) Patient
consultation through our Physician Training and Consultation
gram, in which we receive telephone calls and individual requests
from physicians treating people who have PCP abuse problems; 4)
Outreach Training and Clinical Work: 5) Inpatient treatment of
PCP abusers at Gladman Psychiatric Hospital: 6) our collective
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private practices; 7) work and patient consultation with other
community based treatment agencies; and 8) fellow clinical in-
vestigators. Our information is based on our clinical experience
and review of literature. There are many more questions than
there are answers, and the clinical staging presented later in
this paper is designed primarily for the clinician, not the PCP
researcher. As the PCP abuse problem has increased, clinicians
all over the country are faced with management of various stages
of PCP abuse with relatively little help on diagnosis and treat-
ment.
The effects observed when PCP is ingested result from a complex
interaction among pharmacological, physical, and sociocultural
variables, and the pre-PCP psychological makeup of the individual.
In the natural setting, of course, these variables cannot be iso-
lated. In designing the diagnostic and treatment plan, one is
confronted with their simultaneous interaction.
Our clinical findings show four behavioral phases of the PCP a-
buse syndrome, which may appear as successive stages.
Stage I. Acute PCP toxicity: These reactions are a direct result
of PCP intoxication. Their onset may be minutes to hours follow-
ing PCP ingestion.
Stage II. PCP toxic psychosis: This stage is apparently not re-
lated to toxic blood levels of PCP and does not inevitably follow
stage I.
Stage III. PCP-precipitated psychotic episodes: In some individ-
uals, PCP may precipitate a psychotic reaction lasting a month or
more which clinically appears much like schizophrenia.
Stage IV. PCP-induced depression: PCP can produce a depressive
reaction in some individuals. This may follow any of the previous
stages and last from one day to several months.
Each stage is shown in outline in table I and will be described
in more detail, followed by case histories illustrating salient
clinical features.
DISCUSSION AND CASE HISTORIES
STAGE I. ACUTE PCP TOXICITY
In acute PCP toxicity there are four "C's": combativeness, cata-
tonia, convulsions and coma. These effects are dose-related.
Combativeness and catatonia are frequently observed together at
the lower dosages, while convulsions and coma are related to higher
dosage effects. During this stage, one also sees hypertensive
crisis sufficiently severe to be fatal, although such crises are
relatively rare in our experience. Illusions can dominate:
space walking, the detachment of sounds, objects changing in
size, shape, and distance. Visual illusions rather than true
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TABLE 1
DIAGNOSIS AND TREATMENT OF THE PCP ABUSE SYNDROME
hallucinations are common, but occasionally auditory hallucina-
tions occur. If the dose of PCP is high enough, the patient may
have many grand mal seizures and coma which require hospitaliza-
tion and supportive care to stabilize and maintain the respira-
tory and cardiovascular function. With proper management, most
patients who go into a PCP-induced coma survive, although the
period of coma may be quite prolonged. Our experience indicates
that the usual duration of acute PCP toxicity is 0 to 72 hours.
Lab results indicate that blood is almost always positive and
urine is positive. A large number of people clear after stage
I, PCP acute toxicity; some go into stage II, PCP toxic psychosis.
Case 1
At a rock concert in the San Francisco Bay Area, six adolescents
who had previously experimented with a variety of psychoactive
drugs, including PCP, ingested an unknown quantity of PCP in
tablet form. Although they had experience with PCP, they had been
primarily smoking it in a form of "krystal joints," and this was
their first exposure to the tablet form of PCP. All six became
acutely intoxicated; one, a 17-year-old white male high school
senior, became comatose. Friends took him to the emergency room
of a local hospital after observing the young man for a couple
of hours and becoming concerned over his extreme muscular rigidity
and shallow respirations. He was hospitalized and maintained on
a respirator for over three days. With this supportive management
he recovered fully, but there was a period of cerebral dysfunction
with poor memory and depression lasting for over a week following
the acute PCP toxicity. This case example also demonstrates that
a patient can go from stage I acute PCP toxicity to stage IV,
cerebral dysfunction and depression, without going through stage
II and stage III psychotic phases.
Treatment of Stage I
Acute PCP toxicity patients can be divided into two groups: those
who are comatose, and those who are acutely intoxicated but con-
scious.
A. Comatose Patients
As in the management of any coma patient, the first level of con-
sideration is stabilization of the ventilation and cardiovascular
systems, and protecting the individual from inflicting bodily harm.
Secondly, consideration should be given to the elimination of the
offending agent.
1. Stabilization of medical signs and psychiatric signs and
symptoms.
a. Cardiovascular System
Treatment of the hypertension with Hyperstat has been recommended
(Eastman and Cohen 1975).
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b. Convulsions
Convulsions may occur and are not necessarily limited to one or
two. Therefore, treatment is recommended with intravenous diazepam
(ValiumR) given over a period of two minutes following the sei-
zure.
c. Respiratory Depression
Respiratory depression with pure PCP is unusual except in very
high dosages. However, respiratory depression may be marked when
combined with alcohol, other sedative hypnotics, or opiates. If
the patient is sufficiently depressed, respiratory assistance on
a respirator is necessary.
B. Conscious Patients
Patients in acute toxicity may also present as psychiatric emer-
gencies with symptoms of paranoia, agitation, thought disorder,
negativism, hostility, and grossly altered body image. Assaultive
and antisocial behavior often results in the individual's coming
to the attention of treatment personnel. In the management of
such individuals, Luisada and Brown (1976) have delineated the
immediate goals of treatment as: 1) prevention of injury to
the patient or others; 2) assurance of continuing treatment; 3)
reduction of stimuli; 4) amelioration of the psychosis: and 5)
the reduction of agitation. The reduction of external stimulation
through the use of seclusion or a "quiet room" is of prime impor-
tance. Clinicians disagree as to the most appropriate pharmaco-
logical intervention. Luisada and Brown (1976) recommend chlor-
promazine (Thorazine), although we generally prefer diazepam
(Valium) for symptomatic or behavioral control. Haloperidol
(Haldol) has also been used (Showalter and Thornton 1977).
C. Elimination of PCP from the body
Although many clinicians prefer conservative supportive management,
Aronow, Miceli, and Done (this volume) have successfully utilized
continuous gastric suction, acidification of the urine, and a
potent diuretic such as furosemide (Lasix) to enhance elimination
of the PCP. Their technique and rationale for use are described in
detail in other papers in this volume. PCP is recycled through
the enterohepatic circulation, and introducing a slurry of acti-
vated charcoal into the intestine may decrease reabsorption of
PCP from the small intestine. This should not be used instead of
gastric suction in a comatose patient; however, 100 ml of activated
charcoal slurry should be inserted into the stomach just before
the nasogastric tube is removed, or may be given orally to a non-
comatose patient.
STAGE II. PCP TOXIC PSYCHOSIS
After the acute PCP toxicity phase has passed, some individuals
develop a prolonged toxic psychosis. Our experience has been
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that incidence of the PCP toxic psychosis is highest among chronic
abusers. In trying to detemine prognostic indicators to why
certain patients will become psychotic, we have looked at dif-
ferent clinical variables, but found chronic abuse to be the major
factor. In this stage, one finds impaired judgment and paranoid
delusions with agitation and both auditory and visual hallucina-
tions. The individual can be self-destructive or destructive to
others. Hallucinations and flattened affect are characteristic.
The usual duration is 24 hours to 7 days or more. Lab results
indicate blood negative and urine positive for PCP. The amount
of PCP excreted in the urine is highly dependent upon urinary
acidity, and an attempt to collect the urine under conditions of
urinary acidification with ammonium chloride or ascorbic acid
(vitamin C) should be made.
Case 2
A 38-year-old black male with no previous history of drug abuse
or psychiatric problem acquired some new marihuana which was
described to him as "superweed." He had regularly smoked mari-
huana for over twenty years and described no adverse consequences
of any sort with its use. He began smoking this new "superweed"
and found himself (according to his girlfriend) beaming paranoid,
delusional, and uncharacteristically hostile. After approximately
two weeks of daily smoking of the "superweed" he felt that there
might be some correlation between this new drug and his symptoms
and stopped smoking the drug for a day. He found no symptom
relief; after that, he actually increased the dosage, as he felt
it might help him feel better and recover from the symptoms which
he felt were unrelated to the drug use. Shortly after, he became
quite assaultive, cut off the head of his dog, and assaulted a
stranger on the street with a razor. His girlfriend, who had
read in the newspaper of the bizarre behavior PCP can produce,
brought him to the Haight-Ashbury Free Medical Clinic where he
was examined. The material was analyzed and found to be mari-
huana laced with a significant quantity of PCP. The toxicity of
PCP was explained to both the patient and his girlfriend. Both
decided on an abrupt cessation of the drug. Following a brief
period of hospitalization in which antipsychotic medication was
administered, the patient was discharged and refused further
hospitalization or medication, but remained in supportive counsel-
ing. After approximately two weeks the psychotic symptomatology
faded, but the patient still complained of impaired thinking,
difficulty in believing that the delusions that he perceived dur-
ing his PCP intoxication were unreal, and prolonged depression.
Weekly supportive counseling without medication gradually resolved
these symptoms in approximately twelve weeks.
Treatment of Stage II
Most clinicians recommend the use of non-phenothiazine tranquiliz-
ers such as haloperidol (Haldol). Some clinicians use sedative
hypnotic medication. There is no sound research basis for the use
of either of these medications; nor in our experience, is there
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any indication that these medications shorten the course of acute
PCP toxic psychosis. It does appear, however, that they make the
patient more manageable in a ward, which is probably the major
reason that these medications are used. In those clinical cases
that we have seen where patients have received either no medica-
tion, sedative hypnotic medication, or antipsychotic medication,
these variables do not appear to change the total length of time
the individual is psychotic, but they do modify the characteristic
symptoms.
STAGE III. PCP-PRECIPITATED PSYCHOTIC EPISODE
Early investigators reported on the tendency of PCP to exaggerate
signs and symptoms in schizophrenic patients (Luby et al. 1959,
and Domino 1964). Many other studies have described the PCP-
induced psychosis. Luisada and Brown (1976) have described in-
dividuals who were not previously schizophrenic, who became so
following ingestion of PCP, and who periodically have return of
symptoms, although of less intense nature than when the PCP was
first used. To what extent it is possible to have a prolonged
psychosis in an individual who is not predisposed to schizophrenia
is not known. Certain individuals, mostly with psychotic or
prepsychotic personalities, tend to develop a PCP-precipitated
psychotic episode that mimics schizophrenia. This may occur after
a single dose administration of PCP. This is not a result of
chronic PCP abuse producing a toxic psychosis, but rather a PCP-
precipitated adverse reaction to an underlying psychological
condition. The characteristics of the episode are of the schizo-
affective type with paranoid features and a waxing and waning
thought disorder, A majority of the cases that we have seen in
stage III have had psychotic or prepsychotic personalities, and
we believe that this is the major prognostic indicator. However,
we have seen a few cases that have had a prolonged PCP-precipitated
psychotic episode after single dose administration, with no un-
equivocal history of preexisting psychosis. Our time range is 7
days to 30 days or more, with patients moving from the PCP toxic
psychosis into the PCP-precipitated psychotic episode. Lab re-
sults indicate blood negative, urine negative. Most investigators
recommend the use of chlorpromazine (Thorazine) in dosages com-
parable to those used in schizophrenia and remark that the paranoia
appears to yield at a slower rate (Luisada et al. 1976). The need
for long term antipsychotic drug maintenance for the individual
with PCP-precipitated psychotic episodes makes it important to
differentiate the PCP-induced toxic psychosis from the PCP-precipi-
tated psychosis. It is also important to emphasize that individ-
uals with schizophrenia can go into a prolonged psychotic phase
after a single dose of PCP. This is demonstrated by the following
case:
Case 3
A 26-year-old white female with a long history of psychiatric dis-
turbance, including hospitalization for psychosis, but no history
of alcohol or drug abuse, was at a party and shared a joint of
235
"angel dust," a drug with which she had no previous experience.
After smoking approximately half of the joint, she started be-
coming quite paranoid and delusional, and developed both auditory
and visual hallucinations. After remaining at home with her
parents for two days, she was taken to a San Francisco psychiatric
hospital where she was admitted. The material she smoked was
analyzed and found to contain PCP. At the time of hospitaliza-
tion, both her blood and urine were negative for PCP. She re-
mained psychotic for over two weeks, but the thought disorder
gradually faded, giving way to a substantial depression. Her
psychosis was treated with haloperidol (Haldol).
Treatment of Stage III
A. Immediate goals of treatment are the same as those described
for acute PCP toxicity, including prevention of injury and
reduction of stimuli.
During the PCP-related psychotic break, it appears that the drug
precipitates an underlying thought disorder, rather than produc-
ing a direct toxic psychosis, which we define as a major break
with reality secondary to an intoxicant. In general, many clini-
cians use a non-phenothiazine major traquilizer, such as halo-
peridol (Haldol), for the PCP toxic psychosis because of the
concern over the additive effect between PCP arid chlorpromazine
(Thorazine). However, there is no controlled research in humans
to support this. Domino and Luby (1972) have described animal
research which shows some additive effect of chlorpromazine
(Thorazine) and PCP. In PCP-precipitated psychosis, however,
experienced clinicians (Luisada and Reddick 1975) recommend resi-
dential seclusion with frequent observation and high doses of
antipsychotic phenothiazine medication, such as chlorpromazine
(Thorazine) given daily, starting with 400 mg a day in divided
doses and increased as necessary by 200 mg a day to an average
daily dose of 1600 mg per day. Clinical experience in the San
Francisco Bay Area has varied between the use of sedative hypnotic
medication such as diazepam (Valium) and low doses of haloperidol
(Haldol) and has avoided the high doses of chlorpromazine (Thora-
zine) as described by Luisada and Reddick (1978). All clinicians
treating stage III, however, agree that the PCP-induced psychotic
reaction can be quite prolonged and should be managed on an in-
patient basis.
STAGE IV. PCP-INDUCED DEPRESSION
PCP-induced depressionis a very frequent condition that many
clinicians miss, particularly when it comes after a stage III PCP-
precipitated psychotic reaction. The clinician is so relieved
when the psychosis is over that s/he discharges the patient with
relatively little followup and without realizing that in this de-
pression the individual has high suicide liability or may use
other types of drugs to alleviate the depression. A paradox with
PCP is that it does give an energizing, numbing, consciousness-
altering effect which the patient perceives as antidepressant.
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Clinically, it appears that many of these patients have prolonged
cerebral dysfunction, as well as depression. The complaints of
memory impairment subside as the depression clears. The patients
who we have treated have indicated that they feel less depressed
as they think their "brain damage" is clearing. It becomes very
difficult to figure out whether depression clears as the cerebral
dysfunction itself clears or as their concern over the cerebral
dysfunction waves. In addition, some of the symptoms may be the
result of the depression rather than the cause. PCP-induced de-
pression can last from one day to several months, and can follow
any of the preceding stages. That is to say, the patient can be
in PCP acute toxicity and clear with no problem, or go into stage
II PCP toxic psychosis, or into stage III PCP-precipitated psy-
chotic espisode, and then have prolonged PCP-induced depression.
Or, the patient can wake up from a PCP acute toxic reaction and
go right into the prolonged depression. Laboratory results will
show blood and urine both negative for PCP.
Case 4
A 19-year-old white female came to the Haight-Ashbury Free Medical
Clinic after a PCP overdose. She described a long history of
agitated depression and suicidal ideation from which she found
she gained relief when she "snorted" two lines of PCP containing
approximately 20 mg each day. She indicated that drugs such as
amphetamines actually made the depression worse because they in-
creased the agitation. Conversely, when she took PCP, the al-
teration in consciousness and energizing effect gave her relief
from the depression. When she stopped the PCP, however, she
found the depression became worse than it was prior to use of the
drug. She indicated that she had no intention of stopping prior
to this me overdose episode. She expressed amazement about the
overdose because she indicated that she had not snorted a higher
dose on the day she became comatose.
This case illustrates a number of principles, including motivation
for usage in individuals who are self-medicating their depression.
In addition, it demonstrates that chronic abusers can have over-
dose episodes even if the dosage of the drug is not increased,
and it suggests clinically that this may be the result of accumu-
lation of the drug in both brain and fatty tissues of the body.
Also, there is a high incidence of secondary drug abuse following
this stage IV PCP-induced depression. Many individuals turn to
other drugs, including alcohol, stimulants such as amphetamines
or cocaine, or even heroin to deal with the PCP-induced depression.
This is illustrated by the following case:
Case 5
A 34-year-old white male used PCP by the intranasal route on a
daily basis for three years. He developed a grandiose religious
delusion in which he described himself as the "Prince of Peace"
and thought he was "Jesus Christ." He was using PCP with a number
of other friends, who also felt he was "Jesus." Following an
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adverse PCP reaction and confrontation with another individual
using PCP, this religious delusion was shattered and he became
extremely depressed. In an attempt to self-medicate this depres-
sion, he began snorting and finally injecting heroin and eventually
became dependent on heroin. He also used large quantities of co-
caine. As a consequence of antisocial activities undertaken in
order to acquire the drug, he was arrested and served time in
jail. He is how drug-free and involved in treatment in a non-
medical outpatient program stressing a chemical-free philosophy.
He denies that he had any history of depression prior to his pro-
longed period of PCP abuse, or any history of religious delusion.
He feels that the depression and religious delusions were a direct
result of his daily and prolonged abuse of PCP.
Treatment of Stage IV
We have not had notable success in treating PCP-induced depression
with the tricyclic antidepressants amitriptyline (Elavil) and
imipramine (Tofranil). Certainly, the PCP depression can re-
sult in return to PCP usage, or to a suicidal attempt for individ-
uals who are self-medicating a preexisting depression with PCP.
If treatment is initiated with antidepressants, full therapeutic
dosages should be given 100 to 250 mg/day). Many of these patients
take medication erratically, and the usual precautions used with
patients on tricyclic antidepressants should be observed. We
certainly prefer inpatient treatment. If antidepressants are
prescribed on an outpatient basis, not more than two or three
days' dosages should be dispensed at once. The patient should
be cautioned about possible interaction of tricyclic antidepres-
sants with PCP, alcohol, and other drugs, and advised to dis-
continue the tricyclic antidepressants if PCP usage is resumed.
The underlying basis of a PCP-induced depression is unknown, and
no controlled clinical procedures are available to guide the
clinician.
SUMMARY AND QUESTIONS FOR FUTURE RESEARCH
PCP abuse may present in a variety of ways to the clinician.
Treatment strategies may be conceptualized in terms of four
stages, each having specific types of treatment intervention:
acute PCP toxicity: PCP toxic psychosis; PCP-precipitated psy-
chosis; and PCP-induced depression. Clinical treatment of the
severe overdose in coma is best understood and defined by clinical
protocol. The treatment of other stages is still primarily dicta-
ted by clinical intuition; disagreement exists among experienced
clinicians as to what constitutes the most appropriate treatment.
For the clinician responsible for treating PCP abuse, a number of
Clinically important questions remain unanswered. For example:
1. Does chronic PCP use produce long-lasting, perhaps permanent,
brain damage? Is the association observed by clinicians spur-
ious in that most PCP users have used a variety of other drugs?
Are the effects thought to be long term actually secondary to
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2.
3.
4.
chronic intoxication?
Does PCP ingestion produce long-lasting psychological dis-
organization in individuals who are not schizophrenic? If so,
how can these effects be characterized and distinguished from
schizophrenia?
Are the antipsychotics useful in shortening the duration or
intensity of PCP acute toxicity, the PCP toxic psychosis,
or the PCP-precipitated psychosis? Should patients  who mani-
fest prolonged psychoses following PCP ingestion be diagnosed
or treated differently than schizophrenics?
Is the PCP-induced depression observed in PCP users actually
induced by the drug? If so, what is the underlying biochemical
mechanism, and should the antidepressants be used in treatment
of the depression?
The answers to these and other clinically relevant questions can
be resolved by careful clinical research. In view of the current
differing opinions as treatment, double blind random treatment
assignment studies should be undertaken. Practically, the barriers
to definitive research include the difficulty in establishing in-
formed consent to participate in a study while the patient is
acutely psychotic and the difficulties inherent funding such
research. Until answers are available, prudent clinical treatment
must proceed according to clinical intuition. We believe the
concept of distinct clinical stages is a step toward rational
treatment.
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Chapter 14
The Phencyclidine Psychosis:
Phenomenology and Treatment
Paul V. Luisada, M.D.
INTRODUCTION
Washington, D.C. has been a major center for phencyclidine (PCP)
production and abuse since the early 1970's. This phenomenon,
however, did not reach the awareness of the public or of most
mental health professionals until mid-1977.
Phencyclidine's propensity for reactivating schizophrenic psy-
choses also remained buried in the literature on model psychoses
from the early 1960's. Finally, the fact that phencyclidine can
produce long-term treatment-resistant schizophreniform psychoses
in subjects who have had no prior psychiatric histories was not
known until 1974. This paper concerns itself with the diagnosis
and clinical management of the phencyclidine psychosis.
During the fall of 1973, the admission rate for what appeared to
be unusually long, severe, and treatment-resistant initial schizo-
phrenic psychoses suddenly tripled at the Area D Community Mental
Health Center in Washington, D.C. (Luisada and Reddick 1975).
These patients had all smoked a drug called "Angel Dust" before
becoming psychotic. Unlike the vast majority of toxic psychoses,
however, these episodes often required two weeks of aggressive
inpatient treatment before resolution began. In addition, violent-
ly agressive behavior was characteristic of the onset, and the
presenting picture was at first indistinguishable from a florid
schizophrenic episode.
The first case to catch our attention was unusual in several ways
and presented a diagnostic dilemma: An 18-year-old high school
senior was admitted after becoming violently psychotic at home
without any prodromal signs. He presented with the primary and
secondary signs of a florid schizophrenic psychosis. Escalating
doses of major tranquillizers and intensive staff involvement
failed to influence his illness during the first two weeks in the
hospital. In fact, contact with staff appeared to aggravate his
symptoms. His ambivalence and paranoia made him unpredictable
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and posed a constant threat of violence. He assumed bizarre
autistic postures, demonstrated a formal thought disorder, and
voiced the delusions that his mother was dead and that he had
a "knot" in his head .
The diagnosis was complicated by several factors: his mother
denied a family history of schizophrenia or the presence of pro-
dromal signs and symptoms in the patient. A toxic psychosis
seemed improbable on the basis of lack of history or physical
stigmata, the absence of a clouded sensorium, the persistence of
the psychosis, and the presence of all four primary signs of
schizophrenia.
When the patient's personality was dramatically reconstituted to
its premorbid level in the third and fourth weeks of hospitaliza-
tion, however, he reported smoking a drug called "angel dust"
just prior to admission.
Similar admissions rose from a trickle to a flood, peaking in
February 1974 at the rate of one third of the first inpatient
admissions. The epidemic ended even more suddenly, with no more
than three cases each during April, May, and June. This decline
followed by several weeks a police raid on local PCP laboratory.
Another epidemic began toward the end of 1974, and for some periods
of 1975 and 1976 PCP psychosis became our leading cause of in-
patient psychiatric admissions, surpassing both schizophrenia and
alcoholism. By the beginning of 1976, the Drug Enforcement Ad-
ministration was calling the Washington Metropolitan Area the PCP
capital of the country. However, despite a proliferation of
local laboratories (and an increase in raids on these laboratories),
admissions to our center for PCP psychosis began a slow but steady
decline. At the same time, experienced drug users presenting for
treatment of other drug abuse problem began referring to PCP as
a drug to avoid "because it makes people crazy." Meanwhile, the
suburbs began experiencing noticeable increases in the incidence
of PCP psychoses.
PCP presently remains the major drug of abuse in the Washington
Metropolitan Area. This situation prevails despite a recent wave
of local media publicity about its adverse effects.
DEFINITION
The PCP psychosis may be defined as a schizophreniform psychosis
which occurs in some individuals after phencyclidine use and
which persists for more than a day. The psychosis may last for
days or weeks despite abstinence, and it characteristically be-
comes more severe during the first few days of its course.
The PCP psychosis is characterized by the appearance of the cardi-
nal signs of schizophrenia and unpredictable aggressive or with-
drawn behavior. Characteristically, there is autistic and delu-
sional thinking, commonly including global paranoia, delusions
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of superhuman strength and invulnerability, as well as delusions
of persecution and grandiosity. A formal thought disorder, with
loosening of associations, blocking and auditory hallucinations
can be demonstrated. Affect is generally blunted, with periods
of suspiciousness often alternating with extreme anger or terror.
Patients are ambivalent and unpredictable even toward their close
friends and relatives.
Behavior is extremely unpredictable. These patients may be re-
luctantly cooperative one minute and violently assaultive the
next. Some carry lethal weapons to protect themselves from
their imagined persecutors. Bystanders have often been furiously,
unexpectedly, and unremittingly attacked without provocation, be-
cause the psychosis may include both extreme global paranoia and
delusions of superhuman strength.
REVIEW
PCP was originally developed in the 1940's by Parke, Davis & Co.
as an intravenous general anesthetic under the trade name "Sernyl."
Animal trials demonstrated very high levels of general anesthesia
(Chen et al. 1959). Lower doses produced a cataleptic state, and
still lower doses a tranquilized state during which fingers could
be inserted in wild animals' mouths with impunity (Davies and
Beech 1960). PCP was later used to tranquilize wild animals for
handling (Domino 1964), and it is still available for veterinary
use (Reed and Kane 1972).
Initial trials with humans were undertaken with the expectation
that PCP would have great promise for surgical anesthesia. As
an anesthetic, it fulfilled all expectations until the patients
woke up: one-sixth of the original group were severely psychotic,
but only for several hours. Their behavior was described as ex-
tremely agitated and bizarre, with echolalia and logorrhea as
prominent symptoms (Greifenstein et al. 1958). Significantly,
this psychotic reaction was most common in young or middle aged
males (Johnstone 1960).
Because of these severe postoperative reactions, the focus of in-
vestigation of PCP in humans shifted from its possible use as an
anesthetic  to its utility for producing model psychoses. The drug
was given to "normal volunteers" whose psychoses were documented
in an eruption of papers which lasted until 1965, when Parke-
Davis withdrew PCP from experimental use in humans (Reed and Kane
1972).
The major finding of these studies was that PCP had no equal in
its ability to produce brief psychoses nearly indistinguishable
from schizophrenia (Rosenbaum et al. 1959). Generally, the psy-
choses began immediately after infusion of the drug (Davies and
Beech 1960), lasted about two hours, and were characterized by
changes in body-image, thought disorders, estrangement, autism,
and occasional catatonia (Luby et al 1959). Subjects reported
feeling numb, had great difficulty differentiating between
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themselves and their surroundings, and complained afterward of
feeling extremely isolated and apathetic (Bakker and Amini 1961).
Of particular interest was the observation that these volunteers
often became violently paranoid while acutely psychotic.
Other workers who compared PCP is mescaline and LSD commented on
the ego-alien quality of the psychoses (Dan et al. 1961). Pre-
occupation with death and fear of death was common while under
the influence of the drug, and it had an impressive ability to
loosen up these subjects! unconscious conflicts.
Although these studies agreed that PCP can produce schizophrenia
on demand in "normal volunteers," the psychoses were limited to
a maximum of several hours. By contrast, when Luby gave PCP to
four hospitalized chronic schizophrenics, the results were much
more severe (Luby et al. 1959). "It was as though in these pa-
tients, the acute phase of their illness had been reinstated."
They became nearly unmanageable in an inpatient setting, not for
several hours, but for six weeks. Other observers noted that
PCP's effects on schizophrenics are exactly the opposite of LSD's,
since schizophrenics are considerably more resistant than "normals"
to that drug.
The literature on PCP in humans therefore describes two related
but distinct psychotic effects:
A schizophrenic syndrome lasting several hours in "normals."
An extreme exacerbation of their psychoses lasting up to 6
weeks in chronic schizophrenics.
The psychoses we have seen seem to fall between these categories.
Although our patients had not been hospitalized before, lacked
prior psychiatric histories, and were living in the community,
their psychoses were longer and more severe than those described
in "normal volunteers," but shorter than those described in
schizophrenics: yet they seemed to resolve without sequelae.
METHOD
To describe the clinical aspects of this syndrome more precisely,
we selected for study a group of PCP users in the following way:
We screened the 200 inpatient admissions to a single catchment
admission ward in the CMHC between July 1973 and June 1974, which
approximated the epidemic's time-frame. The records of all pa-
tients who were psychotic on admission or had a history of drug
use were examined for an explicit history of exclusive PCP use
during the two months before admission. After applying these
selection criteria, we were left with 11 men.
These selection criteria resulted in the exclusion of about two-
thirds of PCP-related admissions. These exclusions were all on
the basis of multiple drug-use, and were made in order to limit
the drug effects to those of PCP as much as possible. The
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following observations were assembled from the patients' charts,
nursing notes, ward logs, and shift reports.
CLINICAL COURSE
The course of the treated psychosis was found to consist of three
distinguishable phases of approximately equal length over the
course of an average two-week hospitalization: The initial phase
is characterized by the violent, psychotic behavior described
earlier, and this persists for an average of five days. During
the second phase, behavior is more controlled, but patients remain
restless and unpredictable for approximately five more days. The
final phase lasts about four days and is characterized by rapid
personality reintegration and rapid disappearance of thought dis-
orders and paranoia.
The majority of patients presenting with this entity were in their
late teens to mid-twenties, and the majority have been males.
most did not reach treatment until hours or days after the onset
of the psychosos, and did so during its initial phase. Chief com-
plaints ranged from mute posturing to "attacking everyone in
sight." The majority of these patients were brought to treatment
after their aggressive behavior exceded the limits tolerated by
family, friends and police. Those few patients who presented
themselves voluntarily were generally treatable on the outpatient
basis, and were neither as violent, as agitated, nor as psychotic
as those described here.
Where admission histories were obtained from these patients, they
generally included several days of confusion, paranoid ideation,
insomnia, and intermittent restlessness. However, a history of
phencyclidine use was not reliably obtainable on admission, and
some of the patients were initially misdiagnosed as schizophrenic.
Family numbers generally describe the pre-admission period as
characterized by continuous insomnia, tension, hyperactivity,
and intermittent, unexpected aggressive behavior, bizarre paranoid
delusions, ideas of reference, delusions of being controlled by
others, and grandiosity, but no fixed or systematized delusional
system.
Apart from the characteristic history of acute onset, and an ir-
regularly obtained history of using PCP in its current street
guises, the majority of these patients lacked prior psychiatric
histories and tended to be more independent of their families
than schizophrenics. Most were doing reasonably well in high
school, college, or work, although some did have poorer social
adjustments prior to the onset of their psychoses.
Other patients we have seen had prior admissions for schizophrenia
but experienced sudden psychotic reactivations after experiment-
ing with PCP. As a rule, these psychoses involved significantly
more violent and unpredictable behavior than the initial schizo-
phrenic psychoses.
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CLINICAL MANAGEMENT
Phencyclidine psychosis in the initial phase constitutes a psy-
chiatric emergency; hence, its early, acurate diagnosis is of
great importance. These patients are an immediate danger to
others merely on the basis of their misperceptions, paranoia and
hostility; and this threat is compounded by their confusion,
tendency toward violence, and the extreme unpredictability of
their behavior. They also constitute a danger to themselves not
only on the basis of impaired judgment and inability to care for
themselves, but also because their violent, threatening behavior
may provoke lethal countermeasure by those around them. Burns
has reported a case of PCP intoxication in which the patient was
shot and killed by police after not heeding their warnings. One
of our patients was hospitalized involuntarily on the basis of
"attacking everyone in sight," including the investigating police
officer, after a car accident.
Patients in the initial stages of the PCP psychosis almost in-
variably require inpatient psychiatric treatment. Furthermore,
these patients are poor candidates for voluntary treatment, first
because their paranoia makes them unlikely to sign on admission,
and second because their restlessness, ambivalence, confusion,
and unpredictability at this stage of the psychosis lead to a
high percentage of premature discharges against medical advice.
A factor which further militates against successfully continuing
treatment on a voluntary basis is admission under pressure from
family or friends. These patients often demand to leave as soon
as their relatives and friends return home. In our experience,
they cannot be dissuaded on the basis of rational discussion
during this phase of their illness. In one instance, a newly
admitted patient insisted on "fighting my way out" despite the
presence of sixteen male nursing staff, some of whom were injured
in the process of restraining him.
As discussed above, patients in the initial stage of the PCP
psychosis are dangerous, ambivalent, unpredictable, psychotic
and agitated. The immediate goals of treatment are therefore:
(1) Prevention of injury to the patient or others
(2) Assurance of continuing treatment
(3) Reduction of stimuli
(4) Amelioration of the psychosis
(5) Reduction of agitation
Treatment which meets the first three of these goals included
prompt inpatient hospitalization, preferably on an involuntary
Isolation in a bare, locked seclusion room with frequent
but unobtrusive observation is the treatment of choice. Seclusion
not only safegards other patients and staff but also calms the
patient through the reduction of stimuli which he can misperceive
as threatening. This applies particularly to the sight of other
people.
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Chlorpromazine is the only antipsychotic agent which meets the
last two goals: amelioration of the psychosis and sedation. Our
experience indicates that the use of nonsedating antipsychotic
agents prolongs the time these patients require seclusion, delays
improvement of the insomnia, and makes them more difficult for
staff to manage at mealtimes. Although the use of sedatives such
as diazepam and chlordiazepoxide has been suggested for the manage-
ment of acute phencyclidine intoxication, the dual treatment
goals of ameliorating the psychosis and reducing agitation make
the use of a single drug which meets both goals (chlorpromazine)
more attractive than the combination of a nonsedating antipsychotic
agent and a sedative.
Some authors have noted that chlorpromazine has not been shown
to antagonize the behavioral effects of PCP, and even enhances
some of then (Balster and Chait 1976). These conclusions, how-
ever, are based upon observations of animals intoxicated with
PCP who were given chlorpromazine. There is some doubt as to
whether these conclusions apply to the PCP psychosis as seen in
humans. First, behavioral changes persisting for days or weeks
after PCP intoxication have been reported only in humans. Thus
there is no animal model for the PCP psychosis. Second, the
experiments were performed chiefly on monkeys, and PCP's effects
on monkeys is tranquilization, not the psychotic agitation seen
in humans. Finally, chlorpromazine enhances the depressant
effect of PCP on these animals. Our experience has been that
chlorpromazine also acts as a depressant in our patients, and
that it antagonizes the persistent excited behavior seen in humans
with the PCP psychosis.
Once the possibility of anticholinergic drug intoxication has been
ruled out, the daily dose of chlorpromazine is increased by 200
to 400 milligrams per day from a starting dose of 400 milligrams
per day in divided doses. On the average, a daily dose of 1600
milligrams per day has been reached by the end of the initial
phase of the psychosis.
Behavior in seclusion during the initial phase is characterized
by continuing global paranoia, insomnia, anorexia, intermittent
agitation, and strong reactions to such stimuli as the presence
of staff during meal times. Patients may throw food about the
rooms or smear it on the walls. They are extremely suspicious of
food and oral medication, and may vacillate at length before re-
luctantly accepting it. It is helpful if the same staff members
bring the patient's food and medication from day to day.
This slow response to the most aggressive treatment is character-
istic of the phencyclidine psychosis and sets it apart from para-
noid schizophrenia, in which equally agitated patients respond
much more rapidly. Indeed, the sense of lack of progress engen-
dered by this slow treatment response was a factor leading to our
first investigation of these psychoses.
The transition from the initial to the mixed phase is characterized
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by several gradual changes which become prominent around the fifth
day of treatment: Although restless, the patient is no longer
hyperactive: he is less threatened by or overtly hostile to the
presence of others in the seclusion room. He is cooperative to
the extent of following simple concrete suggestions, and accepts
medication without suspicious vacillation. He can agree to se-
clude himself if he becomes upset.
Thus, although he is confused, still demonstrates a thought dis-
order, hallucinations, blocking, and paranoid ideation, he is
relatively calm and reasonable a good portion of the time and can
accept some degree of responsibility for and control of his be-
havior.
Despite these signs of progress, there are still intermittent
periods of gross paranoia, agitation, terror, and hyperactivity
alternating with quiet paranoid watchfulness. Affect remains
quite constricted, and inappropriate demands which are not met
immediately may explode in an unexpected flurry of violence.
Thus, patients in the second (mixed) phase are psychotic, paranoid,
unpredictable and intermittently dangerous, although they are no
longer as sensitive to stimuli.
The goals of treatment in this stage are:
(1) Prevention of injury
(2) Amelioration of the psychosis
(3) Reduction of paranoia
The first goal may be met by close and continuous monitoring of
behavior and a flexible seclusion policy aimed at helping the
patient voluntarily to seek seclusion at the first signs that he
is losing control. Operationally, a patient who sits near other
patients shows stability, whereas a patient who isolates himself
in a comer with his back to the wall, watching others suspicious-
ly, requires further isolation.
Clinical judgmemt will indicate whether further increases in
chlorpromazine dosage, or switching to an equipotent dose of a
nonsedating antipsychotic agent is indicated. Reestablishment of
sleep pattern may be aided by switching the entire dose to bed-
time. Participation in group and milieu therapy is helpful in
restoring the patient's confidence in his perceptions and in es-
tablishing rapport.
The third phase begins, on an average, during the tenth day of
hospitalization, and is characterized by rapid reintegration of
the premorbid personality and the development of insight into the
events leading to the hospitalization. There is often some amnesia
for the early events of the psychosis, but a history of the use
of phencyclidine prior to its onset is usually obtained during
this period. Patients may be converted to voluntary status during
this stage, and the groundwork for outpatient followup laid.
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Outpatient followup is helpful as patients are tapered off medica-
tion. In this connection, it is interesting to note that despite
repeated warnings against further phencyclidine use, a large pro-
portion of our patients use it at least one more time and return
for treatment of a second psychotic episode. Most of these pa-
tients explained using the drug again on the basis of "feeling
good" and wanting to see if they could "handle it."
Less encouraging is our finding that about one fourth of the
patients originally treated for phencyclidine psychoses return
within a year with schizophrenic psychoses in the absence of
drug use. By contrast, these later episodes have lacked the
characteristic violence of the phencyclidine-induced ones, and
they have been much more quickly responsive to antipsychotic
drugs; yet they have also left behind typical schizophrenic per-
sonality changes. Those patients who had experienced the longer
phencyclidine psychoses were generally the same ones who returned
later with schizophrenic ones.
Epidemics of drug abuse are nothing new in the United States.
The past two decades have seen epidemics of heroin, LSD and
several other drugs, while alcoholism has been endemic for cen-
turies. Our experience with several epidemics of PCP psychosis,
however, shows that widespread use of PCP in a community produces
manifestations which are not only different, but also more danger-
ous in some ways.
As noted earlier, our epidemic of PCP psychoses did not initially
seem related to drug abuse at all. Our community was experiencing
what appeared to be an epidemic of schizophrenia. This was un-
usual only because the rate of new cases of schizophrenia in a
given population does not fluctuate widely and because our com-
munity mental health center admits only patients who live in a
specific part of the city. Even with our present hindsight, we
cannot be certain about the exact time when patients with PCP
psychoses began appearing at the doors of our center. Until we
learned that those psychoses were drug-induced, these patients
were diagnosed and treated as schizophrenic.
Our experience indicates that although PCP abuse is spreading
to other parts of the country, its incidence, and particularly
that of the PCP psychosis, tends to be under-reported for a
number of reasons:
(1) The incidence of overdose, which is a common indicator of
drug abuse patterns in a community, tends to be lower for
PCP than the incidence of psychoses in areas where the drug
is smoked rather than taken internally.
(2) As we have noted, the presenting symptoms of the PCP psychosis
arc often indistinguishable from schizophrenia. This is com-
pounded by the amnesia induced by PCP. Where it is possible
to perform admission interviews on these patients, they usu-
ally do not recall taking the drug. Unless family or friends
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are aware of the patient's drug use, no history is obtained
and routine laboratory screens for drugs do not detect PCP.
Consequently, these patients are reported as cases of schizo-
phrenia, a label which may follow them for the rest of their
lives.
(3) As Burns and others have reported (Burns et al. 1975), some
PCP intoxications and psychoses result in violent or acci-
dental deaths. In the absence of a routine toxicologic
test for PCP, medical examiners may report such deaths as
accidents rather than as the consequences of drug use.
The only signs that PCP abuse is prevalent in a community may be
police seizures of the drug, an increase in violent and accidental
deaths, and an increase in the number of new cases of "schizo-
phrenia" admitted to mental hospitals. Unless public awareness
of the dangers of PCP is raised, these statistics may never come
together.
Another dimension of the PCP problem is the connection between
the PCP psychosis and schizophrenia. The connection between
schizophrenia and phencyclidine psychosis appears to go well be-
yond the phenomenological similarities. As reported by Luby, one
of phencyclidine's unique qualities is not only to mimic schizo-
phrenia, but also to reactivate schizophrenic psychoses. The
treatment of phencyclidine psychoses outlined in this paper is
also quite similar to that for extremely agitated schizophrenics.
Furthermore, our experience indicates that people whose sensitivity
to phencyclidine has been demonstrated by the development of a
psychosis will develop another psychosis upon reexposure to the
drug. Finally, there are some patients who have first experienced
phencyclidine psychoses and later have developed schizophrenia.
The PCP psychoses seen in our patients approached those reported
in chronic schizophrenics in terms of severity and duration: they
were far more severe than those reported in 'normals" in term of
both parameters. Yet none of the patients in our initial study
had experienced prior schizophrenic psychoses, and most had been
leading lives which demonstrated a fairly high level of social
integration.
One interpretation of this apparent paradox might be that our
patients literally do fall between the two groups reported in the
literature in some way: Those PCP users in the catchment area
with psychoses as brief as the ones experienced by "normal volun-
teers" would have improved before becoming inpatients and conse-
quently would not have been admitted. All the hospitalized chronic
schizophrenics in the catchment area were already on the CMHC's
inpatient units and were therefore not exposed to the drug.
Our results support this interpretation, since they show a varia-
tion in the time required for recovery in our eleven patients
which nearly spans the extremes reported in the literature. The
patient with the briefest stay went through the three phases
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described earlier in about three days. The longest-hospitalized
patient required about four weeks, and those in between tended to
be evenly distributed. Furthermore, those patients who later re-
turned and were rediagnosed as schizophrenics were at the upper
end of the distribution in terms of the duration and severity of
their psychoses. Thus, our study patients might represent that
part of the population of the catchment area which is significantly
more sensitive to PCP than "normals" but not so sensitive as
chronic schizophrenics.
These findings suggest several further conclusions: First, they
support those studies cited earlier which linked schizophrenia
and sensitivity to PCP. Second, they suggest that sensitivity to
the drug varies with the individual. Third, they suggest that
this sensitivity, rather than being extreme for schizophrenics and
mild for "normals," covers a wide sprectrum, with chronic schizo-
phrenics at one extreme, and "normals" at the other: the patients
studied here would therefore be distributed in between. Our
"schizophrenia epidemic" might therefore be interpreted as evidence
that the distinction between having or not having schizophrenia is
not clearcut; perhaps it implies that in a large population, a
graded continuum of "schizophrenia" exists between those who are
most "schizophrenic" and those who are least so.
Thus, our experience with phencyclidine psychoses not only supports
earlier finds that schizophrenics are highly sensitive to the
drug, but also suggests the existence of an individual sensitivity
to the drug, a sensitivity which is related to schizophrenia in
some way. The widespread use of phencyclidine in our catchment
area might even be viewed as a crude "screening test" for
"schizophrenicity." The ease with which phencyclidine may be
synthesized in large quantities on a clandestine bases raises the
possibility that this "screening test" may soon spread elsewhere.
Finally, because PCP was so well-studied in its days as a promis-
ing anesthetic, we can offer some other more speculative correla-
tions: Domino's research on monkeys with chronically implanted
electrodes found that PCP had two major central effects which
correlated with behavior: an enhancement of neocortical activity,
and a nearly complete suppression of evoked potentials in the
amygdala (Domino 1964). Delgado (1971) has found that electrical
stimulation of this part of the limbic system in monkeys inhibits
rage and enhances placidity. The studies suggest that an explana-
tion for the high incidence of violent and aggressive behavior
observed in our patients might include PCP's suppressant activity
on the amygdala.
Domino's work also suggests a neurophysiological mechanism which
might account for the persistence of our patients' psychoses long
after the drug was presumably metabolized: He found that PCP
selectively enhances the sensitivity of adrenergic and serotonergic
neurons to their neurotransmitters, and that this enhancement
persists long after the drug has been fully metabolized (Domino
1964). This explanation also supports recent studies implicating
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adrenergic and serotoninergic components of the limbic system in
the mechanism of schizophrenia.
If there is a solution to the problem of PCP abuse, that solution
is prevention. Practitioners must be alerted to the fact that
PCP is not just another hallucinogen, to be warned about in the
same breath as LSD. The public must be alerted to the fact that
PCP is far more dangerous to some individuals than the other
abused drugs. Medical examiners should consider toxicologic
analysis for PCP in all deaths resulting from drowings, falls
from high places, apparently avoidable accidents, and from attempts
to contain violently assaultive subjects. Psychiatric facilities
should investigate any sudden local increases in the incidence
of schizophrenia, and should routinely include PCP psychosis in
the differential diagnosis of all apparent schizophrenics in
whom the illness is of acute onset and characterized by violent
behavior, whether or not a history of drug abuse is obtained.
Policemen should be alerted to the unique dangers of dealing with
those individuals who have violent paranoid reactions to the
drug. And. finally, schizophrenic patients who have any leanings
towards drug experimentation should be warned that they are un-
usually sensitive to the adverse effects of PCP.
Further research is needed to determine whether there are more
effective treatment methods for the PCP psychosis than what has
been presented here. Research is also needed to document further
PCP's adverse effects, and the Drug Enforcement Administration
might consider whether this drug warrants reclassification under
Schedule I.
PCP use is spreading rapidly because of ignorance of its unpre-
dictable adverse effects among potential users, and because of the
ease with which the drug is illicitly manufactured. It is im-
portant to increase awareness of PCP and its effects, as we might
well anticipate a nationwide epidemic, an epidemic which, as far
as we know, may exist even now.
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Chapter 15
Long Term Treatment of
Adolescent PCP Abusers
Gerald G. DeAngelis, Ph.D., and Elliott Goldstein, M.A.
INTRODUCTION
The population described in this publication are residents in a
licensed, social rehabilitation facility, known as Pride House.
This 70 bed facility specializes in the treatment of adolescents
with mental health and substance abuse problems. Males and fe-
males between the ages of 14 and 22 years are accepted into the
program The mean age for the past two years has consistently
approximated 16.5 years.
Over the years Pride House has developed a reputation for offer-
ing services to "difficult to treat" adolescents. Basic problems
presented by these adolescents are as follows:
 Psychiatric illness such as depression, anxiety,
character disorders, suicidal ideation, and
schizophrenia.
Substance abuse: approximately 95 percent of the
client population are polydrug abusers who have
ingested many substances ranging from marihuana to
PCP and heroin. Some of these drugs have been in-
gested on a regular basis.
Criminal offenses including grand theft auto,
possession and dealing of drugs, pimping, prosti-
tuition, burglary, assault, running away, et
cetera.
Most clients are referred to Pride House through the Probation
and Social Welfare offices of Los Angeles County by a placement
order from the courts. Clients are also referred from the major-
ity of surrounding counties. In addition, there are a number of
private referrals from hospitals, practicing psychiatrists, and
psychologists in the area, as well as from local families. Most
of these clients have had social-psychological profiles done by
the referring institution's psychologist or psychiatrist. These
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profiles reveal that the majority come from broken homes. Approxi-
mately 78 percent of the total population come from single parent
families: 45 percent come from divorced families; in the other
33 percent a parent was lost through death. The remaining 22 per-
cent of the clients come from intact families.
Approximately 29 percent of the total population have been involved
in aberrant family sexual behavior, primarily in the form of incest.
This incestuous behavior is far more prevalent among the females
than the males. Approximately 60 percent of females who have en-
tered the program during the last six months report involvement in
incestuous relationships with either parents, grandparents, or
other members of the immediate family. To date, we have validated
23 percent of these reported incidents. The process of validation
is ongoing and will continue for some time. Verification is diffi-
cult for clients who have left the program.
The majority of adolescents served by this program have been phys-
ically or emotionally battered and would qualify as "battered"
children. Most are emotionally and educationally handicapped and
have little opportunity to experience normal maturation and growth.
TREATMENT: GENERAL PROGRAM SUMMARY
Treatment of drug abusers in the context of an adolescent rehabili-
tation center has been specifically defined at Pride House. An
initial prospect interview is done with each client. After this
pre-intake interview is canpleted, the client's suitability for
the program is evaluated. If the client is deemed suitable for
Pride House, a lengthy diagnostic intake process is initiated.
During the initial interview, a detailed personal, psychiatric,
drug, family and social history is taken. An initial treatment plan
is then formulated from these intake profiles. The treatment plan
discusses existing relationships between the presenting symptoms and
underlying psychopathology, and choice of drugs and the extent of
drug use. This is especially important when the staff feels the
client has chosen drugs as the major palliative of internal and/or
external emotional conflicts. A basic assumption is that most
adolescents coming to us are troubled and have chosen the use of
drugs as the major vehicle to resolve these conflicts.
Substance abuse is seldom discussed during the course of therapy.
In fact, the discussion of drug abuse during the therapeutic pro-
cess is generally proscribed as antitherapeutic and distracting.
This parallels our approach in working with all special problem
areas. For instance, with homosexual clients the discussion of
sexual activity is usually proscribed except in specific therapy
sessions dealing with the sexuality of the client (Wellisch, De
Angelis, and Paternite 1978). Our research has shown that young-
sters will usually use their major behavior problem as the dis-
cussion focus in order to prevent the therapist from dealing with
the underlying issues causal to their abnormal behavior.
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Long term treatment includes a regimen of individual and group
therapy, as well as family therapy. There is an educational pro-
gram at Pride House which includes remedial mathematics, reading,
tutoring and study for the California Proficiency and GED examina-
tions. Pride House provides a complete and intense recreational
program for the male population. Currently, the recreation program
for females is not as sophisticated. The average number of hours
of therapy per client each month is 36. Furthermore, 6.5 recrea-
tional sessions per resident per month are provided. In addition,
40-60 hours of teaching and tutoring activities per resident per
month are available, excluding study time. On the whole, the milieu
is totally supportive with little, if any, classical confrontation
used. Generally, therapeutic approaches include Gestalt, Trans-
actional Analysis, psychotherapy, and other supportive, humanistic,
therapeutic regimes.
METHODOLGY
Initial investigation into the use of PCP in clients who entered
Pride House during the last 6 months (from September 1977 through
February 1978) identified approximately 50 percent of the popula-
tion as either chronic or occasional PCP users. Chronic users were
defined as those using at least 3-4 times a week and occasional
users were identified as those using PCP once a week or less. This
definition may seem arbitrary considering the powerful effects of
PCP. However, our definition is similar to chronic PCP use as des-
cribed by Fauman and Fauman (1978) who report use ranging from
2.5-5.8 days per week. This paper will report the results of our
work with these PCP users/abusers.
Prospect and intake evaluation forms for 87 clients were analyzed
in order to identify all PCP users in a 6-month cohort. Forty-five
(45) clients representing 52 percent of the study cohort were
identified as users of PCP. Clinical records of these 45 individ-
uals were further analyzed to ascertain behavioral, familial, sexual,
psychological, and other characteristics. The data collection form
used is shown as appendix I.
After the data were collected, the information was sent to the
Health Care Delivery Service Evaluation Research Unit. There, the
data were validated and tallied, tabulated and analyzed as percent-
age differences. Results are provided in tables 1 through 7 and are
discussed below.
RESULTS
Table 1 compares the demographic variables for (1) the occasional
PCP user, (2) the chronic PCP user, and (3) the general Pride House
population. In terms of sex, approximately fifty-eight percent
(58.4 percent) of the general population are males as compared to
78.3 percent and 31.8 percent of the occasional and chronic PCP
users, respectively. Females represent the majority of chronic PCP
abusers (68.2 percent) while they are a minority of the general
population (41.6 percent).
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Only slight racial differences are seen a percentages of
Caucasian, black and Hispanic chronic and occasional PCP users.
However, there are greater percentages of Caucasians in the two
groups of PCP users thah in the general Pride House population.
Eighty-seven percent of the occasional users and 81.8 percent of
the chronic users are Caucasians, as compared to 64.7 percent of
the general population who were Caucasians.
Racial differences for degree of PCP use proved to be statistically
insignificant (X2 = 0.28; d.f. = 2; .90 < p < .80). However, the
observed sex difference in PCP use proved to be statistically sig-
nificant (X2 = 9.82: d.f. = 1; p < .01). Females represented a
greater proportion than males of the chronic PCP users. Mean age
is approximately the same for the two PCP users groups and the
general population. Only slight variations are observed in the
age ranges for the three groups.
Table 2 describes frequency of PCP use for the sample. The largest
proportion of occasional users ingested PCP once per week. Usage
ranging from twice to several times month accounted for 34.8 per-
cent of the occasional users. Approximately nine percent of the
occasional users ingested PCP only once per month.
The majority of chronic users (61.9 percent) ingested PCP on a daily
basis. About thirty-eight percent used PCP three to four times per
week.
Equally significant is the extremely high daily use of drugs other
than PCP in both groups. Approximately 86 percent and 91 percent
of both the occasional and chronic use groups, respectively, in-
gested a variety of drugs on a daily basis. Therefore, it is safe
to assume that both groups are chronic drug abusers, with one group
supplementing its other daily drug usewithheavy PCP usage.
While occasional and chronic users show about the same percentages
displaying depressive symptomatologies (table 3), they differ quite
drastically in other clinically observed behaviors. Comparisons in
terms of anxiety show that 44.8 percent of the occasional users
exhibited anxiety symptoms as compared to only 7.7 percent of the
chronic users. On the other hand, 30.7 percent of the chronic
users were described as having character disorders as compared to
3.4 percent of the occasional users. Interestingly, while clinical
management of chronic PCP users is similar to that of schizophrenic
adolescents, neither the occasional nor the chronic users were
diagnosed as being schizophrenic. Accurate diagnosis of this ill-
ness is even more difficult in a drug abusing population. In the
past, Pride House has treated adolescents who have been diagnosed
as schizophrenic. None of the present cohort displayed symptoms
or behaviors which would result in such a diagnosis.
In other work with this population, we have uncovered relatively
large numbers of cases wherein clients have been sexually molested
or violated (incest). Approximately 32 percent of chronic PCP
users report sexual molestation and/or incest. In the occasional
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FREQUENCY OF USE
TABLE 3
PSYCHIATRIC DIAGNOSES
PCP use group this was universally absent. Chi square (x2) was
calculated and the differences between the two groups were found
to be significant (X2 = 8.67; d.f. = 1; p < .01).
We investigated the behavior of PCP abusers within the treatment
milieu. This was important in light of the common belief that PCP
abusers are hostile and disruptive. Table 4 verifies this belief
to some extent. Surprisingly, the occasional users of PCP acted
out in an angry or belligerent manner far more often than the
chronic users. Sexual acting out was much more prevalent for the
chronic PCP user (30.8 percent) than for the occasional PCP users
(12 percent). Hostility was displayed at about the same level in
both groups, but the chronic users reported themselves as delusion-
al, while occasional users did not (X2 = 7.46; d.f. = 3; < .10
p < .05).
Table 5 shows that chronic PCP users were more likely to commit
rule infractions based on sexual conduct(49.9 percent) than oc-
casional PCP users (39.0 percent). On the other hand, occasional
PCP users were more likely to commit drug-taking infractions (73.7
percent) or violent acts (12.9 percent) than chronic users. Chronic
users violated drug rules 68.2 percent of the time and commited
acts of violence only 4.5 percent of the time. It should be noted
that violent behavior is defined as extreme verbal abuse as well as
such activities as destruction of property and vandalism. No vio-
lent acts against persons have been recorded in either group.
For both occasional and chronic users, drug-taking is the most
frequently occuring rule infraction. Acts of violence are the
least frequently occurring infraction.
Table 6 verifies the data presented in the previous table. When
all rule infractions are totalled it can be seen that drug-taking
predominates in both the occasional and chronic use groups. Sexual
misbehavior is the second most frequent rule infraction, and vio-
lent behavior is the least frequent.
We also investigated length of stay or program retention rate of
chronic, occasional and non PCP-using residents. Table 7 demon-
strates that chronic PCP abusers remain in the program longer,on
the average, than the other groups. No statistically significant
difference was found when length of stay for occasional users was
compared to chronic users. On the other hand, statistical signifi-
cance was achieved when length of stay of all PCP users was compared
to an equal nunber of non PCP users (t = 2.29; d.f. - 74; p < .05).
T-tests were computed after excluding members of both comparison
groups whose length of stay was far beyond the standard deviations
(n = 39 PCP users; n = 37 non PCP users). Nevertheless, it should
be noted when all data for length of stay were included in
the computations, the computed t-value was 1.98.
DISCUSSION
It is difficult to compare our results with published reports of
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TABLE 4
TYPE OF BEHAVIOR DISPLAYED
TABLE 5
FREQUENCY OF ABERRANT BEHAVIORS
TABLE 6
OCCURRENCE OF PROGRAM RULE INFRACTIONS
TABLE 7
LENGTH OF STAY COMPARISON
(a) t-tests between all PCP vs. non PCP users done initially included extremes of stay. Corrected
t-tests were performed eliminating 3 lower end 2,3,3,6,13,13 and 2 upper end 225,226,276,316 lengths
of stay for each group. Both ends far exceeded standard deviations and high end represents lengths
of stay longer than present study period. When all of these days are included the t-test was as
follows: t=98; d.f.=84; 0.10<p<0.05; a t of 1.99 would have been significant at the 0.05 level.
PCP use. Most of the previous studies used "ever used" and "never
used" categories, whereas we chose "occasional" and "chronic" use
categories. Lerner and Burns (1978) and Fauman and Fauman (1978)
reported that males constituted the majority of their samples
(68.7 percent and 80.0 percent respectively). In our study this is
true only of the occasional user. Chronic use was much more prev-
alent for females.
In terms of race, the Faumans report the highest use for blacks.
Lerner found that Caucasians predominated in his work. Our find-
ings parallel Lerner's, since Caucasians predominate in our popula-
tion. This my be due to our treatment program's physical location
in a suburb of Los Angeles that is predominantly Caucasian. Most
referrals to our program over the last four years have been Cau-
casian youth. No significant age differences exist between the
population we have studied and those studied by Lerner and Burns
and the Faumans.
Approximately fifty-two percent (51.7 percent) of our entire sample
cohort (87) reported use of PCP. The Faumans report 66.6 percent
of the treatment population which they studied used PCP, while
Lerner and Burns report 31.8 percent use in their study. Our
similarity to the Faumans' results may be due to similar residential
treatment program milieus, whereas Lerner and Burns'data are taken
from DAWN and the National Youth Polydrug study.
Approximately forty-nine percent (48.8 percent) of out study cohort
who used PCP were classified as chronic users. Lerner and Burns
(1978) reported 35.6 percent of PCP users in their study had used
PCP with the same frequency.
Both the chronic and occasional users reported high usage of drugs
other than PCP. This is not surprising when the following are con-
sidered: (1) These clients are in a social rehabilitation program
known to treat all types of drug abuse, and (2) polydrug combina-
tion with the increased psychopathology observed in the polydrug
abuser (Bienvenuto and Bourne 1975; Raynes, Patch, and Cohen 1975)
my help to explain the high percentage of reported anxiety, de-
pression and character disorders found in our study population.
These clients may be ingesting drugs in an effort to reduce the
psychic and emtional distress which they are experiencing.
Of foremost importance is that we have diagnosed little or no
schizophrenia in this population. Perhaps this is due to our
unwillingness to label a child as schizophrenic simply because his
or her behavior does hot fit the norm. This may account for the
little difficulty we have had in working with PCP-abusing youth.
A significantly larger proportion of chronic PCP abusers in our
sample report sexual molestation and/or incest. We have had no
explanation for this other than to offer the possibility that. PCP
provides a drug-induced respite from the emotional pain and anger
suffered by most of our adolescent clients who have had these ex-
periences. Perhaps PCP intoxication controls this rage at some
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stage of the intoxication. It may be that as the drug effects
diminish, the suppressed anger may surface in the form of overt
hostility, belligerence and verbal abuse which we witness. The
long term acting out observed with clients in residential treat-
ment settings may represent an extended and necessary catharsis
which offers an excellent opportunity for therapeutic intervention.
Although differences were seen in the types of behavior displayed
by PCP users, statistical differences were not achieved when the
groups were compared. Both groups act out; the type of acting out
may be influenced by drug states or therapeutic milieu. We have
no way to determine this at the present time.
The fact that chronic PCP abusers stay in treatment longer than
non PCP or occasional PCP users, is probably the most important
practical finding of this study. If one assumes that chronic users
are more in need of treatment than other types of drug users,then
length of stay is an important therapeutic variable, since thera-
peutic intervention takes time to have effect. Whether or not
chronic abusers stay longer because they are more troubled and
realize they need help, or whether our therapeutic interventions
are effective with this group is difficult to detemine. Perhaps
it is safe to say that were our therapeutic endeavors not effective,
the more troubled PCP abusers would leave. The increased length
of stay may indicate that whatever conflict resolutions were pro-
vided by PCP use are provided by the treatment staff. This
will be discussed in more detail below.
TREATMENT CONSIDERATIONS
Occasional users of PCP having no history of long term effects are
treated similarly to all other clients in the program admitted for
substance abuse treatment. In effect, staff and client expectations
are the same for the occasional PCP abuser as for the general popu-
lation. With the exepction noted below, all clients participate
in all normal therapeutic activities, taking responsibility in the
program, attend school, et cetera. Therapeutic responses are dic-
tated by the client's present behavior, combined with our knowledge
and understanding of the child's family and personal history. The
client's abuse of PCP at one point in his/her life is considered
fairly irrelevant within the context of the milieu.
As shown in tables 1, 3, 4, 5, and 6, clinical differences exist
in psychiatric diagnoses, acting out behaviors and program rule
infractions. These differences do not necessarily mean that clini-
cal interventions in the PCP-using group need be dramatically dif-
ferent than those in non PCP-using groups of adolescents which we
treat. Anxiety and depression, commonly seen in our general popu-
lation, are treated similarly to the same states seen in PCP abusers.
Program clinicians target their efforts at the behavior and symptoms
rather than on a substance(PCP)which may or may not be the cause
of these reactions. As shown in table 4, occasional users are often
angry and/or belligerent. Clinically this is handled as is any
angry confrontation with a client. However, in the PCP population
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staff is more aware of the frequency of an angry reaction and is
prepared for this response. It is important that staff anticipate
these angry outbursts in order to take control and demonstrate an
understanding of the situation.
Both the occasional and chronic PCP users have little difficulty
integrating into the general population and responding to treat-
ment. As mentioned, PCP users stay in treatment longer than non-
users. (Certain clinical differences are observed between chronic
PCP users, occasional users, and the general population. The
treatment of chronic PCP abusers coming into Pride House with his-
tories of adverse drug reactions is somewhat different from the
treatment of the general population. In many ways, treament simu-
lates our work with schizophrenic and other very troubled young-
sters.
Basically, PCP abusers who enter the program and are past the
acute intoxication phase are treated as follows:
Minimal confrontation or hostility-provoking be-
havior cm the part of staff or other clients is
the rule.
Particular care is taken to provide PCP users a
non-threatening environment in which they can
begin to feel comfortable.
Minimal involvemnt in specific therapeutic inter-
vention is expected immediately.
Many PCP users display flattened affect, depression, agitation,
hostility and belligerence. They are usually unable to cope with
the demands and expectations of a structured, intensive therapy
regimen. With these clients, staff expectations are drastically
lower. This means that the PCP abuser is not expected to partici-
pate extensively in either group or individual therapy, school or
recreation programs. It is understood that he/she may be bellig-
erent and refractory to treatment. Hostility, agitation, and de-
pression, as well as memory loss and motor impairment are con-
sidered part of the pathology to be treated, rather than major
impeding problem. A program of support and reinforcement is
provided both within the milieu and in therapy.
Drug therapy, either with the administration of tricyclic anti-
depressants or tricyclic and other antipsychotic agents is minimal.
Use of these agents has not been shown to be effective and caution
has been urged in their application in treating PCP abusing clients
(Varippa 1977).
Certain acting out behavior is tolerated in these clients, more so
than in clients having no history of PCP abuse. Generally, acting
out behavior takes the form of extreme verbal abuse. We assume
that these outbursts of anger and hostility will occur and we work
with them, rather than prohibit the behavior and thereby exacerbate
the situation.
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Finally, another aspect of dealing with PCP abusers is a remedial
education and tutoring program. It is therapeutic to help a
young client understand that any existing memory loss and/or motor
impairment is most likely a drug related event and will usually
reverse itself over a period of time. At this point, careful
tutoring and handling by the education staff are very important.
In this way, the client is actually engaged in a therapeutic pro-
cess (school), yet not expected to do "therapy." Individual at-
tention provided by the educational tutors, coupled with the edu-
cational testing and the learning diagnostician's work, give the
client a sense that he/she will soon be able to function normally.
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APPENDIX I
APPENDIX I (continued)
Chapter 16
Phencyclidine, Criminal Behavior, and the
Defense of Diminished Capacity
Ronald K. Siegel, Ph.D.
“The cause of the world-wide consumption of hashish, opium, wine,
and tobacco,” wrote Leo Tolstoy (1890), “lies not in the taste,
nor in any pleasure, recreation, or mirth they afford, but
simply in man’s need to hide from himself the demands of consci-
ence.” Tolstoy argued that men “stupefy” themselves with drugs
that make them commit actions contrary to conscience. He cited
robbery, rape, and murder as examples.
Modern courtrooms in the United States are becoming increasingly
plagued by examples of such drug related acts, acts which would
have surely outraged Tolstoy’s 19th Century moralism and support-
ed his notion that man is an “animal being.” The magical elixir
which is usually credited with this transformation of man from
a “spiritual being” to an “animal being” is phencyclidine (PCP).
Perhaps more than any other drug, with the exception of alcohol,
PCP is becoming increasingly conspicuous in both criminal be-
havior and in the criminal defense of diminished capacity. Di-
minished capacity itself is a “defense in which criminal culpa-
bility is gauged upon various mental states. If the defense is
proven, it can reduce the degree of the crime or even result in
an acquittal” (Schwab 1976).
A young man smokes some PCP and proceeds to rob a gas station
at gunpoint. A juvenile smokes PCP and rapes his baby sister.
A witness to a fatal stabbing is admittedly intoxicated with PCP
but claims to remember clearly all the events. A witness to
another murder claims to be intoxicated with PCP and amnesic
for most of that time. A police officer encounters a young man
who may have ingested an analog of PCP. The man, naked and un-
armed, reportedly becomes combative and assaultive and is shot
to death by the officer. Two lovers are smoking PCP alone in
their bedroom. Within a few minutes one is bleeding to death
from a knife wound which may or may not have been self-inflicted.
A middle-aged woman takes some cocaine which has been adulterated
with PCP and tries to rob a bank armed only with a broom which
she manipulates as if it were a gun. In these and many similar
cases the law enforcement and judicial systems are turning more
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and more to expert witnesses in order to help clarify the effects
of PCP on behavior. The process is rapidly defining a new field:
forensic psychopharmacology. Forensic psychopharmacology can be
considered the application of the study of drugs and behavior to
legal issues. The present chapter attempts to discuss aspects
of PCP-induced behavior which can be applied to legal issues.
DRUGS AS SCAPEGOATS AND THE ORIGINS OF DIMINISHED CAPACITY
Psychopharmacology is essentially the study of drugs and behavior.
The underlying lay assumption is that drugs inevitably affect
behavior. A corollary is that abnormalities in behavior often
may be blamed on drugs. In his critique of the drug abuse field,
psychiatrist Thomas Szasz (1974) noted that this assumption has
led to the persecution (and prosecution) of drugs, drug users,
and drug dealers throughout history. Indeed, even in their lin-
guistic roots drugs have been associated with scapegoats. The
pharmakos in ancient Greece was the human who was sacrificed as
a scapegoat in primitive ceremonies. Later, when human sacri-
fice was abandoned in Greece, the term pharmakoi came to mean
“human medicine” and was applied to poisons and drugs. The
classic association of drug-induced altered states of consciousness
and diminished capacity was most dramatically portrayed through-
out the tragedies of fifth century Greek playwrights. The associ-
ation of drugs with scapegoats has been with us ever since those
times.
In Euripides’ The Bacchae, Agave, the bacchante queen, kills her
son, Pentheus,in an altered state which was probably a combina-
tion of alcohol intoxication and religious hysteria (Embo-
den 1977). Agave believes she has killed a lion as a scapegoat,
and the murder itself is perhaps one of the most gruesome in
the annals of psychopharmacology, rivaling even the Tate-
LaBianca murders of the present century:
But she was foaming at the mouth, and her crazed eyes
rolling with frenzy. She was mad, stark mad,
possessed by Bacchus. Ignoring his cries of pity,
she seized his left arm at the wrist; then, planting
her foot upon his chest, she pulled, wrenching away
the arm at the shoulder--not by her own strength,
for the god had put inhuman power in her hands.
Ino, meanwhile, on the other side, was scratching off
his flesh. Then Autonoë and the whole horde
of Bacchae swarmed upon him. Shouts everywhere,
he screamed with what little breath was left,
they shrieking in triumph. One tore off an arm,
another a foot still warm in its shoe. His ribs
were clawed clean of flesh and every hand
was smeared with blood as they played ball with scraps
of Pentheus’ body (Euripides, p.204).
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Emerging from that intoxicated state, Agave realizes that what
she has killed is not a lion but her son. Agave confused the
reality in which she confronted a lion with the reality in
which she confronted her son. Crucial to an understanding of
the lay are the Greek concepts of sophia (meaning wisdom,
skill , expertise) and amathia (meaning uncontrolled violence).
Specifically, sophia implies a firm awareness of one’s own
actions, judgements, and morals. Conversely, amathia  means an
uncontrollable ignorance of one’s actions and capacities,
someone prone to violence, harshness, and brutality. In its
essence, Euripides’ play tries the case on the merits of di-
minished capacity (amathia) versus premeditation and intent
(sophia). A modern day defense attorney might argue that Agave
was diminished in capacity as a result of both the alcohol and
religious intoxication. A prosecutor might successfully argue
(and win a first degree murder conviction) that the killing was
motivated, since Pentheus bitterly opposed Agave’s involvement
in Dionysian rites and Agave knew it all along. However, the
jury at the time--the Greek chorus in the play--finds Pentheus
guilty of amathia because he want only and violently refused to
accept the necessity of the Dionysian rites (wine, dance, and
religious ecstasy), thus committing an immoral act against a
god Accordingly, Agave is declared sophia in supporting the
sacrificial rites. While the judge, Dionysus himself (who
could be challenged in a modern courtroom for obvious prejudice),
finds the murder justified, he banishes Agave from the city
forever. The verdict of the play is probably the equivalent of
voluntary manslaughter with absence of malice due to diminished
capacity. Thus concluded history’s first diminished capacity
trial.
INTOXICATION AND BEHAVIOR
The case discussed above is important in emphasizing the numerous
variables that can influence drug-induced intoxication and be-
havior. Although the definition of the word intoxication (which
comes from the Latin intoxicatio, meaning poisoning or inebria-
tion) is far from precise, one that is generally accepted in
pharmacology and medicine is “the abnormal state induced by a
chemical agent....excitement or exhilaration beyond self-control.”
Pollack (1976) defines such intoxication for legal purposes as:
a temporary state of mental impairment due to drugs
or alcohol in which the alcohol or drug influence
creates a mental impairment that makes the person un-
able to form the specific intent for the crime charged
against him, although the defendant committed an illegal
act at the time.... Intoxication is thus a clinical
condition that is defined by clinical signs and symp-
toms, ranging from mild, moderate, to severe, with
coma and eventual death (p. 258).
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This clinical condition can be modified by a wide variety of
variables, including both drug variables and user variables.
Among the important drug variables are: preparation and purity,
dose, route of administration, rate of ingestion of the drug,
rate of absorption, site of action, rate of metabolism, rate
of elimination, mechanism of action? and others. Among the
important user variables are: individual variability, age, sex,
weight, general state of health, medical history, drug history,
behavioral history, presence of other psychoactive agents
(prescription and nonprescription drugs), personality, psycho-
logical set (attitudes, expectations, etc.), setting (physical
environment and psychological state of others present), and
others. The more specific this information is, the more precise
can be the description of drug induced behaviors and the
stronger can be the opinion of the expert witness in court.
While a full understanding of these interactions is presently
restricted by limited knowledge about phencyclidine, the presence
of such a myriad of variables should temper a desire to simplify
behavior with labels such as sophia, amathia, “diminished cap-
acity," “criminal responsibility,” “legal insanity,” “mental
incompetency ,” “unconscious ,” “psychotic ," “loaded,” “dusted,”
“toasted,” “stoned,” “wasted,” or even “high.”
PHENCYCLIDINE AND BEHAVIOR
The nature of phencyclidine-induced effects on behavior are dis-
cussed in several sections elsewhere in this volume. The nature
and phenomenology of phencyclidine intoxication are also described
more fully in another chapter (see “Phencyclidine and Ketamine
Intoxication: A Study of Pour Populations of Recreational Users,"
by Siegel, this volume). Only those behaviors which are char-
acteristic of intoxication for purposes of diminished capacity
defenses or for purposes of understanding criminal behavior are
discussed here.
While phencyclidine remains medically classified as an anesthetic
agent, it is well known that intoxication with the drug can be
marked by excitatory, sedative, hallucinatory, catatonic, and
even seizure behaviors. These apparently paradoxical reactions
have prompted numerous investigators to re-examine the effects
of phencyclidine on the brain and behavior. In an important
series of preclinical studies with animals, Winters and his co-
workers (e.g., Winters et al. 1967) have demonstrated that there
is a progression of effects following increasing doses and these
differ considerably from the modes of action of most anesthetics
but compare more closely with most hallucinogens. like LSD. This
progression forms a continuum ranging from an awake state, to
a hyperactive aroused state, to a state of inappropriate move-
ments, to a state of unresponsive behavior, to generalized sei-
zures, and to death. In animal studies with cats these states
are marked by changes in both behavior and electroencephalograms
(EEGS). The progression is described in the following way:
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The initial effects of administration of phen-
cyclidine consisted of cortical desynchroniza-
tion and development of hippocampal theta waves.
After 5 to 6 minutes, intermittent and then con-
tinuous hypersynchronous bursts appeared ac-
companied by inappropriate movements of the
head. Within 15 minutes an increase of ampli-
tude and a decrease of frequency of the hyper-
synchrony, separated by short periods of desyn-
chronization, were observed. At this time the
animal (cat) was crouched, unresponsive to
stimulations, had a fixed gaze, pupillary
dilation, salivation and increased muscle tone.
Desynchronization became more prominent and
finally a generalized high frequency high vol-
tage seizure pattern appeared which was accom-
panied initially by limb twitching, then gen-
eralized convulsions (Winters et al.,  1967, p. 75) .
In man, there are four basic types of behavioral responses to
these excitatory states of the central nervous system. Initial-
ly the user becomes excited in terms of motor activity and
this is usually accompanied by mood elevation. Secondly, as
excitation increases, the mood becomes euphoric but the motor
behavior becomes ataxic. Thirdly, further excitation produces
bizarre and inappropriate motor movements coupled with subjec-
tive reports of hallucinatory intoxication. Fourthly, a state
of epileptoid activity is reached which is marked by myocionic
jerks and generalized seizures. At this point the user may
appear cataleptic and subsequently report amnesia for the
experiences.
Typically, when PCP is smoked, the onset of symptoms appear with-
in 2 to 5 minutes (Burns and Lerner 1976). These authors also
report that a peak, plateau, or “high” period ensues for 15 to
30 minutes followed by a “loaded” period of 4 to 6 hours. Re-
covery time to normal behavior may take from 24 to 72 hours or
longer. Indeed, some cases may require as long as 15 days for
behavior to become alert, oriented and normal. During such in-
toxications, PCP can be detected in blood or urine but detected
levels are not necessarily associated with specific behavioral
states (Reynolds 1976). Burns and Lerner (1976) and Siegel
(this volume) offer numerous clinical features of both the acute
confusional state or delirium (low to moderate doses) and the
state of stupor or coma (high doses). Some of these features
are discussed in the sections which follow.
CLINICAL ENCOUNTERS WITH INTOXICATED INDIVIDUALS
Typically, the vital signs of the PCP-intoxicated person would
indicate normal or slightly increased respiratory rate, increas-
ed blood pressure, increased pulse, and normal or slightly in-
creased temperature. In terms of the motor system, the gait
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may be grossly ataxic and the person may be unable to stand or
walk properly, perhaps due to increased muscle tone and rigidity.
The body movements may appear restless, repetitive, and often
facial grimacing is observed. High doses can produce “purpose-
less movements,” muscle tremors and twitching, and generalized
motor seizures which are unpredictable in frequency or duration.
Other features include: repeated episodes of vomiting (pro-
duced by the central action of the drug); increased salivation,
tearing, and perspiration; and increased discharge of mucus
from the nose, mouth, and throat.
With low doses or during early stages of high dose intoxication,
the person would initially appear responsive, awake, and cap-
able of responding to simple yes/no questions. Speech, however,
is commonly slurred (dysarthria). As intoxication progresses
through the continuum of excitation, verbal responses to yes/no
questions may be replaced by simple nodding or facial gestures.
This usually results from increased slurring which progresses to
stuttering and extreme difficulty in speaking properly. The
user may simply “give up” trying to verbalize, but this does
not necessarily imply attentional dysfunction. Indeed, sensa-
tion is heightened at this point, and the user may have increased
sensitivity to visual and auditory stimuli. Conversely, some
individuals may appear more talkative and communicative, but
this is rare. Individuals are usually disoriented in both time
and space and consequently may appear confused and even fearful,
especially if environmental stimuli are overly intrusive or
intense.
However, in deprived environments, such as dark and quiet rooms,
these clinical features may be absent. Since the brain is in a
state of hyperexcitability, it is not surprising to find that the
user will be unable to sleep or rest during acute intoxication.
The eyes remain open in low dose conditions (“stare” appearance)
and sometimes the upper eyelids droop due to the sympathetic
innervation induced by PCP. High doses may cause the eyes to
close but the user is still clinically awake, although s/he may
not respond to stimuli. Examination of the eyes may reveal
additional findings. Low doses have been characterized by an
inability to fixate, and the eyes may appear to gaze indepen-
dently at different points. Attempts to control and fixate the
vision may result in involuntary, abrupt, and rapid movements
or jerks of both eyes. High doses simply exaggerate these symp-
toms which have been described as “roving eye movements” and
“doll’s eye movements.” In both high and low dose intoxications,
intermittent horizontal and vertical nystagmus as well as a de-
creased or absent corneal reflex have been noted.
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POLICE ENCOUNTERS WITH INTOXICATED INDIVIDUALS
When encountering PCP-intoxicated individuals, law enforcement
officials frequently observe some of these characteristic
clinical features. Specifically, speech is usually described
as slurred, the gait is unsteady, and the eyes glassy, staring,
or blank. Consider the followed edited excerpts from the re-
ports of arresting officers:
Subject’s speech was slurred and at times subject
was unable to talk. Subject’s reactions were very
slow. In officer’s opinion the subject was under
the influence of a drug.
He was oblivious to all of the occurrences around
him, and walked about in a dazed condition. It was
the arresting officer’s opinion that the minor was
under the influence of a hallucinogenic drug,
possibly that of PCP.
Suspect looked in officer’s direction and immediately
tensed up. He stopped and his anns went stiff. As
officer exited his vehicle and approached suspect,
officer noted his breathing to be extremely heavy.
The suspect’s eyes bulged and he began to lick his
lips as he looked about numerous directions.
Of course, such observations alone, while helpful to the forensic
psychopharmacologist, may not indicate intoxication per se.
Indeed, arresting officers are frequently misinformed as to the
nature of drug-behavior interactions, and there is admittedly
a paucity of police knowledge concerning PCP use itself (Overend
1977). One police officer told the author that “the smell of a
minty breath” was characteristic of his encounters with PCP users.
While PCP is frequently smoked on mint leaves, without observa-
tion of other clinical features of intoxication, smell alone is
insufficient to warrant the presumption of PCP use. Other
police officers are beginning to attribute any bizarre behavior,
even some motor vehicle violations, to PCP intoxication.
Reynolds (1976) reports that in nine such cases, seven suspects
failed field sobriety tests, while the remaining two individuals
were judged incapable of even attempting tests.
Police encounters with PCP-intoxicated individuals are frequent-
ly associated with violent, assaultive, combative, suicidal, and
even homicidal behaviors, In most such cases, the intoxicated
individual is hyperexcitable, hypersensitive, disoriented, and
confused. Therefore, violent and aggressive reactions can be
triggered in these individuals by common police practices in-
cluding: interrogation, detainment, physical contact, restrain-
ing holds, handcuffing, and general arrest procedures. Even
seemingly mild stimuli, such as shining a flashlight in a sus-
pect’s eyes, may trigger aggressive behavior. Aggression in-
duced by PCP may take the form of fear, flight, or fight reac-
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tions. The nature of the reaction can be influenced by the
police officer’s own behavior and approach to the individual.
Mild verbal behaviors and minimal physical contact are usually
indicated (see “Clinical Management of the Phencyclidine Psy-
chosis;’ by Luisada and Brown 1976). Nonetheless, violent en-
counters occur frequently. Consider the following edited ex-
cerpt from an arresting officer’s report:
The suspect vehicle driver exited the vehicle and
attempted to flee. He stopped abruptly and stared
at the arresting officers who were approaching on
foot. Suspect ignored the arresting officers’ de-
mands to lay on the ground. Arresting officers
forced him to the ground and attempted to handcuff
him. Suspect displayed a phenomenal strength and said
absolutely nothing. Sgt. C. and Officer R. assisted
the arresting officers in subduing the suspect,
which took approximately 1 1/2 to 2 minutes. During
that time, the suspect was struck several times on
the right elbow and arm in attempt to force same be-
hind him for handcuffing. Such striking had no effect
at all on the suspect’s resistance. Officer R.
finally used a carotid choke hold to render the sus-
pect unconscious.
Not all aggression is emitted by the intoxicated individuals.
Unaccustomed to the often bizarre and inappropriate behavior of
phencyclidine users, police officers occasionally react with con-
s iderable force. Arrest techniques for suspects involve an “es-
calation process” of control. Techniques range from "no contact”
with a cooperating suspect to “deadly force” for use in situa-
tions of life-endangering attack. Under certain circumstances
where the suspect becomes violent, unconsciousness-rendering
holds are considered necessary. These holds include the "bar
arm” hold (forearm across the front neck) and the “carotid
hold” (pressure on carotid artery). Durning the process of es-
calating force, the police officer depends, to some extent, on
the reactions of suspects to force or pain (threatened or actual)
in order to gauge appropriate levels of force. The PCP intoxi-
cated suspect is often analgesic, feels no pain, and thus de-
prives the officer of much of the deterrent value of his force.
In addition, unconsciousness-rendering holds on PCP-intoxicated
individuals may complicate the respiratory difficulties seen in
cases of toxic overdose. Contact force with police batons or
other weapons runs the risk of provoking hyperexcitability and
even triggering psychomotor seizures. Probably the best proce-
dures are those that employ manual restraint by several (3-4)
officers. Officers and users alike would be well advised to
note those final words in Leary, Metzner, and Alpert’s (1964)
guide to handling hallucinogenic emergencies: “Remain calm, re-
member the teachings” (p. 159) . Otherwise, the escalation pro-
cess may run its full and tragic course. Consider the follow-
ing account from the Los Angeles Times (Overend 1977):
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While the controversy continued over the fatal
shooting of a 35-year-old biochemist by a Los
Angeles policeman, the county coroner’s office con-
firmed earlier this month what narcotics officers
had suspected since the morning of Aug. 4. It was
then that (the victim), described by  friends and
relatives as a “nonviolent and peaceful man,” was
shot to death while allegedly resisting arrest
after being spotted at 5:30 a.m., naked and trying
to climb a street sign near his Laboratory. The
coroner’s report that traces of a drug similar to
PCP, also known as angel dust, had been found in
(the victim’s) blood did not resolve the issue of
whether the policeman was justified in shooting
(6 times at close range) the unarmed man. It re-
mained for the legal system to determine that (p.2).
STATEMENTS OF INTOXICATED INDIVIDUALS
When the legal system tries to determine the role of PCP in
cases such as the one discussed above, statements made by the
intoxicated individuals, either to arresting officers or wit-
nesses, can be as helpful as the clinical observations them-
selves. Even when intoxicated individuals make no statements,
subsequent examination and interviewing by a skilled forensic
psychopharmacologist may probe for and elicit information re-
garding the specific phenomenology of PCP intoxication (see
Siegel, this volume) . However, owing to the possibility of con-
fabulation, post-hoc statements must be accepted with extreme
caution. While such statements are hearsay and cannot be ad-
mitted in court, they do add to the weight of the examining
expert’s opinion. Several types of statements seem character-
istic of PCP intoxication, but by themselves are insufficient
proof of such intoxication. The following edited statements are
typical of those made to police or witnesses:
I was smoking Dust. I had two hits. That was bad
stuff. (Statement later denied by suspect).
I was smoking Dust and got really whacked out.
Like I was driving in a dream, felt funny at times.
We were laughing a lot, riding the bumps and
floating. I remember hitting another car, some-
one telling me to get out of the car, and waking
up at the police station.
I thought I had been shot by the police at the
party and I started running and fell to the ground.
Then I was attacked by black widow spiders. They
were over everyone and all over me. It was  like a
dream.
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Everything was loud, real loud. Lights were very
bright. It was a trip. I don’t remember a lot.
I got sick of it and threw up.
She tried to jump out the window through the glass.
I pulled her back once. She was Busted. She
said she can fly.
I couldn’t walk. I don’t know where I am. I don’t
remember anything.
It was like tying myself in knots. I couldn’t
communicate. I got mad, screamed, cried. They
were all afraid of me.
I was feeling out of my body and liked it. It’s
all right.
It could have been a dream. To be honest, I don’t
know if I was physically up there (indicating
scene of crime) or spiritually there.
I felt spaced, things were for real but distorted.
Things were moving, patterns overlaying things and
people, patterns projected onto people.
My hands won’t fit in there (indicating handcuffs).
They’re all swollen and big. Too big.
You guys (indicating officers) seemed so far away.
Miles away. I thought I had plenty of time. What
a trip. Wow!
THOUGHTS OF INTOXICATED INDIVIDUALS
Even when overt verbal statements or other motor behaviors are
absent, the PCP- intoxicated individual may engage in a wide
variety of cognitive processes. An appreciation of these inner
subjective thoughts and mental images will enable a better
understanding of PCP-induced behaviors and possible criminal
actions. Such knowledge also may help in both predicting and
controlling behavior when encountering intoxicated individuals.
Two stages of intoxication can be distinguished: the acute
stage and the psychotic stage. The acute stage results from
recreational patterns of intoxication which are discussed else-
where (Siegel, this volume). The psychotic stage may occur from
acute usage, but it more often represents high dose or chronic
administration, and the psychosis may not be manifested until
several hours or even days later. Only data from acutely in-
toxicated individuals are  discussed here and such individuals
may differ substantially from those seen in the psychotic
stage by other authors (e.g., Fauman et al. 1976; Luisada and
Brown 1976) .
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Traditionally, psychologists consider cognitive processes to in-
clude perception, learning, and thinking, since they all deal,
to some extent, with the problem of knowledge (including the
knowledge of right and wrong). Perception can be defined as
the process by which an individual receives or extracts certain
information about the environment, Learning is defined as the
process by which this information is acquired through experience
and becomes part of the individual’s storage of facts (memory).
Thus, the results of learning facilitate the further extraction
of information, since the stored facts become models against
which cues are judged. The most complex of these cognitive pro-
cesses, namely, thinking, is an activity that is inferred to be
going on when an individual is engaged in solving problems,
which also involves the use of models. Thinking is also in-
ferred to be going on when an individual simply “scans” his own
memories or perceptions. Hallucinogenic drugs such as PCP can
cause these thoughts to be elaborated into fantasies, dreams,
and hallucinations.
Thoughts of PCP-intoxicated subjects are usually short, confused,
wandering, rapidly changing, and unvolitional in nature. The
intoxicated individual experiences waves of such thoughts inter-
rupted by waves of blank (amnesic) periods. The rapidly
accelerated thinking itself, coupled with the drug-induced hyper-
excitability and euphoria, can lead to the clinical condition
called “flight of ideas” or “mania.”
The most common thoughts during intoxication concern changes in
body image. Each individual normally develops techniques for
integrating the feelings and experiences emanating from his/her
body. This is referred to as body image, body concept,
or body scheme. ‘The PCP-intoxicated individual has difficulty
in experiencing and organizing his/her body as a perceptual ob-
ject. Individuals become so unaware of their bodies that they
often feel free of them and have the sensation of floating out
of them. They often float back and forth into and out of their
bodies. When they do perceive their bodies, their thoughts con-
tain exaggerated and elaborated views such as inflated limbs,
changes in head size, difficulty in estimating size of body
parts, difficulty in estimating distance between body parts, and
a general tendency to overestimate body size and height. While
such subjective reactions have not been confirmed experimentally,
they are similar to those findings reported for the hallucino-
gen LSD (Fisher 1970).
Frequently, the intoxicated individual considers himself/herself
endowed with unique and superior abilities (both bodily abilities
and mental abilities) as a result of the thought changes. In
the extreme cases, this state can be manifested as paranoia,
whereby the subject tries to account for these thought distur-
bances with persecutory or grandiose delusions.
282
THINKING ABOUT DEATH
Intense hallucinogenic experiences, including PCP experiences,
can be regarded as journeys to new states of consciousness
(Lear-y, Metzner, and Alpert 1964). The characteristic features
are “the transcendence of verbal concepts, of space-time di-
mensions, and of the ego or identity” (p. 11). The journey has
been described as one resembling psychological death and many
similarities between hallucinogenic experiences and those of
dying patients have been noted (Grof and Halifax 1977). There
are also considerable similarities between PCP intoxications
and death experiences.
Domino and Luby (1972) describe a salient feature of PCP intoxi-
cation as reduced verbal productivity, the appearance of calm
in the subjects, and reported experiences of sheer “nothingness.”
One subject reported lying in a meadow and that “this meadow was
a place that he has often considered he would like to be buried
in. The theme of death ran through most of his retrospective
account of the episode. Possibly the experience of combined cut-
off of interoceptive and exteroceptive cues is close to one’s
conception of what death must be like” (p.42).
Other common deathlike experiences in PCP intoxications include
ineffability of the experience and difficulty in verbal behavior;
feelings of peace and quiet; disturbances in space and time per-
ception; out-of-body phenomena (including ecstatic feelings of
timelessness, weightlessness, peace, serenity, and tranquility);
no perception of smells, odors, temperature, or kinaesthesia;
fear; and confusion. Naturally, this can lead to a concern with
death and deathlike thoughts for the PCP-intoxicated individual.
This state of preoccupation with death has been termed meditatio
mortis.
It is well known that survivors of near death situations develop-
ed, as a result of such experiences, new concepts about death.
Many of these individuals lost their fear of death and develop-
ed positive attitudes toward it. Indeed, it is this observation
that forms the basis for much of the recent psychotherapy with
hallucinogenic compounds for terminal patients. However, it
must be emphasized that these positive changes in attitudes
about death are not associated with a desire for death or with
suicidal tendencies. Nonetheless, it may be speculated that in
the acutely intoxicated PCP user, such attitudes may function
to remove or reduce fear in situations which risk extreme bodily
harm or death.
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AGGRESSION AND CRIMINAL BEHAVIOR
A variety of factors contribute to the development of aggression
and criminal tendencies. Many of these can be understood in
terms of social psychological concepts: frustrations creating
an emotional arousal predisposing to aggressive behavior; ag-
gressiveness habits also predisposing to such behavior; external
cues evoking the hostile actions; and, disinhibition of social-
ly disapproved responses (Berkowitz 1962).
PCP intoxication can produce frustration by interfering with a
person’s ongoing goal-directed activity, arousing anger, and
thus leading to aggressive reactions if suitable aggression cues
(stimuli associated with the frustrater) are present. Even if
such cues are not present in reality but simply inferred by
the user to be present due to hallucinations and/or thought
disorders (e.g., paranoia state), the individual may display
relatively uncontrolled, intense emotional responses. These
intense reactions to real or imagined frustrations predispose
him/her to extremely hostile behavior. However, the predisposi-
tion to aggression is not manifested necessarily by aggressive
behavior per se, and this depends on individual personality,
social, and cultural factors. Nonetheless, given the presence
of the hostility-evoking cues as found in police encounters or
in criminal activities where resistance is encountered (as in
robbery or rape), violent aggressive behaviors are more likely
to be elicited from the user.
Chronic use of PCP may induce a poor judgement syndrome which
could be a factor in nonviolent criminal acts such as perjury
and theft. The hypersexuality sometimes reported during some
psychotic stages of PCP intoxication may influence motivation
involved in assault and rape situations. Conversely, one could
speculate that crime related to continuous use of drugs (e.g.,
theft to support the drug habit) would be infrequent among PCP
users owing to the drug’s low price and availability. In
addition, like most hallucinogens, PCP does not appear to be
used in escalating doses indicative of addiction.
PCP intoxication also can produce panic reactions in the sense
that the individual becomes frightened due to the overwhelmingly
intense hallucinogenic effects. Changes in body image, per-
ceptual distortions, and mental confusion can catapult the naive
user into a state where s/he feels and fears loss of ego and
identity, loss of contact with reality, and even permanent mental
dysfunction. Consequently, panic ensues, and deviant behavior,
including aggression, can occur. It is probable that assaultive
behavior, when it does occur during PCP intoxication, takes
place for many individuals at this time. This is similar to the
occurrence of aggressive behaviors during intoxication with other
hallucinogens: "Aggressive outbursts do occur during the panic
reaction of psychedelic intoxication, especially if the reaction
includes paranoid components” (Tinklenberg 1973, p.265).
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The PCP-intoxicated user’s orientation toward the immediate pres-
ent and disregard for long range consequences of his/her behav-
ior would make it difficult for him/her to premeditate criminal
acts. But the tendency to react strongly to sensory stimuli in
the immediate environment, the inclination to refer everything
to oneself that often develops into paranoia, and the need to
do something due to intense psychomotor stimulation can all pro-
duce an aggression-prone individual. Once again it must be
emphasized that emotionally stable people under the influence
of low doses of PCP probably will not act in a way very differ-
ent from their normal behavior. To the extent that this is true,
case histories and statistics regarding PCP-related crime,
aggression, and violence should thoroughly investigate the user’s
prior conduct and social psychological history.
THE DIMINISHED CAPACITY DEFENSE
Forensic psychopharmacologists and psychiatrists are frequently
called upon as expert witnesses in cases involving PCP and
diminished capacity. The expert will frequently evaluate sever-
al sources of data regarding the defendant’s possible state of
intoxication at the time of the alleged offense. These sources
include: chemical and laboratory reports and studies, field
sobriety tests, observations made by arresting officers, arrest
reports, investigative reports, statements of witnesses, medical
and psychiatric histories, and allied materials. According to
Pollack (1976), the expert “must be able to assess, integrate,
and evaluate all of these data on the question of whether the
defendant at the time of the alleged act was intoxicated; and
if he was, whether his mental functions of significance for
forming the specific intent for the crime were substantially
impaired” (p. 257) . Thus, the threshold for simply being intoxi-
cated or under the influence of a drug such as PCP is signifi-
cantly lower than that defining intoxication for purposes of
diminished capacity. The former requires minimal evidence of
impairment while the latter requires a substantial degree of
mental impairment. In an effort to gather as much information
as possible, experts will frequently employ additional data such
as physical medical examination of the defendant soon after the
alleged offense, EEG examinations, in-depth interviewing and
testing of defendants and witnesses regarding the specific
phenomenology of the intoxication, among other methods. All
such materials can be used as collateral and supporting data.
Since there is no statutory presumption identifying PCP intoxi-
cation for diminished capacity (in contrast to the statutory
presumption of being under the influence of alcohol with blood
alcohol levels of .10 percent), the expert witness can only
offer considered opinion. In court, when accepted according to
the rules of evidence, psychopharmacologic or psychiatric expert
opinion carries weight as “opinion evidence” and is not accepted
as “scientific fact.” The ultimate legal question will be de-
cided by the trier of fact, namely, the judge or jury.
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Since PCP intoxication can resemble closely some forms of schizo-
phrenia, superficially it would appear to be an ideal candidate
for defenses of diminished capacity. PCP intoxication can show
all the essential ingredients for such a defense: altered con-
sciousness wherein the defendant’s attention, awareness, and
ability to respond meaningfully to the environment and situation
are disturbed; mental confusion regarding the meaning of the act
or its consequences; involuntary behavior which might prevent
optional courses of action; and interference with goal-directed
behavior so as to prevent organizing and directing physical
movements. Thus, PCP can diminish the capacity to form
or to harbor criminal intent. It does so by interfering
with the mental functions which are essential to the mental
process of forming intent for an act.
Diminished capacity defenses are extremely difficult to prove
and are generally far less successful than the insanity defense,
which is probably successful in about 66 percent of the insanity
trials. Even when the diminished capacity defense is successful,
the outcome may not result in the adequate treatment of the defen-
dant for the drug abuse and mental health problems signified by such
extreme PCP use. Whereas the defendant who is found legally insane
is usually diverted to a state mental health system for evaluation,
disposition, and treatment, the defendant who ‘is successful in
a diminished capacity defense is usually committed to prison for
punishment.
OVERVIEW AND SPECULATIONS
Euripides presented us with the notion that drugs work in some
magical way. The figure of Dionysus was clearly that of sorcer-
er and his magic was to be found in wine. The social importance
of Dionysian intoxication and ecstasy was that it permitted
temporary impairment of reason for the folly and madness of
criminal behavior. Ever since those ancient times, drugs, and
especially alcohol, have been used as scapegoats for the argu-
ment of diminished capacity in criminal acts. The mechanisms
of action for such effects are neither magical nor predictable.
They are not magical because they reflect characteristic states
of behavior induced by the pharmacological properties of drugs
on the central nervous system. They are not predictable because
of a wide range of interactions with nondrug variables, including
set and setting.
Phencyclidine is not a magical drug. It does not magically pro-
duce violent, assaultive, or criminal behavior. When the psycho-
pharmacology of the drug is fully appreciated, we can begin to
understand that the criminal behavior associated with its use is a
result of interactions between the drug and the user. At that
time the magical notions will begin to disappear from courtroom
trials of diminished capacity which often turn into trials of
the drugs themselves as good or evil.
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Such a future state of enhanced knowledge about drugs has already
been envisioned by science fiction writer H.H. Hollis (1972) in
his short story "Stoned Counsel.” In that fictitious world of
the future, hallucinogenic drugs have become a routine part of
the legal process as both defense attorneys and prosecutors have
had personal experiences with drugs which enhance their under-
standing and sympathy for the defendants. Even some present day
PCP users have coined the term “Pig Killer” for the drug in
order to connote that if ingested by police it would kill their
ideas about the drug turning people into “beasts.” While such
personal use is unnecessary and certainly ill-advised with drugs
such as PCP, a full understanding of phencyclidine will undoubt-
edly reveal it to be simply a hallucinogenic drug with certain
chemical properties and behavioral possibilities.
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Chapter 17
Control of Drug Self-Administration:
The Role of Aversive Consequences
Nancy K. Mello, Ph.D.
Despite a continuing search for commonalities across the
various forms of substance abuse, it has been difficult to
identify factors which apply equally to the abuse of opiates,
alcohol, stimulants and hallucinogens. The traditional focus
on specific syndromes associated with the abuse of certain
drugs, e.g., alcoholism and heroin addiction, has tended to mili-
tate against appreciation of similarities between drugs. More-
over, known differences in the pharmacological and behavioral
consequences of alcohol, heroin, cocaine and phencyclidine in-
toxication would appear to argue against the notion that any
meaningful similarities could be found.
Re-examination of the behavioral consequences of drug use and
abuse suggest that one pervasive factor has often been over-
looked. Many drugs of abuse have now been shown to have
aversive consequences during intoxication. These data have
led to the hypothesis that “aversive” consequences may be an
important factor in the control of many forms of drug abuse
(Mello 1977). Recent findings relevant to this hypothesis will
be examined in the remainder of this review. One basic
assumption is that drug self-administration behavior is con-
trolled or maintained by its consequences. Therefore, any
consistent consequence which transcends drug specific effects
may be a common factor which contributes to the maintenance of
substance abuse.
EFFECTS OF DRUGS IN NAIVE USERS
In thinking about the way in which drugs come to control
behavior leading to their self-administration, it is instruct-’
ive to review some reported effects of acute drug use by naive
users. It would be convenient if the initial drug experience
was so overwhelmingly positive that repeated drug use would be
almost inevitable. Yet the reported effects of acute doses of
opiates, barbiturates, alcohol and nicotine summarized in
Table 1 do not appear to be especially appealing. These drugs
each produce a variety of somatic and emotional effects that
would seem disadvantageous to the user. Yet, despite these
“aversive” consequences of initial drug use, many individuals
persist in self-administration of these same drugs to the point
of abuse and addiction.
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TABLE 1
SOME REPORTED ACUTE EFFECTS OF DRUGS IN NAIVE USERS*
*From Mello, Stimulus Self-administration: Some implications for
the prediction of drug abuse liability. In: Thompson and Unna, eds.
Predicting Dependence Liability of Stimulant and Depressant Drugs.
© 1977 University Park Press, Baltimore. Reprinted with permission.
Adapted from Jaffe 1975, Mello and Mendelson 1976, Russell 1976.
It has often been observed that alcohol addicts tend to have
a clear recollection of their “first drink” (Kuehnle,
Anderson, and Chandler 1974). However, clinical impressions
suggest that the first drink was not memorable because of its
relaxing, euphorigenic, tension-reducing, or self-actualizing
effects for the drinker (Kuehnle, Anderson, and Chandler 1974;
Catanzaro 1968). It is more likely that the future alcoholic
drank to the point of intoxication with associated despondency,
nausea and vomiting.
The process by which an initial aversive drug experience becomes
translated into a repetitive drug use pattern is not understood.
It could be postulated that with the development of drug toler-
ance, these seemingly unpleasant somatic and emotional effects
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undergo a transition to a more positive state, i.e., euphoria,
relaxation, tranquility. Alternatively, it could be postulated
that the initial dysphoria, nausea, and vomiting is an integral
part of the reinforcing properties of subsequent drug abuse.
It is now evident that drug abuse is maintained despite the
recurrence of these seemingly aversive consequences.
EFFECTS OF DRUGS IN CHRONIC USERS
It is generally acknowledged that the long-term effects of
chronic substance abuse are adverse and may compromise health
and employability as well as disrupting family and social
relationships. However, the immediate consequences of drug
use are usually believed to be sufficiently positive to out-
weigh these long-term effects. If in fact, abused drugs con-
sistently produced relaxation, euphoria, relief from anxiety,
tranquility and serenity, then chronic drug use and abuse
might be more understandable. However, common expectancies
about drug related pleasures have not been confirmed in
clinical studies of addicts during intoxication. Direct ob-
servations of intoxicated individuals are often discordant
with retrospective self-reports of drug effects obtained
during a period of sobriety. This discrepancy is particularly
troublesome since most of our information about the effects of
abused drugs is based on retrospective reports of users during
sobriety.
It now appears that increases in dysphoria, anxiety, and agi-
tation frequently accompany chronic intoxication, both with
alcohol (Mello and Mendelson 1978) and with heroin (Mirin
et al. 1976; Meyer and Mirin 1978). These findings challenge
the traditional view of the behavioral effects of these drugs,
and are one basis for the idea that “aversive” consequences
are important in the maintenance of drug self-administration
behavior. Clinical research has shown that the behavioral
effects of drugs are far more complex than concepts related
to hedonism would suggest.
Behavioral Effects of Alcohol Intoxication
Many of the consequences of alcohol intoxication are similar
for the naive or social drinker, and for the alcohol addict.
The major determinant of the behavioral effects of alcohol
appears to be the dose of alcohol consumed, relative to the
experience and behavioral tolerance of the drinker. A list
of some of the subjective states that alcohol is believed to
improve or enhance, and findings from clinical studies of
intoxicated individuals appears in Table 2.
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Low doses of alcohol, sufficient to produce a blood alcohol
level of between 30 and 50 mg/100 ml often produce the antici-
pated pleasurable consequences. However, social drinkers
report increased depression, dysphoria and anxiety after an
acute high dose of alcohol (6 to 8 ounces) (Williams 1966;
Warren and Raynes 1972).
Alcohol addicts often ingest between 26 and 32 ounces of dis-
tilled spirits per day (or the equivalent in beer or wine)
(Mello and Mendelson 1978). Since the alcoholic is tolerant
to alcohol, considerably higher doses of alcohol may be
required to produce significant changes across a range of
subjective experiences and interpersonal reactivity. However,
clinical studies from many laboratories, employing a variety
of techniques agree that chronic intoxication, sufficient to
maintain blood alcohol levels between 150 and 300 mg/100 ml,
is associated with increased depression, agitation, anxiety,
and belligerence in the drinker (Mello and Mendelson 1978).
Severe chronic alcohol intoxication may also be associated
with illusions and hallucinatory experiences during drinking
as well as during alcohol withdrawal (Wolin and Mello 1973).
TABLE 2
OBSERVED EFFECTS OF ALCOHOL INTOXICATION*
*Adapted from Mello and Mendelson 1978.
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It is not clear why the discrepancies between the expected and
the observed effects of chronic alcohol intoxication are not
more generally recognized and why they appear to have so little
effect on the behavior of the alcohol addict. It has been
found that alcohol addicts, interviewed before, during, and
after an episode of alcohol intoxication tend to recall pre-
drinking expectancies about the experience even if these are
completely at variance with the actual effects of alcohol
intoxication (McGuire et al. 1966). Alternatively, it may be
that these “aversive” consequences, similar to the “first
drink” experience summarized in Table 1, are an important
aspect of the reinforcement for drinking.
Behavioral Effects of Heroin Intoxication
Retrospective reports of the effects of heroin intoxication by
heroin addicts emphasize euphoria and serenity. As Jaffe (1975)
has described it:
Narcotics do more than produce indifference to pain.
They also suppress those drives that motivate an
individual to appease hunger, seek sexual gratifi-
cation and respond to provocation with anger. In
short, they seem to produce a state of total drive
satiation. Nothing needs to be done because all
things are as they should be. For certain types
of personalities, but clearly not for all, such
a state is extremely pleasant (Jaffe 1975, p. 284).
Clinical observations of heroin addicts during a period of
opiate intoxication are at variance with these reports.
Chronic opiate use appears to be accompanied by an increase
in dysphoria, irritability, hypochondriasis, psychopathology,
belligerence, negativism and motor retardation (Wikler 1952;
Haertzen and Hooks 1969; Mirin et al. 1976; Meyer and Mirin
1978). These dysphoric consequences of chronic heroin in-
toxication appear to be directly related to heroin use rather
than to situational or social factors. Heroin addicts,
maintained on the long-acting opiate antagonist, naltrexone,
during the same period of residence on a clinical research
ward did not develop dysphoria, anxiety, or belligerence com-
parable to that shown by heroin users (Mirin et al. 1976;
Meyer and Mirin 1978).
It could be argued that a brief and transient positive mood
change which is purportedly associated with the induction of
alcohol and heroin intoxication is sufficient to maintain drug
self-administration behavior (Mirin et al. 1976; Davis 1971).
In the case of alcohol intoxication, these initial changes
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during the induction of intoxication have been difficult to
characterize either in terms of subjective quality or tem-
poral duration (Davis 1971). In the case of heroin addiction,
the intensity of the positive feelings associated with the rush
appears to be attenuated as tolerance develops during the course
of chronic heroin use (Meyer and Mirin 1978).
Comparisons           with   Phencyclidine
Clinical reports of the consequences of phencyclidine self-
administration appear to be a further extension of the “aversive”
end of the drug effect continuum. Acute effects of dose-related
illusions, dissociation, perceptual disturbance, and depersonal-
ization, which may culminate in convulsions and coma would be
difficult to categorize as “positive” effects according to the
usual criteria. Yet even the development of toxic psychosis
does not appear to be an effective deterrent to repeated use.
However, re-evaluation of the consequences of alcohol and opiate
intoxication suggests that phencyclidine abuse may differ only
in the intensity of aversive effects.
ANIMAL MODELS OF “AVERSIVE” STIMULUS SELF-ADMINISTRATION
Although it is tempting to dismiss these clinical data as
optimistic expectancies failed, the quest for aversive stim-
ulation is not restricted to man. There is evidence that
seemingly aversive consequences will also maintain self-admini-
stration behavior in animals under certain conditions. Two
examples of aversive stimulus self-administration will be
described.
Narcotic Antagonist Self-Administration
Narcotic antagonists induce withdrawal signs in opiate
dependent monkeys. A summary of some typical withdrawal signs
appears in Table 3. It is evident that the somatic consequences
of opiate withdrawal resemble some consequences of acute intoxi-
cation in naive drug users shown in Table 1. It is not sur-
prising that opiate-dependent monkeys will work to escape and
to avoid the infusion of narcotic antagonists (Downs and
Woods 1975; Hoffmeister and Wuttke 1973). However, it has also
been found that under certain conditions morphine dependent
monkeys will work to produce injections of narcotic antagonists.
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TABLE 3
SOME SIGNS OF OPIATE WITHDRAWAL IN OPIATE-DEPENDENT RHESUS MONKEYS*
Autonomic and Gastrointestinal
Signs Motor Activity Signs
Vomiting
Retching
Coughing
Tachypnea
Dyspnea
Salivation
Sweating
Tearing
Miosis
Erection Masturbation
Loose stools
Tremors
Rigidity in extremities
Spasticity
Shivering
Piloerection
Holding of abdomen
Gross Behavioral Changes
Yawning and grimacing
Restlessness
Screaming (provoked and un-
provoked)
Attacking [provoked and un-
provoked)
*Adapted from Villarreal and Karbowski 1974.
Goldberg and co-workers (1972) were the first to observe self-
administration of the narcotic antagonist nalorphine by opiate-
dependent monkeys. During studies in which either saline or
nalorphine was substituted for morphine injections during a 7.5
hour session, it was found that responding that was followed by
nalorphine injections was maintained at a higher rate than
responding that was followed by saline injections. The distri-
bution of responses within successive 2.5 hour segments of the
7.5 hour saline and nalorphine substitution sessions is shown
in Figure 1. It is apparent that nalorphine maintained respond-
ing. Monkeys continued to self-administer nalorphine despite
severe withdrawal signs which included vomiting? coughing,
salivation, tremors, and irritability. Responding for nalor-
phine did not extinguish during the substitution sessions.
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FIGURE 1
Distribution of responses within the
last three saline substitution sessions and nalor-
phine-substitution sessions (100 mcg/kg injection),
compared to the distribution of morphine-maintained
responses at comparable times on control days.
Abscissa: successive 2.5-hour segments of 7.5-hour
saline or nalorphine substitution sessions; Ordinate:
cummulative  number of  responses during successive 2.5-
hour segments. Each point represents the mean of
results of three sessions with two monkeys. From:
Goldberg, S.R., Hoffmeister, F., Schlichting, U.U.:
Morphine antagonists : Modification of behavioral
effects by morphine dependence. In: J.M. Singh,
L. Miller and H. Lal eds. Drug Addiction I.
Experimental Pharmacology, pp. 31-48. ©1972, Symposia
Specialists, P.O. Box 610397,
Reprinted with
Miami, Florida 33161.
permission of the publisher.
These data indicate that under certain conditions, response
produced nalorphine injections can maintain responding in monkeys
which are physiologically dependent upon morphine. Goldberg and
co-workers concluded that these findings illustrate that the
experimental history of the organism, and the behavioral schedule
under which a stimulus event is presented, rather than the type of
event may determine the effect that an event may have upon
behavior (Goldberg, Hoffmeister, and Schlichting 1972).
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These findings have recently been confirmed and extended by
Woods and co-workers (Woods, Downs, and Carney 1975). It was
found that under certain conditions, morphine dependent monkeys
will work to produce the same injection of a narcotic antagonist,
naloxone, that they previously worked to avoid. Cumulative
records of narcotic antagonist self-administration by a morphine
dependent monkey is shown in Figure 2. Each response on an
operant manipulandum advances the stepping pen of the cumulative
recorder approximately one-quarter of a millimeter and con-
sequently, cumulative records provide a direct analog of
response rate. The top row of figure 2 show cumulative
records of responding on a second-order schedule of reinforce-
ment (FR 10 (FR30:S). Every 30 responses produced a secondary
reinforcing stimulus (i.e., a 1.5 second flash of light),
previously associated with drug infusion and every three
hundred responses produced an injection of naloxone (0.002
mg/kg). Antagonist injections were followed by a one-minute
time out and a light signal. The downward deflection on the
event marker indicates the delivery of each successive
naloxone injection.
It is clear that naloxone, rather than any associated stimuli
maintained responding since removal of naloxone resulted in
extinction of response behavior. The second row of Figure 2
shows the effect of disconnecting the naloxone infusion pump
when the secondary reinforcing stimuli, i.e., the light signal,
the time-out, etc., remain unchanged. The monkey worked briefly,
then stopped responding when no naloxone infusion was delivered.
The third row of Figure 2 illustrates the reinstatement of
naloxone maintained responding during the first session after
the naloxone pump was reconnected. The reinforcement schedule
requirement was reduced from 300 to 150 responses for each
naloxone injection. Under these conditions, morphine depen-
dent monkeys could earn approximately 10 naloxone injections
over the course of an hour. It is apparent that the monkey
resumed and maintained responding for naloxone injections.
ELECTRIC SHOCK SELF-ADMINISTRATION
The aversive properties of electric shock stimuli have been
amply documented. However, it has also been found that the
same electric shock event that can maintain escape and
avoidance behavior, may under certain conditions, be self-
administered by the same monkey. Identification of this
phenomena, called response-produced shock, developed from
the initial observations of Kelleher and co-workers that
during a pre-shock stimulus, responding increased and if
the terminal shock was removed, responding decreased
(Kelleher, Riddle, and Cook 1963). Response produced shock
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FIGURE 2
Cumulative records of responding maintained
by naloxone in a morphine-dependent monkey. The upper
record shows the eighth session of responding when
every completed FR 30 unit produced a 1.5~sec flash
of the house light and every tenth completed FR 30
unit produced an injection of naloxone (0.002 mg/kg
per injection) plus a 1-min time-out accompanied by
house light illumination. The center record shows
performance in the third session with the naloxone
infusion pump disconnected. All other aspects of
the procedure were as described above. The lower
record shows reinstatement of naloxone-maintained
responding in the first session with the naloxone
pump reconnected. In this and subsequent sessions,
the schedule value was reduced to FR 5 (FR 30).
Injections of naloxone or saline are indicated by
downward deflections of the center event pen.
Each session was terminated after 10 injections
or about 1 hour. From Woods, J.H., Downs, D.A.,
and Carney, J. 1975. Behavioral functions of
narcotic antagonists: Response drug contingencies.
Reprinted with permission of the publisher, from
FEDERATION PROCEEDINGS 34(9): 1777-1784, 1975.
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has now been observed in many laboratories, across several
species, and has been shown to be a reliable and persistent
phenomena (Byrd 1969; Eubanks et al. 1975; Kelleher and Morse
1968; McKearney 1968, 1969, 1972; Morse and Kelleher 1970;
Morse, McKearney, and Kelleher 1977; Morse, Mead, and
Kelleher 1967; Stretch, Orloff, and Dalrymple 1968; Stretch,
Orloff, and Gerber 1970). Under certain conditions monkeys
will continue to self-administer electric shock for months
and even for years.
An illustration of behavior maintained by the delivery of
electric shock is shown in Figure 3 (Morse and Kelleher 1970).
Cumulative response records of the operant performance of a
single monkey are shown under two different conditions;
shock termination and shock production. The top row of
Figure 3 shows behavior on a schedule of shock termination
(FI 5 min) in which the first response after five minutes
have elapsed terminates a 7 ma electric shock which is presented
every five minutes. Cumulative responses of the same monkey on
a schedule of shock production are shown in the second row of
Figure 3. Instead of terminating a shock presented every five
minutes, the monkey self-administers a shock of 1 ma every five
minutes, If a response did not produce shock within five
seconds after elapse of the five minute fixed interval, a 7 ma
shock was presented automatically. It is obvious that the rate
of responding was higher when responses produce shock than when
responses terminate shock.
Another example of response-produced electric shock is shown
in Figure 4 which compares the effects of non-contingent and
response produced shock on operant behavior (Morse and
Kelleher 1970). In the cumulative record shown at the top of
Figure 4, a monkey with a particular behavioral history
received 5 ma shocks every two minutes, independent of his
response behavior, Each shock was followed by a brief time-
out period. In the lower portion of Figure 4, a shock of the
same intensity (5 ma) was scheduled to occur after the first
response after an interval of two minutes had elapsed (an FI
2 min schedule), Shock presentation was followed by a brief
time-out. Response behavior was maintained by electric shock
presentation. The rate of responding increased and the pattern
of responding was more positively accelerated on a shock
presentation schedule than when shocks were not contingent on
responding. These findings that an animal will work to self-
administer a seemingly noxious electric shock, indeed the same
electric shock he previously worked to avoid, or to escape
from is eloquent testimony to the capacity of “aversive”
events to control behavior leading to their self-administration.
Morse, McKearney, and Kelleher (1977) have reviewed data on the
control of behavior by noxious stimuli and discussed the
generality of this phenomenon.
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FIGURE 3
Performance under an FI 5 min schedule
of termination of electric shock and an FI 5 min
schedule of presentation of electric shock (Monkey
S-28). A: Short diagonal strokes in the event
record (bottom) indicate successive electric
shock presentations (7 ma); diagonal strokes
on the cumulative record (top) indicate the
termination of shock. B: Strokes on the cumu-
lative record indicate 1 ma electric shock presen-
tations. If a response did not produce shock
within 5 seconds after 5 minutes had elapsed, a
7 ma shock was presented automatically. When
responses produced shock, rates of responding
became higher and patterns of positively acceler-
ated responding became more marked. From Morse,
W.H., and Kelleher, R.T., 1970. Schedules as
fundamental determinants of behavior. In: W. N.
Schoenfeld, ed. The Theory of Reinforcement
Schedules. pp. 139-185. Appleton-Century-Crofts,
New York. © 1970. Reproduced by permission of
Prentice-Hall, Inc., Englewood Cliffs, New Jersey.
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FIGURE 4
Comparison of performances under schedules
of response-independent and response-dependent 5-ma
electric shocks (Monkey S-13). Short diagonal strokes
on the cumulative records indicate presentation of
electric shock; a time-out period, in which the
paper did not moue, followed each shock. The
recording pen reset to the baseline whenever 275
responses had accumulated. A: Performance under the
schedules of response-independent shock. B: Perfor-
mance wader FI  2-min schedule of response produced
shock after eight sessions. The rate of responding
increased, and the pattern of responding was more
clearly positively accelerated with response-produced
shocks. From Morse, W.H., and Kelleher, R.T., 1970.
Schedules as fundamental determinants of behavior. In:
W. N. Schoenfeld (ed.) . The Theory of Reinforcement
Schedules, pp. 139-185. Appleton-Century-Crofts,
New York. © 1970. Reprinted by permission of
Prentice-Hall, Inc., Englewood Cliffs, New, Jersey.
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The parallels between these data on response-produced shock
and narcotic antagonist self-administration in primates, and
the aversive consequences of drug self-administration in
humans are provocative. Although the control of drug self-
administration by aversive consequences has not been shown
unequivocally in man with the degree of precision that it
has been shown in primate models, the inference that aversive
consequences are one part of the reinforcement complex that
maintains human drug self-administration behavior is compelling.
IMPLICATIONS AND CONCLUSIONS
These clinical and experimental data challenge common sense
assumptions about what constitutes a “positive” and an
“aversive” event, and what types of events will be rein-
forcing. In the language of the experimental analysis of
behavior, reinforcement is any event that maintains
behavior, i.e., a reinforcer is a consequence of behavior
that increases the probability of the recurrence of that
behavior (Skinner 1938, 1953). Although behavioral
scientists are usually careful to distinguish between
reinforcement and reward, the terms reinforcing, rewarding,
and euphorigenic are often used interchangeably to describe
the consequences of drug abuse and by inference to explain
its recurrence and persistence. The notion of “reward” has
a compelling face validity that does not invite critical
examination. One advantage of the term reinforcement is that
it does not imply anything about the nature of the rein-
forcing events, but rather describes a functional relation-
ship between events and behavior.
The defining characteristics of reinforcements and punishers
are how they change behavior. The same stimulus may have
either reinforcing or punishing effects, depending upon the
condition under which it is presented. According to this
empirical formulation, shown schematically in Table 4, if
the presentation or removal of the stimulus event increases
the behavior leading to that consequence, it can be defined
as a reinforcer. If the presentation or removal of the
stimulus event decreases the behavior leading to that con-
sequence, it can be defined as a punisher (Morse and
Kelleher 1977).
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TABLE 4
BEHAVIORAL EFFECT *
EVENT
INCREASE BEHAVIOR DECREASE BEHAVIOR
PRESENT
STIMULUS REINFORCEMENT PUNISHMENT
REMOVE
STIMULUS REINFORCEMENT PUNISHMENT
*From Mello, Stimulus self-administration: Some implications for
the prediction of drug abuse liability. In: Thompson and Unna, eds.
Predicting Dependence Liability of Stimulant and Depressant Drugs.
© 1977 University Park Press, Baltimore. Reprinted with permission.
Defining stimulus events in terms of their behavioral effects,
rather than in terms of an apriori assumption about the
alleged properties of the stimulus event and conclusions
about its consequences, represents a radical departure from
our usual ways of thinking. However, a definition of rein-
forcement and punishment in terms of behavioral effects, can
account for data on response-produced shock and antagonist
self-administration as well as the persistence of drug self-
administration which results in aversive consequences during
intoxication.
Electric shock and antagonist self-administration data indicate
that it is not the inherent properties of the event, per se, but
the way in which the event is scheduled that determines the sub-
sequent effect on behavior (Morse, McKearney and Kelleher 1977).
The reinforcing or punishing properties of stimulus events are
dependent upon a variety of factors including the behavioral
history of the organism, the schedule of presentation of that
event, and the ongoing behavior at the time. Clearly, it is
impossible to assume an invariant effect of any particular
Stimulus event. We have seen that under certain conditions of
behavioral history and schedule controls, substances that were
so noxious that animals would work to avoid them, undergo a
transition from punishing to reinforcing stimuli as a
function of the schedule of presentation.
Since consequences which appear to be aversive do maintain
behavior leading to their self-administration, more careful
attention to the role of “aversive” consequences in human
drug self-administration seems indicated. Traditional concepts
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that drug abuse is maintained primarily as a function of
rewarding or euphorigenic consequences are not consistent
with the clinical data. Reward related concepts appear
too limited to account for clinically observed consequences
of many forms of drug abuse including phencyclidine self-
administration.
Stimulus Self-Administration ?
Beyond the issue that both seemingly “aversive” and “positive”
consequences contribute to the maintenance of drug self-admini-
stration, there are many other apparent paradoxes which remain
unaccounted for. One example is polydrug use which often
involves the simultaneous and sequential use of several drugs
with different pharmacological properties and presumably differ-
ent effects, e.g. stimulants and depressants; opiate analgesics
and stimulants. Phencyclidine may be used concurrently with
other drugs, e.g. alcohol, barbiturates, marihuana, each of
which has different pharmacological effects and presumably
modulates the effect of phencyclidine in different ways.
Twenty-five years ago, Wikler and Rasor (1953) wrote that one
reason for using drugs advanced by some opiate addicts is to
“get off the normal”. The nature of the positive effects of
drugs described by addicts varies considerably in different
types of drug addiction (Wikler and Rasor 1953). Anecdotal
accounts of voracious polydrug use, and extreme drug effects
produced by agents such as phencyclidine, suggest that the
users goal is to achieve a rapid change in state. The
direction of the change, up or down, may be of secondary
importance. Accumulating clinical evidence of aversive con-
sequences during intoxication also lends credence to a state
change hypothesis. An extreme example is the repeated intra-
venous injection of phencyclidine to the point of unconscious-
ness (Fauman and Fauman 1978).
To the extent that stimulus change affected by drug use may be
more important than any inherently positive or negative char-
acteristics of that stimulus, it may be useful to consider
drug self-administration within a more general framework of
stimulus self-administration (Mello 1977). Central to the
idea that stimulus self-administration is important in the
maintenance of drug self-administration is the notion that
the stimulus properties of drugs, rather than the specific
qualities of the stimuli, may be important determinants of
this behavior. State change may be the subjective response
to the drug induced stimulus, whatever that stimulus may be.
Perhaps, under some conditions, in individuals with a
certain behavioral history, drug self-administration
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has less to do with the pharmacological properties of the
compound, or with its anticipated effects, than with its
properties as a definite stimulus event that results in a
change in subjective state. This hypothesis implies that
any drug which has definite stimulus properties, i.e.,
behavioral effects for the user, is a drug which has abuse
potential.
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